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Norcoclaurine synthase (NCS) is a biocatalyst, involved in plant alkaloid biosynthesis. 
In plants, NCS catalyses a stereoselective Pictet-Spengler reaction between dopamine 
and 4-hydroxyphenylacetaldehyde (4-HPAA), to give (S)-norcoclaurine, the first 
committed intermediate in benzylisoquinoline alkaloid (BIA) biosynthesis. Previous 
work has shown that a range of aldehydes and ketones are accepted by NCS, in place 
of 4-HPAA, to generate single isomer tetrahydroisoquinolines (THIQs). The THIQ 
moiety is found in many biologically active molecules and NCS provides a facile route 
towards novel analogues.   
 
The aim of this project was to rationalise and extend the substrate scope of NCS, in 
particular towards a-substituted aldehydes. Despite previous reports, a range of a-
methyl substituted aldehydes were shown to be accepted by NCS. A kinetic resolution 
of the aldehyde was also observed, with the (R)-enantiomer preferentially accepted, 
leading to THIQ products with two well-defined stereocentres. Single point variants of 
NCS were shown to improve activities compared with the wild-type enzyme. One 
variant, M97V was particularly promising and lead to the acceptance of the 
benzaldehydes as substrates and so the single step syntheses of various (1S)-aryl-
THIQs was achieved. To expand the amine substrate scope of NCS, N-methyl-
phenylamines were also explored as substrates. 
 
Chemoenzymatic cascades were developed to increase the molecular complexity of 
the NCS-generated THIQs and crystallographic investigations, involving the co-
crystallisation of reaction intermediate mimics helped to rationalise NCS activities. 
Routes towards (R)-THIQs were also explored, involving screening novel variants, 
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Chapter 1: Introduction 
1.1 Background 
1.1.1 Benzylisoquinoline alkaloids 
Benzylisoquinoline alkaloids (BIAs) are a diverse group of nitrogen-containing plant 
metabolites, commonly found in the Ranunculales order of plants which includes plants 
such as poppies, meadow grass and buttercups. Over 2,500 different natural BIAs have 
been identified and are characterised by the common benzylisoquinoline moiety. 
Despite the in planta roles of these metabolites being largely unknown, many BIAs 
possess potent medicinal properties which have been exploited for many centuries.1 
For example, the opium poppy has been used for its analgesic properties since the 
Neolithic age, with the widely-known BIA, morphine (1) being responsible for these 
activities.  Other examples of widely used BIAs include berberine (2), with anti-microbial 
properties and noscapine (3), an antitussive.2 Many others have been shown to exhibit 
anti-HIV, anti-tuberculosis and anti-cancer properties.3,4 Figure 1.1 exemplifies the large 
structural differences of three medicinally important BIAs.  
 
Figure 1.1: Examples of biologically active BIAs.  
 
The medicinal properties of BIA-producing plants have been exploited for millennia, 
leading to recent scientific efforts into the identification of the active components. 
Currently, around 50% of marketed drugs are based upon natural products,5 however, 
isolation of a single metabolite from plants is challenging as it must be separated from 
other structurally similar molecules and low quantities are produced. Therefore, 





















pathways involved so that the transformations can be replicated in the laboratory, either 
by using analogous chemical transformations using the relevant recombinantly-
expressed enzymes in vitro or biosynthesised via whole-cell production. Due to the 
pharmaceutical relevance of the BIAs, the full biosynthetic pathways to the most widely 
known BIAs have been elucidated over a number of years. Indeed, despite the obvious 
medicinal value of morphine, the biosynthetic pathway was not fully realised until 2015 
with the discovery of the reticuline epimerase enzyme.6,7 The biosynthetic pathways to 
several BIAs are given in Scheme 1.1.  
 
Scheme 1.1: The biosynthetic pathways towards a variety of BIAs. Given on the arrows (in 
bold) are some of the enzymes responsible (NCS: norcoclaurine synthase, 6OMT: 
norcoclaurine-6-O-methyltransferase, BBE: berberine bridge enzyme). A double arrow signifies 
where multiple enzymatic reactions are responsible for conversion. Scheme adapted from Hagel 
et al.1 
 
1.1.2 The Pictet-Spengler reaction  
The first-committed intermediate in the biosynthetic pathway to BIAs is currently known 




































































between two tyrosine (4) derived molecules, dopamine (5) and 4-
hydroxyphenylacetaldehyde (6) (Scheme 1.1). The Pictet-Spengler reaction was first 
reported by Amè Pictet and Theodor Spengler in 1911 and can be considered as an 
intramolecular version of the Mannich reaction.8 The reaction involves an intramolecular 
cyclisation reaction between a b-phenylethylamine and an aldehyde or ketone. First, 
the amine and the aldehyde condense to give an iminium ion, followed by electrophilic 
addition of the aromatic system to the iminium ion, with aromaticity regained by 
deprotonation. The reaction is advantageous for the generation of significant molecular 
complexity in a single reaction step as a new ring and two bonds (C-C and C-N) are 
formed. The reaction is generally performed chemically under acidic conditions and a 
representative scheme of the reaction is given below (Scheme 1.2). 
 
Scheme 1.2: The general reaction pathway of the Pictet-Spengler reaction.  
 
1.2 Norcoclaurine Synthase 
All BIAs have the common precursor, (S)-norcoclaurine (7), which is generated by a 
Pictet-Spengler reaction between two tyrosine-derivatives, dopamine (5) and 4-HPAA 
(6) (Scheme 1.3). The selectivity is generated by the Pictet-Spenglerase, norcoclaurine 
synthase (NCS). The role of a Pictet-Spengler reaction in BIA biosynthesis was initially 


































* represents the new chiral centre formed
 30 
 
Scheme 1.3: The biosynthesis of (S)-norcoclaurine. The THIQ moiety generated is shown 
in red.  
 
Initial feeding studies for the discovery of the first committed intermediate in BIA 
biosynthesis, involved the BIA-producing opium poppy (Papaver orientale). Isotopically-
labelled 14C-tyrosine (4) was incorporated into both aromatic rings and labelled 14C,3H-
dopamine (5) was found to be incorporated into norlaudanosoline (15) and 
norlaudanosoline-1-carboxylic acid (14).10 Therefore, it was proposed that a Pictet-
Spengler reaction between dopamine (5) and 3,4-hydrohydroxyphenylpyruvate (13) 
occurred, followed by a decarboxylation of norlaudanosoline-1-carboxylic acid (14) to 
give norlaudanosoline  (15) (Scheme 1.4). Complementary incorporation experiments 
into P. somniferum have also been performed by Battersby et al.11  
 
Scheme 1.4: Proposed biosynthetic pathway to give norlaudanosoline. This route was 
hypothesised by Wilson et al.10 based upon feeding studies.  
 
The Pictet-Spenglerase involved in this first step was identified in 1981 by Rueffer et 
al.12 Kinetic isotope effect experiments on the enzyme-containing extracts of ten 
different BIA-producing plants identified an enzyme that formed norlaudanosoline (15) 
by a Pictet-Spengler reaction between dopamine (5) and 3,4-















































(13) which was previously proposed by Wilson et al.10 No incorporation of 3,4-
hydrohydroxyphenylpyruvate (13) was observed, leading to the assumption that the 
condensation observed may be chemical rather than enzymatic. Feeding studies 
showed the acceptance of 4-HPAA by the enzyme and the stereochemistry of the C-1 
centre (Scheme 1.4) was realised by circular dichroism of isolated norlaudanosoline 
(15) compared with standards of known absolute configuration.12 
 
Further feeding studies by Schumacher et al. in 1983 confirmed the lack of 
incorporation of phenylpyruvates and the incorporation of 4-HPAA (6) and 3,4-DHPP 
(13) as the carbonyl substrate.13 However, analysis of the results by Stadler et al. 
suggested that the two tyrosine-derivatives incorporated differ from one another as 
dopamine was not incorporated into the benzylic portion of norlaudanosoline (15) ; i.e. 
the biosynthesis of one of the substrates is not via the same biosynthetic pathway as 
the other.14 Feeding studies involving labelled (R) or (S)-norcoclaurine showed the 
specific incorporation of the (S)-enantiomer into cocolaurine (8), reticuline (9) and 
thebaine, an opiate alkaloid which is structurally similar to morphine (1). This therefore 
suggested that (S)-norcoclaurine (7) was the first committed precursor in BIA 
biosynthesis and the Pictet-Spenglerase involved was renamed (S)-norcoclaurine 
synthase (NCS).14  
 
1.2.1 Isolation and characterisation of norcoclaurine synthases  
The first wild-type NCS was isolated from a member of the poppy family, Eschscholzia 
tenuifolia in 1983.13 The enzyme was found to be a 15.5 kDa protein with pH and 
temperature optima of 7.8 and 40 oC respectively. A non-enzymatic, racemic, 
phosphate-catalysed background Pictet-Spengler reaction was also noted, the full 
potential of which was not realised until recently.15 In 2001, Samanani et al. isolated 
NCSs from three different BIA-producing plants; Thalictrum flavum (common meadow-
rue), Eschscholzia californica (California poppy) and Papaver somniferum (opium 
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poppy).  It was found that the optimal temperature for NCS activity for the three 
enzymes was between 42 and 55 oC and the optimal pH for the reactions was between 
6.5 and 7. The enzyme also exhibited sigmoidal saturation kinetics for dopamine with 
4-HPAA at saturating substrate concentrations, indicating that there is positive co-
cooperativity between substrate binding sites, i.e., the binding of 4-HPAA increases 
dopamine binding. Based upon analysis of other enzymes with similar substrate 
binding, the authors suggested that NCS has a regulatory role in BIA biosynthesis and 
is involved in controlling the flux of the biosynthetic pathway.16  
 
The genes encoding for TfNCS (isolated from Thalictrum flavum) were identified in 
2004, leading to the first recombinant expression of the enzyme in E. coli. Constructs 
with N-terminal truncations (10 or 19) and a C-terminal hexahistidine tag (His-tag) were 
successfully expressed and shown to retain typical NCS activity. The first 19 N-terminal 
residues were identified to be a signal peptide, suggesting that NCS is located in a 
subcellular compartment.17 Indeed, studies of the subcellular localisation of dopamine 
and related alkaloids in Papaver bracteatum have indicated that dopamine is 
predominantly located within a ‘vacuolar’ compartment.18 The sequence similarity of 
NCS to other proteins was also explored. Significant similarity to the Bet v 1 allergen 
and PR10 proteins was noted, however, there was no similarity to any other known 
Pictet-Spenglerases such as strictosidine synthase and deacetylipecoside 
synthase.17,19 
 
To date, NCSs have been identified in several BIA-producing plants, expressed 
recombinantly and the activities studied.20 The two variants that are mostly widely 
explored are TfNCS and CjNCS2 (isolated from Coptis japonica).21,22 A multiple 
sequence alignment of CjNCS2 and TfNCS is shown in Figure 9.56. 
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1.3 Structural and mechanistic investigations of norcoclaurine synthase  
1.3.1 Preliminary kinetics experiments 
Initial substrate saturation kinetics experiments of TfNCS performed by Samanani et al. 
indicated that hyperbolic saturation kinetics are observed upon 4-HPAA (6) addition, 
i.e., saturation of the enzyme is observed at high substrate concentrations, in the 
absence of the other substrate. Sigmoidal saturation kinetics were observed with 
dopamine, indicating positive cooperativity, i.e., the affinity of binding of dopamine (5) 
to another binding site is increased upon binding of 4-HPAA (6). These results 
therefore, suggested that 6  binds to the NCS active site before dopamine (5) and that 
there are possibly multiple ligand binding sites.16,23 
 
The first complete purification and mechanistic investigations of TfNCS were performed 
by Luk et al. in 2007. Recombinant protein was expressed in E. coli and purified by 
affinity chromatography.24 Circular dichroism (CD) and 1H-NMR based kinetic assays 
were used to elucidate the mechanism of action. It was hypothesised that the reaction 
would proceed via either a direct cyclisation (Route 1, Scheme 1.5) or a spirocyclic 
intermediate (Route 2, Scheme 1.5).  
 
Scheme 1.5: Two possible NCS mechanisms proposed by Luk et al. (redrawn from Figure 
3).24 Route 1 (blue) proceeds via a quinone intermediate which is deprotonated to regain 
aromatisation. Route 2 (red) proceeds via a spirocyclic intermediate which undergoes a semi-
























































Various analogues of dopamine were tested as substrates and the para-hydroxyl was 
shown to be non-essential for a successful enzymatic reaction, leading to the 
conclusion that the reaction proceeds via Route 1 (Scheme 1.5). In both proposed 
routes, deprotonation of 5-H in dopamine (5) is essential to regain aromaticity and 
generate the product. A kinetic isotope effect was observed when comparing reaction 
rates between using unlabelled dopamine (5) and [3,5,6-H2]-5, thus suggesting that the 
rearomatisation step is partially rate determining.24 Subsequent product inhibition 
kinetics experiments also suggested that the conformations of the enzyme upon 
aldehyde or product binding differ, eluding to structural changes of the enzyme during 
the mechanistic process. The presence of a CD signal when monitoring the progress 
of the reaction also confirmed that the NCS reaction is stereoselective, as previously 
observed by Stadler et al.14  
 
1.3.2 Nuclear magnetic resonance studies  
The first structural studies of TfNCS were performed by nuclear magnetic resonance 
(NMR) spectroscopy. NCS had previously been shown to have high sequence similarity 
with the Bet v 1 allergen family of proteins.25 Comparison of the CD spectra of TfNCS 
and a Bet v 1 protein (PDB: 1BV1) suggested that the two proteins contained similar 
proportions of the same secondary structure elements. Therefore, a Bet v 1 protein was 
used as the template in structure determination.26 The enzyme was recombinantly 
expressed with a 19 residue N-terminal truncation (D19TfNCS), however, SDS-PAGE 
analysis of the isolated protein showed the presence of the desired construct with an 
additional degradation product, with a 29 residue N-terminal truncation (D29TfNCS).25 
Enzymatic activity was unaffected by this additional truncation, so NMR studies were 
performed with D29TfNCS. The results confirmed that NCS is structurally similar to 
PR10 and Bet v 1 proteins. Substrate binding assays were performed with dopamine 
(5) and methyl 4-hydroxyphenylacetate or 2-(4-hydroxyphenyl)ethanol (i.e. methyl ester 
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and alcohol analogues of the natural substrate, 4-HPAA (6)). 6 was not used due to 
issues of oxidative sensitivity, meaning that the substrate could not be obtained in 
sufficient purity.  
Upon dopamine binding, conformational shifts of residues 69-72 and 150-155 were 
observed and binding of both aldehyde analogues resulted in significant conformation 
changes across the entire protein. Unfortunately, this meant that the key active site 
residues involved in NCS catalysis, and the locations of substrate binding sites could 
not be identified. The Kd value of dopamine was found to be high (in the mM range), 
meaning that there is low affinity to the enzyme. Dopamine in BIA-producing plants has 
been shown to accumulate in vacuolar compartments, which could compensate for the 
low substrate binding affinity observed. Oligomerisation of the enzyme was also noted, 
with dimerisation observed at concentrations over 10 µM. Enzymatic activity was 
retained in the monomeric state during NMR studies at < 10 µM.26 
 
1.3.3 Initial crystallographic studies 
Although NMR studies had successfully identified the overall fold of NCS, the apparent 
dynamic nature of the mechanistic process hindered the identification of the key active 
site residues involved. The first crystallographic investigations of TfNCS were 
performed by Ilari et al.27 with D29TfNCS. A structure was gained at 2.1 Å (PDB: 2VQ5) 
with the enzyme complexed with dopamine (5), and a non-productive 4-HPAA (6) 
analogue, 4-hydroxybenzaldehyde, thus leading to the identification of catalytically 
relevant active site residues. The structure confirmed the PR10 fold of the enzyme and 
identified a 23.4 Å catalytic tunnel. The two ligands were built into the positive difference 
density observed in the active site, suggesting that the aldehyde binds first followed by 




Scheme 1.6: The ‘aldehyde-first’ mechanism. The mechanism was proposed based upon a 
crystal structure of TfNCS with dopamine (5) and a non-productive 4-HPAA (6) analogue bound 
in the enzyme active site. Redrawn from Figure 6 of Ilari et al.27 
 
In the proposed mechanism, the aldehyde is held in the enzyme active site by a 
hydrogen-bonding interaction between the aldehyde carbonyl and K122. Dopamine (5) 
then binds to the active site and there is a nucleophilic attack of the amino group onto 
the aldehyde carbonyl, leading to condensation of the two substrates and iminium ion 
formation. The iminium ion then reorientates so that it is in the correct orientation for 
intramolecular cyclisation via electrophilic attack of the catechol aryl ring to the iminium 




























































































1.3.4 Confirming the NCS mechanism  
Further analysis of the co-crystallised structure of TfNCS (PDB: 2VQ5)27 and 
computational docking experiments revealed mechanistic flaws with the ‘aldehyde-first’ 
mechanism.28 Fundamentally, the ligands modelled into the active site in the paper 
published by Ilari et al. did not fit the electron density map convincingly. Some enzymes 
are capable of retaining and / or exhibiting altered catalytic activity when crystalline, so 
with the first NCS structure (PDB: 2VQ5), it is possible that a combination of poor ligand 
occupancy, multiple ligand orientations or a mixture of different reaction intermediates 
was observed, thus resulting in poor difference density in the active site.29 The R-factors 
after refinement were also poor. The ‘aldehyde-first’ mechanism assumes that the 
aldehyde is buried in the active site which would not be possible for bulky aldehydes 
such as citronellal and napthylacetaldehyde for which NCS activity is observed.21,22 
Many of the aldehydes capable of turnover by NCS would furthermore not be able to 
form the interaction with D141 that was suggested as they lack the phenolic hydroxyl 
group. In addition, there was no evidence that the suggested rearrangement of the 
iminium intermediate would be possible, water is not basic enough to deprotonate the 
C-3 phenol of dopamine (and so a basic active site residue must be needed) and the 
hydrogen bond between the quinone intermediate and Y108 would not provide 
sufficient stabilization. Indeed, the enzyme is active without the presence of the C-4 
phenol so this interaction must not be involved.  
 
Subsequent crystallographic studies were used to support the ‘dopamine-first’ 
mechanism proposed from computational docking experiments.28,30 Initial crystallisation 
attempts with the D29TfNCS construct resulted in poor resolution datasets (3.5 – 4 Å) 
and it was hypothesised that the long C-terminal extension was preventing tight crystal 
packing.31 A novel construct was therefore designed, omitting residues 1-33 and 196-
210, to give just the globular fold. Enzymatic activity was retained, and this construct 
was used for crystallographic studies. Instead of attempting to bind substrates, a non-
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productive analogue of the iminium ion intermediate of a successful NCS reaction was 
synthesised and successfully co-crystallised with ∆N33C196TfNCS (PDB: 5NON, 1.8 
Å resolution). The mimic used was based upon the reaction between dopamine (5) and 
a non-productive analogue of 4-HPAA (6), 4-methoxyphenylacetaldehyde (4-MOPAA) 
to avoid issues of oxidative-sensitivity. Visualisation of the structure gained and the 
rationale for the design of the mimic is given in Figure 1.2. Upon mimic co-
crystallisation, the tertiary structure of NCS was conserved (PDB: 5NON, beige, Figure 
1.2c) compared with the apo structure (PDB: 5N8Q, blue, Figure 1.2c). There were 
some changes in the positions of amino acid side chains of key active site residues 
(e.g. E110, M183, D141, Y108, M97).  
 
 
Figure 1.2: Co-crystallised structure of TfNCS with an active site bound reaction 















grey.30 Amino acids 65-79 were removed to aid visualisation of the active site. Image was 
prepared using USCF Chimera.32 b) Rationale for mimic design, based upon the iminium ion 
intermediate of the Pictet-Spengler reaction between dopamine and a non-productive analogue 
of 4-HPAA (6). c) Overlayed apo (PDB: 5N8Q, blue) and holo (PDB: 5NON) structures of 
D33TfNCS.30 
 
The mimic-bound structure revealed two different binding modes of the ligand: 
productive and inhibitory. The productive mode has the meta-hydroxyl of the catechol 
of 16 hydrogen-bonded to K122, whereas in the inhibitory mode, the interaction is 
observed with the para-hydroxyl instead. The para-hydroxyl is non-essential for a 
productive reaction and so this binding mode will not lead to turnover by the enzyme.  
A revised, ‘dopamine-first’ mechanism considering these factors was proposed and 
confirmed through site-specific mutations at key active site residues; K122, E110, D141 
and Y108.  Further studies of the  mechanism and the enantioselectivity of the reaction 
have been performed using quantum chemical modelling.33 The investigations involved 
the two natural substrates, dopamine (5) and 4-HPAA (6). Both reaction pathways, 
‘aldehyde-first’ or ‘dopamine-first’, were shown to be accommodated in the enzyme 
active site but lower energy barriers were associated with the ‘dopamine-first’ pathway. 
The selectivity of the reaction was shown to be determined in the final step, whereby 
the quinone intermediate is deprotonated to yield the THIQ product (Scheme 1.5). In 
the pathway to give the (R)-norcoclaurine, the 4-hydroxybenzyl moiety would be held 
in an axial position, leading to an unfavourable steric clash with L72. The pathway to 
(S)-norcoclaurine avoids this interaction and, therefore, is favoured. The study also 
confirmed the key mechanistic roles of K122, D141 and E110. The current proposed 




Scheme 1.7: The currently accepted, ‘dopamine-first’ mechanism of NCS catalysis. The 
mechanism was proposed based upon computational docking28 and crystallographic30 studies. 
Hydrogen bonding interactions are shown by dotted lines.  
 
1.3.5 Further kinetics studies of NCS 
Preliminary kinetics experiments performed by Samanani et al.16,17,23 and Luk et al.24 
were performed in phosphate buffer, which is known to catalyse a racemic Pictet-
Spengler reaction so a high non-enzymatic background reaction was observed. More 
recent kinetics experiments were performed by Lichman et al.28 in HEPES buffer, with 
a minimal background reaction observed. Contradicting previous experiments, co-
operativity was not observed and at saturating levels of 4-HPAA (6) and varying levels 
of dopamine (5), values of kcat and Km were shown to be 24 s-1 and 22 mM, respectively, 

























































































therefore, demonstrated to have very low catalytic efficiency with kcat/Km = 1.1 s-1 mM-1 
whereas the median value for all enzymes is 125 s-1 mM-1.34 High substrate loading is 
therefore required for highly productive NCS reactions. 
 
Further attempts to understand the kinetics of the NCS mechanism have proved 
challenging due to the many intermediates involved.31 It is possible that several of the 
reaction steps could occur either inside or outside the active site; intermediates can 
diffuse in and out of the active site. Understanding is complicated by the possible 
isomers and protonation states of reaction intermediates. The racemic, background 
reaction observed has also complicated studies as saturating substrate concentrations 
cannot be used.31 
 
1.4 Substrate scope of norcoclaurine synthases 
1.4.1 Aldehyde substrate scope 
Expanding the substrate scope of NCS beyond that observed naturally is valuable for 
developing stereoselective syntheses of THIQs. The first attempts to expand the NCS 
substrate scope beyond dopamine (5) and benzylic aldehydes were performed by Ruff 
et al.21 and Pesnot et al.22 using two different NCSs, D29TfNCS and CjNCS2, 
respectively. Studies of D29TfNCS showed a versatile aldehyde substrate scope when 
using dopamine as the amine donor. A wide range of aldehydes, from those with bicyclic 
heterocyclic and linear aliphatic substituents were successfully turned over and THIQ 
products generated in high yields (most >50% after 3 h), although enantiopurities of the 
products were not determined. Alpha-substituted aldehydes, benzaldehyde and 1-α-
methyl-napthylacetaldehyde and small aldehydes, acetaldehyde and formaldehyde 
were not accepted.21 This led to the assumption that alpha-substituted aldehydes, 
generally are not accepted as substrates by TfNCS, rationalised as being due to the α-
carbon being deeply buried in the enzyme active site, leading to a lack of conformation 
freedom of the iminium ion intermediate.28 Subsequently, low activities of TfNCS with 
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benzaldehyde and cyclohexanecarboxaldehyde have been observed, however, 
product formation and enantioselectivity have not been verified.31 The D29TfNCS 
variant, L76A has been shown to modulate aldehyde acceptance. Compared with the 
wild-type enzyme, increased conversions were observed with both enantiomers of 
citronellal, and in particular were enhanced with the (S)-enantiomer and decreased 
conversions were observed with hexanal and 4-HPAA.28  
 
Similar activities were observed with CjNCS2 in studies performed by Pesnot et al., with 
a range of linear aliphatic and benzylic aldehydes being well-tolerated as substrates22 
and investigations demonstrated that the THIQ products were generated in high e.e.s 
(>95%)22,35 and low activities were also observed with alpha-methyl substituted 
aldehydes.35 The investigations by Nishihachijo et al. also revealed the acceptance of 
linear, aliphatic aldehydes by CjNCS2.35 The observed aldehyde substrate scopes of 
both variants are given in Scheme 1.8. 
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Scheme 1.8: The observed aldehyde substrate scopes of TfNCS and CjNCS2. A range of 
different C-1 substituted (S)-THIQs can be synthesised. Given in pink, are the aldehydes tested 
where no or trace conversions were observed. Given in yellow are aldehydes where very low 
conversions were observed.  
 
1.4.2 Expansion of the carbonyl substrate scope 
The carbonyl substrate scope of D29TfNCS has recently been expanded towards 
ketones, leading to the formation of chiral 1,1-disubstituted and spirocyclic THIQs.36,37 
Chiral synthetic routes towards these THIQs is challenging and has involved the use of 
chiral formamidine auxiliaries and titanium-catalysed acylations.38,39 A range of benzylic 
methyl ketones and cyclohexanone analogues were accepted, and the activity shown 
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observed with hydrophobic substrates and variants A79I and A79F, likely due to 
increased hydrophobic interactions. A diketone was also shown to be accepted, with 
different variants giving different ratios of mono- and disubstituted Pictet-Spengler 
product formed i.e. reaction at one or both of the carbonyl groups (Figure 1.3). Variants 
A79I and A79F favoured mono Pictet-Spengler product whereas F80L favoured 
diproduct formation.37 Assays involving CjNCS2 have shown that the enzyme does not 
accept ketones as substrates, and the lack of activity is still not understood. The key 
active site residues in TfNCS and CjNCS2 are mostly conserved, other than at position 
79 (A in TfNCS and I in CjNCS2) and there is an extra alanine in this loop (residues 76-
80) in CjNCS2.22  
 
Figure 1.3: Non-aldehyde carbonyl substrate scope of TfNCS explored to date.  
Several other NCS variants have also been explored. Mutations of M97 were 
investigated as the sidechain is thought to occupy space near to the iminium ion 
intermediate. It was hoped that reducing steric bulk and flexibility of the amino acid side 
chain (by mutation to leucine or valine) could result in increased conformational 
freedom of the iminium ion intermediate and thus improve substrate conversions. 
Unfortunately, these mutations resulted in a decrease in activity with hexanal and 
phenylacetaldehyde as aldehyde substrates.36 The use of DMSO as the reaction co-
solvent also resulted in a five-fold increase in activity compared with using acetonitrile, 
and it was hypothesised that this was due to altering the reaction equilibrium to favour 
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iminium ion formation and it is also possible that this may have simply aided substrate 
solubility.  
 
Several alpha-keto acids have also shown to be accepted as substrates for TfNCS and 
CjNCS2. 3,4-Dihydroxyphenylpyruvate (13) was initially hypothesised to be the natural 
carbonyl substrate, followed by decarboxylation to give (S)-norlaudanosoline (15).12 4-
Hydroxyphenylpyruvate has also been reported to be accepted as a substrate,  
however enzymatic reactions were performed in phosphate buffer which is known to 
catalyse a racemic Pictet-Spengler reaction.15 Activity has also been observed for the 
TfNCS catalysed reaction between dopamine (5) and a-ketoglutaric acid, although the 
product formed was not isolated.31 The carbonyl substrate scope of TfNCS beyond 
aldehydes is given in Figure 1.3.  
 
1.4.3 Amine substrate scope  
A narrow amine substrate scope has been observed for both TfNCS and CjNCS2. The 
meta-hydroxyl group of dopamine (5) is essential for catalytic activity and removal or 
methoxy- substitutions of the meta-hydroxyl group are currently not tolerated. These 
modifications are tolerated on the para-hydroxyl group. Minor substitutions on the alkyl 
region of dopamine are also tolerated to date, with metaraminol and norepinephrine 
accepted as substrates, although few analogues have been screened.  
 
1.5 Phylogenetic analysis of norcoclaurine synthase 
1.5.1 Proteins related to norcoclaurine synthase  
NCS has the most significant sequence similarity with the PR10 and Bet v 1 family of 
proteins. PR10 proteins are a sub-class of pathogenesis-related proteins which are 
upregulated by plants under stress. Despite a wealth of structural insights and the 
ubiquitous nature of the PR10 proteins, the in planta role is largely unknown.40 Bet v 1 
proteins are a subclass of the PR10 proteins with a high sequence similarity to NCS 
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(50 - 60%) and are widely studied due to the allergic response in around 25% of 
humans.41 
 
Enzymatic activity in proteins with a PR10 fold is uncommon. There are few known 
examples beyond NCS. A fungal enzyme involved in polyketide tetracenomycin 
aromatase/cyclase, biosynthesis has low sequence similarity to PR10 proteins, but the 
topology is remarkably similar.42 Two other enzymes involved in BIA-biosynthesis, 
neopinone isomerase (NISO) and thebaine synthase (THS) are also classified as 
PR10/Bet v 1-like proteins.43 
 
Recently, an enzyme involved in Amaryllidaceae alkaloid biosynthesis has been 
identified with high sequence identity to NCS (38% identity to TfNCS) considering that 
other NCS homologues also have this level of similarity to each other. The enzyme in 
question, norbelladine synthase (NBS), has been isolated from Narcissus 
pseudonarcissus and was shown to catalyse the condensation of tyramine (17) and 
3,4-dihydroxybenzaldehyde (18) to give norbelladine (19) as shown in Scheme 1.9.44 
 
 
Scheme 1.9: The biosynthetic role of norbelladine synthase (NBS). The enzyme 
synthesises norbelladine, the first committed intermediate towards the Amaryllidaceae alkaloids. 
 
The mechanism of NBS is thought to proceed via the condensation of the two 
substrates to form an iminium ion intermediate. No additional co-factors are required 
for a successful enzymatic reaction. However, 30 equivalents of aldehyde with respect 
to the amine are required in in vitro reactions, suggesting that the aldehyde (or hydrate) 
is acting as the reducing agent by providing a hydride source. It is unknown whether 

















NCSs are unique compared with other PR10 proteins due the presence of N- and C-
terminal extensions, which are suspected to be involved in subcellular localisation. NBS 
lacks N-terminal residues 1-41 compared with NCS and these residues have been 
shown to be non-essential for the catalytic activity of NCS.  
 
Recent phylogenetic analysis of N. nucifera, the sacred lotus, has identified two 
different subfamilies of NCS: NCSI and NCSII. NCSII genes are found in all plants 
whereas NCSI genes are only found in BIA-producing plants. It is hypothesised that 
NCSI genes have evolved from the duplication of NCSII genes. No recombinant 
proteins encoded for by NCSII genes have been isolated and characterised, so it is 
unknown whether they have any NCS- like activity. Some non-BIA producing plants 
have been shown to possess enzymes with similar activity to NCS, however, this has 
not been fully investigated.45,46 
 
1.5.2 The PR10 fold  
There have been structural investigations of numerous proteins within the PR10 family, 
and a common protein fold has been noted. The fold consists of a seven-stranded anti-
parallel b-sheet wrapped around a C-terminal a-helix, giving a ‘baseball glove – like’ 
framework. There are two additional alpha-helices located between the sixth and 
seventh N-terminal beta-sheet strands. A large (ca. 3900 Å3), internal hydrophobic 
cavity is also present, which is thought to be functionally relevant to many PR10 proteins 
and has been shown to be a ligand binding site.40 The common PR10 fold is given in 
Figure 1.4.  
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Figure 1.4: The common PR10 fold. The connectivity of the different secondary structure 
elements is given. b-sheets (arrows) and a-helices (cylinders) are connected by 9 loops 
(denoted L1-9). The N- and C- termini are given by circles. Adapted from Figure 2A of Fernandes 
et al.40 The tertiary fold is demonstrated by the fold of TfNCS given in Figure 1.2a, in the same 
colour scheme.   
 
1.5.3 Native NCS enzymes 
To date, several NCSs capable of catalysing a Pictet-Spengler reaction to give 
norcoclaurine have been identified and isolated. Those most extensively explored are 
those isolated from Coptis japonica and Thalictrum flavum, as previously mentioned 
and other variants in Argemona mexicana, Corydalis Saxicola and Papaver braceatum 
have been shown to be highly productive. However, the substrates scopes have not 
been investigated beyond the natural reaction.20 In all cases, (S)-norcoclaurine has 
been isolated from these plants and key active site residues in the NCSs are conserved, 
suggesting that all act by a similar mechanism.  
 
Nelumbo nucifera (sacred lotus) is an aquatic, BIA-producing plant found throughout 
Eastern Asia. The plant has been used in traditional medicine for centuries to treat 
cancers, bacterial infections and other illnesses.47 Identifying and isolating the active 
















amongst BIA-producing plants due to the apparent isolation of (R)-norcoclaurine from 
the seed embryo.48,49 (R)-Coclaurine and (S)-norcoclaurine (7) have also been isolated 
from the leaves of the plant by solvent extraction and chromatography and identified by 
NMR, optical rotations and melting point data.50 The biosynthesis of (R)-norcoclaurine 
is unknown, but it could arise from; the in vivo epimerisation of (S)-norcoclaurine (7), a 
non-enzymatic, racemic Pictet-Spengler reaction with selective transport and 
accumulation of each enantiomer in different parts of the plant or condensation by an 
(R)-selective Pictet-Spenglerase. Seven different genes encoding for NCS have been 
identified in the lotus and characterised into two different families: NCSI and NCSII. The 
genes of the NCSI subfamily are found in plants which express BIAs whereas the genes 
encoding for the NCSII subfamily are found in all plants.46  One of the NCSs noted was 
found to be of the NCSII subfamily and of the six in subfamily NCSI, two were found to 
be pseudogenes (i.e., non-functional copies of others) and so there are four different 
NCSs which may be responsible for the production of (R)-norcoclaurine. The enzyme 
designated NnNCS7 was found to be most significantly correlated with alkaloid content 
in the leaf in most cultivars. The paper gave no mention of alkaloid content in the seed 
embryo or which NCSs are most highly expressed there. Interestingly, unlike previously 
investigated NCSs such as TfNCS and CjNCS2, the lotus NCSs do not contain any 




1.6.1 Medicinal significance of tetrahydroisoquinolines 
The THIQ moiety is found in many pharmacologically relevant molecules which act on 
a range of different receptors. It is therefore known as a privileged scaffold, so there is 
an interest in developing a range of analogues for drug discovery efforts. A range of 
useful biological properties have been observed for drug candidates containing a THIQ 
scaffold, including anti-tubercular52, anti-cancer53 and anti-HIV50. The family of 
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molecules also includes tetrabenazine, which is used for hyperkinetic movement 
disorders and was the first drug marketed to treat Huntington’s disorder and Tourette’s 
syndrome.54 The THIQ, solifenacin is a widely prescribed antimuscarinic.55 Developing 
facile, economically-feasible synthetic routes towards THIQ is therefore highly valuable.  
 
When assessing the pharmacological properties of chiral molecules, it is important to 
determine the activities of both enantiomers as they may vary in terms of toxicity, 
potency and selectivity of receptors and rate of metabolism.56 For example, (S)-
norcoclaurine (7) has a higher inhibitory effect on epinephrine-induced platelet 
aggregation than the corresponding (R)-enantiomer.57 As many biologically-relevant 
THIQs contain one or more chiral centres, it is also important to be able to isolate each 
isomer so that the activities of each can be assessed.  
 
 1.6.2 Routes towards racemic THIQs 
There are several well-established synthetic routes towards racemic formulations of 
THIQs. The two most employed strategies are via a Pictet-Spengler reaction (discussed 
in Section 1.1.2) or a Bischler-Napieralski reaction. The Pictet-Spengler reaction is a 
single-step route involving the condensation between a phenethylamine and an 
aldehyde or ketone. Most often, the reaction is acid-catalysed, however, more recently 
a phosphate-catalysed reaction has been realised, leading to the synthesis of a range 
of C-1 substituted THIQs under mild conditions.15 The reaction proceeds via a two-step 
mechanism, whereby one phosphate bridges the iminium ion and the aromatic ring, 
both aiding the cyclisation reaction and deprotonating the transition state to regain 
aromaticity in the product. Another phosphate deprotonates the meta-hydroxyl group to 
increase the ring nucleophilicity and also reprotonates this hydroxyl during the 
cyclisation reaction.58 The phosphate-mediated reaction has also avoided the use of 
high temperature reactions when using ketones as substrates, conditions which also 
usually preclude the use of oxidatively-sensitive substrates such as catechols.59 The 
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main limitations of the racemic, chemical Pictet-Spengler reaction are the challenges of 
generating single regioisomer products and the requirement for a meta-hydroxyl group 
on the phenethylamine. Nucleophilic attack of the aryl ring π-system towards the 
iminium ion carbon can also proceed from the ortho or para position, so two 
regioisomers of product are generated. The ratio of the two regioisomers generated is 
dependent on the pH of the reaction media60 and the carbonyl substrate used.15 
Separation of the two regioisomers is challenging and can require preparative HPLC so 
is not feasible on larger scales. Interestingly, when performing the reaction between 
metaraminol and 2-bromobenzaldehyde, stereochemical control at the C-1 position was 
observed, with the (1S,3S,4R) product generated in >97% diastereomeric excess.61  
 
The Bischler-Napieralski reaction is an intramolecular electrophilic aromatic substitution 
reaction of an amide, leading to the formation of a dihydroisoquinoline.62 This can be 
followed by a reduction to give the THIQ scaffold (Scheme 1.10). The Bischler-
Napieralski reaction requires a strongly dehydrating Lewis acid, most often phosphorus 
oxychloride (POCl3). Although generating a multi-step strategy is required to generate 
the THIQ scaffold, regioselective control is achieved and only the para-isomer of 
product is normally generated.  
 
 
Scheme 1.10: The general synthetic route to generate the THIQ scaffold when a Bischler-
Napieralski reaction is involved.  
 
1.6.3 Chemical routes towards single enantiomer tetrahydroisoquinolines 
The synthesis of the THIQ scaffold with a Pictet-Spengler or Bischler-Napieralski 
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synthetic strategies, stereochemical control can be achieved. Asymmetric Pictet-
Spengler reactions can be performed using a chiral Brønsted acid catalyst63, 64 or a 
chiral auxillary.65 If a chiral hydrogenation catalyst (usually rhodium, iridium or 
ruthenium-based) is used for the reduction step, single regioisomer and enantiomer 
THIQs can be generated via a Bischler-Napieralski route. Although many synthetic 
routes towards single isomer THIQs have been reported, there are no general routes 
that can be applied to all substrates.66 
 
1.6.4 Biocatalytic routes towards single isomer tetrahydroisoquinolines  
Biocatalysis is being increasingly employed for single enantiomer syntheses, with 
enantiopurity generated via either the kinetic resolution of a racemic formulation or 
stereochemical control when a new chiral centre is generated in a reaction. Enzymes 
are advantageous over traditional synthetic methods as reactions are performed under 
mild conditions and they often exhibit exquisite stereoselectivity. However, high reaction 
selectivity can go ‘hand in hand’ with narrow substrate scopes, poor versatility and the 
discovery of novel enzymes is challenging and requires significant research efforts. 
However, as the repertoire of known enzymes and their sequences increases, these 
challenges are diminishing, and a large range of chemical transformations can be 
performed using recombinantly expressed enzymes.  
 
As discussed in Section 1.4, TfNCS is a versatile catalyst and can generate a wide 
range of C-1 substituted, (S)-THIQs in high yields and e.e.s. Many carbonyl substrates 
are accepted, however the meta-hydroxyl group on the phenethylamine is required for 
a successful reaction to occur and only the (S)-enantiomer of product can be generated 
to date. There are also other biocatalytic routes towards THIQs.  
 
Monoamine oxidases (MAOs) catalyse the oxidation of an amine to an imine. A kinetic 
resolution of the amine is performed, with one stereoisomer of the amine preferentially 
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oxidised. The imine can then be reduced in situ to regenerate the racemic amine and 
over time, this leads to the accumulation of a single enantiomer of amine, of opposing 
stereochemistry to the amine oxidised by the MAO. One MAO has been developed by 
Ghislieri et al.67 which accepted racemic THIQs. The enzyme was developed using a 
combination of structure-guided engineering and high-throughput screening. The novel 
enzyme was used to generate (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline, the main 
synthetic precursor of solifenacin succinate in 90% yield and 98% e.e. (Scheme 1.11). 
Although a highly productive reaction was observed, there is a synthetic requirement to 
generate the racemic THIQ precursor and the substrate scope with other THIQs has 
not yet been explored. Moreover, as an oxidising enzyme, oxidatively sensitive 
substrates cannot be used. 
 
Scheme 1.11: The generation of (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline using an 
engineered MAO. The in situ reduction of the imine formed results in the accumulation of the 
THIQ enantiomer that is not oxidised by the MAO. 
 
An alternative approach is the reduction of imines. Instead of using a chiral 
hydrogenation catalyst, the stereoselective reduction of a dihydroisoquinoline to a THIQ 
can be performed using an imine reductase. A number of imine reductases have been 
explored and are capable of generating THIQ products in high e.e.s.68–71 The reported 
substrate scopes are, however, limited to either no or methoxy substituents on the 
phenyl ring; i.e. no oxidatively sensitive hydroxyl groups are tolerated, and there is the 
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Two other enzymes have potential for generating single-enantiomer THIQs, although 
both have not been widely explored. Firstly, the reticuline epimerase enzyme (REPI or 
STORR) which is responsible for the inversion of stereochemistry at the C-1 position of 
(S)-reticuline (9) to (R)-reticuline (21).7,72 REPI was the final enzyme to be isolated in 
the biosynthetic pathway towards opiate alkaloids and has since led to the in vivo 
production of morphine in yeast.73 The enzyme is a cytochrome P450 fusion protein 
with two domains; 1,2-dehydroreticuline synthase (DRS) oxidises (S)-reticuline (9) 
towards, 1,2-dehydroreticuline (20) and 1,2-dehydroreticuline reductase (DRR) 
reduces the iminium ion to give (R)-reticuline (21). A range of O- and N-methylated 
analogues of 9 have been investigated as substrates, for REPI, DRS and DRR. The N-
methyl group is essential for catalytic activity and various methylation patterns on the 
O-heteroatoms are tolerated. No structural studies of the enzyme have been performed 
and the mechanism of action is unknown. This information would be valuable to develop 
variants via structure-guided mutations to lead to an enzyme capable of generating the 
(R)-analogues of THIQs synthesised by an NCS-mediated synthesis. The reaction 
pathway of REPI is given in Scheme 1.12.  
 
 
Scheme 1.12: The reaction pathway of the reticuline epimerase enzyme.  
Another enzyme that may be valuable in generating single enantiomer THIQs is the 
berberine bridge enzyme (BBE). The enzyme catalyses an intramolecular carbon-
carbon bond forming reaction between the N-methyl group of (S)-reticuline (9) and the 
aryl ring, forming a new six-membered ring to give (S)-scoulerine (11, Scheme 1.1). 
This gives the tetracyclic berberine scaffold, the formation of which is essential in the 
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Structural evidence for the mechanism has been gained from a crystal structure of the 
enzyme with (S)-reticuline (9) bound in the enzyme active site.74,75 The enzyme requires 
a flavin (22) as a co-factor for substrate turnover and the proposed mechanism of action 
is given in Scheme 1.13.  
 
Scheme 1.13: The proposed reaction mechanism of the BBE. Interestingly, the reaction is 
proposed to proceed via the loss of a hydride leaving group which is incorporated into the flavin 
co-factor. Adapted from Scheme 1 of Winker et al.74 The co-factor is regenerated by reaction 
with molecular oxygen, giving hydrogen peroxide. Co-factor re-oxidation was measured using a 
stopped-flow instrument.   
 
The reaction is initiated by the deprotonation of the meta-hydroxyl of 9 by E417, leading 
to a carbon-carbon bond forming reaction and the incorporation of the hydride leaving 
group into the flavin co-factor (22). Rearomatisation gives the final product, (S)-
scoulerine (11) and the flavin co-factor (22) is regenerated by oxidation with molecular 
oxygen. The substrate scope of heterologously expressed BBE (in Pichia pastoris) 
from Eschscholzia californica has been explored. The N-methyl group is essential for 
catalytic activity and various methylation patterns on the aryl rings are tolerated and 



















































enzyme is selective for substrates with (S) stereochemistry at the C-1 position, a feature 
which has been exploited to give a range of (R)-benzylisoquinoline derivatives.76 The 
regioselectivity of the ring closure step can also be inverted when fluorinated substrates 
are used.77 
 
1.7 Other Pictet-Spenglerases 
NCS is not the only Pictet-Spenglerase enzyme, many others have been identified as 
performing a key biosynthetic role in alkaloid production. Pictet-Spenglerases are 
lyases (EC 4) but there is no dedicated sub-class. This section discusses other known 
Pictet-Spenglerases, their biosynthetic roles and their biocatalytic applications. The 
natural substrate scopes of the known Pictet-Spenglerases, with the products 
generated are given in Figure 1.5.  
 
Figure 1.5: The natural substrate scopes of known Pictet-Spenglerases. Each segment 
corresponds to an enzyme, which condenses a b-arylethylamine (inner circle) and a carbonyl-
containing substrate (middle circle) to give the product (outer). Protein structures, where known, 
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1.7.1 Strictosidine synthase 
Strictosidine synthase (STR) catalyses the Pictet-Spengler reaction between 
tryptamine (23) and secologanin (24) to form 3-a(S)-strictosidine (25), the biosynthetic 
precursor to monoterpenoid indole alkaloids.78 There are over 2,000 different 
monoterpenoid indole alkaloids (MIAs), many of which have important medicinal 
activities, such as quinine (anti-malarial), camptothecin (anti-tumour agent) and 
ajmaline (anti-arrhythmic).79 Two STRs have been most extensively characterised, 
isolated from Rauvolfia serpentia (RsSTR) and Catharanthus roseus (CrSTR).80,81 
 
The mechanism of action was elucidated by Maresh et al.82 in 2008. A crystal structure 
of recombinant RsSTR co-crystallised in the presence of the two natural substrates, 
secologanin (24) and tryptamine (23) was solved. The structure of STR is unusual, 
being the first example of a b-propeller protein found in the plant kingdom.81 
Mutagenesis identified the key active site residues as E309, Y151 and H307. Kinetic 
isotope effects and pH dependence of the reaction suggested that formation of the 
iminium ion intermediate is acid-catalysed and that the final deprotonation step is base-
catalysed. Ab initio calculations have indicated that the reaction mechanism does not 
go via a spiroindolenine intermediate (similar to that initially suggested for the NCS 
reaction, Scheme 1.5).82 
 
The amine donor substrate scope is not limited to tryptamine and screens have been 
performed with wild-type and mutated STRs.83–85 Analogues with hydroxyl and methoxy 
groups at C-5 and C-6 respectively of tryptamine (23) were accepted.86 Activity was 
also retained when the tryptamine benzene ring was substituted for a pyridine moiety 
or if the pyrrole ring of 23 was exchanged for a furan ring.87 The aldehyde substrate 
scope has also been altered using active site mutants.85,86,88  
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Despite these successes, recombinant expression and isolation of STRs has proven 
challenging. A recent paper by Pressnitz et al. improved the expression and activity of 
clarified cell lysates 100-fold via optimisation of the expression protocol and removal of 
signal peptides.89 Interestingly, a variety of non-natural, aliphatic aldehydes have been 
accepted by four different STRs to give single enantiomer products with (R)-
stereochemistry at the C-1 position. This led to the enantioselective chemoenzymatic 
synthesis of (R)-harmicine (via the condensation of 23 and 26), in an analogous method 
to the synthesis of trolline-derivatives using TfNCS (Scheme 1.14).89 Rationale for the 
inversion of configuration was gained from a combination of molecular dynamics 
studies and a crystal structure of OpSTR (isolated from Ophiorrhiza pumila) with a non-
productive reaction intermediate analogue bound in the active site, using an analogous 
design to the mimic used to probe the NCS mechanism.30,90 The structure shows the 
substrates binding in an inverted manner compared to reactions performed with the 
natural substrates.   
 
Scheme 1.14: Two-step, chemoenzymatic synthesis of (R)-harmicine 
 
STR has also been employed in the stereoselective synthesis of N-substituted 
strictosidine derivatives as novel topoisomerase inhibitors and other alkaloids via 






























1.7.2 Deacetylipecoside synthase 
Two different Pictet-Spenglerases have been identified in Alangium lamarckii with the 
ability to condense dopamine (5) and secologanin (24). Deacetylipecoside synthase 
(DIS) forms the (R)-enantiomer at C-1, while deacetylisoipecoside (DIIS) forms the (S)-
enantiomer (Figure 1.5). Both undergo spontaneous lactamisation followed by 
subsequent enzymatic modifications to give alangiside and isoalangiside-type 
glucosides respectively. DIS has been successfully isolated and purified from A. 
lamarckii and found to be 30 kDa in molecular weight, however, DIIS was found to be 
too labile for purification.92 
 
1.7.3 Bacterial Pictet-Spenglerases  
Five different bacterial Pictet-Spenglerases have been identified; McbB, NscbB, 
mikimopine synthase, cucumopine synthase and the SfmC module of the non-
ribosomal peptide synthetase (NRPS). The enzyme McbB has been found to perform 
the Pictet-Spengler reaction between L-tryptophan (28) and oxaloacetaldehyde (29) to 
give 30 (Figure 1.5). Subsequent oxidation and decarboxylation steps give a b-
carboline scaffold, found in many pharmacologically active molecules including 
benzodiazepine inverse agonists.93,94 The enzyme has been shown to accept the non-
natural substrates, 5-methyl-DL-tryptophan, 7-methyl-DL-tryptophan and smaller 
aldehydes such as methylglyoxal, formaldehyde, acetaldehyde, propanal and 
isobutyraldehyde instead of oxaloacetaldehyde.  The co-crystallised structure of McbB 
with L-tryptophan was obtained by Mori et al. in 2015. The active site is formed by a 
homodimerisation where each monomer adopts a slightly different conformation. The 
catalytically important active site residues have been determined and site-directed 
mutagenesis resulted in the formation of various active mutants. Mutations of two bulky 
residues, H87 and R72, located at the entrance of the active site, to alanine lead to the 
acceptance of the unnatural aldehyde, phenylglyoxal.94 
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NscbB (identified in Nocardiopsis synnemataformans, derived from a kidney transplant 
patient) catalyses the Pictet-Spengler reaction between L-tryptophan (28) and 
methylglyoxal (31) to give 1-acetyl-3-carboxy-b-carboline (30) i.e., the same reaction 
as with McbB (Figure 1.5). Both enzymes have high sequence identity (66%) and 
similarity (80%) with a conserved active site residue E97 suggesting that that both 
operate via similar reaction mechanisms. NscbB has ca. a 30 fold higher kcat/KM than 
McbB, but NscbB is less thermally stable.95 
 
Mikimopine (32) and cucumopine (33) are opines, formed via the Pictet-Spengler 
condensation of histidine (34) and a-ketoglutaric acid (35) (Figure 1.5). Opines are 
found in plant tumours induced by the parasite, Agrobacterium. The T-DNA encoding 
for the enzymes responsible for opine biosynthesis are passed to the plant via 
horizontal gene transfer. Opines are then synthesised by the plant cells and provide 
carbon and nitrogen sources for the invading bacteria. There has been little 
characterisation of the two enzymes; however, the genes encoding mikimopine 
synthase have been isolated from A. rhizogenes and both enzymes have been 
expressed recombinantly in E. coli and enzymatic activity confirmed.96–98 Interestingly, 
the carbonyl substrate is an 𝛼-ketoacid, whereas other Pictet-Spenglerases typically 
have an aldehyde as the natural substrate.  
 
Stnk2 is a Pictet-Spenglerase involved in the biosynthesis of streptonigrin, an alkaloid 
antibiotic with antitumor activity and it has high sequence identity with McbB (41%). The 
enzyme performs a stereospecific reaction between (2S,3S)-b-methyl-tryptophan (36) 
and D-erythrose-4-phosphate (37), with the newly formed chiral centre in the (R)-
configuration (38) (Figure 1.5). (S)-Stereochemistry at C-3 in tryptophan is essential for 
its reactivity. The aldehyde substrate scope is limited: methylglyoxal (31) and ethyl 
glyoxalate were not accepted. Interestingly, several fluoro-substituted L-tryptophan 
analogues were accepted, and improved affinity was observed with 5- and 6-fluoro-
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(2S,3S)-β-methyl tryptophan compared to the natural substrate. This is, therefore, a 
promising strategy towards generating fluorinated analogues of streptonigrin.99 
 
Finally, the NRPS SfmC module has been found to perform seven sequential reactions, 
including two Pictet-Spengler condensations in the biosynthesis of Saframycin C, an 
anti-tumour antibiotic with a THIQ scaffold.100 
 
1.7.4 Fungal Pictet-Spenglerases 
Comparative genetic analysis has been used to identify a silent Pictet-Spenglerase in 
the fish-derived fungi, Chaetomonium globosum. It was found that 1-methyl-L-
tryptophan can upregulate the expression of the Pictet-Spenglerase which results in the 
condensation of 1-methyl-L-tryptophan (39) with the aldehyde, flavipin (40) (Figure 1.5). 
The product is then altered by other fungal enzymes to give a novel class of alkaloids 
the ‘chaetoglines’(41-44) and pharmacological activities have been assessed.101 Two 
have anti-bacterial activities and another acts as an inhibitor of acetylcholinesterase.102 
 
1.7.5 Salsolinol synthase 
Salsolinol  has gained significant interest due to links with Parkinson’s disease and 
alcoholism.103 It is a THIQ alkaloid, formed by the condensation of dopamine (5) and 
acetaldehyde (45) (Figure 1.5). Higher levels of (R)-salsolinol have been found in the 
human brain, than the (S)-enantiomer based on chiral HPLC studies,104,105 suggesting 
that salsolinol is formed enzymatically.106  An enzyme, isolated from Rattus norveticus, 
has been overexpressed recombinantly in PC21 cells and expression correlated with 
an increased production of salsolinol. Chiral HPLC analysis of isolated salsolinol formed 
gave an e.e. of 20% (R-isomer).107  
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1.7.6 Putative Pictet-Spenglerases 
THIQ alkaloids with an isobutyl group at C-1 (lophocereine (47)) have been isolated 
from L. schotti, a desert cactus (Figure 1.6).108,109 No other naturally-occurring THIQs 
with an aliphatic group at the C-1 position have been identified. Feeding studies have 
suggested that both leucine and mevalonic acid are precursors to 47. It is however 
known that leucine is not incorporated via mevalonic acid.110,111 Although the enzymes 
present in L. schottii have not been identified, 3-methylbutanal was also incorporated 
during feeding studies suggesting that 47 may be formed by a Pictet-Spenglerase.112,113 
 
Figure 1.6: THIQ alkaloids isolated from plants with unknown biosynthetic origins.  
 
A range of enantiopure 1-phenyl-tetrahydroisoquinolines, known as the cryptostylines 
(48-50), have also been isolated from two species of orchid. In one species, Cryptostylis 
erythroglossa, only the (R)-enantiomer was isolated and in C. fulva, only the (S)-
enantiomer was isolated (Figure 1.6).114–116 The apparent enantiopurity of the isolated 
alkaloids suggests that the biosynthesis is enzymatic, likely via an epimerase or a 
Pictet-Spenglerase.   
 
1.8 Synthetic biology routes towards THIQ syntheses 
1.8.1 Biocatalytic cascades in vitro 
NCS is a versatile biocatalyst, capable of generating a range of C-1 substituted THIQs 
beyond the natural product, (S)-norcoclaurine. Cascade processes involving NCS and 
other biocatalysts to generate THIQs are an attractive route to avoid the use of 
oxidatively-sensitive aldehydes as substrates and to generate further molecular 



























environmentally benign production of a range of small molecules, containing the 
pharmaceutically relevant THIQ moiety. Both natural and unnatural THIQs can be 
generated in this manner, whilst avoiding the challenges of isolating compounds from 
the natural environment, where active components are often produced in low yields 
alongside other, structurally similar metabolites.  
 
There are two examples of NCSs being employed in chemoenzymatic cascades, i.e., a 
cascade process involving both chemical and biocatalytic steps. (S)-
Tetrahydroprotoberberine (THPB) alkaloids have been generated in a one-pot cascade 
involving three reaction steps. Firstly, a transamination reaction was performed with a 
phenethylamine (meta-tyramine (51) or dopamine (5)), to convert half of the amine into 
the analogous aldehydes, 52 and 18, respectively. The amine and analogous aldehyde 
were then condensed via an NCS-mediated Pictet-Spengler reaction to give a 1-benzyl-
THIQ (53 and 15). Finally, a phosphate-catalysed, racemic Pictet-Spengler reaction 
was performed between the 1-benzyl-THIQ and formaldehyde, giving the tetracyclic, 
tetrahydroprotoberberine scaffold (54 and 55). Products were generated in high isolated 
yield (up to 86%) and e.e. (99%) (Scheme 1.15).117 
 
Scheme 1.15: Chemoenzymatic cascades involving TfNCS. Routes were reported by 
Lichman et al.117 and Zhao et al.118 
Route towards (S)-tetrahydroprotoberberine alkaloids



































n = 1 (56), 2 or 3
NCS
Na2CO3
R = OH (5) or H (51)
R = H (52) or OH
5
n = 1 (58), 2, 3
n = 1 (57), 2 or 3
R = H (54) or OH (55)
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Another chemoenzymatic cascade involving NCS was used to generate (S)-trolline (58) 
(an alkaloid with anti-viral properties) and analogues.118,119 An NCS reaction was 
performed between a phenylethylamine (dopamine (5), metaraminol or fluorinated 
analogues) and a linear, aliphatic aldehyde with a terminal methyl ester (56), to give the 
THIQ scaffold (57). The addition of sodium carbonate led to the formation of a lactam 
ring, between the secondary amine of the THIQ and the methyl ester introduced from 
the aldehyde. The products generated in both chemoenzymatic cascades are given in 
Scheme 1.14.  
 
A range of natural and non-natural BIAs have also been generated in vitro, starting from 
L-tyrosine and analogues. Tyrosinases, decarboxylates, transaminases and NCS were 
utilised leading to the generation of a range of products in high yield (35-99% 
conversion) and high e.e.s (often >90%). This route is advantageous over in vivo routes 
as steps can be introduced which are not biologically-compatible, leading to greater 
range of possible structures generated.120 
 
1.8.2 Whole-cell approaches towards BIAs and related alkaloids 
Another route towards the production of alkaloids, involves a whole-cell approach 
whereby all suitable enzymes for a biocatalytic transformation are co-expressed in the 
same host. This strategy is attractive for industrial scale syntheses, especially when 
numerous enzymes are required, as this route avoids the recombinant expression and 
isolation of each biocatalyst. The alkaloids generated are also highly complex and no 
cost effective total synthetic routes have been developed.121 Due to the medicinal 
relevance of BIAs, there are a number of research efforts into developing routes for in 
vivo production.  
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Many of the challenges of using NCS in whole-cell BIA approaches are due the 
simultaneous production of racemic norcoclaurine, likely from a phosphate mediated 
background reaction. Early attempts towards BIA production bypassed the use of NCS 
and involved the production of (R,S)-norlaudanosoline towards (R,S)-reticuline and on 
to salutaridine, one of the key intermediates towards morphinan alkaloids, using 
Saccharomyces cerevisiae as the host.122 Following this study, (S)-reticuline was 
produced in Escherichia coli starting from dopamine, then subsequent modifications 
towards magnoflorine and scoulerine (11) were performed using S. cerevisae as many 
of the enzymes involved in the later stages of BIA biosynthesis are not very active when 
expressed in bacteria.123 (S)-Reticuline was produced to give a 11 mg L-1 culture 
volume, but this was later improved to give 54 mg L-1 when the NCS expression level 
was increased.124 The pathway has also been extended to start from L-tyrosine (4). A 
fermentative E. coli based system has been used generate (S)-reticuline (9), with a final 
yield of 46 mg L-1.125  
 
The steps from thebaine towards morphine (1), codeine and other opiate BIAs were 
developed by Thodey et al. in 2014 in S. cerevisiae and optimisation of the platform 
resulted in high titres of products, up to 131 mg L-1 of culture volume.126 The complete 
de novo production of (S)-reticuline in S. cerevisiae was completed in 2015,127 however, 
the complete biosynthesis of opioids in yeast was only possible with the discovery of 
the final enzyme in the biosynthetic pathway, the reticuline epimerase, which converts 
(S)-reticuline (9) into the corresponding (R)-enantiomer.7,72,128 Although low titres of 
product were achieved, the study provides a valuable starting point towards alternative 
routes for morphine (1) production, that avoid farming vast quantities of poppies.128 
Further development of an analogous system has led to the biosynthesis of noscapine 
and halogenated (S)-reticuline (9) derivatives in yeast using halogenated tyrosine 
analogoues.129 Recently, the yeast production of 9 has been achieved at high levels 
(more than 3 g L-1) by over 20 strain successive modifications on three metabolic 
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pathways, particularly by removing genes corresponding to redundant oxidoreductases 
which had thus far limited the production of the NCS substrate, 4-HPAA (6) which is 
highly oxidatively sensitive. Non-natural THIQs with aliphatic and benzylic substitutions 
at C-1 have also in 2019 been biosynthesised using a yeast strain engineered to 
maximise NCS activity.130 CjNCS2 has also been shown to be cytotoxic to S. cerevisiae, 
restricting the production of (S)-reticuline (9) in vivo and compartmentalization of NCS 
in the peroxisome helped to improve product titres.131 
 
1.9 Project Aims 
The overall aim of the PhD project was to further the understanding of the NCS reaction, 
and expand the accessible substrate scope of NCS, thus leading to the synthesis of 
novel alkaloids, either using the wild-type or variant constructs of TfNCS.  
 
When the project was started, significant efforts had been made to explore the natural 
substrate scope and mechanism of NCS. Most investigations had focused on TfNCS, 
with mechanistic studies previously performed by Dr. Benjamin Lichman (Ward and 
Hailes groups), in collaboration with Dr. Altin Sula (Keep group), involving 
computational docking, crystallographic investigations and the generation of a library of 
single- and double-point mutants of TfNCS. The substrate scope had also been 
explored and Dr. Daniel Méndez-Sánchez and Dr. Jianxiong Zhao (both Hailes group) 
were working on expanding the ketone substrate scope. Enzymatic cascade processes 
involving NCS, dehydrogenases, tyrosinases, regioselective O- and N-
methyltransferases and/or transaminases were being developed by other members of 
Hailes and Ward groups (Dr. Daniel Méndez-Sánchez, Dr. Jianxiong Zhao, Dr. Yu 
Wang, Dr. Fabiana Subrizi and Benjamin Thair).  
 
The aim of this project was to investigate the use of sterically crowded aldehydes, in 
particular, alpha-substituted aldehydes, as NCS substrates. The acceptance of the 
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benzaldehydes is of particular interest, to develop enantioselective routes towards 
novel (1S)-aryl-THIQs. Approaches to be explored include the screening of existing 
TfNCS variants and the rational design and screening of novel variants, with the design 
process guided by crystallographic investigations of TfNCS, with active site bound 
reaction intermediate mimics. Redesign efforts will also be focused towards switching 
the enantioselectivity of the NCS reaction to generate (R)-THIQs. Cascade processes 
will also be investigated to expand the range of (1S)-THIQs that can be generated via 
an NCS-mediated Pictet-Spengler reaction. Novel products generated can be isolated 
(by workup or preparative HPLC) and characterised by common analytical techniques, 
including NMR spectroscopy, mass spectrometry and chiral HPLC analysis to 
determine the structures and enantiopurities of the THIQs generated. Other avenues of 
investigation include structural studies of related Pictet-Spenglerases or NCSs isolated 








Chapter 2: Novel Biocatalytic Routes Towards 
Tetrahydroisoquinoline Alkaloids 
2.1 Introduction 
2.1.1 Generating novel biocatalysts  
Biocatalysts are enzymes or microbes that can be used in synthetic chemical 
transformations. As sustainability becomes increasingly relevant, biocatalysis is an 
attractive alternative to traditional synthetic methods as reactions are performed under 
mild conditions using aqueous media under ambient pressures and temperatures. 
However, one of the major limitations to the widespread applicability of biocatalysts in 
chemical syntheses is the lack of catalytic promiscuity. Enzymes are proteins that are 
evolved in nature to perform a specific catalytic role, often exhibiting high regio- and/or 
stereoselectivity so often the substrate scope of wild-type enzymes is limited. Enzymes 
may also exhibit poor stability and there are issues with reusability, although many of 
these shortcomings have been overcome by immobilization strategies. Therefore, to 
expand the possibilities of biocatalytic reactions, there are research efforts into the 
discovery of novel enzymes and into modifying known enzymes to alter their activities. 
As the number of known, sequenced enzymes with verified activities increases, new 
enzymes are rapidly discovered in newly sequenced genomes. Although the activities 
of each enzyme must be determined, this has expanded the portfolio of useful 
biocatalysts and enzymes are an increasingly viable alternative to traditional organo- 
and metallocatalysis.132 
 
Protein engineering technologies have also led to the expansion of the substrate 
scopes of enzymes. There are two main approaches; rational design and directed 
evolution. Rational design involves designing and screening novel variants based upon 
protein structures or homology models. The results from substrate screens help to 
guide further, iterative rounds of mutagenesis and screening, leading to the generation 
of enzymes with improved activities. The directed evolution of enzymes was pioneered 
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by Frances Arnold, leading to the award of the Nobel Prize in 2018.133 Directed evolution 
involves iterative rounds error-prone PCR (polymerase chain reaction). Each round 
generates a library of random mutants which are screened and at each stage, the most 
promising mutant is taken through to the next round. Both techniques have been used 
to develop enzymes with dramatically improved activities compared to the wild-type and 
enzymes have even been developed to form chemical bonds which are not known 
biologically.134,135 There are also efforts into the computational, de novo design of 
enzymes of which there have been many successes, although development times are 
long.136 However, as our understanding of how protein sequence relates to structure 
and function grows, de novo protein design may become an exciting area for the 
development of novel biocatalysts.  
 
2.1.2 Studies of NCS 
NCS is a useful biocatalyst, with the wild-type enzyme capable of generating numerous 
(1S)-THIQs. The products generated are relevant for drug discovery purposes and in 
many cases, there are no analogous chemical routes. To aid rationale design of the 
enzyme and increase the catalytic utility, various structural studies have been 
performed leading to significant mechanistic insights, as discussed in Section 1.3. 
However, there are still gaps in our understanding. For example, why the carbonyl 
substrate scope is so promiscuous i.e., the acceptance of ketones and aliphatic 
aldehydes and why activities vary between variants such as why ketones are accepted 
as substrates by TfNCS but not CjNCS2. The development of enzyme mutants has the 
benefit of both furthering understanding of the mechanistic process and potentially 
altering catalytic activity.  
 
Several NCS variants have been developed by a previous PhD student, Benjamin 
Lichman.31 Notable changes in activities were observed with a range of single point 
mutants of TfNCS. Mutations E110D, E110Q and K122L reduced catalytic activity by 
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>90%, indicating that the chain length, position, and functionality at these two positions 
are all essential for a successful reaction. Reactions with F112L had 10-20% of the 
activity compared with the wild-type for all tested substrates, A79I increased activities 
(20-50%) with hexanal, and 4-HPAA and L76A showed increased activities with 
citronellal, particularly with the (S)-enantiomer, but not with hexanal. For reactions with 
ketones, M97F and M97V showed lower conversions compared with the wild-type, A79I 
and A79F showed improved activities. A range of double mutants, swapping the 
locations of key active site residues, were also developed with the aim of altering the 
regioselectivity of the enzyme towards the ortho-product. However, only F112K-K122F 
and K122F-F112K were investigated and shown to generate the para-product.31 
 
Figure 2.1: Structure of D29TfNCS with key active site residues altered in previous studies 
shown in blue. The crystal structure shown was gained by Illari et al.27 (PDB: 5N8Q) and the 
figure was generated using USCF Chimera.  
 
Therefore, there is potential to further alter NCS activities through mutagenesis and 
there is scope to extend structural studies to NCS variants other than wild-type NCS. 
This chapter describes these attempts; the co-crystallisation of intermediate analogues 
with unnatural substrates or products, studying other enzyme variants and/or proteins 
 72 
with high similarity but differing activities, and the generation and screening of novel 
NCS variants. 
 
2.2 Results and discussion 
2.2.1 Expression and purification of D33TfNCS 
Successful crystallographic studies of TfNCS have been previously carried out, in which 
the ‘dopamine-first’ mechanism was confirmed by the co-crystallisation of a non-
productive reaction intermediate analogue with a construct consisting of predominately 
the globular fold, DN33C196TfNCS (herein referred to as D33TfNCS).30 As well as 
removing the N-terminal signal peptide (1-19), further flexible residues 20-33 and 196-
210 have been removed. Therefore, to investigate the activities of the wild-type enzyme 
for the reactions with non-natural substrates, the enzyme was first expressed and 
purified based upon the protocol published.30 
 
The expression and purification were straightforward, following the reported three-step 
procedure. Notably, the protein was first isolated by nickel-affinity chromatography 
(Figure 2.2a), followed by TEV cleavage to remove the His6 tag. To isolate the TEV-
cleaved protein and remove TEV protease, another nickel-affinity column was 
performed, followed by gel filtration to further purify the protein. Complete cleavage of 
His6-tag was achieved (lanes 2 and 3 of Figure 2.2b). SDS-PAGE analysis of the 
purification process is shown in Figure 2.2. Pure protein was isolated and concentrated 
to around 12-13 mg mL-1 ready for crystallisation trials. Multiple expressions and 
purifications of this construct of TfNCS were performed to generate enough protein for 















Figure 2.2: SDS-PAGE analysis of the purification of D33TfNCS. a. His-trap purification of 
∆33TfNCS at 20.7 kDa. Lanes: 1, Benchmark™ Protein Ladder masses given in kDa. 2, clarified 
cell lysate. 3, flow through with lysis buffer. 4, wash with 6 CV 20 mM imidazole buffer. 5, wash 
with 6 CV 40 mM imidazole buffer. 6-11, wash with 500 mM imidazole buffer and collected 4 mL 
fractions. b. His-trap purification of ∆33TfNCS to remove TEV protease and isolated TEV-
cleaved D33TfNCS at 18.1 kDa. Lanes: 1, Benchmark™ Protein Ladder, masses given in kDa. 
2, Pre-TEV cleavage sample (Lane 7 from gel 1, protein at 20.7 kDa) 3, sample loaded onto 
column. 4, flow through with lysis buffer. 5, 3 CV 20 mM imidazole. 6, 8 CV 20 mM imidazole. 7, 
2 CV 40 mM imidazole. 8, 5 CV 40 mM imidazole. 9 and 10, 2 CV 500 mM imidazole. 11, 5 CV 
500 mM imidazole. c. Gel filtration of ∆33TfNCS: gel of peaks isolated from major peak from 
Superdex S75 gel filtration. D33TfNCS is indicated by an arrow, at 18.1 kDa. Some dimerization 
of the protein was observed by SDS-PAGE (at 39.2 kDa). Lane 1: Benchmark™ Protein Ladder, 





2.2.2 Improving crystallographic resolution 
Initially, structural studies of TfNCS by NMR and X-ray crystallography were performed 
using a construct lacking the first 29 or 19 N-terminal residues, respectively.27 NCS is 
predicted to have signal peptides at the N and C-termini which are non-essential for 
catalytic activity. Although a high-resolution structure (2.1 Å) of D19TfNCS was 
achieved by Ilari et al. when crystallised in the presence of dopamine and 4-
hydroxybenzaldehyde (PDB: 2VQ5), the apo structure was gained at 2.7 Å (PDB: 
2VNE).27 Attempts by two previous PhD students, B. Lichman and A. Sula, to gain high 
resolution structures of the D29TfNCS construct with a C-terminal His-tag proved 
challenging, with apo structures gained at resolutions of around 3.5 to 4.0 Å. This 
suggested that the ten N-terminal residues removed were providing an interaction 
essential for tight crystal packing. The resolution gained was not sufficient to probe the 
NCS mechanism as the conformations of residue side chains could not be 
determined.31 A construct was developed with an N-terminal His-tag with a TEV-
cleavable linker, so that that His-tag could be removed, however little improvement in 
resolution was observed. A long C-terminal extension was noted during refinement, 
leading to the development of a novel construct, consisting of solely the globular fold of 
the protein, named DN33C196TfNCS (also referred to as D33TfNCS) removing 
residues in the terminal signal peptides, 1-33 and 196-210. The construct had an N-
terminal His-tag with a TEV cleavage site for removal of the His-tag, leading to a more 
globular fold.  
 
This construct led to high resolution apo structures (ca. 2 Å, PDB: 5N8Q) and a co-
crystallised structure (1.85 Å, PDB: 5NON) was gained with a non-productive reaction 
intermediate analogue, to mimic the natural NCS reaction. This structure was used to 
support the proposed ‘dopamine-first’ mechanism of action, as discussed further in 
Section 1.3. Analysis of the structures gained with the D33TfNCS construct showed that 
the N-terminal residues could not be resolved (residues 33-39 for PDB: 5NON) or were 
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not part of the globular fold (38-41 for PDB: 5N8Q). Therefore, to maximise the 
proportion of globular fold in the construct to improve tight crystal packing and further 
improve crystallographic resolution, it was hoped that a new construct, removing 
residues 1 to 41 and 196 to 210 could be used, also with an N-terminal His-tag with a 
TEV-cleavable linker. Unfortunately, no expression of the protein was observed by 
SDS-PAGE analysis or by western blot using an anti-His-tag antibody. It is possible that 
the N-terminal residues 33-40 are required for stabilisation of the enzyme. Indeed, 
studies of truncated CjNCS2 constructs by Nishihachijo et al. showed that significantly 
lower levels of expression were observed for D42CjNCS2 compared with D29CjNCS2.35 
 
2.2.3 Initial crystallisation trials of TfNCS 
Structural studies of TfNCS in this work were performed using the D33TfNCS construct. 
Initially, studies focussed on reproducing high resolution apo structures of the enzyme 
to help focus the range of conditions that would be useful for co-crystallisation 
purposes. Crystallisation trials of the apo protein immediately after purification (at 12.3 
mg mL-1 in 20 mM Tris, 50 mM NaCl, pH 7.5) were prepared using commercially 
available 96-well screens, Structure, PACT, JCSG and Index. Although crystallisation 
was observed in numerous conditions, only those observed in the Structure screen 
were of appropriate size for data collection. A range of crystals were sent to a 
synchrotron (Diamond i24); however, diffraction was only observed for three crystals. 
The crystallisation conditions, resolution and space group of each dataset collected is 








Table 2.1: Apo D33TfNCS data collection. The crystallisation conditions, dataset resolution 
and space group are given.  
 
Dataset  Salt Buffer pH Precipitant Dataset 
resolution / Å 
Space 
group 
1 - 0.1 M 
sodium 
citrate 





2 - 0.1 M 
sodium 
HEPES 





3 - 0.1 M 
MES 




A high resolution apo structure was gained from dataset 3, in a novel space group to 
that previously reported (P3121 vs. P22121 for PDB: 5N8Q). To gain mechanistic 
insights, resolution up to 2.5 Å would be sufficient to resolve the amino acid side chains. 
A four-corner screen was therefore prepared around the condition of dataset 3 in an 
attempt to further improve resolution. Numerous crystals were obtained, however there 
was no improvement.  
 
Previous co-crystallisation and soaking attempts of substrates and products, dopamine 
(5), 4-HPAA (6) or (S)-norcoclaurine (7) by A. Sula and B. Lichman were unsuccessful. 
No positive difference density was observed in the active site of the enzyme and the 
resolution was negatively affected.31 To see whether these results were reproducible 
and to attempt to understand the acceptance of ketones by TfNCS, co-crystallisation 
screens were prepared using dopamine (5) or one of three spirotetrahydroisoquinoline 
products (59-61), prepared by Jianxiong Zhao (Figure 2.3) at 10 mM in DMSO with 12.6 




Figure 2.3: Spiro-THIQs used for co-crystallisation. The acceptance of ketones as the 
carbonyl substrate for a TfNCS-catalysed reaction has led to the production of a range of novel, 
single isomer spiro-THIQ products. 
 
Structure screens were individually prepared for each of the four co-crystallisations 
(dopamine and 59-61), using 10 mM final concentration of ligand, however few crystals 
were observed with significant evidence of catecholamine oxidation in the crystallisation 
wells as evidenced by the precipitation of a brown solid within the crystallisation drop.137 
Three datasets were collected (as given in Table 2.2) but unfortunately, no co-
crystallisation was observed. It is likely that dopamine simply diffuses in and out of the 
enzyme active site and so is not bound sufficiently during crystallisation. The spiro-
THIQs are products of an NCS reaction so to drive the NCS reaction, product binding 
to the active site is probably highly disfavoured. Therefore, in future studies to 
understand the NCS mechanism beyond the natural substrates, non-productive 
reaction intermediate analogues were synthesised, mimicking the iminium ion 
intermediate in the reaction pathway. This approach has already been used 
successfully to support the ‘dopamine-first’ mechanism of TfNCS, however had not yet 
been applied towards non-natural substrates.30 
 
Table 2.2: Data collection for D33TfNCS co-crystallised with dopamine or spiro-THIQs. 
The crystallisation conditions, dataset resolution and space group are given.  
Ligand Salt Buffer pH Precipitant Dataset 
resolution / Å 
Space 
group 
5 - 50 mM 
KH2PO4 
- 20% w/v PEG 
8000 
2.0 P22121 
59 - 50 mM 
KH2PO4 
- 20% w/v PEG 
8000 
3.2 P3121 
60 - 0.1 M 
MES 















2.2.4 Towards understanding the acceptance of aliphatic aldehydes by TfNCS 
Previous studies of TfNCS by Lichman et al. and Ruff et al. demonstrated that the 
aldehyde substrate scope of TfNCS can be extended from benzylic aldehydes towards 
a range of aliphatic aldehydes, including linear and b-methyl substituted aldehydes.21,31 
Unusually, long alkyl chains on the aldehyde are tolerated, with decanal and citronellal 
used productively by the enzyme. To understand how TfNCS can accept these 
aldehydes as substrates, the aim was to use x-ray crystallographic studies with active-
site bound non-reactive mimics of reactions between dopamine (5) and two aldehydes, 
one linear (62) and one b-methyl substituted (63). Enzymatic reactions were performed 
to confirm the substrate acceptance as neither aldehyde had been tested before 
(Scheme 2.1). Isolated yields are given, and both were shown to be highly productive 
as NCS substrates.  
 
Scheme 2.1: TfNCS catalysed reactions performed between dopamine HCl and linear and 
b-methyl substituted aldehydes. Reactions were performed on a 10 mL scale using 10 mM 5, 
20 mM 62 or 63, using 0.1 mg mL-1 final concentration of D33TfNCS. Products (64 and 65) were 
isolated by preparative HPLC (method 1).  
 
Attempts to co-crystallise the THIQ products generated (64 and 65) were unsuccessful 
with only apo datasets collected. Therefore, two secondary amines for co-crystallisation 
with D33TfNCS were designed based upon the iminium ion intermediates of reactions 
of the Pictet-Spengler reactions towards 64 and 65, respectively (Scheme 2.2). The 
synthetic route was similar to that performed by Lichman et al.30 Starting from 
commercially-available dopamine hydrochloride (5), an O-benzyl protected analogue 


















50 mM HEPES, pH 7.5
10% v/v DMSO
37 oC, 18 h
+
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followed by benzyl protection to give 67 and Boc deprotection. The reagents used for 
the amide coupling step differed from the previous route.30 Attempts to use DCC 
(dicyclohexylcarbodiimide) and DMAP (4-dimethylaminopyridine) as a coupling reagent 
were unsuccessful as the cyclohexylurea by-product co-eluted with the desired amides 
(69 and 70) by thin-layer chromatography. Instead, a one-pot route was used, involving 
the in-situ activation of the carboxylic acid to the acyl chloride.138 Both amides were 
obtained in reasonable yield (38% and 43% for 69 and 70, respectively) after 
purification by silica column chromatography. The amide reduction steps using borane 
reagents proceeded to completion in both cases and the secondary amines (71 and 72) 
were taken through to the benzyl deprotection step without further purification. Benzyl 
deprotection was achieved through refluxing under acidic conditions and the desired 
mimics for co-crystallisation were isolated by preparative-HPLC as the TFA salts in 21% 
and 53% yield for 73 and 74, respectively. The synthetic route is summarised in Scheme 




Scheme 2.2: Synthetic route towards two aliphatic aldehyde reaction mimics for co-
crystallisation with D33TfNCS. The final products are isolated as the TFA salt after purification 
by preparative HPLC.  
 
Many crystals were obtained from commercial screens and optimisation was performed 
for numerous conditions. However, convincing positive difference density was never 
observed in the enzyme active site. Poor resolution was observed (3 – 4 Å) compared 
with apo structures gained under the same conditions (ca. 2 Å) suggesting that the 
presence of the ligands disrupted tight packing in the crystal lattice. Both mimics are 
also significantly more conformationally flexible than the one used previously (16). The 
lack of a second aromatic ring also means that there is less electron density. Very high 
occupancy, and a single ligand orientation would be required for significant difference 
density and accurate ligand placement. It is known that the NCS mechanism is highly 
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the NCS mechanism, so co-crystallising the ligand in a single orientation proved 
challenging, hence the large number of datasets collected. Soaking of the apo crystals 
was also unsuccessful, with crystals destroyed upon addition of the mimics. Therefore, 
for future crystallographic investigations, mimics were prepared with two aromatic rings 
present, as discussed in Sections 3.2.6, 5.2.13 and 6.2.4.  
 
2.2.5 Sacred lotus NCSs  
To date, two variants of NCS have been most widely explored, TfNCS (isolated from 
Thalictrum flavum) and CjNCS2 (isolated from Coptis japonica). A range of 
phenethylamines and aldehydes beyond the natural substrates have been shown to be 
accepted by both enzymes to generate a range of novel (1S)-THIQs in a single-step. 
Single enantiomer syntheses are valuable as often only a single enantiomer possesses 
the desired biological activity, with the other enantiomer enhancing unfavourable side-
effects, possessing other biological activities or simply being inactive.139 Therefore, 
being able to access all isomers of a small molecule drug candidate is highly valuable. 
 
NCSs have proved to be highly effective for generating (1S)-THIQs in facile, single-step 
syntheses, therefore a variant or mutant capable of generating the corresponding (R)-
enantiomers would be highly valuable. In all cases, norcoclaurine in plants has been 
identified as the (S)-enantiomer, with a single exception from the sacred lotus, Nelumbo 
nucifera.140 There is scientific interest in the identification and isolation of active 
components of N. nucifera as extracts of various parts of the plant have been used in 
traditional medicine to treat a variety of disorders, from smooth muscle and uterine 
relaxation141 to dyspepsia.47 
 
A range of interesting, novel benzylisoquinoline alkaloids (BIAs) have been isolated 
from N. nucifera and can be divided into three different subclasses: aporphine, 1-
benzylisoquinoline, and bisbenzylisoquinoline (from the oxidative coupling of two 1-
 82 
BIAs). A summary of some of the known (1R)-aporphine and (1R)-benzylisoquinoline 















Figure 2.4: Various (1R)-BIAs isolated from Nelumbo nucifera. * indicates that the S 
enantiomer has also been isolated. Other THIQ alkaloids have also been isolated from N. 
nucifera but the absolute stereochemistries have not been determined.  
 
The aporphine alkaloids isolated from N. nucifera are interesting due to the lack of 
substitution on the benzylic moiety and R stereochemistry at the C-1 position. The 
common intermediate to all BIAs is widely regarded to be (S)-norcoclaurine (7), with 
alkaloids with the opposing stereochemistry at C-1 often derived from (R)-reticuline (21) 
so the biosyntheses of these alkaloids is clearly unique. 21 and 1-benzylisoquinoline 
(1R)-
benzylisoquinoline 
R1 R2 R3 R4 
 
Norcoclaurine* (75) H H H H 
Coclaurine Me H H H 
N-methylcoclaurine Me H H Me 
Norarmepavine Me Me H H 
  Armepavine* Me Me H Me 
(1R)-aporphine R1 R2 R3 
 
Caverine Me H H 
Asimilobine H Me H 
Lirinidine Me H Me 
O-Nornuciferine H Me Me 
N-Nornuciferine Me Me H 
Anonaine -CH2- H 









alkaloids lacking para-hydroxy or -methoxy substitution on the benzylic ring have also 
never been isolated from plants although this does not rule them out as intermediates 
that are later modified. Biosynthetic possibilities include the involvement of a 
dehydroxylase enzyme (although rarely reported)142 to remove the benzylic para-
hydroxyl group with a route via R-norcoclaurine (75), the presence of a Pictet-
Spenglerase that catalyses the reaction between dopamine (or an analogue) and 
phenylacetaldehyde or an epimerase or other stereoselective enzyme involved to 
generate the THIQ moiety. The aporphine scaffold is likely then generated by an 
oxidative coupling between the two aromatic rings, likely catalysed by a P450 
enzyme.143   
A range of 1-benzylisoquinoline alkaloids have also been identified in N. nucifera, with 
structures based upon norcoclaurine, with various methylation patterns on the 
heteroatoms (Figure 2.4). A unique feature of these alkaloids is that again, (R)-
stereochemistry at C-1 was observed in some cases. Different enantiomers also appear 
to localise in different parts of the plant. The presence of solely the (R)-enantiomer of 
norcoclaurine in the seed embryo was first identified by Koshiyama et al. in 1970, by 
comparison of the optical rotation found of the compound isolated to those of known 
stereochemistry. This was also confirmed by HPLC analysis based on derivatisation 
with a chiral, fluorescent agent.144 
The biosynthetic origin of these alkaloids is again unknown, although the presence of 
seven isoforms of NCS (NnNCS1-7) in the N. nucifera genome means that it is highly 
likely that one of these enzymes is involved. Multiple sequence alignment of the 
NnNCSs, CjNCS2 and TfNCS is shown in Figure 9.56. However, the observation of 
both enantiomers of norcoclaurine, localised in different parts of the lotus, means that 
elucidating the biosynthetic origins is challenging. It is possible that a racemic reaction 
occurs followed by in planta transport systems to localise the varying enantiomers, an 
epimerase enzyme is also present to convert (S)-norcoclaurine (7) to the corresponding 
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R enantiomer or that one of the NCS variants present is capable of biosynthesising 
solely (R)-norcoclaurine (75).  
Seven isoforms of NnNCS have been identified in the sacred lotus genome and 
categorised as being one of two subfamilies of NCS, NCSI and NCSII.46 NCSI genes 
are found in BIA-expressing plants whereas NCSII genes are found in plants which do 
not express BIAs. Both NnNCS2 and NnNCS6 were deemed to be pseudogenes due 
to a frameshift from a single nucleotide deletion and partial coding sequences, 
respectively. Phylogenetic analysis also deemed that NnNCS4 was part of the non-BIA 
producing NCSII clade. Interestingly, unlike other encoded NCSs, all NnNCSs did not 
possess terminal signal peptides thus suggesting an alternative subcellular localisation, 
the cytoplasm rather than the vacuole.18 
Therefore, it was possible that one of the four remaining NnNCSs may be capable of 
catalysing (R)-norcoclaurine (75) so were considered for investigation. Unfortunately, 
there is no detail on enzyme expression in the seed embryo, where 75 is localised. Most 
significant alkaloid production in the leaves was correlated with NnNCS7 expression. 
The sequence similarities of the four variants with TfNCS and comparisons of the key 
active site residues are given in Tables 2.3 and 2.4, respectively.  
Table 2.3: Sequence similarity and identity between TfNCS and the four NnNCSs.  
NnNCS variant Identity (%) Similarity (%) 
NnNCS1 30 46 
NnNCS3 30 45 
NnNCS5 32 47 









K122 E110 Y108 D141 M97 A79 F99 L72 L68 F80 F112 
NnNCS1 K E W V I V L F L Y F 
NnNCS3 K E W I I V L F L Y F 
NnNCS5 K E W D I V L V L Y F 
NnNCS7 K E Y I V V L C L I F 
 
All NnNCSs had high sequence similarity with TfNCS (Table 2.3 and Figure 9.56). 
Active site residues were compared with TfNCS (Table 2.4) to help determine whether 
catalytic activity would be retained. Key active site residues, known to be essential for 
catalytic activity, K122 and E110 were retained (Table 2.4). K122 is responsible for 
catechol binding and E110 is thought to be important for iminium ion formation and 
orientation.28 Interestingly, D141 was not conserved across all variants. This residue is 
implicated in iminium ion formation and activity is significantly reduced in TfNCS when 
mutated to D141E or D141N, implying the importance of residue chain length and 
charge for successful catalysis.28 The putative gatekeeper residue, F112 is also 
conserved. Y108 is only conserved in NnNCS7 and although it is thought to aid 
aldehyde binding to the active site, the phenol is not essential for catalytic activity; 
Y108F is also a highly productive catalyst.31 
 
Interestingly, residue L72 was not conserved. Computational studies of TfNCS by 
Sheng et al.33 demonstrated that the pathway towards both enantiomers of 
norcoclaurine are favoured until the final deprotonation step of the final quinone 
intermediate to give the THIQ product. Moreover, the route towards (R)-norcoclaurine 
is disfavoured in part due to an unfavourable steric clash between the para-hydroxyl of 
the benzylic moiety and L72. The alteration, L72F increases steric bulk at this position, 
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thus suggesting that the steric repulsion would be enhanced, and R-product would be 
disfavoured. However, the variation L72V in NnNCS5 does decrease steric bulk but it 
is unknown if this creates enough space in the active site to avoid the steric repulsion 
and favour R-product formation. To avoid formation of the S-enantiomer as well, a steric 
clash on the other side of the active site would also be required. The residue change to 
L72C (in NnNCS7) decreases steric bulk but also side chain flexibility.  
 
Therefore, two NCSs isolated from the sacred lotus, NnNCS5 and NnNCS7 were 
investigated due to apparent decreased steric bulk at position 72 and correlations with 
increased alkaloid production, respectively. Due to the lack of signal peptides, no 
truncations of the termini were performed when designing synthetic genes for protein 
expression. Synthetic genes were designed and subcloned into pET29a(+), then used 
to transform BL21(DE3). This work was performed by Prof. John Ward. A construct was 
developed with an N-terminal His-tag with a TEV cleavage site because if a productive 
enzyme was found, crystallographic studies would be of interest and this construct was 
promising with TfNCS.30 Expression was performed using the same protocol as for the 
expression of TfNCS (wild-type and variants) as it was hoped that due the high 
sequence homology observed between the NCSs, this would be successful. Multiple 
sequence alignment of the NnNCSs and TfNCS is shown in Figure 9.56. SDS-PAGE 
analysis of the whole-cell and lysed supernatant of the whole-cell expression cultures 
(Figure 2.5) lacked the presence of an over-expressed protein. Therefore, western blot 




Figure 2.5: SDS-PAGE and western blot analysis of NnNCS5 and NnNCS7 expression. 
Expected protein sizes are: NnNCS5 at 21.7 kDa and NnNCS7 at 21.1 kDa. Expression was 
performed using the same method as reported for the generation of TfNCS (1 mM final 
concentration IPTG to induce followed by incubation at 25 oC). a. SDS-PAGE analysis. b. 
Western blot analysis using an Anti His-tag antibody. Lanes: 1, Benchmark™ Protein Ladder 
(masses given in kDa). 2, NnNCS5 whole cell. 3, NnNCS5 supernatant. 4, NnNCS7 whole cell. 
5, NnNCS7 supernatant.  
 
No expression was observed for NnNCS7. Two bands were observed for NnNCS5 
expression, perhaps indicating the presence of a degradation product and very low 
levels of protein expression were observed. The pure protein was isolated to minimise 
the observation of the non-enzymatic background reaction. Nickel-affinity 
chromatography was performed followed by TEV-cleavage, nickel-affinity 
chromatography to remove TEV protease and size-exclusion chromatography. SDS-





























Figure 2.6: SDS-PAGE analysis of NnNCS5 purification. CV = column volume. a. SDS-PAGE 
analysis of nickel-affinity chromatography purification of NnNCS5. Lanes: 1, Benchmark™ 
Protein Ladder (masses given in kDa). 2, clarified cell lysate loaded onto column. 3, flow through 
with lysis buffer (20 mM imidazole). 3 – 6, 20 mM imidazole buffer wash, 2 CV fractions. 7 – 9, 
40 mM imidazole buffer wash, 3 CV fractions. 10 – 15, 500 mM imidazole buffer washes. 1 CV 
fractions. b. SDS-PAGE analysis of second nickel-affinity chromatography purification of 
NnNCS5 after His-tag removal to remove TEV protease. Lanes: 1, Benchmark™ Protein Ladder 
(masses given in kDa). 2, NnNCS5 sample before TEV cleavage at 21.7 kDa. 3, NnNCS5 
sample loaded onto His-trap after TEV cleavage, protein expected at 19.1 kDa. 4, flow through 
with 20 mM imidazole buffer. 5 - 7, 3 CV 20 mM imidazole buffer wash. 8 - 12, 3 CV 40 mM 
imidazole buffer wash, 13 – 15, 3 CV 500 mM imidazole buffer wash. c. SDS-PAGE analysis of 
size exclusion chromatography purification of NnNCS5, showing isolated protein at 19.1 kDa. 
Lanes: 1, Benchmark™ Protein Ladder (masses given in kDa). 2 – 15, 3 mL fractions collected 
across the major protein containing fractions eluted from the column.  
 
The first nickel-affinity purification of NnNCS5 removed most of the other protein 
impurities and fractions were pooled corresponding to lanes 11-15 by SDS-PAGE 
analysis (Figure 2.6a). TEV cleavage of the His-tag did not go to completion as shown 
in Figure 2.6b, and since no issues had been observed before during His-tag cleavage 
of TfNCS, it was hypothesised that in NnNCS5, the His-tag is less accessible, hindering 
access by the TEV protease. Unusually, despite removal of the His-tag from some of 
the protein sample, NnNCS did not elute in the flow through or 20 mM imidazole buffer 
washes and instead eluted later in 40 mM and 500 mM imidazole washes. A reasonably 
pure sample of protein was achieved after size exclusion chromatography (Figure 2.6c) 
with fractions corresponding to lanes 7 – 15 pooled. A low yield of protein was isolated, 
1 mg from 3 L of culture volume. This is significantly lower than yields of TfNCS where 
100 – 200 mg of pure protein was regularly isolated from a single litre of culture. Poor 
expression could be due to toxicity or instability of the NnNCS5. There are also clearly 
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issues associated with having an N-terminal His-tag, so in future a C-terminal tag could 
be considered instead. The reported C-terminal of NnNCS5 contains five consecutive 
serine residues, which could be due to sequencing errors. Therefore, truncated 
constructs of NnNCS5 could also be considered.  
 
Purified NnNCS5 was concentrated to 1 mg mL-1 in buffer (20 mM Tris, 50 mM NaCl, 
pH 7.5) and stored at -80 oC or used directly for enzymatic reactions. Assays were then 
performed to determine whether the isolated enzyme was active. Reactions were 
considered based upon reactions with TfNCS because, due to the high sequence 
homology of the two NCSs, if active, it was hoped that NnNCS5 would have similar 
reactivity to TfNCS. The two substrates chosen for assays were dopamine (5), the 
natural NCS phenethylamine substrate and phenylacetaldehyde (76), a commercially 
available and less oxidatively sensitive analogue of the natural substrate, 4-HPAA (6). 
Product formation was monitored by RP-HPLC analysis and confirmed by LC-MS. 
Background, control reactions were performed by substituting the protein sample for 
buffer (20 mM Tris, 50 mM NaCl, pH 7.5).   
 
Unfortunately, using 1 mM or 10 mM of either substrate, with or without 10% v/v DMSO 
as co-solvent and at 37 oC or 4 oC, no product formation was observed above that 
observed for the non-enzymatic background reaction. A 0.4 mg mL-1 final concentration 
of enzyme was used which should be sufficient to demonstrate if the enzyme was 
active. Therefore, due to a combination of very low expression yields and no (or 
potentially trace) activity, further optimisation of NnNCS5 expression and assay 
conditions was not performed.  
 
NnNCS7 expression was attempted following the same protocol as NnNCS5 and 
TfNCS expression however, no expression of NnNCS7 was observed. Therefore, 
expression trials were performed, varying IPTG concentrations (0.1 mM or 0.5 mM final) 
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used for induction and two different incubation temperatures post-induction (18 oC and 
26 oC) were attempted. Protein expression could not be determined by SDS-PAGE 
analysis; therefore, the presence of NnNCS7 was identified by western blot analysis 
using an Anti His-Tag Antibody to detect protein containing a His-tag (Figure 2.7). To 
determine whether the expressed protein was soluble, samples were prepared after 
lysis (whole cell), the isolated supernatant after centrifugation (supernatant) or the 
resuspended cell pellet (pellet) and were analysed.  
 
 
Figure 2.7: Anti His-Tag western blot analysis of NnNCS7 expression trials. Protein 
expected at 21.1 kDa. Lanes: 1, Thermo Scientific™ PageRuler™ Plus Prestained Protein 
Ladder. 2, 0.5 mM IPTG, 18 oC, whole cell. 3, 0.5 mM IPTG, 18 oC, supernatant. 4, 0.5 mM 
IPTG, 18 oC, pellet. 5, 1 mM IPTG, 18 oC, whole cell. 6, 1 mM IPTG, 18 oC, supernatant. 7, 0.5 
mM IPTG, 26 oC, whole cell. 8, 0.5 mM IPTG, 26 oC, supernatant. 9, 1 mM IPTG, 26 oC, whole 
cell. 10, 1 mM IPTG, 26 oC, supernatant. 
 
Presence of the desired protein (at 21.2 kDa) was observed for all expression 
conditions, however in all cases, a degradation product was observed at around 15 
kDa, thus indicating the instability of the protein. Induction with 1 mM IPTG and 
incubation at 26 oC resulted in only degraded protein. Therefore, to isolate NnNCS7 to 
determine whether it was active, the enzyme was expressed with 0.5 mM IPTG and 
incubation at 18 oC post-induction. To purify the protein, nickel-affinity chromatography 
was performed, with SDS-PAGE analysis of fractions eluted shown in Figure 2.8. There 
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Due to the likely instability of the protein, further purification steps (TEV cleavage, 
secondary His-trap and size-exclusion chromatography) were not performed. A poor 
yield of impure protein (0.2 mg from 3 L culture volume) was obtained 
 
Figure 2.8: SDS-PAGE analysis of NnNCS7 purification by nickel affinity chromatography. 
Protein expected at 21.1 kDa. CV = column volume. Lanes: 1, Thermo Scientific™ PageRuler™ 
Plus Prestained Protein Ladder. 2, lysate loaded onto His-trap. 3, flow-through from column. 4 
– 6, 5 CV of 20 mM imidazole buffer. 7 – 8, 2 CV 40 mM imidazole buffer. 9, 5 CV 40 mM 
imidazole buffer. 10, 2 CV 80 mM imidazole buffer. 11, 5 CV 80 mM imidazole buffer. 12, 2 CV 
500 mM imidazole buffer. 13, 5 CV 500 mM imidazole buffer.  
 
The isolated protein (sample in lane 12 of Figure 2.7) was concentrated and prepared 
in buffer as for NnNCS5 and enzymatic reactions were performed using a range of 
conditions, analogous to those used to determine the biocatalytic potential of NnNC5. 
Unfortunately, NnNCS7 also showed no reaction above the background reaction using 
all conditions tested. It is unknown why such poor stability and expression is observed 
with these two sacred lotus NCSs, considering the high homology to other NCS 
variants. It is possible that the introduction of long N-terminal extensions, from the 
incorporation of a His-tag and a TEV cleavage site are poorly tolerated and disrupt the 
proteins.  
 
Aligning the sequences of the two NnNCSs investigated and TfNCS (Figure 9.56) also 
revealed an unusual feature of the NnNCS5 sequence; five sequential serine residues 
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sequence is truncated at the C-terminus, however studies of TfNCS have shown that 
the C-terminal unstructured region is not essential for catalytic activity. In future 
attempts to isolate these enzymes, truncations of C-terminal residues and C-terminal 
His-tagging could be explored. There is also a possibility that the five isoforms of NCS 
isolated from N. nucifera have evolved to become inactive, with both enantiomers of 
norcoclaurine generated via a phosphate-mediated Pictet-Spengler reaction15 and each 
enantiomer selectively transported to and accumulating in different parts of the plant.140 
 
2.2.6 Investigations of double point variants of TfNCS 
A range of double point variants of TfNCS have been generated by a previous PhD 
student, Benjamin Lichman with the aim of altering the regioselectivity of the Pictet-
Spengler reaction towards ortho-THIQs rather than the para-THIQs generated by the 
wild-type enzyme. Eight different variants were generated by site-directed 
mutagenesis, moving key active site residues with the aim to alter the binding location 
of the meta-hydroxyl of the phenethylamine substrate used. The aim was to favour 
formation of the spirocyclic intermediate via activation of the ortho-hydroxyl group. 
Mutations of K122 (to which the catechol binds) towards non-reactive residues was 
performed and changing other active site residues might mean that the amine substrate 
would be bound in a different orientation in the active site and perhaps alter catalytic 
activity. Some screening had been previously performed by B. Lichman, investigating 
a range of ketones and an a-keto acid as the carbonyl substrate, however no or trace 
conversions were observed.31 
 
Investigation of these eight double point variants of D29TfNCS were investigated as 
part of a collaborative project with another PhD student, Yu Wang, whereby the aim of 
the project was to further investigate NCS activity and alter reactivity through rational 
design of the enzyme. SDS-PAGE analysis of the double point variants is given in the 
PhD thesis of Yu Wang.145 The enzymes were expressed using the standard protocol 
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for TfNCS expression and all were found to be highly expressed. Enzymatic reactions 
were performed with desalted cell lysate to remove any phosphate or other salts which 
may be catalysing a racemic, non-enzymatic Pictet-Spengler reaction.15 Due to the 
movement of key residue, K122 in the active site, and thus the potential for significant 
lower enzymatic activity, higher concentrations of enzyme were used in reactions 
compared with conditions usually used (1 mg mL-1 vs. 0.1-0.2 mg mL-1). Screening was 
performed of the reactions between dopamine and phenylacetaldehyde (76) to give 77, 
or hexanal (78) to give 79, respectively (Scheme 2.3). These aldehydes were chosen 
as analogues of the natural substrate, 4-HPAA (6) and to determine the activities with 
linear aldehydes. Peak areas by analytical RP-HPLC (method 1, Figure 2.8) above the 
background reaction  (substituting enzyme sample for buffer instead) indicated a 
productive biocatalytic reaction and chiral HPLC analysis (method 5, Figure 2.8) using 
reported conditions was used to determine the stereoselectivity of the reactions.117 
Conversions of reactions with the eight, double-point variants with either 76 or 78 
(Scheme 2.3) as the aldehyde substrate are given in Figure 2.9.  
 
 
Scheme 2.3: Reactions performed to assess the activity of the double point variants of 
D29TfNCS. a. Reaction between dopamine and 76. b. Reaction between dopamine and 78. 
Yields given are for isolated yields after a 10 mL scale reaction using 10 mM 5 and 20 mM 76 

























variant (1 mg mL-1)
50 mM HEPEs pH 7.5
10% v/v MeCN
37 oC, 18 h
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Δ29TfNCS
variant (1 mg mL-1)
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Figure 2.9: Conversions and enantiomeric excesses of reactions involving double-point 
variants of TfNCS. Reactions were performed using standard conditions between dopamine 
(10 mM) and a. phenylacetaldehyde (76) or b. hexanal (78) (20 mM), catalysed by a range of 
double point variants of D29TfNCS (at 1 mg mL-1 using desalted cell lysate). Conversions were 
determined based upon product formation compared with calibration curves of isolated product. 
Enantiomeric excesses for each reaction condition are given above each bar as percentages 
and were determined by chiral HPLC (method 5).  
 
Compared with reactions with involving wild-type TfNCS, conversions and enantiomeric 
excesses were significantly poorer. With both aldehyde substrates, using 0.1 mg mL-1 
wild-type TfNCS, near complete conversions were observed in high enantiomeric 
excess (>95%).31 For reactions between dopamine (5) and 76 (Figure 2.9a), 
conversions above the background were observed with all double-point variants and in 
all cases an excess of the (S)-enantiomer was observed by chiral HPLC, albeit with 
poor e.e.s. Poor selectivity was likely due to a combination of a high background 
reaction and perhaps some racemic reaction associated with the protein sample. This 
was also observed with reactions involving the benzaldehydes (Section 5.2) although it 
is possible here that by altering these residues, that instead of providing catalytic 
activity, the active site instead acts as a hydrophobic pocket. The shape of the active 
site therefore has some influence over the selectivity of the reaction and enhances 
turnover compared with the background reaction. The activity of the enzyme was 
however greatly decreased with significantly lower conversions observed (<64% with 
a b 
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all double point variants with 1 mg mL-1 TfNCS) compared with the wild-type enzyme 
(>95% with 0.1 mg mL-1).  
 
Similar results were also observed for reactions with 78 and in all cases, significant 
reactivity above the background was observed, along with stereoselectivity in all cases 
(Figure 2.9b). Overall, the best selectivities were observed when using K122L-F122K 
as the catalyst (e.e.s of 34% and 37% for 76 and 78, respectively). F112 neighbours 
K122 in the active site and is thought to act as a ‘gatekeeper residue’, influencing 
substrate acceptance.30 Perhaps as the two residues are nearby, this means that the 
catechol can still bind in the active site in a similar location so reactivity is hardly altered. 
Clearly the presence of an aromatic residue buried in the active site is important 
although it is unclear why the reactivity varies greatly between using the benzylic and 
linear aldehyde as substrates. Perhaps enhanced reactivity was observed for reactions 
with hexanal (78) rather phenylacetaldehyde (76) as 78 is more conformationally 
flexible and less bulky, so there is more space in the active site for substrate maneuver. 
It is particularly interesting that reactivity was observed, with retained stereo- and 
regioselectivity for all these mutations, considering that the key lysine residue (K122) is 
moved far from the original location in some cases, even into the entrance/exit of the 
active site (K122L-M126K). The activity of the enzyme was however greatly decreased 
with poor conversions (<64% with 1 mg mL-1 TfNCS) observed compared with the wild-
type enzyme (>95% with 0.1 mg mL-1).  
 
2.2.7 Rational design of NCS towards altering reaction stereoselectivity 
Density functional theory calculations of TfNCS, to investigate the reaction mechanism 
and stereoselectivity indicated the role of L72 in producing solely the (S)-product. As 
previously discussed in Section 1.3.4, it was hypothesised that the reaction pathways 
towards either enantiomer are favoured until the final quinone intermediate, where an 
unfavourable steric repulsion is observed between the benzylic moiety of the (R)-
 96 
quinone and the side chain of L72, therefore meaning that deprotonation of the (R)-
quinone by E110 is disfavoured. Since the all reactions are reversible except for this 
final deprotonation step, this means that the formation of (S)-norcoclaurine is favoured. 
Therefore, it was hoped that a rational design of TfNCS could be performed, minimising 
the unfavourable interaction of the (R)-quinone, by reducing steric bulk at position 72, 
towards residues with smaller side chains, valine and alanine. This may help generate 
racemic or (R)-selective para-THIQ products. To disfavour deprotonation of the S-
quinone, it was hypothesised that a steric clash between the benzyl moiety and an 
active site residue would be required. Residue, Y108 appeared to be on the other side 
of the active side compared to L72, and the quinone intermediate so providing extra 
steric bulk at this position could result in a steric clash and thus disfavour S-quinone 
formation. 
 
Based on this hypothesis four single point variants of D29TfNCS were generated; L72A, 
L72V, Y108S and Y108W. Cloning and expression of these variants was performed by 
Yu Wang. Initially, only the single point mutations were considered so that any changes 
in activity could be directly correlated to each mutation. Enzymatic assays were 
performed under standard conditions for reactions between dopamine and 
phenylacetaldehyde or hexanal (like Scheme 2.3). Reactions were performed at higher 
enzyme concentrations (1 mg mL-1) as before, as it was expected that enzyme activity 
would be negatively affected. Enzyme samples were prepared using desalted cell-
lysate to remove any phosphates which could contribute to a background, racemic 
Pictet-Spengler reaction. Conversions and enantiopurities of the THIQ products 














Figure 2.10: Conversions of reactions using single point variants of D33TfNCS at 
positions 72 and 108. Reactions were performed using 1 mg mL-1 enzyme under standard 
reaction conditions between dopamine (5) and phenylacetaldehyde (76) or hexanal (78). 
Conversions were determined by product formation calibration curves and enantiomeric 
excesses determined by chiral HPLC (method 5) are given above each bar and enantiomeric 
ratios are shown by split bars.  
 
For reactions with all four variants and both substrates, selectivity towards the (S)-
enantiomer of product was observed (Figure 2.9). The amount of (R)-product observed 
was comparable to that observed in the background reaction, unless conversions were 
at or approached completion (reactions involving hexanal and Y108S/W, Figure 2.9). 
In all cases, higher e.e.s were observed using hexanal as the aldehyde substrate. 
Activity was poor with both substrates using the L72 variants and the stereoselectivity 
of the reaction was unaltered. Conversions decreased as the side chain was shortened, 
from valine to alanine. Perhaps this is because this residue is important to provide 
hydrophobic interactions with the substrates rather than being involved in a steric 
repulsion with the aldehyde side chain that affects the stereochemical outcome of the 
reaction.  
 
Y108W had high activity, with complete conversions observed with both substrates.  To 
compare the activity of Y108W to the wild-type enzyme, enzyme reactions were 
performed at a range of different enzyme concentrations between dopamine (5) and 
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hexanal (78). 78 was chosen as the aldehyde substrate because for reactions with 1 
mg mL-1 enzyme (Figure 2.11), the Y108W was highly productive; complete conversion 
to the product, 79 was observed in 98% e.e. It was shown that the activity of Y108W 
was approximately half of that of the wild-type enzyme. This resulted in poorer 
enantiopurities of the THIQ (79) generated, likely due to an increased proportion of 













Figure 2.11: Conversions of NCS-catalysed reactions between dopamine and hexanal 
using wild-type or Y108W D33TfNCS at varying concentrations. Enantiomeric excesses of 
the products generated are given above each bar and shown as an enantiomeric ratio by split 
bar. Enantiopurities were determined by chiral HPLC method 5. 
 
The mutation of tyrosine to tryptophan also increases the hydrophobicity of the pocket. 
Smaller chain aldehydes (such as acetaldehyde (45)) are poorly accepted as substrates 
by TfNCS. Therefore, enzyme catalysed reactions between dopamine and 
acetaldehyde, catalysed by Y108W, were investigated. However, no conversions were 
observed by RP-HPLC nor LCMS.  
 
Double point variants of TfNCS based upon L72A/S and Y108S/W were therefore not 
generated because L72 did not appear to have a role in determining reaction selectivity 
and mutations at this position instead greatly reduced enzyme activity. Instead, another 
approach was considered, taking advantage of the fact that TfNCS has two entrances 
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to the active site (Figure 2.12). During the NCS mechanism, the aldehyde side chain 
sits in a cleft near residues L76, A79, F80 and M97. On the other side of the active site, 
there is another cleft, flanked by the side chains of Y131 and P179, and the loop 173 – 
176. This pocket is inaccessible to the aldehyde side chain, as it is blocked by the side 
chains of Y108 and P179.  
  
 
Figure 2.12: The active site entrance/exit of TfNCS. The structure shown is PDB:5NON; co-
crystallised structure of wild-type D33TfNCS with a non-productive reaction intermediate 
analogue (16) of the reaction between the two natural substrates, 5 and 6. There are two 
pockets, one which is accessible to the substrates, and another that is inaccessible, as 
highlighted in green.  
 
Mechanistically supported by the NCS crystallographic studies, the iminium ion 
intermediate of the NCS reaction is held in the active site, with the nitrogen of the 
iminium ion hydrogen-bonded to charged residues E110 and D141.  The hydroxyl 
groups of dopamine interact with the nitrogen of K122. These interactions mean that 
the aldehyde side chain is forced forwards, forming a trans iminium species. This 
means that nucleophilic attack from the catechol ring onto the iminium ion can only 
occur onto the Re face of the iminium ion, forming (1S)-THIQs (Scheme 2.4). Therefore, 
if the face of attack or the geometry of the iminium ion can be reversed, the 
stereochemical outcome of the reaction would be switched.  
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Scheme 2.4: The stereochemical outcome of a Pictet-Spengler reaction, based upon 
which face of the cis / trans iminium ion formed is attacked.  
 
Therefore, to see if the other active site entrance/exit pocket could be accessed, 
mutations were considered at P179, to glycine, alanine, and serine, to see if this would 
create extra space. This could allow the aldehyde side chain to sit in either pocket, 
forming either a cis or trans iminium ion, altering the stereochemistry of the reaction, 
but generating racemic para-THIQs. It would also be interesting if mutations at this 
position were tolerated because this proline is at the end of an alpha helix (Figure 2.11) 
and is known as a ‘helix-breaker’ residue.146 Mutations at F80 to more bulky side chains, 
tyrosine and tryptophan, were considered to increase the hydrophobicity of the active 
site and to see if the secondary cleft could be blocked further to help increase activity 
of the enzyme. This was because with some substrates screened, particularly the 
benzaldehydes, a racemic reaction associated with the enzyme sample had been 
observed.  
 
These five TfNCS variants, P179A/G/S and F80Y/W were purchased as synthetic 
genes, codon optimised for E. coli expression, and subcloned into pET29a(+). The 
D33TfNCS construct was used, containing an N-terminal His-tag and a TEV-cleavage 
site in case any of the variants were particularly promising and structural studies could 
be performed by protein crystallography. All five variants were well-expressed, at 17 – 
22% of the total protein concentration as determined by SDS-PAGE analysis (Figure 

































Figure 2.13: SDS-PAGE analysis of D33TfNCS variant expression. Expected protein size = 
20.7 kDa. Lanes: 1, BioRad Precision Plus Protein™ Dual Color Standards with masses given 
in kDa. 2, D33TfNCS-P179A total protein. 3, D33TfNCS-P179A soluble protein. 4, D33TfNCS-
P179G total protein. 5, D33TfNCS-P179G soluble protein. 6, D33TfNCS-P179S total protein. 
7, D33TfNCS-P179S soluble protein. 8, D33TfNCS-F80W total protein. 9, D33TfNCS-F80W 
soluble protein. 10, D33TfNCS-F80Y total protein. 11, D33TfNCS-F80Y soluble protein. 12, 
empty pET29(+) total protein. 13, empty pET29(+) soluble protein. 
 
Enzymatic assays were performed for the reaction between dopamine (5) and 
phenylacetaldehyde (76) or hexanal (78) (like Scheme 2.3), with these variants as cell 
lysate at 0.1 mg mL-1 TfNCS. Lysed BL21(DE3) cells containing the empty pET29a(+) 
vector was used as a control (empty pET, Figure 2.13) and reactions were also 
performed a no enzyme control (i.e. buffer added rather than purified protein) to 
compare with the empty pET vector control to and determine the origin of the 
background Pictet-Spengler reaction. Comparable conversions were observed for both 
reactions (Figure 2.13) so the background reaction is associated with the reaction 
buffer, rather than any phosphates or other proteins present in the cell lysate. All five 
TfNCS variants were highly stereoselective with e.e. >92% in the product for reactions 
with 76 and e.e.s >98% for reactions with 78. A significant background reaction is 
observed (generating around 30% racemic product) so it can be assumed that any (R)-
product generated is by this reaction and so reflects a decrease in enzyme activity. 76 
is more activated than 78, which likely accounts for the generally lower 












stereoselectivities observed. Conversions and enantiomeric ratios of the products 
generated are given in Figure 2.14. P179S had comparable activity with the wild-type 
enzyme and variants, F80W and P179A gave slightly improved conversions. The 
variant P179G gave decreased conversions for reactions with phenylacetaldehyde but 
comparable activity to the wild type with hexanal, perhaps reflecting a structural change 
in the exit of the active site, hindering the access of the larger, benzylic aldehyde. F80Y 
was also less active, perhaps due to the hydroxyl group of tyrosine reducing favourable 
hydrophobic interactions which promote substrate binding. It is therefore clear that the 
mutations P179A/G/S alone cannot alter the NCS reaction selectivity. It is unclear 
whether these variants create enough space to allow the aldehyde to access the 
secondary cleft of the active site entrance/exit nor the effect of the variants F80W/Y. 
Therefore, future work could explore double point variants at positions 80 and 179 or 
structural investigations. Future rational design attempts could focus on the charge 
residues E110 and D141 to hold the iminium ion intermediate on the other side of the 
active site, to hopefully either generate the cis iminium ion or force Si face attack in the 
cyclisation reaction step (Scheme 2.4).  
Figure 2.14: Conversions of reactions using single point variants of D33TfNCS at 
positions 179 and 80. Reactions were performed using 0.1 mg mL-1 enzyme under standard 
reaction conditions for reactions between 5 and phenylacetaldehyde (76) or hexanal (78). 
Conversions were determined by product formation calibration curves (see Appendix) and 
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enantiomeric excesses determined by chiral HPLC (method 5) which are given above each bar 
and enantiomeric ratios are shown by split bars.  
 
2.2.8 Salsolinol synthase  
Another biocatalytic route towards (1R)-THIQs may already exist in nature. Salsolinol 
synthase, a ubiquitin-like enzyme found in rats, is thought to catalyse a stereoselective 
Pictet-Spengler reaction between dopamine and acetaldehyde, giving (R)-salsolinol 
(56) (Scheme 2.5). The enzymatic reaction is thought to compete with a racemic 
background Pictet-Spengler reaction as both enantiomers of salsolinol are isolated, with 
the (R)-enantiomer in excess. However, isolation of the other possible THIQ 
regioisomer, the ortho product has not been reported which would also be formed if a 
racemic Pictet-Spengler reaction is present.15 
 
Scheme 2.5: The formation of salsolinol in rat brain. A racemic Pictet-Spengler reaction 
competes alongside a stereoselective enzymatic reaction by the putative enzyme, salsolinol 
synthase.  
 
Increased levels of expression of the enzyme in the brain have been shown to be 
correlated with increased production of 46 in both humans and rats, although the 
molecular weights of the isolated proteins differ greatly (ca. 33 kDa vs. 8.6 kDa). The 
sequence is only known from the variant isolated from Rattus norvegicus and is a 
ubiquitin-like protein, consisting of 77 amino acids. The sequence of ubiquitin is highly 
conserved throughout nature. Salsolinol synthase differs by only four residues and is 
the only known enzymatic homologue of ubiquitin.107 The recombinant expression and 



















the catalytic scope has been performed and for the enzyme in vivo rather than using 
the isolated protein.  
 
Three different constructs of salsolinol synthase were purchased as synthetic genes, 
codon optimised for E. coli expression, each with different promotors, pTAc, pP1 or T7 
for salsolinol synthase SSv1, SSv2 and SSv2 respectively and all were transformed 
into BL21(DE3). C-terminal His-tags were also introduced to aid protein purification if 
required, although the protein has been previously isolated by acid precipitation as it is 
reported to be highly soluble.147 
 
Expression was performed using analogous conditions to those used for TfNCS 
expression. Ubiquitin is highly stable and high levels of protein can be generated from 
recombinant expression; therefore, it was hoped that expression conditions need not 
be optimised. Unfortunately, only a small band around 10 kDa was observed by SDS-
analysis of SSv1 expression and no expression was observed for the other two 
constructs (Figure 2.15).  
 
Figure 2.15: SDS-PAGE analysis of salsolinol synthase expression. Lanes: 1, Benchmark™ 
Protein Ladder. 2, supernatant of cell pellet lysis after salsolinol synthase expression. Protein 
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To determine whether SSv1 had in fact been expressed, purification was attempted 
following the reported protocol. Due to the apparent high stability of the enzyme, it can 
be purified via acid precipitation of the other proteins. Removal of the other, precipitated 
proteins by centrifugation and SDS-PAGE analysis of the supernatant showed that 
protein was present, however despite the use of a reducing agent, oligomers were 
observed. To check if the isolated protein was active, enzymatic reactions were 
performed between dopamine and acetaldehyde, however no THIQ products (46) were 
observed above the background reaction as determined by RP-HPLC and LCMS.  
 
The poor or no expression levels observed suggested that there were issues with the 
constructs designed. Since salsolinol synthase has such a short sequence, perhaps the 
introduction of a terminal His-tag affects the stability of the enzyme. Therefore, in future 
investigations, the His-tag should be omitted. Due to the stability of the protein, isolation 
of the pure protein theoretically can be achieved by acid precipitation and so tags are 
not required.  
 
2.3 Conclusions and future work 
To conclude, crystallographic investigations of TfNCS were explored to try and further 
understanding of the mechanism and substrate acceptance. The previously published 
truncated construct, D33TfNCS was used, however a further truncation on the N-
terminus, removing residues 1-42 rather than 1-33, resulted in no protein expression. 
Reaction intermediate mimics based on reactions with aliphatic aldehydes were 
synthesised and co-crystallisation was attempted. However, the molecules were not 
observed clearly in the active site, likely due to conformational flexibility and a lack of 
electron density. In future, mimics based upon reactions with aldehydes containing an 
aromatic ring system should be considered as these have proven promising.30,148,149 
Structural investigations by NMR spectroscopy could also be considered; previous 
studies have shown that NCS has a highly dynamic mechanism and a lot more is now 
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known about the mechanism and substrate scope. Protein NMR may therefore be a 
useful tool to fill in the gaps in our knowledge.  
 
Routes towards generating (1R)-THIQs were also explored: the attempted expression 
and purification of several enzymes, salsolinol synthase and two NCSs from the sacred 
lotus and, single point variants of TfNCS. Although little change in stereoselectivity was 
observed where enzymes were expressed and active, these investigations provide a 
useful starting point for future studies. Different constructs of salsolinol synthase and 
the NnNCSs (such as removing His-tags, changing terminus of His-tags or truncating 
termini) would likely improve expression levels and allow for screening. Future 




Chapter 3: The Acceptance and Kinetic Resolution of a-Methyl 
Substituted Aldehydes by Norcoclaurine Synthases 
 
3.1 Introduction 
3.1.1 The tetrahydroisoquinoline moiety as a privileged drug scaffold  
The THIQ moiety is found in many pharmaceutically relevant molecules, so is known 
as a privileged drug scaffold. This is a molecular moiety that has already been shown 
to be present in ligands for a range of different receptors, making them an attractive 
target in drug discovery efforts.150  
 
The THIQ scaffold is found in both naturally occurring and synthetic drug molecules, 
with a vast range of different biological activities exhibited. In plants, many BIAs contain 
the THIQ moiety and have been shown to have useful medicinal properties, including 
anti-microbial (sanguinarine (12) and berberine (2)), anti-tussive (glaucine (80)) and 
anti-cancer (noscapine (3)).1 Other naturally-occurring THIQs with biological activities 
include saframycin, a non-ribosomal peptide with anti-microbial activities and trolline 
(58), an alkaloid with anti-viral properties.119,151 Useful synthetic THIQs include 
solifenacin (81), a widely prescribed anti-diuretic, almorexant (82), with anti-insomniac 
properties and quinapril (83), an ACE inhibitor used in the treatment of 
hypertension.55,152,153 The chemical structures of a range of pharmaceutically relevant 
THIQs are given in Figure 3.1. 
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Figure 3.1: A range of biologically relevant molecules containing the THIQ moiety (given 
in red).  
 
3.1.2 Synthetic routes towards the THIQ scaffold 
The pharmaceutical relevance of the THIQ moiety has led to the development of a 
range of synthetic routes for its formation, as discussed in-depth in Section 1.6. 
Although there is no generally accepted best route, common methods employ Bischler-
Napieralski or Pictet-Spengler reactions.62,154  Gaining regio- and stereoselective 
control often requires a multi-step strategy, metal catalysts (which can be polluting, 
expensive or a limited resource) or toxic reaction conditions.15,76,155 To develop more 
facile syntheses towards single isomer THIQs, the use of suitable biocatalysts has been 
explored. Enzymes are advantageous compared with traditional synthetic methods as 
they often exhibit high regioselective and stereoselective control, and operate under 
mild reaction conditions, however, can be limited by a small substrate scope.  
 
Several enzymes have been used for the biocatalytic syntheses of chiral THIQs, 
including monoamine oxidases (MAOs) and imine reductases (IRs), however there is 
the synthetic requirement to generate the racemic THIQ or dihydroisoquinoline 
precursor, respectively.67,156,157 The use of Pictet-Spenglerase enzymes to generate the 















































and stereoselective step. There are a few known Pictet-Spenglerase enzymes capable 
of generating a THIQ scaffold, as discussed in Section 1.7, however by far the most 
widely explored is NCS, involved in BIA biosynthesis.19 The NCS enzyme isolated from 
Thalictrum flavum, TfNCS has been shown to have a substrate scope that is much 
wider than the natural substrate scope, accepting a range of dopamine analogues as 
the amine substrate and various aliphatic and benzylic aldehydes or ketones as the 
carbonyl substrate, thus generating a wide range of pharmaceutically-relevant 
THIQs.21,36,118 
 
3.1.3 Alpha-substituted aldehydes as NCS substrates 
Previous investigations into the NCS substrate scope have reported poor tolerance 
towards a-substituted aldehydes (84-87, Scheme 3.1). Previously, when Ruff et al. 
explored the use of D29TfNCS with 2-(1-napthyl)propanal (87) and cyclic 
carboxaldehydes with dopamine, no Pictet-Spenglerase products were detected, which 
was rationalised as being due to a lack of conformational space in the active site.21,31 
The acceptance of 1-naphthalene acetaldehyde but not 2-(1-napthyl)propanal (87) also 
led to the rationale that more generally 𝛼-methyl substituted aldehydes were not well 
tolerated by NCS (Scheme 3.1). Interestingly, Nishihachijo et al. and Pesnot et al. 
observed low levels of dopamine consumption when using 𝛼-methyl substituted 
aldehydes isobutanal (84) and 2-phenylpropanal (85) with Coptis japonica NCS 
(CjNCS2), indicating that an NCS catalysed reaction may have occurred but no 
products were isolated or characterised.22,158 
 
 
Scheme 3.1: NCS a-substituted aldehyde substrate scope demonstrated in previous 
















Incorporating a-methyl aldehydes into THIQs is challenging using traditional organic 
synthetic methods as potentially four different isomers can be formed if the reaction is 
regioselective and eight different isomers if not. If a single enantiomer of aldehyde was 
used, which two diastereomers would be generated. Many single-isomer 𝛼-methyl 
substituted aldehydes are not commercially available and have been accessed via 
another available chiral molecule or synthesised using chiral auxiliary methods159,160 
and via asymmetric hydroformylation161. However, these methods are step-intensive, 
often involve the use of toxic reagents and gaining a high e.e. in the product is 
challenging due to racemisation. The resulting aldehyde products can also be volatile 
and prone to oxidation.162 Thus, incorporating a single enantiomer aldehyde into the 
product using non-enzymatic routes is non-trivial and can lead to poor enantiopurity in 
the product.  
 
Accessing the resulting THIQs from reactions between a dopamine analogue and an 
𝛼-methyl aldehyde is also pharmaceutically relevant.  Products of this reaction have 
been reported to possess bronchodilatory activities (88) and a corresponding 
isoquinoline (89) has also been shown to have antimalarial activities.3,163 Indeed, 
corydaline (90), a 13-methyltetrahydroprotoberberine alkaloid is also a major 
constituent of Corydalis tuber which is in clinical trials in Korea for the treatment of 
functional dyspepsia.164 The structures of these compounds are given in Figure 3.2.  
 
 
Figure 3.2: Structures of pharmaceutically relevant THIQs based upon Pictet-Spengler 



















3.2 Results and Discussion 
3.2.1 Initial NCS reactions 
Following the reported acceptance of ketones as substrates,21 with a view to 
significantly extending the scope of the Pictet-Spenglerase NCS towards more sterically 
challenging aldehydes, a range of 𝛼-methyl and 𝛼-ethyl substituted aldehydes were 
initially tested as substrates. Reactions were first performed using 1 equivalent of 
dopamine (5) and 1 equivalent of aldehyde (84, 85, 91, 92) (Scheme 3.2) using either 
DMSO or acetonitrile as a co-solvent as previous studies have shown that the optimal 
co-solvent can be substrate dependent.31 For NCS-catalysed reactions with ketones, 
using DMSO as the co-solvent gives superior reaction rates compared with using 
acetonitrile, with five-fold increases in product formation observed. This is hypothesised 
to be due to shifting the reaction equilibrium from amine/ketone towards imine 
formation, thus enhancing enzymatic turnover.31 This has also been shown to be the 
case with other enzymes, with the presence of different organic solvents capable of 
affecting the stability, reaction rate and selectivity.165 Sodium ascorbate (1 e.q.) was 
added to the reaction mixture to reduce oxidation of 5 and the aldehyde substrates, 








Scheme 3.2: NCS reactions initially performed between dopamine and a range of a-methyl 
substituted aldehydes. Reaction conditions with NCS: dopamine HCl (10 mM), aldehyde (10 
mM), sodium ascorbate (5 mM), D33TfNCS (0.2 mg mL-1) in HEPES buffer (100 mM, pH 7.5) 
with DMSO (10% v/v) at 37 oC for 3 h, 250 µL scale reactions. Conversions determined based 
on product formation compared to calibration curves of the products.  
 
Analytical HPLC results (method 1) showed the presence of product peaks (93 – 96) 
for all aldehydes tested in the expected range (6-8 min).31 Reactions were therefore 
performed on a preparative scale to enable conversions to be determined based upon 
calibration curves of purified product standards. Dopamine and aldehydes are both 
oxidatively sensitive so conversions could not be determined by starting material 
depletion.  
 
Conversions were shown to be 32-57% (Scheme 3.2), determined by measuring 
product formation using HPLC analysis (method 1), compared to calibration curves of 
purified products. Using DMSO as the co-solvent resulted in slightly improved 
conversions with two of the aldehydes tested (91 and 92), therefore in later enzymatic 
reactions, this co-solvent was used rather than acetonitrile. It is unknown why a more 
significant solvent-effect is observed with ketones rather than with a-methyl substituted 
aldehydes. However, iminium ion formation is more readily favoured with aldehydes 
































has less of an effect on iminium formation. The conversions observed with these 
substrates were also significantly higher than those reported previously. Nishihachijo et 
al. reported only 6% and 8% relative activity for reactions between dopamine 5 and 
aldehydes 84 or 85, respectively using CjNCS2 (NCS isolated from Coptis japonica) as 
the biocatalyst.158 The reaction conditions reported were using 10 mM of both 
substrates with 1% DMSO as the co-solvent for 15 min. Lower conversions could 
therefore be accounted for by shorter reaction times (15 min vs. 3 h), lack of reducing 
agent to stabilise the dopamine, issues of aldehyde solubility and differing substrate 
scopes of CjNCS2 and TfNCS.  
 
CjNCS2 has previously been shown to have a different substrate scope to TfNCS, with 
ketones not being accepted as substrates. No product was observed for TfNCS-
catalysed reactions between dopamine (5) and 2-naphthalen-1-ylpropanal (87) 
(Scheme 3.1) in reactions performed by Ruff et al.21 However, this aldehyde is 
significantly bulkier than 85, so it is possible that it does not fit into the enzyme active 
site. Lower substrate loading was also used (1 mM amine and 1 mM aldehyde) by Ruff 
et al. and recent studies have shown that increased substrate loading (ca. 10 mM) 
improves conversions, particularly with non-natural substrates.36 This is unsurprising 
considering that the Kd of TfNCS for dopamine (5) is 5 mM.26 
 
1H-NMR analysis of the products generated using a racemic aldehyde substrate (85, 
91, 92, Scheme 3.2) showed two different environments for the 1-H proton (4-5 ppm), 
with a major and minor product formed, thus suggesting that two diastereomers of the 
product were present (Figure 3.3). TfNCS has been reported previously to generate 
THIQs with S-stereochemistry at the C-1 position and it was rationalised that this 
stereochemical preference is retained. As a racemic aldehyde was used, it is possible 
that only one enantiomer of aldehyde was accepted, i.e., a kinetic resolution of the 
aldehyde occurred. Therefore, if equal molar quantities of amine and aldehyde were 
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used, the maximum conversion possible would be 50%, if no in situ racemisation of the 
aldehyde takes place and that only one enantiomer of aldehyde is accepted. One 
equivalent of aldehyde was used for initial screening with a-methyl substituted 
aldehydes (Scheme 3.2) and the maximum conversion observed in the reactions was 
57%. A conversion >50% may also indicate that some aldehyde racemisation occurred.  
 
Figure 3.3: Two chiral centres are generated in the THIQs resulting from NCS reactions 
between dopamine and racemic a-methyl substituted aldehydes.  
 
Reactions using two equivalents of aldehyde were investigated using wild-type NCS 
(WT-D33TfNCS) and dopamine 5 with aldehydes 84, 85, 91, 92 (Scheme 3.3), using 
otherwise the same conditions as described in Scheme 3.2. Conversions were 
improved, with all 𝛼-methyl substituted aldehydes (84, 85, 91, 92) readily accepted by 
TfNCS to give products 93-96 in high HPLC yields (87-97%). Yields decreased slightly 
with increased steric bulk of the aldehyde, probably due to steric constraints in the 
enzyme active site. Aldehyde 97 was probably less readily accepted likely due to less 
rotational freedom of the alkyl chain in the active site and reduced reactivity of the 
conjugated aldehyde. THIQ 98, formed by reaction with an a-ethyl-substituted aldehyde 
99, was also investigated to see whether the substrate scope could be further extended, 
but the product was formed in a significantly lower HPLC yield (21%) most likely due to 












Scheme 3.3: TfNCS reactions with dopamine and the 𝛼-methyl and 𝛼-ethyl substituted 
aldehydes using two equivalents of aldehyde. Reaction conditions with NCS (black): 
dopamine.HCl (10 mM), aldehyde (20 mM), sodium ascorbate (5 mM), D33TfNCS (0.2 mg mL-
1) in HEPES buffer (100 mM, pH 7.5) with DMSO (10% v/v) at 37 oC, 250 µL scale reactions. 
Reaction conditions with KP (blue)i: dopamine.HCl (10 mM), aldehyde (20 mM), ascorbic acid 
(5 mM) in potassium phosphate buffer (KPi) (0.3 M, pH 6) with acetonitrile (50% v/v) at 60 oC. 
Yields were determined by monitoring product formation against standards (by HPLC) unless 
otherwise indicated; diastereomeric ratios (d.r.s) for stereoselective reactions were determined 
by 1H-NMR spectroscopya. The conversion was determined by monitoring dopamine 
consumption for products 98 and 100. Figure reproduced from Roddan et al.148 
 
Analogous reactions to the higher yielding enzyme reactions were also performed 
without enzyme using potassium phosphate (KPi) and acetonitrile (1:1) to give the 
racemic products 93-96 in 44-82% yield (given in blue, Scheme 3.3).15 Comparison of 
the RP-HPLC data with that generated by an NCS-mediated reaction indicated that no 
or traces of the ortho-product were formed in all cases, reflecting the more sterically 
demanding nature of the 𝛼-substituted aldehydes.15 For reactions with linear, aliphatic, 






























KPi (rac)-2b  56%
 (1S,1’R)-94  92%
d.r.  94:6
KPi (1RS,1’RS)-3b 44%
























observed.31 No reactions were observed using 97 and 99 as substrates, likely due to 
steric constraints in the reaction transition state where there is an unfavourable 
interaction between the aldehyde side-chain and the meta-hydroxyl of dopamine (5), as 
demonstrated in Scheme 3.4.  
 
Scheme 3.4: Trace levels of ortho-THIQs were formed during KPi-mediated Pictet-
Spengler reactions between dopamine and a-methyl aldehydes. This is likely to be due to 
steric clashes between the meta-hydroxyl group and the methyl or R groups of the aldehyde.   
 
In all cases, reaction yields were lower in reactions using KPi as a catalyst (no NCS 
present) compared to with NCS (Scheme 3.3). This also provided a rationale as to why 
no background reaction was observed in NCS-catalysed reactions when replacing the 
protein sample with an equal volume buffer. The racemic product (rac-93) generated 
using the phosphate-mediated Pictet-Spengler reaction and isolated for use as a 
racemic standard for the chiral HPLC analysis for NCS-generated 93. The increased 
reactivity of NCS compared with KPi as the reaction catalyst highlights the synthetic 
value of the NCS-mediated reactions. The phosphate-mediated reaction with these 
substrates is however useful for generating racemic products in a regioselective 
manner.  
 
3.2.2 Extension of the amine substrate scope 
To extend the range of THIQ products accessible by an NCS reaction involving a-
methyl substituted aldehydes, a range of other amine analogues were screened. 
Reactions were also observed with meta-tyramine (51), norepinephrine (101) and 


























based calibration curves, as these amines explored are less oxidatively sensitive than 
dopamine (5). The conversions gained are given in Table 3.1. In all cases, conversions 
of these amines (51, 101 and 102) using aldehydes (84, 85, 91, 92) were lower than 
those with dopamine (5). The products were therefore not isolated and instead product 
formation was confirmed by LC-MS. The lower conversions are most likely due to the 
different binding modes of the unnatural dopamine substrates into the active site 
leading to a decreased acceptance of the more challenging aldehyde substrates. 
Slightly increased conversions were observed for reactions between 51 and aldehydes 
97 and 99 compared to the analogous reactions using dopamine (5) as the amine 
substrate. Despite lower conversions generally, the expansion of the amine substrate 
scope with these aldehydes highlights the more general applicability of using a-methyl 
substituted aldehydes as NCS substrates.  
 
Table 3.1: Conversions when using 𝛼-substituted aldehydes and a variety of different 
amine analogues. Reaction conditions: amine (10 mM), aldehyde (20 mM), sodium ascorbate 
(5 mM), D33TfNCS (0.2 mg mL-1) in HEPES buffer (100 mM, pH 7.5) with DMSO (10% v/v) at 
37 oC for 18 h, 250 µL scale reactions. ✔= product observed but no conversion determined. x 
= no conversion (i.e. no product observed). Reactions were performed in triplicate and were 
consistent within 10% error. Conversions determined based on amine consumption (HPLC 
method 1) and confirmed by the detection of the products by LC-MS. Figure adapted from 
Roddan et al.148 
Amine 
Aldehyde 
84 91 92 85 97 99 
 
5 
97% 92% 90% 87% 16% 21% 
 
51 
34% 48% 45% 69% 25% 26% 
 
101 
✔ 65% 57% 79% x x 
 
102 














3.2.3 Determination of the reaction stereoselectivity  
For reactions with a-methylated aldehydes, stereoselectivities were explored for the 
highest yielding reactions with dopamine (5). Aldehyde 84 is achiral and chiral HPLC 
analysis of the product 93 indicated it was formed in >95% e.e., by comparison to the 
racemic standard prepared using the KPi-mediated reaction (Scheme 3.3). This was 
assigned as the (S)-isomer, based upon literature precedent where NCS has been 
shown to exclusively generate THIQs with (S) stereochemistry at C-1. The elution order 
of the two enantiomers during chiral HPLC analysis using a Astec® Chirobiotic T2 
column was also consistent with the literature, whereby the (S)-enantiomer of THIQs 
always elutes first.14,22 THIQs 94-96 possess two chiral centres, and analysis of the 1H 
NMR spectra revealed two proton environments for 1-H (ca. 4-5 ppm), indicating that 
two diastereomers of product had been formed. A significant majority of one 
diastereomer was observed. Diastereoisomeric ratios (d.r.s) were determined by 1H 
NMR spectroscopy, and high d.r.s were noted for 94 and 96 (94:6) (Scheme 3.3). A 
lower diastereomeric ratio was observed in 95 (82:18).  Since wild-type TfNCS typically 
generates (S)-THIQs at C-1, it was rationalised that the stereoselectivity at this position 
was retained and that a kinetic resolution of the aldehyde had occurred leading to a 
mixture of (S) and (R) stereochemistry at the C-1’ position.  
 
To determine which aldehyde was preferentially accepted and thus determine the 
predominate stereochemistry at the C-1’ position, the synthesis of two single 
enantiomer aldehydes, (2R)-91 and (2S)-91 was explored. Aldehyde 85 was not 
prepared due to the fast racemisation rates reported at pH 7.5, and aldehyde 91 was 
chosen over 92 because higher d.r.s in the resultant THIQ product were observed.166 
The analogous alcohol to aldehyde 91, (S)-2-methyl-butan-1-ol ((S)-103), is 
commercially available in high e.e. (>95%) and the synthesis of (R)-2-methyl-butan-1-
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ol ((2R)-91)was investigated via the use of an Evan’s auxiliary, as shown in Scheme 
3.5.  
 
Scheme 3.5: Synthetic route towards (2R)-91.  
 
The first step, the amide coupling of the oxazolidinone (104) to butyryl chloride, 
proceeded to give the desired product, 105 in high yield (96%) after flash column 
chromatography.167 To achieve high selectivity in the methylation step, it was found 
after several attempts that the methyl iodide needed to be added slowly, over five 
minutes, and cooled to 0 oC before addition to the reaction mixture. A high 
diastereomeric ratio in the methylated product (106, 95:5) was achieved with only trace 
amounts of the other diastereomer (with S stereochemistry in the chiral centre 
generated after methylation) present.167 The reaction to remove the oxazolidinone 
group to give the alcohol used literature reaction conditions, however isolation of the 
alcohol was challenging. Initially, the reaction was performed using LiAlH4, however the 
alcohol was trapped by the aluminium salts and could not be isolated by extraction or 
distillation. The reaction was therefore attempted using lithium borohydride in MeOH.168 
After a straightforward workup (addition of NaHCO3 followed by extraction into diethyl 
ether), a mixture of the alcohol (103) and oxazolidinone (104) remained. Attempts to 
isolate the alcohol by distillation were unsuccessful, likely due to trapping by the solid 
oxazolidinone and the high volatility of the alcohol. Therefore, the alcohol was obtained 
by column chromatography using low boiling point solvents, diethyl ether and n-hexane, 




































attempted using Dess-Martin periodinane, however separation of the aldehyde from the 
Dess-Martin reagent was not possible by extractive workup as both aldehyde and Dess-
Martin periodinane are organic and water soluble. The aldehyde is also highly volatile 
and prone to racemisation and polymerisation, so a simple extraction process was 
required without any further purification steps. Therefore, a Swern oxidation was used 
to give the final product, (2R)-91.169 The resulting residue was partially purified by silica 
chromatography immediately after workup then used directly for enzymatic reactions 
without further purification to avoid issues of aldehyde volatility, racemisation and 
polymerisation. The aldehyde, (2S)-91 was prepared by an analogous Swern oxidation 
from the commercially available alcohol, (2S)-103 (commercially available at 95% e.e.) 
and was obtained in 68% e.e. 1H-NMR spectroscopic data indicated reasonable levels 
of purity for both aldehydes, and chiral GC analysis was used to determine e.e.s (with 
the method devised by Helena Philpott, Hailes group). Chiral GC analyses of the two 
aldehydes compared with a racemic standard are given in Figure 3.4.  
 
Figure 3.4: Chiral GC analysis of (2R)-91 and (2S)-91. Figure adapted from Roddan et al.148 
 
TfNCS reactions were performed with both (2R)-91 and (2S)-91 using the wild-type 
enzyme using the same reaction conditions as previously described, except 3 e.q. of 
aldehyde were added to account for impurities present. Yields were significantly lower 
than previously reported (Scheme 3.3), most likely due to aldehyde impurities present. 
HPLC analysis (Scheme 3.6a) of the reactions under the same conditions indicated that 

























resolution was occurring when using the racemate. Indeed, the low levels of product 
formation with (2S)-91 (68% e.e.) most likely arose from the small amount of (2R)-
isomer present (~16%) or in situ racemisation. Following the established selectivity at 
C-1 for TfNCS and the NMR spectroscopic data, it was concluded that the major isomer 
formed when using rac-91 was (1S,1'R)-94 (d.r. 94:6). It was also rationalised that the 
same stereoselectivity most likely arises when using 92 to give (1S,1'R)-95 (d.r. 82:18) 
as the major isomer out of the 4 possible isomers (Scheme 3.6b).  
 
 
Scheme 3.6: Analytical analysis of the stereochemical outcomes of NCS reactions with 
a-methyl substituted aldehydes. a. Analytical HPLC analysis (method 1) of enzymatic 
reactions between dopamine (5) and isomers (2R)-91 and (2S)-91. Reaction conditions: 5 (10 
mM), (2R)-91 (30 mM) or (2S)- 9 (30 mM) sodium ascorbate (5 mM), purified D33TfNCS (0.2 
mg mL-1) in HEPES buffer (100 mM, pH 7.5) with DMSO (10% v/v). The total reaction volume 
was 250 µL and they were performed at 37 oC with results confirmed in triplicate. b. Analytical 
HPLC analysis of enzymatic and KPi reactions between 5 and 85. Reaction conditions for 
enzymatic reaction: dopamine.HCl (10 mM), 85 (20 mM), sodium ascorbate (5 mM), purified 
D33TfNCS (0.2 mg mL-1) in HEPES buffer (100 mM, pH 7.5) with DMSO (10% v/v) at 37 oC for 
18 h, 250 µL reaction volume. Reaction conditions for KPi reaction: dopamine.HCl (10 mM), 85 
(20 mM), sodium ascorbate (20 mM) in KPi buffer (0.3 M, pH 6) with acetonitrile (50% v/v) at 60 
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RP-HPLC analysis of racemic THIQ 96 generated using the non-stereoselective KPi-
mediated Pictet-Spengler reaction15, revealed two product peaks corresponding to 4-
isomers (2 sets of diastereoisomers) in a ratio of 1:1 (Scheme 3.6b). 1H-NMR 
spectroscopy confirmed that only a trace of the ortho-product was formed. When 
compared to HPLC data for the enzymatic reaction, it was evident that an excess of 
one diastereomer was formed (ratio ~95:5) (Scheme 3b) in the enzymatic reaction 
which was consistent with the 1H NMR data. Since the diastereomers, but not the 
enantiomers are separable by RP-HPLC, it was concluded that the first peak (retention 
time = 5.8 min) corresponded to (1S,1’R)-96 and (1R,1’S)-96 and the second peak 
(retention time = 5.9 min) corresponded to (1S,1’S)-96 and (1R,1’R)-96. Since 
arylacetaldehydes react with TfNCS to give the (S)-isomer at C-1 in high e.e.s,22 and 
following the enantioselectivity data for 91, this highlighted that the major product was 
likely to be (1S,1'R)-96 (d.r. 94:6). Attempts to further confirm this result by chiral HPLC 
separation of the four different stereoisomers present were unsuccessful and the 
diastereomers could not be separated by preparative HPLC. Clearly, the enzymatic 
reaction with wild-type TfNCS is an excellent route to such THIQs, as the reactions give 
higher yields than the KPi reaction and there is potentially stereochemical control at 
both chiral centres.  
 
3.2.3 Scale-up biotransformation 
There are often challenges associated with performing biocatalytic reactions at scale. 
To determine whether the NCS-catalysed reactions involving a-methyl substituted 
aldehydes could be readily scaled up, a 0.5 g scale reaction was performed using 
clarified cell lysate of D33TfNCS with 5 and 91 as the aldehyde substrate. The product 
was isolated via an extractive workup (method 7), developed by Jianxiong Zhao (Hailes 
group) involving the precipitation of the enzyme by addition of acid (1 M HCl) and 
centrifugation, followed by isolation of the product and remaining aldehyde by adjusting 
the pH of the aqueous enzyme reaction mixture to 7.5 and extracting the product into 
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ethyl acetate.118 The amine pKa of dopamine is predicted to be 8.93, therefore it should 
remain in the aqueous layer.170  Drying of the organic phases by evaporation and 
resuspension of the resulting residue in 1 M HCl, followed by extraction with dimethyl 
carbonate (chosen as an environmentally-benign solvent) to remove any remaining 
aldehyde, resulted in the isolation of the pure product, as determined by NMR analysis, 
as the HCl salt. The reaction went to a 96% yield (HPLC yield based upon calibration 
curve of the purified product) and an isolated yield of 88% was achieved, consistent 
with the smaller scale reactions (92% HPLC yield). 1H-NMR spectroscopic analysis of 
the product 94 determined that the stereoselectivity of the reaction was mostly retained 
with a d.r. of 87:13 whereas in the small-scale reaction with purified enzyme, a d.r. of 
94:6 was achieved. The reduction in diastereomeric ratio is most likely due to a small 
amount of background phosphate-mediated reaction arising from the use of cell lysate 
rather than purified enzyme. It is therefore expected that the d.r. could be improved by 
using purified enzyme or buffer-exchanged cell lysate instead.  
 
3.2.4 Reactions with enzyme variants 
To investigate the effect of NCS variants on the acceptance of a-methyl aldehydes and 
products formed, several available 𝛥29TfNCS mutants were used as enzyme lysates, 
namely L76V, A79I, A79F, F80L, M97V, M97L, M97F and Y108F with dopamine 5 and 
aldehydes 84, 91, and 85. The enzymes were expressed as 50 mL culture volumes by 
Daniel Méndez-Sánchez using the standard protocol for NCS expression. The enzyme 
variants all involved single point mutations of active site residues and were designed 
by a previous PhD student, Benjamin Lichman (Ward and Hailes groups),  based upon 
docking experiments and previous mutagenesis studies to increase the space in the 
active site for bulkier substrates.28,22 These enzyme variants were generated by site-
directed mutagenesis by B. Lichman and have been shown to exhibit differing activities 
with different NCS substrates, most notably the mutant A79I has been shown to have 
superior activities when ketones are used as substrates36 and L76A has been shown 
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to affect aldehyde substrate acceptance.28 All NCS variants were over-expressed 
(Figure 3.5) and used as clarified cell lysate in enzymatic reactions. 
 
Figure 3.5: SDS-PAGE analysis of D29TfNCS single point variant expression. Lanes: 1, 
Benchmark protein ladder (masses given in kDa). 2. Wild type. 3. L76V. 4. A79I. 5. A79F. 6. 
F80L. 7. M97V. 8. M97L. 9. DM97F. 10. Y108F.  
 
First, WT-𝛥29TfNCS was used in the reaction and no difference in reactivities or the 
products formed was found compared to with 𝛥33TfNCS. For all three aldehydes, the 
mutant A79I showed higher product yields by HPLC compared to WT and the other 
NCS variants (Figure 3.6), a characteristic that has been observed with ketones to an 
even greater extent.36 This mutation has been rationalised to increase conversions of 
hydrophobic substrates due to enhanced hydrophobicity in the active site resulting in 
increased substrate affinity. For the aldehydes 84 and 85, M97V showed increased 
yields compared to the wild-type enzyme, with complete conversions observed with 
both. M97 mutants have been used with ketone substrates where decreased yields 
were noted with a reduction in steric bulk at this position i.e. poorer conversions with 
M97V compared with the wild-type.36 Interestingly, the opposite trend was observed 
















Figure 3.6: Yields of TfNCS reactions with dopamine 5 and aldehydes 84 (a), 91 (b) or 85 
(c) to give products 93, 94 and 96, respectively. Reaction conditions: 5 (10 mM), aldehyde 
(20 mM), sodium ascorbate (5 mM), D29TfNCS lysate of variant (25% v/v) in HEPES buffer (100 
mM, pH 7.5) with DMSO (10% v/v) at 37 oC for 18 h, 200 µL scale reactions; Yields were 
determined by monitoring product formation against standards by HPLC (see Appendix). 
Diastereoisomeric ratios of the major (1S,1’R) product to the minor (1S,1’S) product for each 
reaction product of 96 are; WT, 90:10; L76V, 97:3; A79I, 89:11; A79F, 89:11; F80L, 95:5; M97V, 
97:3; M97L 91:9; M97F, 92:8; Y108F, 93:7. Reactions were performed in triplicate and error 
bars are the standard deviations. Figure adapted from Roddan et al.148 
 
HPLC analysis of the reactions between dopamine 5 and aldehyde 85 showed that 
different active site mutants of TfNCS gave different diastereoisomeric ratios of the 
products. A ratio of 90:10 was observed for wild-type NCS lysate, lower than with 
purified NCS (94:6), most likely due to the increased background phosphate reaction 
when using lysate. The two most promising active site mutants observed were L76V 
and M97V, with diastereomeric ratios of 97:3 observed in the products (96) generated. 
To fully explore the change in reaction selectivity of these two mutants, both mutant 
enzymes (M97V and L76V) were purified, and reactions performed between dopamine 
5 and aldehydes 84, 91, 85 and phenylacetaldehyde 76. The three NCS variants (L76V, 
M97F and M97V) were expressed on a 500 mL scale and purified by Nickel affinity 
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Figure 3.7: SDS-PAGE analysis of His-trap purifications of three D29TfNCS single-point 
variants; L76V, M97F and M97V. Lanes: 1, Benchmark™ Protein Ladder (or Prestained 
PageRuler Plus™ for L76V), masses given in kDa. 2, clarified cell lysate loaded onto column. 3, 
flow through with lysis buffer. 4, wash with 6 CV 20 mM imidazole buffer. 5, wash with 6 CV 40 
mM imidazole buffer. 6-13, wash with 500 mM imidazole buffer and collected 3 mL fractions. 














Figure 3.8: Yields and e.e.s of reactions of products of enzymatic reactions using purified 
TfNCS active site mutants. Reaction conditions: 5 (10 mM), aldehyde (20 mM), sodium 
ascorbate (5 mM), purified TfNCS (0.2 mg mL-1) in HEPES buffer (100 mM, pH 7.5) with DMSO 
(10% v/v) at 37 oC for 18 h; Yields were determined by product formation against standards 
using HPLC (SI Section 9.2). Reactions were performed on a 250 µL scale for 93, 96 and 77. 
Reactions were performed on a 1 mL scale for 94. e.e.s were determined by chiral analytical 
HPLC for 93 and 77 (method 3). Diastereoisomeric ratios were determined by 1H-NMR 
spectroscopy for 94. The diastereoisomeric ratio was determined by analytical HPLC for 96. No 
background reactions were observed, so HPLC yields for a no enzyme control are not shown. 
Figure adapted from Roddan et al.148 
 
Aldehyde 76 was used as a substrate with all three mutants to help determine whether 
the variants were affecting the stereochemistry of the product at the C-1 position. 76 is 
often used as an alternative to the natural aldehyde substrate, 4-HPAA (6), as it is 
commercially available and less-oxidatively sensitive. As previously reported, the 
reaction with wild-type TfNCS gave a high e.e. in the product 77,22 with only the S-
enantiomer of product observed by chiral HPLC (Figure 3.9), as did all the NCS variants 
tested here, implying that there was no effect on the stereochemistry at the C-1 position. 
The racemic standard of 77 was prepared by a phosphate-mediated Pictet-Spengler 
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HPLC (method 8).31 Comparison with RP-HPLC traces of the same samples 
determined that for all enzymatic reactions, the peak at 28 – 30 min retention time 
corresponded to dopamine rather than (R)-77. 
 
Figure 3.9: Chiral HPLC analysis of 77 by method 3 using NCS variants as reaction 
catalysts. Reaction conditions for enzymatic reactions: 10 mM 5, 20 mM 76, 5 mM sodium 
ascorbate, 0.2 mg mL-1 purified D29TfNCS (wild-type = WT, D29TfNCS-M97F = M97F, 
D29TfNCS-M97V = M97V, D29TfNCS-L76V = L76V) in HEPES buffer (100 mM, pH 7.5) with 
10% v/v DMSO at 37 oC for 18 h, 250 µL scale reactions. Reaction conditions for preparation of 
racemic 77: 10 mM dopamine.HCl, 20 mM aldehyde, 5 mM ascorbic acid in phosphate buffer 
(0.3 M, pH 6) with 50% v/v acetonitrile at 60 oC, 10 mL scale. 77 was isolated by preparative 
HPLC (method 8). A 1 mM solution of dopamine was used and a 5 µL injection volume was 
used. Figure adapted from Roddan et al.148 
 
For all reactions with 84 as the aldehyde substrate, a high enantiomeric excess (> 95%) 
in the product 93 was also retained. The enantiopurity of 93 also demonstrated that the 
variants were not affecting the stereochemistry at the C-1 position of the products with 
a-methyl aldehydes as substrates. Yields with M97F and L76V and 84 as the aldehyde 




Figure 3.10: Chiral HPLC analysis of 93 using HPLC method 3) using NCS variants as 
reaction catalysts. Reaction conditions for enzymatic reactions: 10 mM 5, 20 mM 84, 5 mM 
sodium ascorbate, 0.2 mg mL-1 purified D29TfNCS (wild-type = WT, D29TfNCS-M97F = M97F, 
D29TfNCS-M97V = M97V, D29TfNCS-L76V = L76V) in HEPES buffer (100 mM, pH 7.5) with 
10% v/v DMSO at 37 oC for 18 h, 250 µL scale reactions. Reaction conditions for preparation of 
racemic 93: 10 mM 5, 20 mM 84, 10 mM ascorbic acid in phosphate buffer (0.3 M, pH 6) with 
50% v/v acetonitrile at 60 oC, 10 mL scale. A 1 mM solution of dopamine was used with an 
injection volume of 5 µL. The peak at 21 min corresponds to a small amount of ortho-THIQ 
formed. Figure adapted from Roddan et al.148 
 
Most notably, for all 3 a-methyl aldehydes tested as substrates, the products of 
reactions with the L76V variant showed equal or improved stereoselectivities when 
compared with the wild-type enzyme. An increased yield was observed with 85 as the 
aldehyde substrate, potentially as extra space is created in the active site. There was 
a lowering in d.r. for all products in M97F reactions with the chiral a-methyl aldehydes, 
suggesting that this mutant is affecting the stereochemistry of the C-1’ position. With 
the bulky, chiral aldehyde 85 however, the diastereomeric ratio in the product 96 was 
improved compared with the wild type for both M97V and L76V variants, and both gave 
the product in almost quantitative yields. For both variants, there was also little change 
in diastereomeric ratio between using purified enzyme compared with enzymatic lysate 
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(Figure 3.6 vs. Figure 3.8), highlighting that purified enzyme is not essential for gaining 
a high d.r. in the product for these reactions. Interestingly, when using 91 as the 
aldehyde substrate, a reduction in the diastereomeric ratios in the products were 
observed when using TfNCS variants altered at position-97 (M97F and M97V).  
 
3.2.5 Structural studies of NCS reactions with a-methyl aldehydes 
Previous structural studies of TfNCS by X-ray crystallography and computational 
docking have elucidated that a ‘dopamine-first’ rather than an ‘aldehyde-first’ is the most 
probable mechanism of action. The roles of key active site residues were also 
identified.28,30  One of the important pieces of evidence gained was from a co-
crystallised structure of the wild-type enzyme with a non-productive, secondary amine 
analogue of the iminium ion intermediate bound in the active site, based on the 
assumption that this would mimic the behaviour of the iminium ion. The intermediate 
mimic (16) that was designed was based upon the TfNCS reaction between dopamine 
(5) and a methylated analogue of natural aldehyde substrate, 4-HPAA (6) to minimise 
oxidative sensitivity.30 Therefore, to gain more insight into the acceptance of a-methyl 
aldehydes by TfNCS and expand the mechanistic understanding of TfNCS beyond the 
natural substrates, a similar approach was used, investigating the co-crystallisation of 
a-methyl substituted, secondary amine mimics.  
 
Initially, a reaction mimic was synthesised based on the reaction between dopamine (5) 
and aldehyde 91 because the stereochemical outcome of this reaction with TfNCS had 
been confirmed experimentally (Scheme 3.6). The mimic was synthesised in an 
analogous manner to that performed previously (Section 2.2.4).30 The synthetic route 
is given in Scheme 3.7. 
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Scheme 3.7: Synthetic route towards the secondary amine mimic, 109 of the iminium ion 
intermediate of the Pictet-Spengler reaction between 5 and 91.   
 
The synthesis of 68 is further discussed in Chapter 2 and was performed on a 5 g scale 
so that it could be used for the synthesis of other secondary amine mimics (Sections 
2.2.4, 5.2.13, 6.2.4). The amide coupling step was performed using a one-pot method 
devised by Leggio et al., involving the in situ activation of the carboxylic acid by 
conversion to the corresponding acyl chloride by reaction using thionyl chloride.138 The 
resulting amide (107) was obtained in reasonable yield (24%) and was purified by 
column chromatography to remove any excess benzyl alcohol from the second reaction 
step. The reduction of the amide (to give 108) followed by benzyl deprotection was 
performed in an analogous manner to that described in the literature, with the final 
product 109 isolated in 81% yield after purification by preparative HPLC (method 8). 
109 was prepared as the TFA salt at 200 mM in DMSO ready for co-crystallisation.  
 
A truncated construct of TfNCS, D33TfNCS with residues in the flexible, terminal signal 
peptides removed (1-33 and 196-210) was used previously and shown to be highly 
soluble during purification and crystallisable under a range of conditions. A discussion 
of the expression and purification of D33TfNCS is given in Section 2.2.1. Resultant 
protein crystals can also be formed in a range of conditions and are capable of 
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with the apo structure, the highest resolution structures were found in conditions in the 
96-well Structure Screen (Molecular Dimensions). Therefore, initial screens were 
performed using this commercial screen with the sitting-drop method. The final 
concentration of 109 used was 10 mM (i.e., 5% v/v) with 12.8 mg mL-1 D33TfNCS. 
Crystals were observed under a range of conditions however diffraction was only 
observed in two conditions, D10 (50 mM KH2PO4, 20% v/v PEG 8,000) and F10 (100 
mM MES pH 6.5, 12 % w/v PEG 20,000). However, poor resolution was observed (3 – 
4 Å). All crystals were cryo-cooled using ethylene glycol (20%) in the mother liquor as 
the cryoprotectant.  
 
In an attempt to improve the crystallographic resolution, four-corner screens were 
prepared i.e., optimising the precipitation condition by testing conditions which vary 
slightly from the original condition. For the D10 condition, a 96-well plate was prepared 
varying the buffer condition from 40 – 60 mM KH2PO4 and 15 – 25% w/v PEG 8,000, 
and for F10, the buffer condition was varied from 50 – 150 mM MES pH 6.5 and 8 – 16 
% w/v PEG 20,000. For the D10 four-corner screen, numerous crystals were obtained 
and with five different crystals sent to a synchrotron for data collection. Unfortunately, 
poor resolution was observed for all datasets (2.8 – 3.5 Å) with no positive difference 
density observed in the enzyme active site. More promising results were observed with 
crystals from the F10 optimisation screen, with a dataset collected at 2.5 Å in space 
group P3121. Some positive difference density was observed in the enzyme active site 
near to K122, where the catechol binds, however the ligand could not be built in 
convincingly (Figure 3.11) and it is possible that a water network is being observed. 
This suggested that there were issues with poor ligand occupancy, possibly combined 
with multiple conformations of the ligand in the active site.  
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Figure 3.11: Positive difference density observed in the active site of D33TfNCS gained 
from co-crystallisation with reaction mimic, 109. Map is shown at contour level 0.93 rmsd. 
Structure gained from F10 four-corner screen optimisation. Image generated using COOT.171 
Figure adapted from Roddan et al.148 
 
The crystals gained for previously co-crystallised structure of D33TfNCS with an active 
site bound reaction intermediate analogue (PDB: 5NON) were obtained via the hanging 
drop method in 10% w/v PEG 1000 and 10% w/v PEG 8000. Therefore, crystals were 
prepared using the same method, but instead using the mimic, 109. A small amount of 
electron density was observed in the active site; however, ligand placement was 
indeterminable. Soaking of the mimic into apo crystals was also unsuccessful, with 
crystals dissolving upon incubation with the mimic. It was suspected that issues with 
the binding of this new mimic could be for various reasons. Firstly, a racemic formulation 
of the mimic was used, therefore, if both enantiomers were capable of binding in the 
active site, multiple conformations of ligand would be observed, making modelling of 
the ligand challenging. Also, from enzymatic assays it is known that a-methyl 
substituted aldehydes are more challenging substrates for NCS, with high substrate 
loading (10 - 20 mM) required for a successful reaction. The mimic used here, 109, is 
based on the reaction between dopamine and an aliphatic aldehyde. The aliphatic chain 





occupancy and single ligand placement would be required to observe the ligand clearly 
in the active site. Therefore, with these considerations in mind a new mimic was 
synthesised, based upon the reaction between dopamine (5) and (R)-85, because this 
enantiomer of aldehyde was shown previously to be preferentially accepted by the 
enzyme. It was hoped that having a single enantiomer of mimic and extra electron 
density from the additional phenyl ring would improve ligand placement. An analogous 
synthetic route was performed to generate the new mimic (110) and is given in Scheme 
3.8.  
 
Scheme 3.8: Synthetic route towards a secondary amine mimic (110) of the iminium ion 
intermediate of the TfNCS reaction between dopamine 5 and (R)-85.  
 
The synthetic route proceeded as previously discussed except that the amide coupling 
step was performed under milder conditions, using HATU (Hexafluorophosphate 
Azabenzotriazole Tetramethyl Uronium) as the coupling reagent, to ensure that no 
racemisation of the carboxylic acid occurred. The mimic was isolated by preparative 
HPLC (method 8) and chiral HPLC analysis (method 4) was used to determine whether 
any racemisation had occurred during the synthesis. The analogous racemic analogue 
of 110 was therefore also synthesised (rac-110) to provide a racemic standard, using 
racemic carboxylic acid rather than the single enantiomer used for the synthesis of (R)-
110. A high e.e. was obtained in (R)-110 (>99%) (Figure 3.12), and (R)-110 was 






































Figure 3.12: Chiral HPLC analysis of (R)-110. Rac-110 was synthesised in an identical 
manner. Analysis was performed using chiral HPLC method 4. Figure adapted from Roddan et 
al.148 
 
 Initial crystallisation trials were performed using four commercially available 96-well 
screens (Index, PACT, JCSG and Structure). Crystals were observed in a range of 


















Table 3.2: Conditions in which crystals were observed upon co-crystallisation of mimic 
(R)-110 (10 mM) with D33TfNCS (12.6 mg mL-1). The high-resolution limits of the datasets 
obtained are also given. MIB buffer: sodium malonate dibasic monohydrate, imidazole, boric 
acid, PCTP buffer: sodium propionate, sodium cacodylate trihydrate, Bis-Tris propane.  
 
Dataset  Salt Buffer pH Precipitant Dataset 
resolution / Å 
1 - - - 24% w/v PEG 
1500 
20% v/v glycerol 
2.1 




5.5 17% w/v PEG 
10,000 
3.3 




4.6 - 2.5 
4 - 0.1 M 
MIB 
6.0 25% w/v PEG 
1500 
2.8 
5  0.1 M 
PCTP 
6.0 25% w/v PEG 
1500 
2.9 
6  0.1 M 
Bis-Tris 




7 - 0.1 M 
Bis-Tris 




8  0.1 M 
HEPES 





Although high resolution was achieved for dataset 1, no positive difference density was 
observed in the enzyme active site, although the putative gatekeeper residue, F112 
(discussed further in Section 2.2.6) was present in a different rotameric form to the apo 
structure. Dataset 2 was not refined as poor resolution was achieved. Dataset 3 
resulted in a dataset with space group P1211 with some positive difference density 
observed in the active site, although the R-factors were high. Positive difference density 
was also observed in the active site for datasets 4, 5, 6 and 8, with particularly promising 
results observed with datasets 6 and 8 although poor resolution limited ligand building. 
No positive difference density was observed with dataset 7.  
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Therefore, to optimise the crystallisation conditions, a hanging-drop four-corner screen 
was prepared in a 24-well plate around the conditions used for dataset 6, varying the 
buffer concentration from 80 mM – 120 mM Bis-Tris pH 6.5 and the precipitation 
concentration from 18 – 22% w/v PEG-monomethylether 5,000. Crystals only appeared 
in wells with 22% w/v PEG-monomethylether 5,000 with varying concentrations of Bis-
Tris buffer. A range of crystals were sent to a synchrotron (Diamond i24) and one high 
resolution dataset was collected, at 1.8 Å with the precipitant 22% PEG 
monomethylether 5,000, 80 mM Bis-Tris pH 6.5. Enzyme, D33TfNCS (12.3 mg mL-1 in 
20 mM Tris, 50 mM NaCl, pH 7.5) was incubated with (R)-110 (200 mM in DMSO) to 
give a final mimic concentration of 10 mM.  Crystals were grown for 3 days and cryo-
protected in the crystallisation condition containing 20% ethylene   glycol and 10   mM   
of   the   mimic, (R)-110. A co-crystallised structure of 𝛥33TfNCS with mimic (R)-110 in 
the active site was gained at 1.81 Å with a single copy in the asymmetric unit (PDB 















Table 3.3: X-ray data collection and refinement statistics for co-crystallised structure of 
𝛥33TfNCS with a-methyl substituted reaction mimic, (R)-110 bound in the enzyme active 
site.  
 PDB: 6RP3 
Space group  P3221 
a, b, c (Å)  62.26, 62.26, 73.58 
α, β, γ (o)  90.0, 90.0, 120.0  
Resolution range (Å)  43.49-1.81 (1.84-1.81) 
Total number of 
observation  
159646 (4158)  
Total number unique  15507 (745) 
Completeness  99.9 (98.4)  
Multiplicity  10.3 (5.6)  
<I/σ(I)>  10.1 (0.98)  
CC1/2  0.99 (0.64)  
Rmerge  0.090 (1.949) 
Rpim  0.029 (0.842)  
Molecule per ASU  1 
Refinement 
Resolution Range (Å)  43.49-1.81 (1.856-1.809) 
Rwork  0.203 (0.315)  
Rfree  0.245 (0.358)  
Reflection, working  14703 
Reflection, free  763 
Average B factor  28.8 
Rmsd bond angle  1.816 
Rmsd bond length (Å)  0.014 
Ramachandran plot 
Preferred region (%)  95.5 
Allowed region (%)  3.2 
Outliers (%)  1.3 
 
Data processing was performed using the CCP4i2 package. Images collected were 
integrated using XDS Dials.172 Phases were determined by molecular replacement, 
using Phaser173 using an apo dataset of the same NCS construct (D33TfNCS, wild-
type) in the same space group (P3221) as the search model. COOT171 was used for 
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model building of the protein and the ligand and REFMAC5174 used for refinement with 
TLS refinement used to account for anisotropy in the dataset. Groups of atoms were 
assumed to act as a rigid body, of which there is a mean squared displacement, 
therefore modelling the anisotropic motions of atoms and thus can lead to 
improvements in observed R-factors in structure refinement. The final Rwork/Rfree 
factors after refinement were 0.20/0.25 with three molecules of ethylene glycol (arising 
from the cryo-protectant used) and fourty-four water molecules built in.  
 
Compared to the previous apo structure of 𝛥33TfNCS (PDB: 5N8Q), the overall fold of 
NCS was retained (RMSD Ca= 0.587). The only notable differences in active side 
residue conformations were with E110 and M97. The mimic density in the active site 
was less convincing than with the previously co-crystallised structure (PDB: 5NON) 
suggesting partial occupancy and other, minor multiple conformations of the ligand. A 
Polder175 map of the ligand density showed similar density features, with some 
uncertainty in the placement of the dopamine ring (Figure 3.13). However, the 
‘aldehyde-end’ of the mimic could be observed relatively clearly and so this was used 
to help understand why these substrates are accepted and why activity varies with the 
single-point mutants.  
 
Figure 3.13: Electron density of (R)-110 in the active site at contour level 0.81 RMSD. 
Figure adapted from Roddan et al.148 
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In this structure, the ligand is placed with both hydroxyl groups of the catechol hydrogen 
bonded to Lys122 (with distances of 3.28 and 3.02 Å respectively) in a linear 
configuration, likely reflecting a pre-cyclisation conformation (Figure 3.14). Previous 
studies involving the active site mutagenesis of key residues in NCS have shown that 
K122 is essential for catalytic activity and is required for the deprotonation of the meta-
hydroxyl.7,28 The hydrogen bonding distances are further away than in PDB:5NON and 
the mimic appears to be further buried into the active site. The interaction with both 
hydroxyl groups is interesting considering that lower conversions were observed when 
dopamine (5) was exchanged for meta-tyramine (51) as the amine substrate (Table 
3.1). This suggests that this observed additional hydrogen bonding interaction of the 
para-hydroxyl to K122 may be required for holding the amine substrate in the active site 
leading to increased likelihood of a successful reaction.  
 
Figure 3.14: Location of mimic (R)-110 in the active site. Dotted lines show key distances or 
hydrogen-bonding interactions. Associated numbers are distances given in Å. Figure adapted 
from Roddan et al.148 
 
 A hydrogen bonding interaction can also be observed between the secondary amine 
of the mimic and Glu110, which is in a rare conformation, observed in only 1% of 
glutamic acid residues in the PDB, whereas in the previous structure, the amine was 
bound to both E110 and D141. This interaction is consistent with the ‘dopamine-first’ 
mechanism (detailed in Section 1.3.4) and we are likely observing another ‘snapshot’ 
of the mechanistic process. F112 is present in two different conformations in the novel 
 141 
structure (defined at 1:1 occupancy), as in the first holo structure of TfNCS (PDB: 
2VQ5)27. In subunit B of 2VQ5, the phenylalanine conformation is uncommon, being 
present in only 1% of phenylalanine residues in the PDB. In structure 5NON, Phe112 
is predominately in the conformation predicted by MD simulations and in subunit A of 
2VQ5.28 It is not known whether this unusual phenylalanine conformation is relevant to 
the NCS mechanism, perhaps suggesting an inhibitory mode with the residue acting as 
a ‘gatekeeper’, or if it is simply a crystallographic artefact. 
 
The density of the ‘dopamine-end’ of the mimic was less clear so the ligand was built in 
with both hydroxyl groups hydrogen-bonded to K122, reflecting a likely mixture between 
the two potential conformations, productive and inhibitory. The phenyl group of the 
‘aldehyde-end’ of the mimic sits close to L76. Mutation of this residue to valine resulted 
in improved stereoselectivity for NCS reactions with a-methyl aldehydes. The 
‘aldehyde-end’ of the mimic can be observed clearly and the methyl group of the mimic 
appears to sit close to M97, forcing the residue into a previously unseen conformation 
for this residue in NCS structures. Reducing bulk at this position by mutation to a valine 
residue, lowers d.r.s for the reaction with aldehyde 91, thus providing extra space for 
an ethyl group and so both enantiomers of the aldehyde are more readily able to react 
with dopamine in the active site. However, this does not provide enough extra space 
for the phenyl group of 85 and so one enantiomer is accepted preferentially. An 
increased d.r. in the product 96 compared to the wild type is likely due to improved 
binding of the aldehyde from this extra space provided and resulted in increased 
reaction yields. Conversely, the mutant M97F reduced yields and d.r.s in all products, 
likely due to lack of space in this region of the active site.  The mutant L76V improved 
d.r.s with both chiral aldehydes, possibly due to altering the shape of the active site 
cavity so that binding of the (R)-enantiomer is preferential.  
 
 142 
To further confirm the preferential acceptance of the (R)-enantiomer of a-methyl 
substituted aldehydes, molecular dynamics simulations have been performed by 
Gudrun Gygli.148 This work investigated the binding of dopamine 5 and the (R)- and (S)-
enantiomers of 2-phenylpropanal 85, into the TfNCS active site, analysing near attack 
complexes (i.e. measuring relevant distances between the two substrates, which when 
below a 4.0 Å, suggest that the substrates are orientated to lead to a productive 
reaction). The simulations concluded that the (R)-enantiomer of aldehyde 85 is 
preferred to the (S), with a ratio of 95:5, closely matching experimentally observed d.r.s 
with these substrates (94:6, Scheme 3.3). The results were also consistent with the 
‘dopamine-first’ mechanism of NCS whereby dopamine first binds to the active site, 
followed by the aldehyde.28,30 These simulations have therefore provided supporting 
data that a kinetic resolution of the α-methyl-substituted aldehyde was occurring and 
that the (R)-enantiomer of aldehyde was accepted preferentially.148 
 
3.3 Conclusions  
In summary, this work shows that despite previous reports, a-methyl-substituted 
aldehydes are indeed accepted as substrates by TfNCS using both dopamine and a 
variety of analogues as the amine substrate. Products were generated in high yields 
(up to 97%) with high e.e. (>99%), or d.r.s (up to 94:6) with chiral a-methyl-substituted 
aldehydes, providing a sustainable, facile route to these compounds. For chiral a-
methyl-substituted aldehydes, the THIQ products were generated with two defined 
chiral centres, with (1S,1′R)-stereochemistry as determined by the synthesis of two 
single enantiomeric aldehydes. Active site mutants could improve the d.r.s in the 
products (up to 98:2) with chiral a-methyl-substituted aldehydes and improved the 
reaction yields with several aldehydes. The enzymatic reaction was confirmed to occur 
via a mechanism that involves dopamine binding first to the active site, from a co-
crystallised structure of Δ33TfNCS with a reaction intermediate mimic in the active site. 
Computational studies (performed by Gudrun Gygli) further confirmed the occurrence 
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of the kinetic resolution of racemic α-methyl-substituted aldehydes by TfNCS, whereby 
the (R)-enantiomer of aldehyde is accepted preferentially.148 
 
In future work, confirmation of the stereochemistry at the C-1 and C-1’ positions of the 
THIQ products generated could be gained from small-molecule X-ray crystallography 
of the isolated products from a TfNCS-catalysed reaction between dopamine and a 
racemic a-methyl substituted aldehyde. Two enzyme variants, L76V and M97V, were 
particularly promising for improving d.r.s and conversions in the products. Therefore, 
further studies could involve mutagenesis at these two positions, exploring increasing 
and decreasing the steric bulk of the side chains, or testing these mutants with other a-









Chapter 4: Chemoenzymatic Cascades towards Methylated 
Tetrahydroprotoberberine and Protoberberine Alkaloids 
4.1 Introduction 
4.1.1 Accessing natural product drugs  
For millennia, humans have been exploiting the medicinal and recreational benefits of 
the many bioactive molecules that are synthesised by plants and nearly half of all 
licensed drugs are based upon natural products.176 However, isolating natural products 
from plants is difficult; often the desired compound is produced in very low quantities, 
alongside other structurally similar metabolites. This means that challenging, multi-step 
purification procedures are required, often resulting in poor product yields.177 Total 
synthesis routes to natural products have been successful in some cases and can be 
commercially viable.178 However, for some products with high molecular complexity, 
chemical synthetic routes are often unattainable or not cost effective.  
 
Advances in synthetic biology have led to the production of a variety of natural product 
drugs in vivo via fermentation processes but achieving high enantiopurity in the 
products has proved challenging with some classes of compounds.122,127 Another 
approach is the use of the relevant recombinantly expressed enzymes to mimic the 
biosynthesis in vitro. The use of such over-expressed enzymes provides regioselective 
and stereoselective control of the reactions involved, can minimise side-reactions and 
simplify the purification of the desired product. Enzymes are also generally more 
environmentally friendly than traditional organic synthetic routes, with reactions 
performed under mild conditions (often aqueous, with low temperatures and pressures) 
and thus are being increasingly employed in industrial chemical syntheses as the 
pharmaceutical industry aims to transition to a lower-carbon economy.179 
 
Furthermore, the use of both biocatalytic enzymes and traditional synthetic chemistry 
in cascade processes can lead to the generation of highly complex products in fewer 
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steps and with more facile purification processes than a solely in vivo or for an organic 
synthetic route. These strategies have led to the production of a range of natural and 
non-natural products in vitro to produce naturally occurring alkaloids and relevant 
analogues in significant yields.120,128,180  
 
4.1.2 Unique alkaloids isolated from the Corydalis genus 
Flowering plants in the Corydalis genus are native to high-altitude grasslands in China. 
Protoberberine alkaloids isolated from Corydalis plants are unique amongst isolated 
protoberberine alkaloids as they possess a methyl group at C-13. A range of 13-
methyltetrahydroprotoberberine (13-MeTHPB) and 13-methyl-protoberberbine (13-
MePB) alkaloids (90, 111-114) isolated from Corydalis plants are given in Figure 4.1.  
 
 
Figure 4.1: Examples of 13-methyl-tetrahydroprotoberine and 13-methyl-protoberberine 
alkaloids isolated from plants of the Corydalis genus.  
 
Many of these compounds have been shown to have promising biological activities. 
Corydaline (90) has been shown to act as an inhibitor of reverse transcriptase activity181 
and inhibit the replication of enterovirus 71, one of the major causative agents of hand, 
foot and mouth disease.182 Dehydrocorydaline (111) can act as  a dopamine D-1 























































range of other 13-MePB alkaloids have been shown to have anti-hepatitis B activities.184 
The extracts of C. yanhusuo are used in Chinese traditional medicine for cardiac 
arrythmia, rheumatism and gastric ulcers.183 The ethanolic extracts of C. tuber are also 
licensed in South Korea for the treatment of functional dyspepsia.185 
 
4.1.3 Biosynthesis of 13-MeTHPB alkaloids  
The biosynthesis of 13-MeTHPB alkaloids was investigated in the 1960’s and 1970’s, 
aided by the crystal structure of corydaline (90) and thus the determination of 
stereochemistry at both chiral centres.186 The hypothesised biosynthetic pathway 
towards corydaline (91) is given in Scheme 4.1. Corydaline has been determined to 
have (R) stereochemistry at the C-13 position, so it was initially assumed that the 
stereochemistry at this position would arise from (R)-reticuline  (21).187,188 However, this 
was disproved by MacLean et al. who, using feeding studies, determined that palmatine 
(116) was in fact the immediate precursor to corydaline (90), rather than (R,S)-
tetrahydropalmatine (115). This was also confirmed by feeding studies performed by 
Holland et al., where it was shown that the C-13 methyl group is incorporated from 
methionine after the protoberberine scaffold is formed.189 The biosynthesis of other 13-
MeTHPBs (such as those given in Figure 4.1) is unknown, however it is likely that a 
similar pathway is involved.  
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Scheme 4.1: The hypothesised biosynthetic pathway to corydaline and related alkaloids.  
 
The first committed step in the biosynthesis of benzylisoquinoline alkaloids (BIAs) is the 
formation of (S)-norcoclaurine (7) by the Pictet-Spenglerase enzyme, norcoclaurine 
synthase (NCS). This reaction forms the main benzylisoquinoline scaffold and 
norcoclaurine synthases have been identified in Corydalis plants.20 The NCS in C. 
saxicola has been recombinantely expressed in E. coli and shown to generate (S)-
norcoclaurine in high conversion (90%) and e.e. (>98%).190 Subsequent methylation 
steps, performed by regioselective O- and N- methyltransferases (6OMT, CNMT, 
NMCH, 4’OMT) give (S)-reticuline (9).1 The flavin-dependent, berberine bridge enzyme 
(BBE) then forms a C-C bond between the N-methyl and the aryl ring, giving (S)-
scoulerine (11). The enzyme provides regioselectivity in the ring closure step.74 
Subsequent methylation steps by SAM (S-adenosyl L-methionine) dependent 
methyltransferase enzymes, followed by oxidation of the C-ring gives palmatine (116). 































































and stereoselective, SAM-dependent C-methyltransferase gives corydaline (90), with 
the stereocentres defined as (13aR,13S). This is hypothesised to occur in a single step, 
catalysed by the putative enzyme, corydaline synthase.191  
 
4.1.4 Chemical routes towards 13-MeTHPB alkaloids 
To avoid the challenges associated with isolating alkaloids from natural sources, 
chemical strategies have been devised to synthesise 13-MeTHPBs. The first total 
synthesis of (±)-corydaline (90) was performed by Späth et al.192 starting from 
papaverine (10), however complicated isolation procedures were required and a very 
low yield of product (0.04%) was isolated. An improved synthesis was later performed 
by Cushman et al. in 1977, with the key synthetic step to form the tetracyclic scaffold 
involving the reaction between a homophthalic anhydride with a 3,4-dihydroisoquinoline 
(Scheme 4.2a).193 This forms the tetracyclic protoberberine scaffold, and syn geometry 
of the two hydrogens at C-13 and C-13a in the product is achieved by performing the 
reaction under reflux in acetic acid. This is followed by reduction of the amide and 
carboxylic acid groups, mesyl protection of the alcohol and borohydride reduction to 
cleave the C-O bond, thus yielding (±)-corydaline (90). An alternative route to the same 
compound has also been devised by Saá et al. involving a benzyne cycloaddition 
reaction (Scheme 4.2b).194 Other routes have been developed from the corresponding 
protoberberine alkaloids involving a Wittig reaction followed by a photochemical 
electrocyclic reaction (Scheme 4.2c).  
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Scheme 4.2: Synthetic routes developed towards racemic 13-MeTHPB alkaloids.  
 
The first asymmetric total synthesis towards these compounds was developed by Zhou 
et al. in 2017, involving a CuI-catalysed reaction between an alkyne, a 2-
bromobenzaldehyde derivative and a THIQ. (S,R)-PINAP (117) is used as the ligand 
which was synthesised in four-steps.195 This was followed by a palladium-catalysed 
reductive carbocyclization and an asymmetric hydrogenation step (Scheme 4.3).196 In 
three steps, this route generated 12 naturally occurring 13-MeTHPBs in good yields 





































































Scheme 4.3: A three-step route towards 13-MeTHPB alkaloids. Route developed by Zhou 
et al.196 
 
4.1.5 Biocatalytic approach 
Previous work, described in Chapter 3, demonstrated that the Pictet-Spenglerase, 
norcoclaurine synthase (NCS) can accept a variety of a-methyl substituted aldehydes 
as substrates, leading to a kinetic resolution of the aldehyde if a racemic aldehyde is 
used. This led to the production of a range of (1S,1’R)-THIQs in high diastereomeric 
ratios (up to 98:2) and yields (up to 96%), using a single-point variant of NCS, TfNCS-
M97V (Scheme 3.3). It was hoped that using this enzyme catalysed step, followed by 
other biocatalytic or chemical steps to generate a range of analogues of the 13-
MeTHPBs isolated from Corydalis plants. The products generated would have opposing 
stereochemistry to those isolated from plants, thus providing routes to useful analogues 
of the isolated natural products for drug discovery purposes.  
 
The aldehyde, 2-phenylpropionaldehyde (86), was shown to be well-tolerated as a 
substrate by TfNCS148 (Scheme 4.4a) so it was hoped that a non-oxidatively sensitive, 
methoxy-substituted analogue, 2-(3,4-dimethoxyphenyl)propanal (118) could instead 
be used as the NCS substrate (Scheme 4.4b). This step would provide stereoselective 












































alkaloids generated. This could then be followed by regioselective methylation 
reactions, using catechol O-methyltransferases to functionalise the catechol towards 
corydaline-like, 13-MeTHPBs. A range of catechol O-methyltransferases have been 
identified in the literature and work in our group has identified that some benzylic THIQs 
are accepted as substrates, providing the opportunity to extend the substrate scope 
towards 1’-Me-THIQs.197 The THIQ scaffold generated can then undergo another 
Pictet-Spengler reaction with an aldehyde, to give the desired tetracyclic 13-MeTHPB 
scaffold (Scheme 4.4b). Analogous chemical Pictet-Spengler reactions have already 
been employed with simple benzylic THIQs as substrates to generate THPB alkaloids 
so it was hoped that the substrate scope could be extended here.117,198 The synthetic 
route proposed for this work is given in Scheme 4.4b.  
 
Scheme 4.4: The acceptance of a-methyl substituted aldehydes by NCS may provide a 
route towards 13-MeTHPBs a. Previous work demonstrated that TfNCS-catalysed reactions 
could be used to generate (1S,1’R)-THIQs in high yields and diastereomeric excesses. b. The 
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4.2 Results and Discussion 
4.2.1 Synthesis of 2-(3,4-dimethoxyphenyl)propanal (118) 
The 3,4-dimethoxylated analogue of 2-phenylpropanal (85), was synthesised in three-
steps, starting from the corresponding ester without the a-methyl group. The synthetic 
route used was based upon a literature procedure and is given in Scheme 4.5.199  
 
Scheme 4.5: Synthesis of the a-methyl substituted aldehyde, 2-(3,4-dimethoxyphenyl) 
propanal (118). 
 
The first step, the a-methylation of 120, was performed on a 1 g scale. The ester was 
deprotonated using lithium diisopropylamide (LDA), to give the enolate. Iodomethane 
was then added to provide an electrophilic methyl group and give 121. Two equivalents 
of iodomethane were used to ensure that the reaction went to completion and di-
methylation was unlikely as after mono-methylation at the a-position, electron donation 
from the methyl group via the inductive effect makes the enolate less nucleophilic. The 
reaction proceeded to completion in 1.5 h and the product, 121 was isolated by silica 
column chromatography. Attempts to perform this reaction on a larger scale (2 g of 120) 
were not as effective; a mixture of 120 and 121 were obtained and were challenging to 
separate via silica chromatography as the two compounds have similar Rf values. 
Reduction of the ester, directly to the aldehyde using DIBALH has been reported using 
one equivalent of reducing agent, so reactions were initially attempted using these 
conditions.200 Unfortunately, only starting material was obtained but the addition of 
another equivalent of DIBALH resulted in the formation of the alcohol. The reaction 
proceeded to completion and the pure product, 122, was isolated by extractive workup, 






























The desired aldehyde, 118 was then obtained by the Swern oxidation of 122. The 
reaction proceeds to completion to give the desired aldehyde, which was isolated via a 
simple extractive workup. The crude aldehyde, 118 was used in enzymatic reactions 
directly after the workup to avoid issues of aldehyde oxidation during any purification 
steps.  
 
4.2.2 Reactions with NCS variants 
Based upon work presented in Chapter 3, three TfNCS mutants, M97V, M97F and L76V 
were shown to be particularly promising in providing (1S’1’R)-THIQ products of the 
reactions between dopamine and 2-phenylpropanal, in improved yields and 
diastereomeric excesses compared with the wild-type enzyme. Therefore, it was hoped 
that similar results would be observed for reactions between 5 and 118 to give 119 
(Scheme 4.6). The aldehyde, 118 was used crude and it was likely only one enantiomer 
of aldehyde would be accepted so two equivalents were added to the reaction mixture 
and analogous reactions conditions were used to those used with other a-methyl 
substituted aldehydes. Obtaining values for the diastereomeric ratios of the resultant 
products was straightforward as the two diastereomers, (1S,1’R) and (1S,1’S), are 
separable by RP-HPLC (method 1), as shown in Figure 4.2. A major diastereomeric 
product was observed, again indicating a kinetic resolution of the a-methyl substituted 
aldehyde substrate.   
 
Scheme 4.6: TfNCS catalysed reaction performed to give the THIQ scaffold towards 
generating 13-MeTHPB alkaloids. Reaction conditions: 5 (10 mM), 118 (10 mM), sodium 
ascorbate (5 mM), D33TfNCS (0.2 mg mL-1) in HEPES buffer (100 mM, pH 7.5) with acetonitrile 
(10% v/v) at 37 oC for 3 h, 250 µL scale reactions. Conversions were determined based on 




















Figure 4.2: Analytical HPLC analysis of product 119 formed by NCS-mediated Pictet-
Spengler reactions. Corresponding diastereomeric ratios and the reaction conditions used are 
given in Table 4.1.  
 
No background reaction was observed, consistent with other NCS-mediated reactions 
with a-methyl substituted aldehydes, so it was believed that the product generated 
should have S-stereochemistry at the C-1 position. Based upon previous work (Chapter 
3), it was rationalised that the major isomer formed was (1S,1’R) and the minor isomer 
was (1S,1’S).148 The stereochemistry at C-1’ of the product of NCS reaction between 
dopamine (5) and 2-phenylpropanal (85) has also been confirmed computationally to 
be (R), as increased near-attack conformations were observed between the two 
substrates.148 To further confirm stereochemistry of this product, the structure would 
have to be determined by small molecule crystallography which would require 
significant amounts of material. Due to the highly acidic nature of the a-proton of 118, 
the aldehyde is highly prone to racemisation, so performing enzymatic reactions with 
the two single enantiomer aldehydes is not feasible. The diastereomeric ratios of the 
products obtained, using four different TfNCSs; wild-type, L76V, M97F and M97V, are 
given in Table 4.1.  
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Table 4.1: Diastereomeric ratios of 119, generated by NCS-mediated reactions. Reaction 
conditions were the same as those described for Scheme 4.6.  
 
TfNCS variant used Diastereomeric ratio of 119 
(1S,1’R):(1S,1’S) 
Diastereomeric ratio of 96 
(1S,1’R):(1S,1’S) 
Wild type 77:23 94:6 
L76V 87:13 97:3 
M97F 87:13 94:6 
M97V 96:4 97:3 
 
NCS-catalysed reactions between dopamine (5) and 2-phenylpropanal (85) (to give 96) 
using either mutant, M97V or L76V gave the highest diastereomeric ratios in 119 
generated (97:3 1S,1’R:1S,1’S). M97F also had good selectivity. Reactions with the 
M97V variant were comparable with 118 as the aldehyde substrate, with a 96:4 
diasteromeric ratio achieved. It is therefore interesting here, that with the addition of 
meta- and para-methoxy groups to the aldehyde ring, that a reduced diastereomeric 
ratio was observed when using the L76V variant. Consideration of the crystal structure 
with a non-productive mimic of the reaction between 5 and (R)-2-phenylpropanal (85) 
(PDB: 6RP3), the phenyl group of the aldehyde part of the mimic sits close to L76 
(Figure 4.3). The mutation leucine to valine, creates more space in the active site 
enhancing the fit of the intermediate with (R)-110, to give a higher diastereomeric ratio 
in the product. However, the dimethoxylated aldehyde 118, is bulkier and so activity is 
altered. For reactions with all NCSs tested, complete consumption of dopamine was 
observed, indicating complete conversions to give the products. This was confirmed by 
HPLC-based calibration curves of 119, with all products formed in >99% yield. Based 






Figure 4.3: Structure of co-crystallised wild-type TfNCS with (2R)-phenyl-propanal 
reaction mimic, (R)-110 bound in the active site. The phenyl ring of the aldehyde side chain 
is neighboured by L76, F99, Y108 and the a-helix residues A182 – G178.  
 
The aldehyde, 2-phenyl-propanal (85) is known to be prone to racemisation at pH > 7, 
so it was expected that aldehyde, 118 could also racemise under the NCS reaction 
conditions at pH 7.5.166 Therefore, the reaction was also explored using 1 equivalent of 
aldehyde, rather than 2 used and indeed analogous results were observed, with a 
diasteromeric ratio of 95:5 in the product observed with complete conversion (>99%) 
based upon a HPLC-based calibration curve of the product standard 119.  
 
4.2.3 Increasing the molecular complexity of the THIQ scaffold using 
regioselective catechol O-methyltransferases 
There are several research efforts into the discovery and isolation of methyltransferase 
enzymes, to avoid the challenges of synthetic, regioselective methylations.201 These 
enzymes are used to selectively methylate a single heteroatom in a small molecule 
substrate. Regioselective methylation reactions are also particularly useful for drug 
discovery purposes due to ‘the magic methyl effect’ whereby the substitution of H to 
CH3 can increase the potency of a drug molecule by up to 100-fold.202 In 2011, it was 
noted that methyl groups are found in >67% of the year’s top selling drugs.202  
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Beyond the advantage of controlled regioselectivity, biocatalytic reactions involving 
methyltransferases are more environmentally benign than traditional, chemical 
alternatives as they avoid the use of carcinogenic alkylating agents (for example, methyl 
iodide) as the methyl donor. However, the major barrier to the widespread applicability 
of these enzymes in preparative-scale syntheses is the narrow substrate scope of many 
of the enzymes discovered and the requirement for stoichiometric quantities of (S)-
adenosyl-L-methionine (SAM). SAM is expensive (ca. £1000 for 1 g) and unstable (to 
hydrolysis), so reactions are not economically viable on a preparative scale. Recent 
efforts to overcome this have involved the use of an enzymatic co-factor generation 
system. Instead of using SAM directly, stoichiometric quantities of adenosine 
triphosphate (ATP) and L-methionine are added to the reaction with two other enzymes. 
SAM is then formed in situ using a methionine adenosyl transferase (MAT, E.C.2.5.1.6), 
which is used for methyl donation by the methyltransferases. This results in the 
formation of (S)-adenosyl-L-homocysteine (SAH), which can inhibit the 
methyltransferase reaction, so conversions are improved if SAH is degraded. 
A methylthioadenosine/SAH nucleosidase (MTAN, E.C.3.2.2.9) can therefore also be 
added to the reaction mixture to break down SAH, giving adenine and (S)-ribosyl-L-
homocysteine.203 
 
The MAT and MTAN enzymes investigated in this work to supply SAM and to degrade 
inhibitory SAH, respectively were based upon previous successful reports.203 EcMAT 
and EcMTAN (from Escherichia coli) were available our group from a collaborator and 
were already under investigation by other group members (Fabiana Subrizi, Hailes 
group). EcMAT is the most widely studied methionine adenosine transferase enzyme, 
and the mechanism of action has been elucidated with crystallographic studies.204 The 
reaction proceeds via an SN2 reaction between L-methionine and ATP. The 
triphosphate moiety of ATP is cleaved and SAM results. Triphosphate is then broken 
down into pyrophosphate and orthophosphate which are released with SAM by the 
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enzyme. EcMAT is a dimeric enzyme, with two active sites at the oligomer interface. 
The mechanism has been reported, although elucidation faced significant challenges 
as multiple ligand conformations were observed in crystallographic studies. However, 
it has been hypothesised that a conserved histidine residue likely protonates the O-5’ 
atom of ATP, providing a driving force for SAM formation. Substrate binding residues 
are conserved between other MAT enzymes isolated from both bacterial and 
mammalian sources (with one exception) indicating that the mechanism is conserved. 
A flexible loop (residues 98-114) close to the active site has also been noted and is 
thought to be implicated in the control of substrate binding.205,206 Magnesium (Mg2+) and 
potassium (K+) ion co-factors are also required. The hypothesised mechanism of SAM 
formation by MAT enzymes is given in Scheme 4.7. 
 
Scheme 4.7: Mechanism of SAM formation by MAT enzymes.  
 
The E. coli derived SAH nucleosidase, EcMTAN catalyses the cleavage of the 
glycosidic bond in SAH to generate adenine and (S)-ribosyl-L-homocysteine. In 
eukaryotes and plants, the catabolism of SAH generates adenosine and L-
homocysteine instead.207  In vivo, these enzymes act as feedback inhibitors to control 
biological methylation; when they are inhibited, levels of SAH increase and 































































and proceeds via the formation of a ribocation to which there is nucleophilic addition of 
water to give (S)-ribosyl-L-homocysteine, as demonstrated in Scheme 4.8.208 
 
Scheme 4.8: Degradation of SAH by EcMTAN.  
 
Numerous regioselective catechol O-methyltransferases (COMTs) have been reported 
in the literature and shown to accept various catecholamines as substrates. Two known 
catechol O-methyltransferases; RnCOMT (isolated from Rattus norvettigus) and 
MxSafC (isolated from Myxococcus xanthus) were explored with the 13-MeTHPB 
generated as the substrate.209  
 
For methylations involving RnCOMT, methylation has been most often reported to 
occur on the meta-hydroxyl. The known substrate scope includes a variety of 
catecholamines (dopamine (5), dihydrocaffeic acid (123) and 3,4-dihydroxybenzoic 
acid (124))209,210 and in our group, we have been exploring them with 1-benzyl THIQs 
as substrates.197 The ionisation of the substrate is thought to modulate the observed 
methylation pattern.210 The enzyme is often not completely regioselective, and typically 
some para-methylation is observed, for example with 5. MxSafC is reported to have 
complementary regioselectivity to RnCOMT, with methylation often favoured at the 






































screened.211 MxSafC is involved in the biosynthesis of saframycin MX1, which 
possesses anti-tumour and antibiotic activites.212 Catechol-containing molecules such 
as catechol, dopamine and caffeic acid are also accepted as substrates. The 
regioselectivity observed with MxSafC is often higher than that observed with RnCOMT, 
however this is substrate dependent.209 The regioselectivities of the products generated 
methylation reactions of three substrates for RnCOMT and MxSafC are given in Table 
4.2.  
 
Table 4.2: Observed regioselectivities of two catechol O-methyltransferases, RnCOMT 
and MxSafC for reactions with three catecholamines.   
 
The mechanism and regioselectivity of RnCOMT has been explored through active-site 
modification and crystallographic studies. A successful reaction requires the binding of 
Mg2+ to the active site before SAM, although there is no direct interaction between the 
two co-factors. The catechol binds to the magnesium ion, lowering the pKa of the 
hydroxyl groups. The orientation of catechol binding determines the regioselectivity of 
the methylation as the hydroxyl group closest to the methyl group of SAM is 
deprotonated by K144, leading to methylation. Active site variants (notably W38D, 
W38R and Y200L) were able to improve regioselectivity towards either hydroxyl 
group.213  A similar mechanism of action occurs with MxSafC, with many key active site 
residues conserved.211 The differences in observed regioselectivities between the 
catechol O-methyltransferases is subtle, with many factors at play  beyond protein 


























To increase the complexity of the THIQs product (119) generated from an NCS 
reaction, towards analogues of corydaline (90), the two regioselective catechol O-
methyltransferases, MxSafC and RnCOMT were explored with 119 as the catechol-
containing substrate. Expression of the two COMTs was performed using a published 
protocol, giving high expression of both enzymes209 and biocatalytic reactions were 
attempted using clarified cell lysate as the reaction catalyst. Although reactions using 
RnCOMT were successful, no conversions were observed when using MxSafC. It was 
suspected that this was due to issues of enzyme instability and indeed, protein 
precipitation was observed when the enzyme was purified by nickel-affinity 
chromatography. During dialysis to buffer exchange the protein sample, a significant 
amount of protein precipitation occurred, likely due to the incompatibility of the protein 
samples in high concentrations of imidazole even for a short period of time. Regardless, 
a high yield of pure protein was isolated (55 mg from a 500 mL culture). SDS-PAGE 
analysis of the expression of RnCOMT and the purification of MxSafC, EcMTAN and 




Figure 4.4: SDS-Page analysis of RnCOMT, MxSafC, EcMAT and EcMTAN lysate or 
purifications. a. His-trap purification of MxSafC.  Lanes: 1, Benchmark™ Protein Ladder 
(masses given in kDa) 2, clarified cell lysate loaded onto column. 3, flow through with lysis buffer. 
4, wash with 6 CV 20 mM imidazole buffer. 5, wash with 6 CV 40 mM imidazole buffer. 6-13, 
wash with 500 mM imidazole buffer and collected 3 mL fractions. b. His-trap purification of 
EcMAT. Lanes: 1, Benchmark™ Protein Ladder (masses given in kDa) 2, clarified cell lysate 
loaded onto column. 3, flow through with lysis buffer. 4, wash with 6 CV 20 mM imidazole buffer. 
5, wash with 6 CV 40 mM imidazole buffer. 6-13, wash with 500 mM imidazole buffer and 
collected 3 mL fractions. c Lanes: 0, Benchmark™ Protein Ladder (masses given in kDa). 1, 
purified EcMTAN (some dimerization is observed), 2, expression of RnCOMT.  
 
During initial screening experiments, both methyltransferases were found to be 
incompatible with the use of an organic co-solvent (at 10% v/v). Therefore, NCS 
reactions were performed using acetonitrile as the co-solvent rather than DMSO (as 
described for reactions with a-methyl substituted aldehydes in Chapter 3) as the boiling 
point is lower (82 oC vs. 189 oC). Once the NCS reaction was complete (monitored by 




the enzyme. The reaction mixture was then centrifuged, and the supernatant 
concentrated under reduced pressure or lyophilised to remove the water and 
acetonitrile. The resulting residue was then resuspended in buffer, containing all the 
metal co-factors required for a successful methyltransferase reaction, considering that 
the HEPES from the NCS reaction remained. This method also had the added benefit 
of not needing to isolate the THIQ intermediate.  
 
Reactions were performed using the co-factor generation system detailed in Scheme 
4.9 using purified enzyme as previously reported.203 Conditions were developed in 
collaboration with Fabiana Subrizi (Hailes group) who was working towards the 
regioselective O-methylation of benzylic THIQs generated by NCS reactions,197 and 
conditions used here involve increased concentrations of enzymes 
(methyltransferases, MAT and MTAN) and co-factors (ATP and L-methionine) with the 
aim of gaining complete conversions towards the products. 
 
 
Scheme 4.9: The regioselective methylation reactions performed using catechol O-
methyltransferases, RnCOMT or MxSafC. 119 is methylated to give 125. SAM recycling 
system enzymes are used to avoid the addition of stoichiometric quantities of the methyl donor, 
SAM. SAM is generated in situ by the enzyme, EcMAT and the reaction byproduct, SAH is 
broken down by another enzyme, EcMTAN. 
 
Analytical HPLC analysis of the product (125) generated using either methyltransferase 
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complete consumption of the starting material had occurred. Reactions were performed 
on a 20 mL, 5 mM scale and the resulting products isolated by preparative-HPLC 
(method 8) with the regioselectivity of the reaction determined by 2D-NMR 
spectroscopy (shown in the Appendix, Section 9.5). Using either methyltransferase, 
methylation was observed on the C6-position, with only a single isomer of 125 
observed. High yields were also obtained (complete consumption of the starting 
material when using either RnCOMT or MxSafC) and the product was obtained as the 
TFA salt in 12% isolated yield on a 5 mM, 20 mL scale using RnCOMT as the 
methyltransferase. This also follows literature precedent using RnCOMT, where 
methylation is only observed in the C6 position for reactions with 5. This high 
regioselectivity is interesting as usually a mixture of the two regioisomers is generated 
(Table 4.2).209 MxSafC is reported to have a more promiscuous methylation pattern, but 
predominately reacts at the C7 position.211 However, the differences in regioselectivity 
between reactions with 123 and 124 demonstrate the subtlety of the reaction outcome, 
so it was not completely unexpected that the opposing regioselectivity was observed 
with these THIQs as substrates.  
 
4.2.4 Synthesis of C7-O-methoxy THIQs  
Both catechol O-methyltransferases investigated, RnCOMT and MxSafC were 
observed to be highly regioselective towards the C6-OH, so the C7-methoxylated 
isomer could not be generated in this way. Productive NCS reactions are observed with 
dopamine analogues lacking the C7-OH, so to generate C7-methoxylated analogues, 
NCS reactions were attempted between a dopamine analogue, 126 and the aldehyde, 
118, to give 126 (Scheme 4.10). 126 was synthesised by a MSci student, Joseph 
Broomfield (Hailes group) in four steps (28% overall yield) starting from isovanillin (128) 
as shown in Scheme 4.11.  
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Scheme 4.10: Reaction towards para-O-methoxy THIQs. Reaction conditions: 126 (10 mM), 
118 (20 mM), sodium ascorbate (10 mM), purified D29TfNCS-M97V (final concentration of 0.2 




Scheme 4.11: Synthesis of 4-methoxytyramine (126). Reactions were performed by a 
Master’s student, Joseph Broomfield (Hailes group).  
 
The THIQ product (127) was isolated by preparative-HPLC (method 9) in >99% HPLC 
yield and 81% isolated yield with a 92:8 d.r. (1S,1’R:1S:1’S)-127 as determined by 1H-
NMR spectroscopy (shown in the Appendix, Section 9.5). The slight decrease in 
selectivity compared with using dopamine as the phenethylamine substrate may be due 
to the lack of an additional hydrogen bonding interaction at the C7-OH with K122. The 
C6-OH of the catechol is essential for a productive NCS reaction and although the C7-
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4.2.5 Generation of the tetracyclic tetrahydroprotoberberine scaffold towards 
corydaline-like alkaloids  
The formation of the tetracyclic protoberberine scaffold (Figure 4.1) from a benzylic 
THIQ requires a -CH2- unit bridging the nitrogen, N-7, and the aromatic carbon, C-8a. 
In plants, the biosynthesis of the THPB, (S)-scoulerine (11) from a benzylic THIQ, 
involves a C-C bond forming reaction between an N-methyl group (on (S)-reticuline, 9) 
and the benzylic moiety by the berberine bridge enzyme (BBE),74,75 which also provides 
regioselectivity in the ring closure step, leading to methoxy and hydroxyl substituents 
on the D-ring at positions 9 and 10 (Scheme 4.1). The substrate scope of the BBE has 
not been widely explored, so chemical alternatives to generate the tetracyclic scaffold 
were instead considered.  
 
Intramolecular, chemical Pictet-Spengler reactions on THIQs have proved successful 
in generating a range of berberine-like alkaloids. Lichman et al. used a phosphate-
catalysed Pictet-Spengler reaction between norlaudanosaline (15) and formaldehyde 
to generate two THPB alkaloids with 10,11-dihydroxy substitutions on the D ring i.e. 
with complementary regioselectivity to the BBE route (Scheme 4.12).117  The effect of 
solvent on the regioselectivity of the Pictet-Spengler reaction has been explored by 
Horst et al. where a range of ortho-hydroxylated THPBs were generated (Scheme 
4.12).198 The regioselectivity of the Pictet-Spengler reaction (between the THIQ and 
formaldehyde) upon C-ring formation was shown to be dependent on whether the 
reaction solvent used was protic or aprotic. Using aprotic solvents resulted in 9,10 
substitution on the D-ring, whereas using protic solvents results in complementary 
regioselectivity. Studies of the Pictet-Spengler between norlaudanosaline (15) and 
formaldehyde in aqueous buffer performed by McMurtrey et al. have also indicated that 
pH can also influence regioselectivities.214 The three routes previously explored with 




Scheme 4.12: Chemical Pictet-Spengler reactions between THIQs and formaldehyde 
towards the THPB scaffold.  
 
It was therefore hoped that these routes could be extended towards generating a range 
of 13-MeTHPBs with different regioselectivities. Initially, Pictet-Spengler reactions 
between 119 and formaldehyde were attempted using crude, lyophilised NCS reaction 
products with analogous conditions to those used by Lichman et al.: formaldehyde in 1 
M sodium phosphate buffer (pH 6) at 37 oC. Unfortunately, no desired product was 
observed by LCMS after 30 min (as reported by Lichman et al.) nor after longer reaction 
times (24 h) or with heating of the reaction mixture to 60 oC. Compared with the THIQ 
substrate used by Lichman et al., 119 has methoxy substitution on the D-ring rather 
than hydroxyl groups. Methoxy groups are less activating than hydroxyl groups and this 
therefore suggested that more forcing conditions would be required. Therefore initially, 
acid-catalysed Pictet-Spengler reactions were attempted in protic solvents. No reaction 
was observed using either methanol or 2,2,2-trifluroethanol as the reaction solvent. 
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synthetic development of a range of THPB alkaloids, using formaldehyde and formic 
acid as the reaction solvent and heating to 50 oC. Compound 125 was initially used as 
the starting material, as it was less oxidatively sensitive as the catechol was protected 
by the methyl group. Complete consumption of the THIQ starting material, 125 was 
observed by RP-HPLC after 2 h and subsequent NMR and MS analyses determined 
that the resultant product was 130 (Scheme 4.13) with a 10,11-dimethoxy substitution 
pattern on the D-ring. THPB 130 was isolated in 23% yield after purification by 
preparative-HPLC (method 9). The reaction also went to completion when using the 
analogous, non-methoxylated THIQ 119 as the starting material and the product (129) 
was isolated in 24% yield. The same regioselectivity in the D-ring was observed. As for 
129, Nuclear Overhauser Effect Spectroscopy (NOEsy) NMR analysis of the two 
products isolated confirmed the stereochemistry at C-13 and C-13a (see Appendix, 
Section 9.5). A strong NOE correlation was observed between 13-H and 13a-H, 
indicating syn geometry. A very weak NOE signal was also observed between 13a-H 
and the methyl group protons at C-13, implying anti stereochemistry. (S)-
Stereochemistry at C-13a is most likely to be generated from the NCS reaction, the 
stereochemistry at C-13 must therefore be (R), further confirming previous experimental 
results on the absolute stereochemistry at these positions.148 
 
 
Scheme 4.13: General route of the chemical Pictet-Spengler reactions performed between 
formaldehyde and THIQs 119 and 125.  
 
Formation of the other regioisomeric product i.e., 9,10-dimethoxy substitution on the D-
ring, has been reported by exploiting solvent effects.198 In theory, if an apolar, aprotic 
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129: R1 = H 
(24% isolated yield)
130: R1 = Me
(23% isolated yield)HCOOH50 oC, 3 h
 170 
by an electrostatic interaction between the iminium ion and a hydroxyl group on the 
benzylic moiety. This holds the iminium ion intermediate in an orientation consistent 
with product formation with a 9,10-dimethoxy substitution pattern. Whereas, when a 
protic solvent is used the intermediate is stabilised by the solvent, leading to the less 
hindered product being formed, with 10,11-dimethoxy substitution.198 
 
To attempt to generate the complementary regioisomer to 129 and 130 in the D-ring, 
i.e. the 9,10-dimethoxy product, Pictet-Spengler reactions were attempted using apolar, 
aprotic reaction solvents following methods developed by Horst et al.198 (detailed in 
Scheme 4.12). Paraformaldehyde was used instead of formaldehyde (which is 
commercially available at 37% in water) to ensure that no proton sources were present 
in the reaction mixture and reactions were also performed under anhydrous conditions. 
The starting material was furthermore prepared as the free amine to aid solubility. As 
reported by Horst et al., the best regioselectivity towards products with 9,10-dimethoxy 
substitution, was observed when using toluene as the reaction solvent (81:19 ratio of 
9,10:10,11 dimethoxy substitution), with heating at 105 oC for 4 days (Scheme 4.12). 
Identical reaction conditions were attempted here, however there was only trace 
evidence of product formation by LCMS analysis. Low conversions were likely to due 
to poor solubility of the starting material in toluene. Reactions were also attempted using 
1,2-dichloroethane as the reaction solvent however no product was observed. It is likely 
that the presence of two electron donating methoxy groups on the benzylic moiety 
means the pi-system is insufficiently activated. Therefore, more forcing conditions may 
be required, explaining why formic acid catalysed reactions were successful, and 
reactions performed with just heating in apolar, aprotic solvents were not.  
 
4.2.6 Syntheses of 13-methylprotoberberine alkaloids  
Reactions with other aprotic, high-boiling point solvents were considered to see if 
improved reactivities could be observed. The Pictet-Spengler reaction between 125 and 
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formaldehyde was attempted using DMF (N,N-dimethylformamide) as the reaction 
solvent with increased heating (120 oC) (Scheme 4.14). After 24 h, LCMS and RP-
HPLC analyses showed complete consumption of the starting material (125) and 
identified a product with a m/z of 352 Da i.e. 3 Da lower than expected. This therefore 
led to the hypothesis that the oxidation of one of the rings in the tetracyclic scaffold had 
occurred. The resultant product was purified by preparative-HPLC analysis (with an 
isolated yield of 5% and an HPLC yield of >99%) and 2D NMR analysis was used to 
determine the structure as 131 (Scheme 4.14). NMR spectra are given in the Appendix, 
Section 9.5.  
 
Scheme 4.14: Chemical Pictet-Spengler reaction between 125 and formaldehyde using 
DMF as the reaction solvent.  
 
The presence of four singlets in the aromatic region suggested that the 10,11 
regioisomer of product was formed and the absence of the proton at position 13, 
indicated that the C-ring had been oxidised, giving 131. Although removing the chirality 
at C-13 and C-13a, this reaction may provide a useful route to generating 
protoberberine analogues of THPB alkaloids as the oxidation of the C-ring must occur 
after the Pictet-Spengler reaction.  
 
Therefore, to determine whether protoberberine alkaloids could be generated by simply 
heating the correspond THPB in DMF, 125 was isolated and heated in DMF at 120 oC 
for 24 h (Scheme 4.15). The product was formed in 86% conversion by starting material 
depletion calibration curve and identity confirmed by 1H-NMR and LCMS. An isolated 
yield of 21% was achieved after purification by preparative HPLC. This is a useful route 
















use of a selective oxidase enzyme such as (S)-tetrahydroprotoberberine oxidase 
(STOX)215 or harsh reaction conditions (I2 / EtOH, reflux).216 Since the stereochemistry 
at C-13 and C-13a is lost during the oxidation, the THIQ starting material could  also 
instead be generated via a phosphate-mediated Pictet-Spengler reaction rather than 
an NCS reaction.15 
 
Scheme 4.15: Single step reaction towards 13-methylprotoberberine, 131 from the 
analogous 13-MeTHPB 125. 
 
Routes towards these compounds are useful as a range of 13-MeTHPBs isolated from 
the methanolic extracts of Corydalis saxicola (132-134, Figure 4.5) have been shown 
to possess anti-hepatitis B activities in vitro.184 The methyl group at C-13 had a notable 
effected on activity, as other THPBs screened lacking this methyl group were inactive. 
These compounds are also reported to have sedative, anti-viral and anti-bacterial 
properties and routes towards the isolation of these compounds from C. saxicola are 
patented.217 Protoberberine alkaloids can also be further functionalised at C-8 as the 
iminium ion is susceptible to nucleophilic attack.218 
 
Figure 4.5: 13-Methylprotoberberine alkaloids possessing anti-hepatitis B activities.  
 
4.2.7 Chemical Pictet-Spengler reactions towards C8-substituted THPBs 
Two alkaloids isolated from Corydalis ochotensis, corytenchirine (135) and lienkonine 




















132 : R1 = Me, R2 = Me
133 : R1 = Me, R2 = H




4.6).219,220 The stereochemistry of the C-8 centre in corytenchirine (135) was assigned 
based upon Bohlmann bands (2800-2650 cm-1) whereby the C-H bond that is anti-
periplanar to the nitrogen lone pair is considered to be elongated.221 There are few 
examples of synthetic routes towards 8-MeTHPBs, with one stereoselective route 
reported involving the reduction of a 8-Me-protoberberine scaffold.222 THPB alkaloids 
with methyl groups at both C-8 and C-13 have also been synthesised by Wiegrebe et 
al.223 although no stereocontrol was achieved. One berberine-like alkaloid with a methyl 
group at C-8, coralyne (137) (Figure 4.6) is known to act as an anti-leukemic agent.224 
Therefore, routes towards similar alkaloids are useful for drug discovery purposes.  
 
 
Figure 4.6: THPB and PB alkaloids with possessing a methyl group at C-8.  
 
Therefore, to develop routes towards C-13, C-8 substituted THPBs, chemical Pictet-
Spengler reactions were attempted between the NCS-generated THIQ (119) and a 
range of aldehydes (Scheme 4.16). Performing these reactions with aldehydes other 
than formaldehyde results in the formation of a new chiral centre at C-8 so it was also 
thought to be interesting to see whether the methyl group at C-13 would have an 
influence on this newly formed chiral centre. Acetaldehyde (45) was chosen due to the 
small size and cyclopropanecarboxaldehyde (138), hexanal (78) and benzaldehyde 






















(139) were chosen to probe whether even bulkier aldehydes would be converted. 
Reactions were performed in formic acid as described for the reaction with 
formaldehyde and for an extended reaction time (24 h vs. 3 h with formaldehyde) as it 
was assumed that these reactions would be more challenging. The aldehyde was used 
in significant excess to help drive the reaction and all aldehydes could be easily 
removed under reduced pressure after the reaction was complete.  
 
 
Scheme 4.16: Formic acid catalysed Pictet-Spengler reactions performed between 119 
and four different aldehydes. A new chiral centre at C8 is formed during the reaction, giving 
three stereocentres in the THPB products.  
 
Reaction mixtures were analysed by LCMS to detect for product formation. Product was 
only detected for the reaction of 119 with acetaldehyde (45), which was purified by 
preparative HPLC (56% conversion, determined by HPLC based upon starting material 
depletion). giving a 21% isolated yield. The product generated has three chiral centres; 
the stereochemistry at C-13 and C-13a is predetermined by the NCS reaction and the 
formic acid catalysed Pictet-Spengler reaction should not racemise these two chiral 
centres. NMR spectroscopic analysis of the product isolated (Section 9.5) indicated that 
the reaction was regioselective, with 10,11-dimethoxy substitution on the D-ring. Two 
epimers of product were present in a ratio of 3:1. The stereochemistry at C-8 could be 
determined by NOEsy because the stereochemistry at C-13a is known. For the major 
isomer, a NOEsy correlation was observed between the methyl group at C-8 and the 
proton at C-13a, indicating that the methyl group was below the ring, as drawn (Figure 















50 oC, 24 h
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*
45 R = Me 
138 R = cyclopropane
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140. For the minor isomer, (8S,13R,13aS)-140, the NOEsy spectrum should show a 
correlation between 8-H and 13a-H, however this could not be observed as the 13a-H 
proton was obscured by the residual solvent peak for water. A NOE signal could 
however be observed between the two methyl groups at C-13 and C-8 (shown in the 
Appendix, Section 9.5).  
 
Figure 4.7: Expected NOEsy correlations for the two isomers of 140 generated.  
 
To rationalise why this isomer was predominately formed, energy minimised, 3D 
models of both epimers were generated (Figure 4.8). For both epimers, the C-ring is in 
a half-chair conformation. For the minor isomer generated, the methyl groups at C-8 
and C-13 are on the same side of the ring, in a pseudoaxial orientation. This 
unfavourable steric interaction likely explains why formation of this isomer is 
disfavoured.  
 
Figure 4.8: 3D modelling of the minor epimer formed, (8S,13R,13aS)-140. The two methyl 
groups at C-8 and C-13 are syn with a distance between the methyl group protons of 2.9 Å. The 






























Clearly extending the aldehyde substrate scope of the chemical Pictet-Spengler 
reaction between 1’-MeTHIQs such as 119 towards the analogous 13-MeTHPBs is 
challenging. One limiting factor could be the high volatility of the aldehyde and the 
requirement for forcing reaction conditions. Acetaldehyde has a low boiling point (20 
oC) and heating to 50 oC was required for a successful reaction. To improve conversions 
towards completion, further equivalents of acetaldehyde could be added to the reaction 
mixture over time. It may therefore also be possible to incorporate longer chain, 
aliphatic aldehydes by using longer reaction times or using more forcing conditions, 
perhaps the use of a microwave.  
 
4.2.8 Routes towards N-methylated 13-MeTHPBs 
To further diversify the products generated, it was hoped that a regioselective N-
methyltransferase could be used to selectivity mono-N-methylate the THIQ, 125 
(Scheme 4.17), giving 141. The N-methylated THIQ scaffold is a valuable 
pharmacophore, found in a range of pharmaceuticals and performing regioselective 
mono-N-methylations is challenging chemically due to increased nucleophilicity of the 
nitrogen lone pair after each methylation.   
 
Scheme 4.17: The generation and relevance of N-methylated THIQs. a. N-methylated 
analogues of NCS products generated could be accessed using a selective N-










































One appropriate enzyme, Coclaurine N-methyltransferase isolated from Coptis 
japonica (CjCNMT) was available in the laboratory, provided as a pure, lyophilised 
sample by Michael Richter.  The in vivo role of CNMT is to selectivity mono N-methylate 
(S)-coclaurine (8). Previous studies with CjCNMT have shown that the enzyme has a 
broad substrate scope, although the THIQ scaffold appears to be essential for a 
productive reaction. The enzyme is also not stereospecific, accepting both enantiomers 
of the natural substrate, 8. A range of THIQs accepted as substrates are given in Figure 
4.9,225 although the enzyme has low catalytic activity and complete conversion has not 
yet been observed with any substrate. The enzyme can accommodate THIQ with a 
range of substituents at C-1, including two racemic 1’-substituted THIQs, 142 (5% 
conversion) and 143 (87% conversion).226 Therefore, it was hoped that this could be 
extended towards using the (1S,1’R)-THIQ,  
 
Figure 4.9: A range of THIQs accepted as substrates by CNMT, investigated by Choi et al.225 
and Bennett et al.226 A range of THIQs beyond the natural substrate, (S)-coclaurine, are 
accepted as substrates.  
 
The enzyme is SAM-dependent as the methyl donor for biotransformations, so enzyme 




































catechol O-methyltransferases (RnCOMT and MxSafC). Enzyme reactions were again 
attempted with an excess of SAM formed in vitro, using 2 equivalents of ATP and L-
methionine with 125 used as a crude product from the previous O-methylation reaction 
using RnCOMT. The lyophilised sample of CNMT was resuspended in HEPES buffer 
(50 mM, pH 7.5) and added to the reaction sample to give a final enzyme concentration 
of 0.5 mg mL-1 which was added once the RnCOMT reaction was deemed complete by 
analytical HPLC (method 2). Additional co-factors (1.5 e.q. of ATP and L-methionine) 
and SAM supply enzymes were added. LCMS and analytical HPLC (method 2) of the 
reaction mixture was used to determine if product formation was occurring.  
 
Unfortunately, no product was observed, even with varying concentrations of CNMT 
(0.5, 1.0 and 2.0 mg mL-1 final concentration) and co-factors (5 mM, 10 mM, 20 mM), 
and increasing concentrations of the co-factor recycling system enzymes. Reactions 
were also attempted in a one-step reaction, adding both methyltransferases (CNMT 
and RnCOMT) at the same time, however no desired product was detected. The lack 
of acceptance of this substrate, 125 could be due to issues with not using a purified 
substrate. To generate enough SAM, 3 equivalents of ATP and L-methionine at least 
are required and perhaps the enzyme is incompatible with high phosphate 
concentrations. The remaining aldehyde, 2 from the NCS reaction may also interfere 
with the enzyme. To determine if this is the case, reactions could be attempted using 
purified, rather than crude starting material. It is also possible that this substrate is 
simply not accepted. Poor conversions (5%) were observed with another other 1’-
MeTHIQ, 142.226 125 is significantly larger and simply may not fit into the enzyme active 
site.  
 
Enzymatic routes towards selective mono-N-methylation were unsuccessful so instead 
chemical routes towards di-N-methylated THIQs were explored. This scaffold is present 
in one naturally-occurring BIA, (S)-magnofluorine, an aporphine alkaloid which has 
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been shown to have anti-inflammatory, sedative and anti-fungal activities.227,228 
Quaternary nitrogen atoms are present in other pharmaceutically-relevant BIAs and 13-
MeTHPBs (Scheme 4.17), so routes towards analogues are useful.  
 
It was hoped that chemical conditions could be found which allow selective N-
methylation whilst avoiding reactivity at the free hydroxyl groups to avoid a protecting-
group based strategy. Trimethylammonium dopamine and trimethylammonium 
serotonin have been synthesised by Collins et al.229 without protection of the free 
hydroxyl groups, using iodomethane as the methylating agent in excess (10 e.q.) with 
a single equivalent of potassium carbonate to deprotonate the nitrogen. The reaction 
was performed using crude substrate 4 with and without base as potassium carbonate 
is capable of deprotonating catechol hydroxyl groups (as seen during the benzyl 
deprotection of N-Boc-dopamine, Section 2.2.4). Reactions were performed under 
anhydrous conditions as iodomethane is easily hydrolysed to methanol.  
 
For the reaction without base present, a mixture of starting material, mono- and di-N-
methylated product (144 and 145) was observed by NMR spectroscopy. Increasing the 
number of equivalents of iodomethane used did not improve the selectivity. For 
reactions with base, a mixture of mono and di-N-methylated product was observed 
(Scheme 4.18a). Again, increasing the number of equivalents of iodomethane did not 
improve the outcome of the reaction. It was considered that more forcing reaction 
conditions would be required as perhaps, despite improved nucleophilicity, the mono-
methylated nitrogen was sterically hindered. Therefore, 5 equivalents of potassium 
carbonate were used with heating to 50 oC. Although the quaternary nitrogen was fully 
formed, O-methylation at the para-position was also observed (Scheme 4.18b).  
 
One-step chemical routes towards N-methylated THIQs are not straightforward, 
however with the constant discovery of novel enzymes, in future analogous routes could 
 180 
be performed. 141 could also be generated via a synthetic route involving a protecting 
group strategy (i.e. via Boc-protection of the nitrogen, benzyl protection of the phenolic 
hydroxyl, N-methylation with iodomethane, followed by orthogonal protecting group 
removal under acidic conditions).  
 
Scheme 4.18: Reactions performed towards selective N-methylations of 1’-MeTHIQs 
 
4.3 Conclusions  
A range of novel 13-MeTHPB alkaloids were generated, with opposing stereochemistry 
at C-13 and C-13a to the naturally occurring alkaloids isolated from Corydalis plants. 
This was carried out by extending work on the acceptance of a-methyl substituted 
aldehydes by norcoclaurine synthase in which (1S,1’R)-THIQs can be generated in high 
yields and selectivity in a single reaction step. Two regioselective catechol O-
methyltransferases, RnCOMT and MxSafC were shown to be completely regioselective 
towards the meta-hydroxyl of the THIQ generated, expanding the known substrate 
scopes of these enzymes, and providing a benign, facile, regioselective route towards 
the product. The methyl donor co-factor, SAM was generated using a MAT enzyme, to 
reduce the expense of the reaction, allowing for preparative scale reactions. The side-
product, SAH formed after the methyltransferase reaction was degraded by a MTAN 

















































R = H or Me, mixture obtained
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generation methods by Siegrist et al.209 Chemical Pictet-Spengler reactions were then 
explored to generate the tetracyclic 13-MeTHPB scaffold. Due to reduced 
nucleophilicity of the aromatic D ring due to di-methoxy-substitution rather than phenolic 
groups, harsh reaction conditions involving formic acid were required to form the ring. 
Reactions involving formaldehyde or acetaldehyde as the aldehyde reagent were 
successful, both generating products with 10,11-dimethoxy substitutions on the D-ring. 
A new chiral centre was generated in the reaction with acetaldehyde, two epimers of 
product formed in a ratio of 3:1. Chemical Pictet-Spengler reactions between a 1’-Me-
THIQ were also explored using DMF as the reaction solvent and interestingly, after the 
Pictet-Spengler reaction occurred, oxidation of the D-ring was observed, leading to the 
formation of the biologically relevant protoberberine scaffold. This reaction therefore 






Chapter 5: Single Step Syntheses of (1S)-Aryl-
Tetrahydroisoquinolines by Norcoclaurine Synthases 
5.1 Introduction 
5.1.1 Pharmaceutical relevance of 1-aryl-tetrahydroisoquinolines 
The tetrahydroisoquinoline (THIQ) moiety is present in many biologically active 
molecules so is a desirable synthetic target to generate for pharmaceutical research. 
Generating single enantiomer and single regioisomer products is synthetically 
challenging. The 1-aryl-THIQ moiety is found in many synthetic biologically active small 
molecules (as given in Figure 5.1) which have been shown to have a variety of 
medicinal benefits, including anti-tumour230, anti-HIV231 and contraceptive232 activities. 
Solifenacin succinate (81) is a widely-prescribed muscarinic-receptor antagonist, used 
for the treatment of an overactive bladder with around 3 million US prescriptions per 
year.55 
 
Figure 5.1: A range of pharmaceutically relevant 1-aryl-tetrahydroisoquinolines. Figure 
adapted from Roddan et al.149  
 
The general route to racemic 1-aryl THIQs requires a three-step synthesis involving 
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conditions, followed by reduction of the imine to give the final THIQ scaffold. Single-
enantiomer syntheses of these molecules involve a stereoselective reduction of the 
imine using an inorganic catalyst (often iridium-based).233–235 These catalysts however 
can have narrow substrate scopes and so are not a general, versatile route to generate 
a range of these compounds. In another synthetic route developed by Chen et al.,235 
the asymmetric hydrogenation of the heterocyclic ring of a variety of isoquinolines was 
performed using a chiral iridium catalyst, giving a range of (R)-THIQ products in high 
yields (>80%) and high enantiomeric excesses (e.e.s) (90-99%). However, due to the 
resonance stability of the pyridine ring, hydrogenation must be performed under high 
pressure (ca. 80 bar), and the isoquinolines must be prepared synthetically (via Pictet-
Gams or Bischler-Napieralski methods).62,236 Iridium is also one of the lowest 
abundance elements on Earth, making its continued use unsustainable.237 Oxidatively 
sensitive groups on the isoquinoline benzene ring are also not tolerated and so to 
access these compounds, a multi-step synthesis involving a protecting group strategy 
would have to be used.   
 
Acid or phosphate-catalysed Pictet-Spengler reactions can also be employed to give 
racemic tetrahydroisoquinolines products, however regioselectivity can be poor. This 
means that labour-intense preparative-HPLC purification is often required to give single 
regioisomeric products.8,15 The industrial production of the widely-prescribed 
pharmaceutical, solifenacin succinate (81) (Figure 5.1) involves the chiral resolution of 
racemic 1-phenyl-1,2,3,4-THIQ by  tartaric acid recrystallisation. Although high 
enantiopurity in the product is achieved, the process is limited by poor atom economy 
and the THIQ scaffold must be generated via the Bischler-Napieralski reaction.238 
Isolating single enantiomer products of these compounds is meaningful because 
typically only one enantiomer possesses the desired medicinal properties.  
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Some enzymatic routes have been developed to generate 1-aryl THIQs, for example, 
using a stereoselective imine reductase (IRED).156 Zhu et al. have reported the 
screening of a range of IREDs which are capable of generating a range of 1-aryl-THIQs 
in high yields and enantiopurities, with methoxy-, chloro- and methyl- substituents on 
the aryl ring. Ortho substituents were poorly tolerated, likely due to steric hinderance in 
the enzyme active site.239 In a recent publication by Hestericová et al.,156 an artificial 
metalloenzyme was also developed based upon the high affinity between biotin and 
streptavidin. Here, a chiral biotinylated iridium co-factor was irreversibly anchored into 
a streptavidin-binding protein. Directed evolution was used to develop two artificial 
transfer hydrogenases (ATHases) with opposing stereoselectivities. This system could 
generate both enantiomers of product in high enantiomeric excesses, cell-free extracts 
could be used, high substrate loading (100 mM) was tolerated, and the enzymes are 
stable under biphasic conditions. However, addition of an expensive diamide, 1,1-
azobis(N,N-dimethylformamide) is required to prevent irreversible catalyst poisoning by 
glutathione, the imine starting material must be synthesised chemically and a relatively 
narrow substrate scope was presented. (1S)-1-Phenyl-THIQ (the precursor to the 
widely used anti-diuretic solifenacin succinate) was synthesised in 86% e.e.. Another 
enzymatic route to (1S)-1-phenyl-1,2,3,4-THIQ, developed by Ghislieri et al.67 involves 
the use of an enantiospecific monoamine oxidase (MAO). The MAO used was 
engineered using directed evolution methods. Here, the racemic THIQ was generated 
chemically, and the MAO used to selectively oxidise a single enantiomer of the amine 
to give the imine. The imine was then reduced in situ, with ammonia borane to give the 
racemic amine. This results in the accumulation of the opposing single enantiomer of 
amine to the one that the MAO oxidises. A wide range of chiral amines were obtained 
in high yields (45 – 93%) and enantiomeric excesses (90 – 99%). Two disadvantages 
of the system are that firstly, oxidatively sensitive substrates (such as catechols) are 
not tolerated as reactions must be performed under an oxygen atmosphere. Also, the 
racemic substrate must first be prepared chemically, in a regioselective manner.  
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5.1.2 Naturally occurring 1-aryl-tetrahydroisoquinolines 
Most examples of naturally occurring THIQs are benzylic at the C-1 position, generated 
in the NCS-mediated pathway to the benzylisoquinoline alkaloids. A variety of 
enantiopure 1-aryl-THIQs, known as the cryptostylines (48 – 50) were isolated from two 
species of orchid in the 1970s (as shown in Figure 5.2). Interestingly, in Cryptostylis 
erythroglossa, solely the (R)-enantiomer of product was isolated and in Cryptostylis 
fulva., only the (S)-enantiomer was found (Figure 5.2).114,115 The stereochemistry of the 
isolated products was determined by x-ray crystallography.116 
 
Figure 5.2: The cryptostylines, a variety of naturally occurring enantiopure 1-phenyl-
THIQs isolated from Cryptostylis fulva. The analogous levorotatory compounds were isolated 
from Crptostylis erythroglossa.114,116 Figure adapted from Roddan et al.149 
 
Some feeding studies have been performed and determined that the amine required is 
dopamine, generated from tyrosine or phenylalanine in an analogous pathway to the 
biosynthetic routes in BIA-producing plants. The biosynthetic origin of the phenyl group 
at C-1 is unknown.115 Due to the apparent isolation of single isomer products, it is likely 
that the biosynthesis involves an epimerase or Pictet-Spenglerase.  
 
5.1.3 The use of norcoclaurine synthases to generate 1-aryl-
tetrahydroisoquinolines 
The work presented in Chapter 3, showed that despite previous reports, a-methyl 
substituted aldehydes are in fact well tolerated as substrates for TfNCS. When a 























aldehyde was performed by the wild-type enzyme, giving THIQ products with (1S,1’R) 
stereochemistry in high diastereomeric ratios (up to 96:4). Two active site mutants, 
L76V and M97V were shown to improve diastereomeric ratios (up to 98:2) and 
conversions in products (up to >99%), respectively.148 TfNCS has also been shown to 
accept a variety of ketones as substrates, to generate 1,1-disubstituted THIQs. In 
particular, bulky substituted cyclohexanone derivatives were incorporated.36 Therefore, 
it is not implausible that benzaldehydes may also be accepted as substrates. 
 
Previous reports have shown that benzaldehyde derivatives were not well-tolerated as 
substrates by NCSs. Screening by Ruff et al. showed that only trace amounts of product 
are generated using benzaldehyde or 3-hydroxybenzaldehyde as substrates using wild-
type TfNCS.21 Similar results were observed when using CjNCS2 as the reaction 
catalyst.22 In both cases, enzymatic assays were performed with low substrate loading 
(10 µM to 1 mM) and it is also possible that these could have been generated by non-
enzymatic reactions. Subsequent studies have reported high Kd values of both 
substrates, indicating that high substrate loading is necessary for increased turnover of 
the substrates to give product.26 Indeed, attempts to generate unnatural THIQ products 
using alpha-substituted amino acids (L-valine and L-isoleucine) in vivo using a yeast-
based platform have been unsuccessful, likely due to the requirement of high substrate 
loading which is challenging to achieve in these systems.130  
 
Therefore, it was hoped that using these active site mutants as a starting point, we 
could extend the known substrate scope of TfNCS to also accept a variety of 
benzaldehydes as substrates and thus expand the portfolio of enantiopure THIQs that 
can be synthesised via an NCS-mediated reaction. This would also lead to the single-
step syntheses of a range of novel (1S)-aryl-THIQs which are challenging to synthesise 





Scheme 5.1: Summary of the project aim, to generate a variety of novel (1S)-aryl THIQ 
products in a single, regioselective and enantioselective step, using TfNCS as a reaction 
catalyst. This would be achieved from the selective Pictet-Spengler reaction between dopamine 
and a benzaldehyde analogue. Figure adapted from Roddan et al.149 
 
5.2 Results and Discussion 
5.2.1 Expanding the NCS substrate scope  
Previous work (Chapters 3 and 4) has showed that a-methyl substituted aldehydes are 
indeed accepted as NCS substrates, despite previous reports that a-substituted 
aldehydes generally, are not accepted.21,28 Two active site mutants of TfNCS, L76V and 
M97V were utilised to improve diastereomeric excesses and conversions in products 
of reactions between dopamine and a variety of a-methyl substituted aldehydes. Based 
upon this, initial screens were performed using these promising mutants, compared 
with the wild-type enzyme with more challenging substrates, including 2-methyl-2-
pentenal and an a-ethyl substituted aldehyde, 2-ethylbutanal, where low conversions 
were previously observed with the wild-type enzyme (Scheme 5.2).148 
 
Scheme 5.2: NCS catalysed reactions performed between a conjugated a-methyl 
































50 mM HEPES, pH 7.5







There is interest in accessing the THIQ product of the NCS reaction between dopamine 
and 2-ethyl-butanal as the racemic compound has been shown to act as a 
bronchodilator163,240. Conversions with these single-point mutants of TfNCS (L76V, 
M97F, and M97V), compared with the wild-type enzyme are given in Figure 5.3. 
  
 
Figure 5.3: HPLC yields of reactions between dopamine and 97 or 99 using norcoclaurine 
synthases as the reaction catalyst. a. Reaction with 2-methyl-2-pentenal (97) to give 100. b. 
Reaction with 2-ethylbutanal (99) to give 98. Reaction conditions: dopamine HCl (10 mM), 
aldehyde (20 mM), sodium ascorbate (10 mM), purified TfNCS (final concentration of 0.2 mg 
mL-1, WT = D33TfNCS, L76V = D29TfNCS-L76V, M97F = D29TfNCS-M97F and M97V = 
D29TfNCS-M97V) in HEPES buffer (50 mM, pH 7.5) with MeCN (10% v/v) at 37 oC for 18 h. 200 
µL scale reactions; samples were prepared by workup method 1, yields were determined by 
monitoring product formation against standards by analytical achiral HPLC (method 1). Figure 
adapted from Roddan et al.149 
 
For enzymatic reactions between dopamine (5) and 100, conversions were comparable 
when using the L76V mutant and the wild-type construct. Based on a co-crystallised 
structure of NCS gained with an a-methyl substituted reaction mimic (PDB: 6RP3), the 
‘R’ group of the aldehyde sits close to this region in the active site, as shown in Figure 
5.4.148 However, due to the lack of rotational freedom of the aldehyde, it appears that 










The methyl group of the aldehyde part of the mimic sits tightly in the small hydrophobic 
pocket between M97 and E110. This therefore rationalises why conversions are 
lowered with decreasing space in this region (M97F) and improved with increased 
space in this region (M97V), particularly for an aldehyde with restricted conformational 
freedom due to the alkene double bond. For conversions with 2-ethylbutanal (99) as 
the substrate, 50% lower conversions were observed with the L76V mutant, despite the 
creation of additional space in the active site. A similar observation was noted when the 
NCS mutant M97F was used as the reaction catalyst. This suggests that perhaps larger 
conformational changes occur in the enzyme upon the binding of bulkier aldehydes as 
substrates. As the crystal structure gained is simply a ‘snapshot’ of the mechanistic 
process, complete mechanistic insight cannot be gained from a single structure, 
although, it is known that the mechanism is highly dynamic from NMR-based studies.26 
 
 
Figure 5.4: Co-crystallised structure of D33TfNCS with alpha-methyl aldehyde reaction 
mimic bound in the active site. Figure was prepared using USCF Chimera using PDB: 6RP3. 
 
Conversions were improved 4-fold with the single mutation, M97V, further highlighting 
the further applicability of this mutant with a-substituted aldehydes as substrates. 
Unfortunately, enantiomeric excesses of the products were not determined as these 
aldehydes were not converted to racemic products upon reaction with dopamine, using 
a phosphate-mediated, racemic Pictet-Spengler reaction.15 
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5.2.2 Acceptance of benzaldehyde and derivatives by NCS  
In previous screens of reactions between dopamine and benzaldehyde (139), using 
TfNCS as the reaction catalyst, performed by Ruff et al, products were not detected.21 
In these assays, substrate concentrations of 1 mM dopamine and 1 mM aldehyde were 
used, combined with very high enzyme concentrations (300 µM final concentration 
which is equivalent to 6.3 mg mL-1). As demonstrated in previous reports, high substrate 
loading is well-tolerated by NCS and is indeed required to gain high conversions of the 
product. NMR titration experiments were performed by Berkner et al. to further elucidate 
the NCS reaction mechanism. The Kd value of dopamine was found to be 5 mM, thus 
indicating very weak substrate binding.26 With this in mind, assays performed in this 
study used increased substrate loading; 10 mM amine and 20 mM aldehyde (139, 146-
155). High concentrations of aldehyde were used (2 e.q.), with dopamine as the limiting 
reagent. An excess of aldehyde was used in enzymatic reactions because the aldehyde 
degrades with time and so use as the limiting reagent would give inaccurate quantitative 
conversions. 
 
Scheme 5.3: A variety of benzaldehyde analogues were tested as substrates for TfNCS 
using dopamine as the amine substrate.  Reaction conditions: dopamine·HCl (10 mM), 
aldehyde (20 mM), sodium ascorbate (10 mM), purified Δ29TfNCS-M97V (0.2 mg mL-1 final 
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scale reactions; samples were prepared by workup method 1, yields were determined by 
monitoring product formation against standards by analytical achiral HPLC (method 1). 
 
Assays were performed using benzaldehyde (139) and a variety of analogues (146-
155) using 5 as the amine substrate (Scheme 5.3). Conversions to the products (157-
166) using wild-type enzyme and the mutants L76V, M97F and M97V are given in 
Figure 5.5. Reactions were performed for 3 hours to minimise the contribution of the 
spontaneous background Pictet-Spengler reaction between the two substrates, as the 
aldehyde is highly activated. The major enantiomer of product formed was assumed to 
have S stereochemistry, based upon previous reports, and was later confirmed by 
derivitisation of 157 to a known standard. The background reaction, as observed in the 
















Figure 5.5: Conversions of reactions between dopamine and a variety of benzaldehyde 
analogues. The aldehyde substrates used (139, 146-155, Scheme 5.3) are given on the x axis. 
Wild-type or active site mutants of NCS were used as the reaction catalyst with reaction 
conditions given in Scheme 5.3. Enantiomeric excesses in the products are given by showing 
the amounts of (R)- and (S)- product generated through the reactions, determined by chiral 
HPLC analysis (method 4 (for 156 and 157) and 5 for all other compounds). Conversions of the 
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compared to calibration curves of purified standards (method 1), see Appendix. Figure adapted 
from Roddan et al.149 
 
Comparing the difference in conversions of reactions between the aromatic aldehyde, 
benzaldehyde (139) and the aliphatic analogue, cyclohexanecarboxyaldehyde (146), 
increased conversions were observed with 146 for all NCSs tested. Likely little to no 
background reaction occurs with 146 as the aldehyde substrate due to less activation 
of the aldehyde, by donation from the neighbouring pi-system, compared with the 
aromatic aldehyde, 139. Similar results are observed when other aliphatic aldehydes 
are used as substrates. High enantiomeric excesses in the products are therefore 
observed with 139 as the aldehyde substrate (>99% for all TfNCS variants).  
 
In all cases, conversions with the wild-type enzyme and L76V with aldehydes 139, 146-
155 are comparable and conversions with both substitutions at residue 97 resulted in 
improved yields. This is particularly interesting with the M97F variant as due to the bulky 
phenyl group, there is less space in this region of the active site.148 In addition, in 
previous studies with ketones used as NCS substrates, in all cases, mutations at the 
M97 position (to phenylalanine, leucine or valine) resulted in poorer yields compared 
with the wild-type enzyme as the catalyst.36 With the M97V variant, in a majority of 
cases, lower conversions were gained than with M97F. Previous NMR studies of the 
wild-type TfNCS enzyme, have indicated it to be highly dynamic during the catalytic 
process with substrate binding resulting in large conformational changes across the 
entire protein.26 The increased conversions and enantiomeric excesses in products in 
the M97F and M97V could therefore be due to an effect whereby when faster binding 
of the substrates occurs (by increasing hydrophobicity or active-site space, 
respectively) and turnover is faster, so the background Pictet-Spengler reaction is less 
efficient and so product enantiopurity is improved.  
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The effects of electron-donating (147-149) and electron-withdrawing substituents (150-
155) on the aldehyde aromatic ring were tested by performing reactions with ortho-, 
meta- and para- substituted benzaldehyde analogues. It was hoped that altering the 
substitution on the phenyl ring at different positions could help to identify how the 
various enzyme mutants were affecting conversions. For reactions with all substituted 
benzaldehydes (147-155), enantiomeric excesses in the products were decreased 
compared with benzaldehyde (139), despite often low or no observed background 
reactions. This suggested that the lower stereoselectivities were associated with the 
presence of the enzyme, rather than any background reaction. It could be questioned 
whether this is due to reactivity in the enzyme active site, whereby formation of a small 
amount of the (R)-enantiomer of product is formed or perhaps there is an alternative 
hydrophobic surface on which the racemic reaction can occur. Further elucidation of 
this would be challenging and there are also issues associated with quenching both the 
enzymatic and background reactions, as discussed later.  
 
Conversions for all ortho- (147, 150 and 153) and meta- (148, 151, and 154) substituted 
benzaldehydes tested were comparable to those with benzaldehyde, whereas para- 
substitutions (149, 152 and 155) were less well tolerated. Interesting with para-
fluorobenzaldehyde (4h) as a substrate, no conversions were observed with the wild-
type enzyme but with the two M97 mutants tested, enzymatic activity was observed. 
Particularly poor enantiomeric excesses were observed for reactions with all chlorinated 
benzaldehyde derivatives (153 - 155).  
 
To understand which features of the reaction conditions were required for successful 
conversions, a reaction towards 157 was performed using the conditions described by 
Ruff et al.21 The reaction conditions were then adjusted towards the conditions 
described earlier in Figure 5.5 by increasing substrate concentrations, enzyme 
concentrations and reaction temperatures. Resulting product yields with the various 
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reaction conditions are given in Figure 5.6. Product yields are given in percentages of 
product formation, compared with the maximum theoretical percentage yield based 
upon calibration curves of isolated 157. Reaction temperature has little effect on yield 
and a minor increase in yield is observed with increased substrate loading. 3.8 µM is 
approximately 0.08 mg mL-1 of TfNCS, so half the amount of enzyme was used 
compared with the conditions described in Figure 5.5. However, a 10-fold increase in 
enzyme concentration in the conditions used by O’Connor does not improve the yields 
to that observed in this work (11% previously vs. 30% here). Benzaldehyde is highly 
oxidatively sensitive and only one equivalent was used previously.21  To accommodate 
for this oxidation and ensure that at least one equivalent of aldehyde was present 
compared to phenethylamine, in this work, two equivalents of aldehyde were used 
which may account for the increased yields observed. A different co-solvent was also 
used here (acetonitrile vs. methanol previously) which also may have an effect. 
Increased conversions are observed when using DMSO as a co-solvent when ketones 
are used as substrates, compared with using acetonitrile.36 
 
Figure 5.6. Yields of product formation of 157 following reaction conditions described by 
O’Connor et al.21 The reaction conditions performed by O’Connor et al. are given in red. 
Reaction conditions were also altered to determine the cause of low conversions. Reaction 
conditions: Stock solutions of dopamine (100 mM in MeOH) and benzaldehyde (100 mM in 
MeOH) were prepared and added to Tris buffer (100 mM, pH 7) and D29TfNCS (stock at 480 
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µM in 20 mM Tris, 50 mM NaCl, pH 7.5). Reactions were prepared to 100 µL and were performed 
for 3 h. Boiled enzyme was used as the negative control. Reactions were quenched by addition 
of 100 µL MeOH, centrifuged (13,000 rpm, 10 min, 4 oC) and the supernatant analysed by RP-
HPLC (method 1). Conversions were determined based upon a calibration curve of 5b (see 
Appendix). Reactions were performed in triplicate and standard deviations reported. Figure 
reproduced from Roddan et al.149 
 
These initial attempts to perform assays with the benzaldehydes highlighted the issues 
of the spontaneous, racemic background reaction occurring and thus the method of 
quenching the enzymatic reaction needed to be considered. Purified enzyme had been 
used to eliminate any phosphates from the cell-lysate which would catalyse the 
background reaction. Previous enzymatic assays performed using TfNCS have always 
used the addition of acid (aq. HCl or TFA) to precipitate the enzyme.21,36,118 However, 
acidic conditions are also widely known to catalyse the Pictet-Spengler reaction.8 This 
has not previously been an issue with NCS reactions the as previously used carbonyl 
substrates are not particularly activated and mildly acidic conditions at low temperatures 
are unlikely to catalyse the racemic background reaction and thus diminish the 
enantiopurity of the isolated products.  
 
Due to the highly reactive nature of the benzaldehydes, alternative methods to quench 
the reactions were considered. Other commonly used methods to precipitate proteins 
include the addition of base or organic solvents. Dopamine (and analogues) are known 
to undergo radical polymerisation reactions under basic conditions so observed 
conversions would be lower than expected.241 DMSO could not be used as it is a known 
oxidising agent and the high volatility of methanol would affect the quantitative analysis 
of conversions. Therefore, an equal volume of acetonitrile to reaction volume was used 
to quench enzymatic reactions. Due to these considerations, acetonitrile was also used 
as the co-solvent for enzymatic reactions rather than DMSO as previously reported. 
Previous studies using a-methyl substituted aldehydes as substrates showed that 
comparable conversions are observed with either co-solvent (Figure 3.1). 
 197 
 
After precipitation of the enzyme, it was not possible to stop the spontaneous 
background reaction. Therefore, to reduce this reaction, samples were frozen (-20 oC) 
after quenching with acetonitrile and analytical RP-HPLC analysis was performed with 
samples maintained at 4 oC. To halt the reactions and prepare samples for chiral HPLC 
analysis, samples were saturated with sodium bicarbonate, to adjust to pH to 8 and 
immediately extracted into ethyl acetate. The pKa of dopamine amine is around 9, so 
the majority would remain in the aqueous phase and only product and benzaldehyde 
extracted into ethyl acetate, meaning less amine available to participate in a 
background Pictet-Spengler reaction. This method however is not appropriate for 
determining conversions to the product as some may be retained in the aqueous phase 
(and has been shown by RP-HPLC analysis of the aqueous phase after extraction) and 
therefore lost during the extraction process.  
 
5.2.3 Attempts to extend the benzaldehyde substrate scope of NCS  
With a view to further extending the benzaldehyde substrate scope beyond simple 
methylated or halogenated analogues, a variety of bulkier, activated benzaldehyde 
derivatives (given in Figure 5.7) were tested as substrates for TfNCS.  
 
Figure 5.7: A range of other benzaldehyde analogues tested as substrates for TfNCS 
using dopamine as the amine substrate. Reaction conditions: dopamine·HCl (10 mM), 
aldehyde (20 mM), sodium ascorbate (10 mM), purified Δ29TfNCS-M97V (0.2 mg mL-1 final 
concentration) in HEPES buffer (50 mM, pH 7.5) with MeCN (10% v/v) at 37 °C for 3 h, 100 μL 
scale reactions; samples were prepared by workup method 1, product formation was determined 
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For enzymatic reactions using TfNCS (M97V) between dopamine and 2-
pyridinecarboxaldehyde (167), product was observed by LC-MS, however a high 
background reaction was also observed in the control reaction and additional, 
unassignable peaks were also seen by aHPLC. The presence of the pyridine ring is 
likely causing side reactions due to activation of the aldehyde carbonyl by the electron 
withdrawing nitrogen.  
 
Trace conversions were observed for reactions between dopamine and the two 
hydroxylated benzaldehydes (168 and 169), comparable to conversions observed in 
the control samples. Ortho and para isomers of the product observed by RP-HPLC were 
in the same ratios as observed for the control reaction, with higher peak areas in the 
enzymatic reaction. Trace conversions were also observed with the brominated 
aldehyde (170). It is likely that these larger hydroxyl- (168 and 169) and bromo-
substituted aldehydes (170) are not accepted as intermediates simply do not fit into the 
active site of the enzyme.  
 
5.2.4 Improvement of enantiomeric excesses of the products  
Although impressive conversions were observed for reactions using the M97V mutant, 
for some substrates, the enantiomeric excesses observed in the products were lower 
than expected due to the high racemic background reaction occurring simultaneously. 
It was hoped that by altering the concentrations of enzyme used and by stopping the 
reaction at different time points, optimal reaction conditions could be found to achieve 
both high conversions and high enantiomeric excesses in the products without using 
large quantities of enzyme. Timepoint assays were performed for the reactions between 
dopamine and benzaldehyde (139) (Figure 5.8) using varying concentrations of 
D29TfNCS-M97V as the reaction catalyst.  
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Figure 5.8: Conversions and product enantiopurities for reactions between dopamine and 
benzaldehyde (139) to give 157, catalysed by TfNCS-M97V. Varying timepoints and final 
concentrations of enzyme were used. Reaction conditions: 10 mM dopamine HCl, 10 mM 
sodium ascorbate, 20 mM benzaldehyde in HEPES buffer (50 mM, pH 7.5) with 10% v/v MeCN 
and final concentration of Δ29TfNCS-M97V TfNCS at 0.1, 0.2 or 0.5 mg mL-1. Control reactions 
were performed using the same conditions but the TfNCS sample was substituted for enzyme 
buffer (20 mM Tris, 50 mM NaCl, pH 7.5). Reactions were performed at 37 °C for 3 h, 100 μL 
scale reactions; samples were prepared by workup method 1, yields were determined by 
monitoring product formation against standards by analytical achiral HPLC (method 1). Above 
each bar, the enantiomeric excess of 157 formed is given as a percentage. Figure adapted from 
Roddan et al.149 
 
As shown in Figure 5.7, the background reaction occurs between the two substrates at 
all timepoints. Indeed, in the absence of enzyme, a 17% conversion was observed after 
24 h. High enantiomeric excesses (97-98%) in the products were observed for all 
reactions using 0.5 mg mL-1 (final concentration) of enzyme. However, using 0.2 mg 
mL-1 enzyme gave 95% e.e. in the product at both 6 h and 24 h. Therefore, since 
conversions were comparable at 24 h, a 6 h reaction with a 0.2 mg mL-1 final 
concentration of enzyme would minimise the enzyme concentration required, reducing 
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the protein preparation requirements. However, purification of the reaction sample 
prepared using a reaction time of 24 h and a final enzyme concentration of 0.5 mg mL-
1 would be simplest as all dopamine was consumed by that stage. This would mean 
that purification by an extractive workup may be possible.118 A 24 h reaction time was 
therefore selected for performing these reactions with other benzaldehyde analogues.  
 
To optimise the reactions between dopamine and a substituted benzaldehyde, which 
had proved more challenging for gaining high enantiomeric excesses in the products 
(see Figure 5.5), a similar timepoint assay was performed for the reaction between 
dopamine (5) and 3-methylbenzaldehyde (148) (Figure 5.9). For an NCS-mediated 
reaction with an enzyme concentration of 0.1 mg mL-1 and a reaction time of 3 h (Figure 
5.5), the product was obtained in poor enantiopurity (67% e.e.) and low yield (31%). 
Therefore, reactions were focussed on using a 0.2 or 0.5 mg mL-1 final concentration of 
enzyme. Again, a high racemic background reaction was observed (15% conversion 
after 24 h). However, the amount of (R)-product formed was higher than would be 
expected based upon the no enzyme reactions, suggesting that a racemic Pictet-
Spengler reaction is associated with the use of enzyme, but high concentrations of 
enzyme are also required for fast turnover of the substrates to give high e.e.s. For all 
reactions with 0.2 mg mL-1 of enzyme e.e.s of 74-78% were observed, whereas with 
0.5 mg mL-1 enzyme, e.e.s of 84-85% were observed at 2-6 h, increasing to an e.e. of 
87% at 24 h, combined with very high conversion levels. It was therefore likely that 
using these reaction conditions with the other substituted benzaldehyde analogues 
enantiopurities might be improved. Clearly, higher concentrations of pure enzyme (0.5 
mg mL-1) are optimal to achieve high enantiomeric excesses in the (1S)-1-aryl-THIQs 


















Figure 5.9: Conversions and product stereochemistry for reactions between dopamine 
(5) and 3-methylbenzaldehyde (148) to give 159. TfNCS-M97V at varying final concentrations 
was used as the reaction catalysts. Reaction conditions: 10 mM dopamine HCl, 10 mM sodium 
ascorbate, 20 mM benzaldehyde in HEPES buffer (50 mM, pH 7.5) with 10% v/v MeCN and final 
concentration of TfNCS at 0.2 or 0.5 mg mL-1. Control reactions were performed using the same 
conditions but the TfNCS sample was substituted for enzyme buffer (20 mM Tris, 50 mM NaCl, 
pH 7.5). Reactions were performed at 37 °C for 3 h, 100 μL scale reactions; samples were 
prepared by workup method 1, yields were determined by monitoring product formation against 
standards by analytical achiral HPLC (method 1). Enantiomeric excesses of 159 formed are 
given above each bar as a percentage. Figure adapted from Roddan et al.149 
 
5.2.5 Optimised NCS-catalysed reactions with a range of benzaldehydes as 
substrates 
Reactions performed at the higher enzyme concentrations (0.5 mg mL-1) gave high 
enantiopurities in the products of reactions between dopamine (5) and benzaldehyde 
(139) or 3-methylbenzaldehyde (148) (Figures 5.8 and 5.9). Therefore, to improve the 
enantiomeric excesses the products with other benzaldehyde analogues, NCS-
mediated reactions were performed using the most promising mutant, D29TfNCS-M97V 
at a final enzyme concentration of 0.5 mg mL-1 for 24 h. Conversions with the amounts 
of (R) and (S) products generated for each are given in Figure 5.10.  
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Figure 5.10: Yields and enantiomeric excesses of products generated by an D29TfNCS-
M97V catalysed reaction between dopamine and a variety of benzaldehyde 
derivatives. Reaction conditions: dopamine·HCl (10 mM), aldehyde (20 mM), sodium ascorbate 
(10 mM), purified Δ29TfNCS-M97V (0.5 mg mL-1 final concentration) in HEPES buffer (50 mM, 
pH 7.5) with MeCN (10% v/v) at 37 °C for 24 h, 100 μL scale reactions; control reactions were 
performed using the same conditions but the TfNCS sample was substituted for enzyme buffer 
(20 mM Tris, 50 mM NaCl, pH 7.5). Yields were determined by monitoring product formation 
against standards by analytical RP-HPLC (method 1, see Appendix). Enantiomeric excesses of 
the THIQs formed are given above each bar as a percentage.  
 
As previously shown, complete conversions were observed for reactions with 139 and 
146 to give 156 and 157, with both products formed in excellent enantiopurity (97% and 
>99%, respectively). Using these conditions also significantly improved both the 
conversions and enantiopurity of the products with methylated benzaldehyde 
derivatives (147-149) where conversions of 76% and 90% were observed for the ortho- 
(158) and meta- (159) substituted compounds, respectively in >90% e.e. Lower 
enantiopurity and conversions were observed with the para-substituted analogue (160), 
(68% e.e. and 45% yield). Despite the observation of a high racemic background 
reaction for NCS-catalysed reactions involving chlorinated benzaldehyde derivatives 
(153 and 153), reasonable enantiomeric excesses in the products were obtained (68-
88%). An increasingly significant background reaction was observed for reactions with 
chlorinated benzaldehydes. Interestingly, a similar trend was observed with the 
halogenated analogues; lower background reactions were observed with the para < 
 203 
meta < ortho. Presumably, this is due to a combination of sterics and carbonyl 
activation. Despite this, the para-chlorinated product, 155 was generated in reasonable 
yield, 41% compared with only 18% with a reaction time of 3 h and enzyme 
concentration of 0.2 mg mL-1. Increased enantiopurity in the product was also observed, 
75% vs. 21% (Figure 5.9 compared with Figure 5.4).  
 
Gaining high enantiomeric excesses in the products for reactions with halogenated 
benzaldehydes (5f-k) still proved challenging. It was hypothesised that this was due to 
a combination of a high background reaction (as the aldehydes are highly activated) 
and increased lability of the C-1 proton, due to the presence of electron-withdrawing 
halogen atoms on the aryl ring. To minimise racemisation at the C-1 position, reactions 
were performed using analogous conditions to those performed for Figure 5.10, except 
a lower pH (6 vs. 7.5) was used. Conversions and enantiomeric excesses of the 
resulting products (161-166) from reactions with aldehydes 150 – 155, respectively) are 
given in Figure 5.11.  
 
Figure 5.11: Yields and enantiomeric excesses of products generated by an D29TfNCS-
M97V catalysed reaction between dopamine and halogenated benzaldehyde derivatives 
at pH 6. Reaction conditions: 5 (10 mM), aldehyde (20 mM), sodium ascorbate (10 mM), purified 
Δ29TfNCS-M97V (0.5 mg mL-1 final concentration) in HEPES buffer (50 mM, pH 6) with MeCN 
(10% v/v) at 37 °C for 24 h, 100 μL scale reactions; control reactions were performed using the 
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same conditions but the TfNCS sample was substituted for enzyme buffer (20 mM Tris, 50 mM 
NaCl, pH 7.5). Yields were determined by monitoring product formation against standards by 
analytical RP-HPLC (method 1). Enantiomeric excesses of the THIQs formed are given above 
each bar as a percentage. 
 
Remarkably, in all cases, improved yields and enantiomeric excesses in the products 
were observed. With the ortho-chlorinated product (164), at pH 7.5, the yield and e.e. 
observed were 40% and 24%, respectively, whereas at a lower pH, both were improved 
to 57% and 79% respectively. Interestingly, it appears that this was due to the minimal 
background reaction observed, which was unexpected, considering that the Pictet-
Spengler reaction is catalysed by acidic conditions. Previously, reactions catalysed by 
TfNCS have been performed at near neutral pH (7-7.5) and it is unclear how performing 
reactions at pH 6 improves both the enantiopurity and conversions with these 
substrates. Perhaps increased activation of the aldehyde helps improve substrate 
turnover or this NCS variant (M97V) is simply more active at a lower pH. Since the 
background reaction is minimized at pH 6, probably due to protonation of the HEPEs 
buffer, which may help activate the substrates. giving racemic Pictet-Spengler products, 
particularly with the activated benzaldehydes. This therefore means that more substrate 
is available for NCS reactions, leading to increased S product formation. It is therefore 
clear that reaction conditions need to be optimised for each substrate type, also 
considering that decreasing pH to 6 did not improve conversions with N-methyl-
phenethylamines as substrates, as discussed in Chapter 6.  
 
5.2.6 Synthesis of racemic 1-aryl tetrahydroisoquinolines  
To generate racemic standards of the 1-aryl-THIQs for chiral HPLC analysis, the 
phosphate-mediated Pictet-Spengler reaction between dopamine and a variety of 
benzaldehyde derivatives (139, 146 – 155) was investigated15. Reactions were 
performed using previously reported conditions. Conversions were lower than expected 
(14 - 86%), as shown in Figure 5.12, considering the apparent spontaneous reaction 
between the two substrates without a reaction catalyst that was observed during 
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enzymatic reaction controls. Significant precipitation was observed in the reaction 
samples and additional peaks were also observed during RP-HPLC analysis that did 
not correspond to the THIQ products isolated from enzymatic reactions. This suggests 
that side reactions (e.g. oxidations) occur due to the highly reactivity of the 
benzaldehydes. To minimise this, reactions were performed under argon, and it is likely 
that some of the side-products are adhering to the plastic Eppendorf tubes that the 
reactions were performed in. In future attempts, these reactions could be performed in 
glass reaction vials instead.  
 
 
Figure 5.12: Conversions of phosphate-mediated reactions between dopamine and a 
variety of benzaldehyde analogues. Reaction conditions: 10 mM dopamine HCl, 10 mM 
sodium ascorbate, 20 mM aldehyde in KPi buffer (300 mM, pH 6) with 50% v/v MeCN. Reactions 
were performed on a 200 µL scale for 18 h at 60 oC. Samples were prepared by workup method 
1. Yields were determined by monitoring product formation against standards by analytical RP-
HPLC (method 1, see Appendix). Figure adapted from Roddan et al.149 
 
A phosphate-mediated reaction is an excellent way of generating racemic THIQs under 
mild conditions, however one limitation is the lack of regioselective control with some 
aldehydes as substrates. For reactions between dopamine and linear or benzylic 
aldehydes, a ratio of the ortho:para isomers of product of 1:3 was observed, so single 
regioisomer products are typically isolated by preparative-HPLC. For reactions between 
139   146   147   148   149   150   151   152   153   154   155 
Aldehyde substrate 
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dopamine and a-methyl substituted aldehydes, only the para regioisomer was 
generated, likely due to steric hinderance. It was therefore hoped that using 
benzaldehydes, with increased bulk at the alpha-position, single regioisomer products 
would be formed. The conversions and regioisomer ratios of phosphate mediated 
reactions between dopamine and a variety of benzaldehyde analogues are given in 
Figure 5.12. For the majority of substrates, a ratio of the two regioisomers, ortho:para 
of 8-10:1 was observed.  
 
5.2.7 Increasing molecular complexity using regioselective catechol O-
methyltransferases 
A variety of meta-methylated, N-acylated 1,2,3,4-THIQs (Figure 5.13) have been shown 
to down-regulate the production of various inflammatory cytokines and other toxic 
molecules in activated microglial cells. This activation is associated with a variety of 
neurodegenerative diseases such as Huntington’s and Parkinson’s disease. Several of 
these THIQs are under patent for preventing or treating a variety of degenerative or 
inflammatory diseases.242 Performing the regioselective meta-methylation of a catechol 
is challenging chemically, as there is a lack of regioselective control and synthetic 
routes therefore require the use of a precursor with the correct methylation pattern 
and/or employ a multi-step, protecting group strategy. However, in the production of 
THIQs using NCS, the meta-hydroxyl group of the dopamine catechol is currently 
required for a productive enzymatic reaction, so the regioselective methylation reaction 
must be performed after the Pictet-Spengler reaction has occurred if meta-methylation 
is required.21,28 If para-methylation is required, para-methylated dopamine could be 
used but it is not currently commercially available and cannot be generated by a 
catechol O-methyltransferase in complete conversion, so isolation of the pure amine 
would be challenging.209 
 207 
 
Figure 5.13: Examples of some compounds under patent for the treatment of a range of 
neurodegenerative diseases. Single enantiomer analogues of these compounds may be 
generated by an NCS-mediated reaction followed by methylation with a regioselective O-
methyltransferase.  
 
Two regioselective catechol O-methyltransferases, RnCOMT and MxSafC have 
already been explored with the THIQ product of reaction between dopamine (5) and an 
a-methyl substituted aldehyde, as discussed in Chapter 4. Both enzymes were 
regioselective towards the C6/meta-position. Another O-methyltransferase, from 
Thalictrum flavum, 6OMT was also available and was being explored by other group 
members (Fabiana Subrizi and Benjamin Thair, Hailes group) for benzylic THIQs as 
substrates. 6OMT ((S)-norcoclaurine 6-O-methyltransferase), is involved in the same 
biosynthetic pathway as NCS towards the in planta production of BIAs.197 6OMT 
selectively methylates the C6-hydroxyl of (S)-norcoclaurine (7) to give (S)-cocolaurine 
(8) (Scheme 1.1). The substrate scope of 6OMT has not been widely explored however 
(S)-norlaudanosauline (15) is also accepted and there have been crystallographic 
investigations. In the co-crystallised structure gained of 6OMT with active-site bound 
SAH and (S)-norlaudanosauline (15), a hydrogen-bonding interaction can be observed 
between the benzylic hydroxyl groups and Asp-169.243 It is unknown whether this 
interaction is essential for a productive reaction.  
 
However, it was hoped that here, that investigation of three different, appropriate O-
methyltransferases, would lead to the selective C6-hydroxyl methylation of (S)-1-aryl-
THIQs towards the pharmaceutically relevant molecules shown in Figure 5.12. 
RnCOMT and MxSafC were prepared as discussed in Chapter 4. 6OMT was expressed 









IPTG, the temperature was lowered to 16 oC and the cultures left to express for 48 h, 
as expression trials (performed by Fabiana Subrizi) showed that this increased yields. 
However, as demonstrated in Figure 5.14, poor expression was still achieved.  
 
Figure 5.14: SDS-PAGE analysis of 6OMT expression. Lanes: 1, Benchmark™ protein ladder 
(masses given in kDa), 2. Clarified cell lysate of 6OMT expression. Protein expected at 39 kDa.  
 
The three O-methyltransferases (RnCOMT, MxSafC and 6OMT) were tested with two 
(S)-1-substituted THIQ products (5a and 5b) generated from the NCS reaction. Achiral 
HPLC traces of the reactions performed are shown in Scheme 5.4. The analytical HPLC 
trace of the product of the NCS reaction is also shown for comparison, with the 













Scheme 5.4: Achiral HPLC traces of regioselective C6-O-methylation of two THIQ 
products. a. 171, b. 172. Reaction conditions: Once the NCS reaction was completed 
(performed on 100 µL scale), the reaction mixture was quenched and lyophilised (workup 
method 5). The residue prepared in 25 mM HEPES, 20 mM MgCl2, 0.2 M KCl pH 7.5) with ATP 
and L-methionine (10 mM final concentration of each), EcMAT (0.4 mg mL-1 final concentration), 
EcMTAN (0.025 mg mL-1) and appropriate methyltransferase enzyme (10% v/v lysate for 
RnCOMT and 6OMT or 0.6 mg mL-1 final concentration of purified MxSafC). Reactions were 
performed at 37 oC on a 200 µL scale. Reactions quenched by addition of 200 µL MeCN. Yields 
were determined by monitoring product formation against standards by analytical HPLC (method 
1). Figure adapted from Roddan et al.149 
 
For the RnCOMT reaction with the THIQ, 157, a ratio of the two regioisomers C6-
OMe:C7-OMe methylated products (172:174) were observed in an 87:13 ratio, as 
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a) 171: R = cyclohexyl
b) 172: R = Ph
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therefore possible to conclude in the analytical RP-HPLC trace that the peaks at 7.2 
and 7.3 min corresponded to the C6- and C7-O-methylated products, 172 and 174, 
respectively. It was therefore assumed that both enzymes, 6OMT and MxSafC were 
also regioselective towards the C6-position, and this was subsequently confirmed by 
NMR analysis of the purified product generated from the MxSafC reaction. Low yields 
achieved with 6OMT meant that the products generated could not be isolated in 
sufficient quantities for structural determination. It is particularly interesting that C6-O-
methylation is observed with MxSafC, as in previous reports, it is shown to be 
predominately regioselective towards the C7-hydroxyl, although high C6-hydroxyl 
selectivity has been observed for other substrates, as discussed further in Chapter 4.209 
The side-chain attached to the catechol clearly has subtle but effective influence in 
determining the position that methylation occurs. Therefore, using these bulky THIQs 
as substrates means that the substrate can only bind in a single orientation to the 
magnesium ion co-factor. Poor conversions were observed when using 6OMT lysate 
compared with using purified MxSafC, likely due to a combination of poor enzyme 
expression and poor substrate acceptance. The lack of a hydrogen bonding interaction 
of the group at C-1 to key active site residue, Asp139 may also be contributing to low 
conversions due to decreased affinity for the substrate.    
 
Preparative scale reactions were performed using the most productive 
methyltransferase, purified MxSafC. As discussed in Chapter 4, attempts to perform the 
reaction with MxSafC as clarified cell lysate were unsuccessful, likely because the 
enzyme is not particularly stable. Conversions (based upon calibration curves of 
purified product standards) when using 5 mM substrate, 20 mL reaction volume, were 
determined by RP-HPLC analysis of the two products (method 2) 171 and 172, were 
found to be 33% and 46%, respectively. Enantiopurities of the products were assumed 




Interestingly, for reactions involving RnCOMT, altering the phenyl ring in the starting 
material (157) to a cyclohexane ring (156) instead resulted in exceptional 
regioselectivity, with only the meta-methylated product was observed (Scheme 5.4b). 
Attempts to rationalise these results using computational docking were unsuccessful 
and docking results contradicted what was observed experimentally.  
 
5.2.8 Routes to single isomer, para-methylated (S)-1-aryl-THIQs 
Accessing the analogous C7/para-methylated regioisomers of 171 and 172, 173 and 
174, respectively, is valuable to generate analogues for drug discovery purposes. The 
meta-hydroxyl of dopamine is essential for a successful NCS reaction, whereas 
previous reports have shown that the para-hydroxyl is not, with catecholamines such 
as meta-tyramine and metaraminol being well-tolerated as substrates.21,148 Although 
MxSafC is capable of generating 4-methoxytyramine with high regioselectivity, 
conversions of 40% were achieved and isolating the pure product would be challenging, 
requiring preparative-HPLC.209 Instead, 4-methoxytyramine (126) was generated 
chemically in a four-step synthesis, as given in Scheme 4.11 and discussed in Chapter 
4. 
 
NCS reactions were performed between 126 and aldehydes, 146 and 139 to give 
products (173 and 174, Scheme 5.5). With both aldehydes, RP-HPLC analysis showed 
complete consumption of the amine starting material. Isolated yields of (S)-173 and (S)-
174, after purification by preparative-HPLC (method 8), were 32% and 24%, 
respectively. The corresponding racemic products (rac-173 and rac-174) were obtained 
by performing phosphate-catalysed reactions between 126 and 146 or 139 using 
standard conditions. The resulting products were also isolated by preparative HPLC 
and used for chiral HPLC analysis (method 5). High enantiomeric excesses were 
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achieved in both NCS catalysed reactions, >99% and 96% e.e., for (S)-173 and (S)-
174, respectively. Chiral HPLC analyses are given in the Appendix.  
 
Scheme 5.5: Reactions towards C7-O-methylated (1S)-1-aryl-THIQs. 4-methoxytyramine 
(126) was used as the phenethylamine substrate in a M97V-TfNCS mediated reaction.  
 
5.2.9 Determining the selectivity of the catechol O-methyltransferases 
The substrates used for the regioselective methylation reactions (156 and 157) were of 
high enantiopurity, however it is unknown whether the methyltransferases used are 
selective for one enantiomer of substrate. It would be advantageous if so, as this would 
improve the enantiopurity of the resultant products and would mean that if racemic 
substrate was used, the opposing enantiomer of starting material to the product 
generated could be isolated. Generating racemic standards of the C6-methylated 
products, rac-C6-OMe-171 and rac-C6-OMe-172 is labour intensive, involving the 
synthesis of 3-methoxytyramine followed by an acid-mediated Pictet-Spengler reaction 
and preparative HPLC purification.242 Instead, reactions were performed with racemic 
substrates, rac-156 and rac-157 and activities compared to those using the analogous 
(S)-THIQs. Reactions involving MxSafC as the methyltransferase did not go to 
completion and were selective towards the C6 position (Scheme 5.4). Therefore, to 
determine whether there was a preference for one enantiomer of substrate, once the 
methyltransferase reaction had been performed, the starting materials were reisolated 
by preparative HPLC and analysed by chiral HPLC. Racemic standards of C7-O-
methylated THIQs, rac-173 and rac-174, generated previously (Scheme 5.5) were used 
to aid determination of the RnCOMT reaction selectivity as some C7-O-methylated 
product is generated (Scheme 5.4). Analytical RP-HPLC analyses of the final reaction 
HO
MeO NH2.HCl R H
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146: R = cyclohexane





173: R = cyclohexane
32% isolated yield
>99% e.e.






mixtures are given in Figure 5.15 and chiral HPLC analyses of the reaction products 
are given in Figure 5.16. 
 
Figure 5.15: RP-HPLC analysis of methyltransferase-catalysed reactions. Reactions used 
5a or 5b (either as the racemic or S-enantiomer, generated by a M97V-TfNCS reaction) as the 
substrate reaction. In all cases, traces for 156 and 157 correspond to the purified, isolated 
starting material. Reactions were then performed between rac/S-156 and 157 and MxSafC or 
RnCOMT. RP-HPLC analysis of the final reaction mixture is shown, given with the ratios of 
C6:C7 O-methylated products generated. a) Reactions between 156 and RnCOMT. b) 
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Reactions between 156 and MxSafC. c) Reactions between 157 and RnCOMT. d) Reactions 
between 157 and MxSafC. Figure adapted from Roddan et al.149 
 
 
Figure 5.16 Chiral HPLC analysis of methyltransferase reactions. Reactions were 
performed between 156 and 157 (racemic) and methyltransferases, RnCOMT and MxSafC. 
Resultant reaction mixtures or isolated products were analysed by chiral HPLC method 5. 
Products are compared to product standards. a) Isolated reaction product 171/173 obtained 
from RnCOMT catalysed methylation of rac-156 compared with racemic and S-enantiomer 
standards of C7-OMe-173. b) Analysis of the methylation of 156 by MxSafC; blue – standard of 
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rac-156, yellow – reaction mixture after methylation of rac-156, green, standard of S-156, red – 
isolation of 156 after MxSafC methylation, purple – reisolation of 171 generated by MxSafC-
catalysed methylation of 156. c) Isolated reaction product 172/174 obtained from RnCOMT 
catalysed methylation of rac-157 compared with racemic and S-enantiomer standards of C7-
OMe-157. d) Analysis of the methylation of 157 by MxSafC; blue – standard of rac-157, yellow 
– reaction mixture after methylation of rac-157, green – standard of S-157, red – 157 isolated 
after MxSafC reaction. Figure adapted from Roddan et al.149 
 
For the methylation of 156 by RnCOMT (Figures 5.15a and Figures 5.16a), complete 
conversions were observed with both single enantiomer and racemic starting materials. 
With rac-156, a 50:50 product ratio of C6:C7 methylation was observed. Chiral HPLC 
analysis of the C7-methylated product 171 generated with this substrate, 156 compared 
with the racemic standard generated previously, rac-171 (Scheme 5.4), showed that 
84:16 (S):(R) product was generated, meaning that RnCOMT is neither regio- nor 
enantioselective towards rac-156. As described earlier, only C6-O-methylation is 
observed with (S)-156 as the substrate, however the lack of selectivity observed with 
the racemic starting material means that using this methyltransferase will not improve 
enantiopurities in the products generated.  
 
For the methylation of 156 by MxSafC with either rac-156 or (S)-156 as the substrate, 
both reactions were regioselective giving only C6-OMe-171. Improved conversions 
were observed using racemic starting material (46% vs. 33% using (S)-156) (Figure 
5.15b). To determine the enantioselectivity of the reaction, rac-156 was used as the 
substrate and once the reaction was complete, the remaining starting material was 
isolated by preparative HPLC and analysed by chiral HPLC (Figure 5.16b). This 
demonstrated that only (R)-156 remained, so MxSafC is selective towards (S)-5a.  
 
For the methylation of 157 by RnCOMT, complete conversions were also observed 
when using racemic starting material, rac-156. A 50:50 product ratio (172:174) for 
C6:C7 methylation was observed (Figure 5.15c) and no selectivity in the C7-methylation 
(to give C7-OMe-174) (Figure 5.16c).  
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For the methylation of 157 by MxSafC, regioselectivity was observed with both racemic 
and single enantiomer starting materials, rac-157 and (S)-157 (Figure 5.15d) with 
similar conversions observed, 50% vs. 46% respectively. Chiral HPLC analysis of the 
reisolated starting material after reaction with rac-157 indicated that again, the reaction 
was selective towards (S)-157 (Figure 5.16d).  
 
To conclude, with both racemic substrates (156 and 157) RnCOMT exhibited neither 
enantio- nor regioselectivity whereas MxSafC was both enantio- and regioselective.  
 
5.2.10 Reactions of disubstituted benzaldehyde derivatives with NCS 
A variety of THIQs (of the general structure given in Scheme 5.6) are under patent due 
to high selectivity and inhibitory action towards RAS proteins (HRas, KRas and NRas) 
and in particular, the KRas proteins.244 The genes encoding for these proteins are the 
most common oncogenes in human cancers (nearly 30% of all human tumours). 
Mutations in these proteins causes permanent activation resulting in overactive 
signalling and increased cell growth and division, thus giving rise to cancers.244 Finding 
inhibitors of these proteins is challenging as there are no deep, hydrophobic pockets in 
which to bind small-molecules.245 Therefore, identifying selective inhibitors of these 
proteins is important in the ongoing search for novel, effective small-molecules for 




Scheme 5.6: KRas inhibitor THIQs that could feasibly be generated using an NCS-
mediated synthesis followed by a regioselective O-methyltransferase reaction. 
 
 
In the patent, the THIQs are synthesised using a protecting-group based strategy, with 
the ring closure performed via an acid-mediated Pictet-Spengler reaction or a Bischler-
Napieralski reaction, followed by a reduction to give the THIQ scaffold. The 
stereochemistry at C-1 is not defined and only procedures to give the racemic 
compounds are described. It is assumed that the stereocentre would be defined during 
an asymmetric hydrogenation step as detailed previously.244  
 
Therefore, to develop the THIQ scaffold of these small molecules and selectively 
synthesise the (S)-enantiomer of product, it was hoped that an NCS reaction could be 
performed between dopamine and a relevant disubstituted benzaldehyde analogue 
(175 or 176) to give THIQs, 177 and 178. The selective methylation of one of the 
catechol C6 hydroxyls could then be performed using one of the regioselective catechol 
O-methyltransferases. The addition of other groups on the nitrogen and oxygen could 
then be performed sequentially afterwards. This would give a regioselective and 
stereoselective route to these compounds in four-steps compared with the 8 -11 step 










147: R1 = Me, R2 = H
175: R1 = F, R2 = Me























158: R1 = Me, R2 = H
177: R1 = F, R2 = Me
178: R1 = Me, R2 = Me
5
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NCS-mediated reactions were performed between dopamine and two disubstituted 
benzaldehydes; 175 and 176. Reactions were not performed with 2-chloro,4-
methylbenzaldehyde, which would be a route to another desirable THIQ product, due 
to poor enantioselectivities in the products with a single halogen. Low conversions were 
observed with 175 (Scheme 5.7), as the aldehyde substrate, with a minimal background 
reaction observed in the control sample. No conversions were observed for reactions 
with 176, likely due to the bulky nature of the substrate. Representative HPLC of traces 
of both reactions with background traces are given in Scheme 5.7.  
 
 
Scheme 5.7: Achiral HPLC traces of methyltransferase reaction of 177 to give 179 using 
a variety of regioselective O-methyltransferases. Reaction conditions: Once the NCS 
reaction was completed (performed on 100 µL scale), the reaction mixture was quenched and 
lyophilised (workup method 5). The residue prepared in 25 mM HEPES, 20 mM MgCl2, 0.2 M 
KCl pH 7.5) with ATP and L-methionine (10 mM final concentration of each), EcMAT (0.4 mg 
mL-1 final concentration), EcMTAN (0.025 mg mL-1) and appropriate methyltransferase enzyme 
(10% v/v lysate for RnCOMT and 6OMT or 0.6 mg mL-1 final concentration of purified MxSafC). 
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µL MeCN and analysed by HPLC method 2. Yields were determined by monitoring product 
formation against standards by analytical HPLC (method 1). 
 
The enantiopurity of the resultant enzymatic product (179) was determined by chiral 
HPLC (method 5) but unfortunately, the observed product was racemic, suggesting that 
a racemic reaction is associated with the enzyme sample. Regioselective methylation 
reactions were attempted with RnCOMT, 6OMT and MxSafC using racemic 177 as the 
THIQ substrate, as shown in Scheme 5.7.  
 
Complete consumption of the starting material was observed with reactions with 
RnCOMT, however no regioselectivity was observed. It appeared that a 50:50 mixture 
of the C6:C7 O-methylated product (179) was formed. 6OMT and MxSafC were most 
regioselective, generating product in 4:1 and 3:1 ratio of C6:C7 O-methylated products, 
respectively. This assumes that as with products 171 and 172, the C6-OMe product 
elutes first on aHPLC. It is possible that MxSafC is selective towards the (S)-enantiomer 
of 177 but further analysis as in Figures 5.12 and 5.13 would need to be performed to 
determine this. Regardless, the regioselective methylation of the racemic THIQ is still 
synthetically useful.  
 
5.2.11 Removal of catecholic hydroxyl groups  
There would be two advantages of removing the catecholic hydroxyl groups from the 
THIQ products generated by NCS-mediated reactions. Firstly, the catechol is highly 
oxidatively sensitive and can undergo a radical polymerisation in the presence of 
oxygen. Removing the hydroxyl groups would therefore improve the stability of the final 
compounds generated and expand the portfolio of (S)-THIQs that could be generated 
using an NCS-based synthesis. One of the major advantages of using a Pictet-
Spenglerase is the ability to generate products in high enantiomeric excess and high 
yield in a single step. This, combined with the wide substrate scope of NCS, would 
result in the generation of a wide variety of THIQs in high enantiopurity. 
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In particular, this would lead to the synthesis of the THIQ precursor (180) to solifenacin 
succinate (81), a widely used anti-muscarinic for the treatment of an overactive 
bladder.246 Industrial syntheses involve the synthesis of the racemic compound via 
Bischler-Napieralski methods followed by resolution of the two enantiomers using L-
tartaric acid to give the product in high enantiomeric excess (>99%). The (R)-
enantiomer of product remaining in the mother liquor can be then racemised by 
refluxing in KOH/DMSO and the recrystallisation procedure repeated.247 A major 
advantage of an NCS-mediated route would be the ability to generate analogues of 
solifenacin, varying substituents on the C-1’ aromatic rings.  
 
The stereochemistry of all products generated by an NCS-mediated reaction has thus 
far been assumed to always give the (S)-centre at C-1. However, it is possible that the 
stereochemistry of the products can switch with different substrates. Another Pictet-
Spenglerase enzyme, strictosidine synthase (STR), has substrate dependent 
selectivity. When using small, aliphatic aldehydes, to give (R)-products are generated, 
rather than when the bulky natural aldehyde substrate, secologanin, is used,  (S) 
stereochemistry at C-1 is generated.89 This is due to the unusual inverted binding of the 
substrates in the enzyme active site when reactions are performed with smaller, 
aliphatic aldehydes.90 Therefore, with NCS, there is a possibility that using  
benzaldehydes as substrates will change the stereochemistry of the products and so it 
is important to absolutely determine the chirality at C-1 rather than assume that it is (S) 
by literature precedent. As solifenacin succinate is routinely synthesised, chiral HPLC 
data and x-ray crystallography data are known for (1S)-1-phenyl-1,2,3,4-THIQ (180).  It 
was hoped that this molecule could be synthesized via the removal of the catechol 
hydroxyl groups of the THIQ product formed from the NCS reaction between dopamine 




Scheme 5.8: Proposed synthetic route for removal of catecholic hydroxyl groups of THIQ 
products of the NCS reaction between dopamine and benzaldehyde. 
 
The synthesis was performed without isolation of each intermediate due to the expected 
instability of each. The presence of each intermediate was identified by low resolution 
mass spectrometry (LC-MS). There are no reported syntheses to remove catechol 
hydroxyl groups to give benzene, nor any other analogous syntheses. The removal of 
a single phenolic hydroxyl is however, widely reported in the literature, via the  activation 
of the hydroxyl group to a triflate or mesylate, followed by hydrogenation to cleave the 
carbon-oxygen bond neighbouring the aromatic ring.248 It was therefore hoped that 
these synthetic methods could be used to remove the phenolic hydroxyls. 
 
The THIQ starting material, 157 was obtained by an NCS-mediated reaction between 
dopamine (5) and benzaldehyde (139) (0.2 mg mL-1 final concentration D29TfNCS-
M97V) and semi-purified via an extractive workup (workup method 3) to remove any 
unreacted dopamine. Some 139 remained but would not interfere with subsequent 
reactions. As triflic anhydride can be attacked by both oxygen and nitrogen 
nucleophiles, the THIQ nitrogen in 157 was Boc protected. The resulting product (181) 
was isolated via extractive workup. Some Boc anhydride remained however it was 
deemed not to interfere with subsequent synthetic steps and could be easily removed 





















be challenging due to chelation of the catechol to silica. The crude product 181 was 
therefore taken through to the next step of synthesis without further purification.  
 
The method used for triflate protection is widely reported. The reaction involves the 
deprotonation of the hydroxyl groups with base, most commonly triethylamine or 
pyridine. This improves the nucleophilicity of the hydroxyl group and is followed by 
addition to triflic anhydride to give the triflate-protected product. It was confirmed by LC-
MS that triflate protection of 181 to give 182 had occurred, however the Boc-protecting 
group was not observed. It was unknown whether the Boc group is being removed 
during the mass spectrometry ionisation process or whether it is being cleaved during 
the addition of triflate as the conditions are highly acidic. Both di- and tri-triflate 
substitution was observed. This was deemed not to interfere with subsequent steps as 
triflate is commonly used as a nitrogen protecting group and during hydrogenation, the 
group would be removed to regenerate the amine. Hydrogenation to give 183 was 
attempted using 10% palladium on carbon as the catalyst and tetrahydrofuran as the 
reaction solvent. No desired product was observed, only starting material. The reaction 
was also performed with adding a small amount of methanol or formic acid to the 
solvent, and by bubbling hydrogen through the solvent but again, only starting material 
was isolated. It was assumed that the two triflate groups were stabilising each other 
and it was hoped that another catalyst may be suitable. A paper by Miller et al.249 used 
10 mol % Pd(dppf)Cl2 catalyst with formic acid and triethylamine to remove a single 
triflate from a conjugated naphthalene system with methoxy and acetyl groups 
presents, however again, no desired product was observed by LCMS.  
 
It was thought that perhaps the difficultly in triflate removal was due to the strongly 
electron withdrawing aspects of the triflate groups and that the neighbouring triflate 
groups were in some way stabilising each other. Therefore, the synthesis was repeated 
with mesylate groups rather than triflate, however no product was observed when using 
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both methods of hydrogenation (Pd/C and Pd(dppf)Cl2). More harsh hydrogenations 
conditions may be required for the carbon-oxygen bond cleavage and high-pressure 
hydrogenation may be successful in giving the desired product. To avoid the use of 
high-pressure reaction conditions, the same procedure was attempted but meta-
tyramine (51) was used as the amine substrate in the NCS reaction rather than 
dopamine. This would result in a THIQ with a single phenolic hydroxyl group, and it was 
hoped that this could yield the product as the hydrogenation reaction should proceed 
following literature precedent.   
 
5.2.12 Removal of a single THIQ phenolic hydroxyl group 
Meta-tyramine (51) is commercially available, however it is expensive (ca. £200 for 1 
g) and since there is a widely-reported synthetic route (Scheme 5.9), it was synthesised 
in a two-step synthesis starting from 2-(3-methoxyphenyl)acetonitrile (184).22 The first 
step of the synthesis involves the reduction of nitrile (184) to the amine (185), which 
can be purified via an extractive acid-base work-up. The final step of the reaction is the 
demethylation to give meta-tyramine (51). The reaction went to completion (as 
monitored by TLC); however, some material was lost in the workup procedure. The final 
product (51) was purified by recrystallisation in n-hexane.  
 
Scheme 5.9: The synthetic route performed to give meta-tyramine (51) in 74% yield.22 
 
Using meta-tyramine (51) as the amine substrate for NCS reaction often results in 
significantly lower conversions (ca. 50% of those observed with dopamine instead) 
(Table 3.1). Indeed, in ligand-bound structures of NCS with non-productive intermediate 
mimics with the dopamine catechol, both hydroxyl groups of the catechol hydrogen-













-78 oC to rt, 24 h
reflux, 2h184 185 51
N
 224 
successful NCS reaction, but the meta-hydroxyl is. However, the additional para-
hydroxyl group may make the reactions more productive by providing extra ‘anchoring’ 
in the active site or assist with the meta-phenol deprotonation.  
 
To find optimal reaction conditions for gaining a high enantiomeric excess in the product 
186 of NCS reactions between meta-tyramine (51) and benzaldehyde (139), a timepoint 
assay was performed (Figure 5.17), analogous to those performed for the reactions 
between dopamine and benzaldehyde or 3-methylbenzaldehyde (Figures 5.7 and 5.8). 
For all reactions with dopamine as the amine substrate, the highest e.e.s were observed 
with a high concentration of enzyme (0.5 mg mL-1 final concentration). Therefore, here 
all reactions were performed with this concentration of enzyme but instead, the different 
NCS mutants that were previously shown to be promising with a-substituted aldehydes 
(namely M97F and M97V) were used as the reaction catalysts (Figure 5.16), in case 
altered activities were observed when changing the amine donor. For reactions 
performed for 24 h using D29TfNCS-M97V as the reaction catalysts gave complete 
conversion to the product, which was formed in 94% e.e. Therefore, these conditions 













Figure 5.17: Timepoint assay of the NCS-mediated reaction between meta-tyramine (51) 
and benzaldehyde (139). Conversions and enantiomeric excesses in the resulting products 
(186) were messaged. Reaction conditions: 10 mM dopamine HCl, 10 mM sodium ascorbate, 
20 mM benzaldehyde in HEPES buffer (50 mM, pH 7.5) with 10% v/v MeCN and final 
concentration of TfNCS at 0.2 or 0.5 mg mL-1. Control reactions were performed using the same 
conditions but the TfNCS sample was substituted for an equal volume of enzyme buffer (20 mM 
Tris, 50 mM NaCl, pH 7.5). Reactions were performed at 37 °C for 3 h, 100 μL scale reactions; 
samples were prepared by workup method 1, yields were determined by monitoring product 
formation against standards by analytical achiral HPLC (method 1). 
 
The synthetic route performed for the removal of the phenolic hydroxyl group was then 
performed in a similar manner (Scheme 5.10), with the same rationale to that attempted 
for the catechol hydroxyl groups (as shown in Scheme 5.9). Due to potential instability 
of the intermediates, only the Boc-protected amine (187) was isolated, so yields were 




















Scheme 5.10: Synthetic route attempted for the removal of a single THIQ phenolic 
hydroxyl group. 
 
The product of the NCS reaction (186) was purified via extractive workup to remove 
any remaining meta-tyramine or benzaldehyde. To improve the Boc protection reaction, 
the hydrochloride salt was resuspended in saturated sodium hydrogen carbonate and 
extracted into ethyl acetate to give the free amine (186). The Boc protection was 
performed as usual, and monitored by TLC, although it was challenging to determine 
whether the reaction had gone to completion. The product was isolated via extractive 
workup then further purified by column chromatography. A very low yield of product 187 
was isolated (8%). The conversion of the triflate protection of 187 to give 188, was also 
poor. Therefore, as this synthesis proved challenging and would not be a feasible route 
to give stereoselective THIQ products without hydroxyl groups. Instead, to determine 
the stereochemistry at the C-1 position, another synthetic route was attempted based 
on compounds found in the literature with determined stereochemistry and reported 
chiral HPLC conditions.250 
 
5.2.13 Determination of the stereochemistry of (1S)-aryl THIQ products generated 
by TfNCS 
Chiral HPLC and optical rotation data is available for the methoxy protected analogue 
of 157, 143.250 As nitrogen is more nucleophilic than the catecholic hydroxyl groups, the 




















Scheme 5.11: Synthetic route to give (S)-6,7-dimethoxy-1-phenyl-1,2,3,4-
tetrahydroisoquinoline (20) via a stereoselective NCS-mediated Pictet-Spengler reaction. 
 
Based upon timepoint optimisation reactions, the NCS reaction was performed for 24 h 
with 0.2 mg mL-1 final concentration of D33TfNCS-M97V (Figure 5.14). The resultant 
product was purified by extractive workup (method 3) to remove any remaining 
dopamine or benzaldehyde. The workup method was adapted in an attempt to improve 
isolation yields. The workup procedure was monitored by analytical HPLC (method 1) 
to ensure that a minimal amount of product was lost. After the NCS reaction was 
performed, the reaction mixture was directly extracted into ethyl acetate, without 
quenching of the reaction. The product was dried and resuspended in 1 M HCl. This 
aqueous sample was analysed by RP-HPLC and any remaining dopamine had been 
removed but still some benzaldehyde remained which was removed via extraction with 
dimethyl carbonate. The aqueous layer was monitored by RP-HPLC to check for 
benzaldehyde removal. It was found that a single dimethyl carbonate wash was 
sufficient to remove the excess aldehyde, rather than four as previously reported.118 
 
The product (157) was isolated, of high purity and in reasonable yield (60%) and was 
Boc-protected using a standard literature procedure.251 The reaction was performed 
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conversions. The consumption of the starting material was monitored by TLC analysis 
and once completed; 157 was isolated via extractive workup. Due to the presence of 
the catechol and issues with chelation to silica, purification of intermediate, 181 is 
challenging, therefore the product was taken through crude to the subsequent 
methylation step. The methylation reaction is analogous to that used in Chapter 4, 
where the addition of potassium carbonate was sufficient to deprotonate and therefore 
methylate the catechol hydroxyls. The product (189) was isolated by silica column 
chromatography to yield 6.5 mg. The yield was low likely due to the recurring issue of 
poor Boc protection. The product was characterised by HRMS, with m/z values of 
370.30, 314.14 and 270.50 observed, corresponding to masses of the product (189), 
loss of the tert-butyl group and Boc group, respectively.  
 
The Boc deprotection of the product to give 143 was performed using a standard 
procedure. The reaction completed in 5 minutes as monitored by TLC analysis. The 
resulting product was purified by semi-preparative HPLC as the product was present in 
very low quantities. Chiral HPLC was performed using the same conditions reported by 
Evanno et al.250 (chiral HPLC method 6). The two enantiomers have a retention times: 
(S) = 17.8 min, (R)= 25.7 min. As these conditions were already reported, racemic 143 
was not synthesised. Two major peaks were observed, at 16.2 and 24.3 min i.e., both 
eluting 1.4 min earlier than those reported. This is not uncommon, with slight differences 
in column age, temperature and mobile phase composition having significant effects on 
retention time with chiral, normal phase columns. However, minor impurities were 
observed in chiral HPLC analysis which overlaps with peaks corresponding to the 
desired product. To further separate the peaks, the polarity of the mobile phase was 
decreased using 5% isopropanol, rather than 10% isopropanol (method 7). Chiral HPLC 
analysis of 143 is given in Figure 5.18, with Figure 5.18a corresponding to conditions 
given in method 6 and Figure 5.18b corresponding to conditions given by method 7. 
The polarity of the mobile phase was decreased to improve separation of peaks.  
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Figure 5.18: Chiral HPLC analyses of 143. a. Using a mobile phase of 10:90:0.1 isopropanol:n-
hexane:diethylamine tR (S enantiomer) = 16.2 min, 564.2 mAU2, tR (R enantiomer) = 24.3 min, 
499.6 mAU2. b. Using a mobile phase of 5:95:0.1 isopropanol:n-hexane:diethylamine tR (S 
enantiomer) = 26.5 min, , tR (R enantiomer) = 39.2 min.  
 
Using potassium carbonate as the base in the methylation step (181 to 189) gave an 
enantiomeric excess of 6% in the product, with (S)-146 as the major enantiomer. 
Therefore, significant racemisation must have occurred during the chemical 
modification of 181. The C-1 proton is highly acidic, due to the neighbouring electron 
withdrawing Boc-amine and the phenyl groups, so is likely that the basic conditions 
used to deprotonate the catechol hydroxyl groups, potassium carbonate in methanol, 
were capable of deprotonating at the C-1 position and thus causing racemisation.  
 
To improve the enantiomeric excesses in the products, the methylation step was 
attempted using two bulkier bases, caesium carbonate or 2,6-lutidine. It was hoped that 
this would reduce deprotonation at the sterically hindered C-1 position. A large excess 
of iodomethane (20 e.q.) was also used in an attempt to reduce the reaction time. No 
conversion to give 189 was observed using 2,6-lutidine as a base, likely due to the 
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inaccessibility of the nitrogen lone pair. The reaction involving caesium carbonate 
proceeded successfully to give 189, and the product was taken through to the next step 
(Boc deprotection) crude and isolated by preparative-HPLC (method 4). Chiral HPLC 
analysis (by methods 6 and 7) gave a 20% e.e. of the final product (143). Racemisation 
is clearly occurring due to the presence of base but as an excess of the (S)-enantiomer 
is observed, the stereochemistry of the TfNCS reaction with aldehydes is confirmed.  
 
5.2.14 Structural evidence for the acceptance of the benzaldehydes by 
norcoclaurine synthases  
Despite reports that benzaldehydes were not accepted as substrates by TfNCS, the 
first attempted co-crystallised structure of TfNCS was gained by Ilari et al. in 2009, with 
the ligands, dopamine (5) and 3-hydroxybenzaldehyde (168).27 Analysis of the co-
crystallised structure shows weak positive electron density in the active site, suggesting 
low occupancy and multiple orientations of the substrates28,30. Work presented in this 
chapter has demonstrated that 3-hydroxybenzaldehyde is in fact accepted as a 
substrate, albeit poorly. Therefore, as crystals can retain enzymatic activity, it is also 
possible that unclear density was observed because they were in fact observing a 
mixture of reaction transition states. Also, as low conversions are observed with this 
aldehyde as a substrate (Figure 5.6), it is likely that poor occupancy was also a 
contributing factor.  
 
Into this positive electron density, the aldehyde was modelled to be close to the Lys-
122 and the dopamine was modelled to be nearer the active site entrance, leading to 
an aldehyde-first mechanism being proposed. This was later disputed due to other 
chemical and steric reasons (as discussed in Lichman et al.28 and in Chapter 1). It is 
also possible that the two substrates are capable of binding ‘aldehyde-first’ but a 
productive reaction only occurs when they bind ‘dopamine-first’. All computational 
docking studies and the co-crystallised structures gained thus far have not been with 
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benzaldehydes and there is a possibility that different substrates interact with residues 
in alternative ways. For example, with strictosidine synthase (STR), changing the 
carbonyl substrate from the bulky glycosylated monoterpene, selcoganin (Section 
1.7.1) to a variety of low molecular weight, aliphatic aldehydes changes the 
stereochemistry of the resultant tetrahydro-b-carbolines from (S) to (R) at the C-1 
position.89 A co-crystallised structure of OpSTR with a non-productive reaction 
intermediate analogue bound in the active site, was gained by Eger et al., and inverted 
binding of the substrates was observed. It is therefore possible that a similar 
phenomenon may be observed with NCS when benzaldehydes are used as substrates, 
so gaining structural evidence for benzaldehyde acceptance was important.  
 
To understand the acceptance of benzaldehyde and derivatives by TfNCS, it was hoped 
that a co-crystallised structure could be gained with a non-productive intermediate 
mimic of the reaction iminium ion intermediate in the active site. Since improved 
conversions were observed with the M97V active site mutant, a crystallisable construct 
was developed i.e., using a His-tagged, truncated form of NCS, D33TfNCS-M97V with 
a TEV-cleavage site for removal of the His-tag. Cloning of this construct was performed 
by John Ward and the construct was codon optimised for expression in E. coli. This 
construct had proved promising in previous crystallographic trials to give high resolution 
structures.30,148 Expression and purification was performed as previously reported for 
the wild-type construct and pure protein was obtained in high yield (55 mg from a 1 L 
culture). The pure enzyme was concentrated to 12.6 mg mL-1 and stored at -80 oC in 
TRIS buffer (20 mM with 50 mM NaCl, pH 7.5), consistent with previous crystallisation 
trials performed with the wild-type enzyme. SDS-PAGE analysis of the purification 






Figure 5.19: SDS-PAGE analysis of D33TfNCS-M97V purification. a. His-trap purification of 
D33TfNCS-M97V (protein expected at 20.7 kDa): Lanes: 1, Benchmark™ Protein Ladder 
(masses given in kDa) 2, clarified cell lysate loaded onto column. 3, flow through with lysis buffer. 
4, wash with 6 CV 20 mM imidazole buffer. 5, wash with 6 CV 40 mM imidazole buffer. 6-13, 
wash with 500 mM imidazole buffer and collected 3 mL fractions. b. His-trap purification of 
∆33TfNCS-M97V after TEV cleavage to remove TEV protease. Lanes: 1, Benchmark™ Protein 
Ladder, masses given in kDa. 2, Pre-TEV cleavage sample (Lane 7 from gel 1) 3, sample loaded 
onto column. 4, flow through with lysis buffer. 5, 3 CV 20 mM imidazole. 6, 8 CV 20 mM 
imidazole. 7, 2 CV 40 mM imidazole. 8, 5 CV 40 mM imidazole. 9 and 10, 2 CV 500 mM 
imidazole. 11, 5 CV 500 mM imidazole. c. Gel filtration of ∆33TfNCS-M97V: gel of peaks isolated 
from major peak from Superdex S75 gel filtration. Lane 1: Benchmark™ Protein Ladder, masses 
given in kDa. Protein samples corresponding to lanes 4-7 were pooled and used for 
crystallographic studies. Protein expected at 18.1 kDa.  
 
Two different non-productive reaction intermediate mimics were synthesised, based 
upon the iminium ion intermediate of the reactions between 5 and benzaldehyde (139) 
or 4-bromobenzaldehyde (170). Both were synthesised using the same synthetic route 
the two previous co-crystallised structures of TfNCS.30,148 These two aldehydes were 




observed with benzaldehyde. Cyclohexanecarboxaldehyde (146) was not used due to 
a lack of electron density and high flexibility in the ring which could lead to challenges 
in determining ligand placement if multiple conformations and poor occupancy was 
observed (as was the case with attempted to co-crystallise other ligands as described 
in Chapters 2 and 3). In an attempt to overcome these limitations and increase the 
certainty of ligand presence in the enzyme active site, a mimic was synthesised based 
on the reaction between 5 and 170 as the identification of a bromine atom in the active 
site can typically be determined using anomalous diffraction methods.252 Although 170 
was poorly accepted as a substrate by TfNCS (Figure 5.5), it was hoped that co-
crystallisation might be observed. Both mimics were synthesised using an analogous 
synthetic route to other mimics synthesised (Sections 2.2.4, 3.2.6 and 6.2.4), as shown 
in Scheme 5.12.  
 
Scheme 5.12: Synthetic route to give two benzaldehyde reaction intermediate mimics. 
The mimics are based upon the iminium ion intermediates of the Pictet-Spengler reactions 
between dopamine (5) and benzaldehyde (139) or 4-bromobenzaldehyde (170). 
 
The synthesis of the mimics proceeded simply. Once isolated, both final products (190 
and 191) were resuspended in DMSO to give a final concentration of 200 mM. Both 
were stored at -80 oC under argon as DMSO is a known oxidant and the molecules are 
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Initial crystallisation screens were performed by the sitting-drop method using 
commercially available, 96-well screens; Structure, JCSG, PACT and Index. These 
screens have previously contained conditions which have resulted in TfNCS 
crystallisation.31 The protein was prepared for the following screens: apo protein (at 
12.6 mg mL-1), with benzaldehyde reaction mimic (190) (10 mM final concentration, 12 
mg mL-1 protein) and 4-bromobenzaldehyde reaction mimic (191) (10 mM final 
concentration, 12 mg mL-1 protein). In the case of the benzaldehyde mimic, 190, 
addition to the protein resulted in the temporary precipitation of the enzyme which was 
eventually resuspended in the buffer after a couple of minutes of mixing. Unfortunately, 
with addition of the 4-bromobenzaldehyde mimic, 191, irreversible precipitation of the 
enzyme occurred, and crystallisation trials could not be performed.  
 
For both apo and ligand-bound crystallisation trials, crystals were observed using many 
different conditions after one week. A range of crystals were sent to a synchrotron 
(Diamond Light Source, i04) for screening. The conditions of the crystals observed, and 
the resolution of the datasets collected are given in Table 5.1. The cryo-protectant used 
was 80% mother liquor, 20% ethylene glycol.  
 
Table 5.1: Conditions in which protein crystals were observed from initial co-
crystallisation screens with benzaldehyde reaction mimic, 190. 
Dataset Protein Salt Buffer pH Precipitant Dataset 
resolution / Å 





2 Apo 0.2 M NaCl 0.1 M 
Bis-Tris 
5.5 25% w/v 
PEG 3350 
3.4 




5.5 17% w/v 
PEG 10000 
3.6 
4 Apo 50 mM 
KH2PO4 
- - 20% w/v 
PEG 8000 
3 
5 Holo 50 mM 
KH2PO4 









6.5 - 2.8 





8 Holo  0.1 M 
Sodium 
HEPES 






Unusually, all apo datasets collected were at a lower resolution to the crystals prepared 
in the presence of the mimic. Analysis of the refined holo structures showed that for 
dataset 5 (Table 5.1), no co-crystallisation was observed as a water molecule could be 
seen hydrogen-bonding to the active site residue, K122 where the mimic is expected to 
be bound. The mimic is however clearly aiding crystal packing as the resolution 
observed for an apo crystal under the same crystallisation condition (dataset 4) was 3 
Å, rather than 2.2 Å for the holo structure. In dataset 6, some positive density was 
observed near to the active site residue E110, however the density was not sufficient 
to attempt to build in the ligand, perhaps suggesting partial ligand occupancy. In dataset 
7, some positive density was observed near residues K122 and F112, but as the 
resolution of the dataset was poor, the ligand could not be built into the structure with 
certainty. Dataset 8 showed some promising positive density near E110 and K122, but 
the resolution was also not sufficient to clearly build the ligand. Therefore, the 
crystallisation conditions for datasets 6, 7, and 8 were optimised by preparing crystals 
by the hanging drop method. For the conditions of dataset 8, a four-corner screen of 
the condition by hanging drop method was performed with and without propan-2-ol 
present. Other crystals were also sent to the synchrotron, however there was evidence 
that an increased percentage of cryo-protectant would be required as many crystals 
were very icy or had dissolved in the loop.  
 
Crystals were only observed in the hanging drop four-corner screen prepared for the 
conditions of dataset 8, without propan-2-ol present. As there were issues with the cryo-
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protectant, glycerol was also tested as a cryo-protectant and the amount used was 
increased from 20 to 25% in the precipitation conditions. Other crystals grown in the 
96-well screens (which appeared after one month) were also sent to the synchrotron. 
Unfortunately, the resolution observed during screening for many of these sitting-drop 
crystals, was poor (6 -7 Å), so full datasets were not collected. A range of high-
resolution datasets (2-2.2 Å) were collected for the hanging drop crystals prepared, 
based on the conditions of dataset 8 without propan-2-ol present. Structural refinement 
was performed for the highest resolution structure (referred to as dataset 9), with 
precipitation condition of 0.111 M HEPES pH 7.5, 20 % v/v PEG 4000 using 25% 
glycerol as the cryo-protectant with 10 mM final concentration of the mimic, 190. A 2 Å 
dataset was also collected for a crystal prepared via the 96-well screens, in condition 
25% w/v PEG 1500, 20% glycerol (referred to as dataset 10). No additional cryo 
protectant was added. Both crystals had a similar, cubic morphology and were slightly 
yellow in colour (Figure 5.20). Statistics for both datasets are given in Table 5.2.  
 
 

















Table 5.2: Data collection and refinement statistics of D33TfNCS-M97V in complex with 
reaction intermediate mimic, 190.  
 Dataset 9  Dataset 10  
Wavelength (Å) 0.976254 0.976254 
Space group  P3221 P3221 
Unit cell parameters 
a, b, c (Å)  63.66, 63.66, 73.78 62.66, 62.66, 72.65 
α, β, γ (o)  90.00, 90.00, 120.00 90.00, 90.00, 120.00 
Resolution range (Å)  55.13 – 2.22 (2.26-2.22) 54.27 – 2.30 (2.30-2.38) 
Total number of 
observations  
95041 (4517) 78587 (6945) 
Total number unique  8924 (497) 7696 (719) 
Completeness  99.9 (98.8) 99.7 (97.9) 
Multiplicity  10.7 (9.1) 10.2 (9.7) 
<I/σ(I)>  17.3 (1.1) 26.9 (3.8) 
CC1/2  0.999 (0.754) 1.000 (0.975) 
Rmerge  0.047 (2.113) 0.035 (0.353) 
Solvent content (%) 48 46 
Molecule per ASU  1 1 
Wilson B factor (Å2) 81.615 69.83 
Refinement 
Resolution Range (Å)  55.14 – 1.97 (1.970 – 
2.021) 
54.27 – 2.30 (2.296 – 
2.356) 
Rwork  0.208 (0.242) 0.197 (0.242) 
Rfree  0.295 (0.316) 0.246 (0.302) 
Reflection, working  12637 7285 
Reflection, free  442 389 
Average B factor  70.630 79.715 
RMSD bond angle  1.930 1.728 
RMSD bond length (Å)  0.0140 0.0128 
Ramachandran plot 
Preferred region (%)  89.67 94.87 
Allowed region (%)  8.39 4.49 
Outliers (%)  1.94 0.64 
 
Both datasets collected were in space group P3221, the same space group observed 
with the alpha-methyl aldehyde reaction intermediate mimic co-crystallised with wild-
type TfNCS. The images for both datasets were integrated using the XDS Dials 
software programme. Molecular replacement for both datasets was performed using an 
apo dataset of D33TfNCS (wild-type) in the same space group (P3221) as the search 
model in Phaser.253 Model building of both the protein and the ligand was performed 
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using COOT171 with refinement performed using REFMAC5.174 TLS refinement was 
used as there was some anisotropy in the datasets collected. This is based upon the 
assumption that atoms are part of a rigid body (i.e., a unified group of atoms) of which 
there is a mean squared displacement. TLS refinement therefore models the 
anisotropic motions of atoms and can lower the R-factors during refinement.254 The final 
Rwork/Rfree factors achieved after refinement were 0.21/0.29 and 0.19/0.25 for datasets 
9 and 10, respectively. 24 and 50 water molecules were also built into each model 
(dataset 9 and 10), respectively.  
 
For both datasets positive density was observed in the active site, near to key active 
site residues K122 and E110. Multiple cycles of model building, and refinement led to 
the observation of increased density in the active site in both structures, into which the 
co-crystallised mimic 190 was built. The final ligand placement in both structures, is 
given in Figure 5.21. 
 
Figure 5.21: Ligand placement of the refined structures. Structures are of datasets 9 (blue) 
and 10 (purple). Image was created using USCF Chimera.32 
 
In both structures, the ligand is orientated in a manner consistent with the ‘dopamine-
first’ mechanism. Both catechol hydroxyl groups are hydrogen-bonded to key active site 
residue, K122. A closer hydrogen-bonding contact is observed for the meta-hydroxyl 
group (2.6 Å heteroatom to heteroatom distance for both structures), with a weaker 
interaction observed between K122 and the para-hydroxyl of 190 (3.4 and 3.3 Å for 
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datasets 9 and 10, respectively). These interactions are consistent with previously 
observed structures of TfNCS with co-crystallised reaction intermediate mimics (PDB: 
5NON and 6RP3). It is known that the meta-hydroxyl is essential for a productive NCS-
mediated reaction. The para-hydroxyl is not essential for substrate acceptance, but 
lower conversions are observed (Table 3.1), likely as an additional hydrogen-bonding 
interaction assists the deprotonation of the meta-hydroxyl. An additional hydrogen-
bonding interaction was also observed between the secondary amine of 190 and 
carboxyl group of E110, also consistent with the ‘dopamine-first’ mechanism. This 
residue has been previously shown to be catalytically relevant, in aiding dopamine 
binding and catalysing iminium ion formation. A variety of different conformations have 
been observed in different TfNCS structures, depending on the reaction intermediate 
mimic that is bound.30,148  
 
Although the same hydrogen-bonding interactions were observed in both structures 
(datasets 9 and 10), the ligand placement and the orientation of M183 is different 
between the two. Despite slightly unclear density in the active site, attempts to force 
either ligand into the placement of the other were unsuccessful. During analysis of the 
two ligand structures, it was found that rotation of each of the ligands by 180o results in 
the overlay of the two. Both ligands are in a pre-cyclisation conformation, with a distance 
from the aromatic carbon to which attack at the analogous iminium carbon would occur 
of 3.1 - 3.2 Å. Both are poised to attack on the Re face of the cis iminium ion, to give a 
(S)-quinone intermediate, which is subsequently deprotonated by E110 to give the 
product. The NCS active site is very narrow (as shown in Figure 5.22), and it is unlikely 
that the mimic would be able to rotate in the active site without wider conformational 
changes to the enzyme’s structure. The intramolecular cyclisation of the mimic would 
require movement of the phenyl group at the ‘aldehyde-end’ of the molecule, thus 
requiring widening of the active site and large conformational changes. The NCS 
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reaction mechanism is known to be highly dynamic, based upon NMR titration 
experiments.26  
 
Figure 5.22: Co-crystallised structure of D33TfNCS-M97V with 190 (dataset 10). A surface 
model is used to the tight active site pocket in which the ligand residues. Image prepared using 
Chimera.32 Figure adapted from Roddan et al.149 
 
Active site residue M183 is known to be involved in enzymatic activity. Knock-out 
mutants, M183F/L developed by B. Lichman removed all catalytic activity of the 
enzyme.31 In the co-crystallised structure published by Lichman, Sula et al. (PDB: 
5NON), the terminal methyl group of M183 is oriented away from the ligand whereas in 
both datasets shown here, the methyl group is directed towards the ligand. Methionine 
is highly flexible, so it is possible that this is simply a crystallographic artefact.  
 
These ligand conformations are particularly interesting as it is the first time that a pre-
cyclisation configuration has been observed with a reaction mimic and it also 
rationalises the stereochemical outcome of the NCS reaction as only conformations 
capable of cyclising to give the (S)-enantiomer of product are observed in the two 
different crystals. It is unclear how both ligand conformations occur and the only 
difference in local protein structure is with M183. Perhaps the ligand can rotate in the 
active site, modulated by this methionine residue.   
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A recent paper by Sheng et al. rationalises the stereochemistry of the NCS reaction 
using density functional theory calculations.33 The reaction pathways to give both the 
(S) and (R) enantiomers of product are both favoured, until the final step i.e. the 
deprotonation of the quinone due to steric clashes of the aldehyde ‘R’ group with active 
site residue L72. In the simulations, to orientate the iminium ion before cyclisation 
occurs, the hydrogen-bonding interaction from the iminium nitrogen to E110 must be 
cleaved and the iminium nitrogen moves closer to D141. Although no clashes of the 
phenyl ring with L72 are observed in either crystal structure, these structures only show 
a single ‘snapshot’ of the mechanistic process and as discussed, it is likely that 
conformational changes of the enzyme and mimic would occur. No single point mutants 
of NCS, altering residue L72 have been generated, so the involvement of this residue 
in determining the product stereochemistry has not been fully assessed experimentally. 
Also, the calculations were performed with the natural substrate, 4-HPAA rather than 
benzaldehyde and an NCS variant was used for these crystallographic studies, rather 
than the wild-type, and perhaps slightly different residue interactions are occurring.  
 
Residue V97 sits close to the alkyl region of the dopamine end of the putative iminium 
carbon of the mimic. The mutation from methionine to valine decreases both flexibility, 
and steric bulk at this position. It is still unclear why this mutant, and the variant M97F 
increase conversions. The M97V mutant is likely creating extra space in the active site 
so the reasons for increased conversions are due to faster substrate binding, whereas 
with the M97F mutant, larger conformational changes across the enzyme may be 
occurring to create additional space in the active site or there may be a pi-stacking 
interaction with the benzaldehyde phenyl ring. Regardless, gaining a co-crystallised 
structure with this mutant would be insightful in understanding why this mutant is still 
highly productive with these substrates. In an attempt to rationalise the observed 
activities with M97F, computational docking studies of the iminium ion of reactions 
 242 
between dopamine (5) and benzaldehyde (139) with this variant were performed with 
Autodock Vina, however the results were inconclusive (Figure 5.23). The mimic is 
orientated with the para-hydroxyl group hydrogen-bonded to K122, so likely indicative 
of a non-productive mode of action, as hypothesised by Lichman et al.30 The ligand is 
observed in an extended conformation and likely due to narrowing of the enzyme active 
site entrance / exit. Further structural studies are therefore required to fully understand 
the improvement in activity of this mutant compared with the wild type. 
 
Figure 5.23: Docking of mimic 190 into the active site of D33TfNCS-M97F. The protein was 
prepared using NAMD, based upon PDB: 5NON of the wild-type enzyme.  Computational 
docking was performed using Autodock Vina255 and the figure prepared using USCF Chimera.32 
 
 
To conclude, both co-crystallised structures therefore rationalise benzaldehyde 
acceptance by TfNCS and confirms the (S)-stereochemistry in the THIQ products 
formed by the enzyme. It is also the first time a non-productive reaction mimic is 
observed in a pre-cyclisation conformation. The potential role of M183 in determining 
iminium ion orientation is noted and the M97V substitution is shown to increase space 
in the active site entrance / exit. 
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5.3 Conclusions and future work  
In conclusion, despite previous reports, a variety of benzaldehydes were shown to be 
accepted as the carbonyl substrate in TfNCS-mediated reactions with both wild-type 
and single-point variant enzymes. Previous reactions were performed with low 
substrate loading (1 mM) and here higher loading is used (10 – 20 mM) due to the low 
Kd of dopamine binding with TfNCS. The active site mutant, M97V proved particularly 
promising and could generate a variety of novel (1S)-1-aryl THIQ derivatives in high 
yields and high enantiomeric excesses, particularly with methylated benzaldehyde 
analogues. This route is advantageous as the chiral THIQ scaffold can be generated in 
a single step under benign conditions, avoiding the use of high temperatures, high 
pressures, and toxic reagents. Oxidatively sensitive hydroxyl groups are also tolerated 
on the THIQ moiety.  
 
High background reactions were observed with a variety of halogenated (fluorinated 
and chlorinated) benzaldehyde derivatives as substrates but when using high enzyme 
loading and lowering the reaction pH to 6 the contribution of the spontaneous 
background reaction was minimised, enzyme activity improved and decreased 
racemisation at the C-1 position, thus improving the enantiopurity of the resultant THIQ 
products. A variety of more challenging, hydroxyl, brominated and disubstituted 
benzaldehyde derivatives were also tested as substrates but were poorly accepted, 
likely due to steric hinderance or issues of electron deficiency and lack of space in the 
enzyme active site. Performing NCS reactions with benzaldehydes as substrates is 
challenging due to their high oxidative sensitivity and reactivity. This was mitigated by 
using a non-oxidative co-solvent, using purified enzyme, quenching reactions with 
organic solvent, and storing samples for analysis at low temperatures. High enzyme 
concentrations are required to rapidly consume the substrates and minimise the 
contribution of the spontaneous, racemic Pictet-Spengler reaction that occurs.  
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The products of NCS reactions between dopamine and benzaldehyde or 
cyclohexanecarboxaldehyde were accepted as substrates by a variety of O-methyl 
transferases. Regioselective methylation of the meta hydroxyl was achieved using a 
SafC enzyme from Myxococcus xanthus, which is unusual as with other 
catecholamines, the methylation is predominantly selective towards the para-hydroxyl. 
Performing regioselective methylation reactions is challenging chemically and the 
products generated here are pharmaceutically relevant. To generate corresponding 
para-methylated products, 4-methoxytyramine was used as the phenethylamine 
substrate and the resulting THIQ products from the NCS reactions were obtained in 
high yields and enantiomeric excesses. 
 
Structural evidence for benzaldehyde acceptance by TfNCS was obtained via a co-
crystallised structure of the most productive single point variant, D33TfNCS-M97V with 
a non-productive reaction intermediate analogue (of the reaction between dopamine 
and benzaldehyde) bound in the active site. The ligand was found to be in a pre-
cyclisation conformation, consistent with the generation of products with (S)-
stereochemistry. The structure also indicated the potential role of M183 in modulating 
ligand positioning and the single point mutant, M97V removes a flexible residue in the 
active site entrance/exit, so perhaps this mutation simply provides extra space in the 
active site for substrates to bind. It is unknown why the active site mutant M97F is also 
more productive than the wild-type enzyme, but this could be due to pi-stacking effects. 
Perhaps it is productive as pi-stacking interactions may occur between this residue and 
the aldehyde phenyl group or that wider conformational changes of the enzyme are 
occurring.   
 
The mutant M97V proved superior in generating a range of novel (1S)-aryl THIQs in 
high yields and enantiomeric excesses. In future studies, further mutagenesis at this 
position could be performed, possibly to even smaller sidechains on the amino acid, so 
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to alanine (M97A) or glycine (M97G). Mutagenesis of neighbouring residues in the 
active site entrance/exit, L95 and F80, could also be considered. Synthetic 
derivatisation of the THIQ products generated via Boc protection of the amine proved 
challenging and poor yields were achieved. Further optimisation of this reaction could 
be performed to improve conversations and improve the viability of an NCS-mediated 
step in multi-step syntheses. The expansion of the portfolio of regioselective 
methyltransferases available will likely lead to increased conversions to give both meta- 
and para- methoxy products, which would be useful in generating analogues for drug-
discovery purposes. The increased conversions using M97F compared with the wild-
type have not been fully rationalised and this could be further understood by gaining a 
co-crystallised structure with this mutant, to see whether wider conformational changes 






Chapter 6 – N-Methyl Phenethylamines as Substrates for 
Norcoclaurine Synthases 
6.1 Introduction 
6.1.1 Expanding the phenethylamine substrate scope of TfNCS 
The amine substrate scope of TfNCS has been explored to some extent, mostly 
focussing on altering the catechol moiety. The meta-hydroxyl on the phenethylamine is 
required for turnover however, the para-hydroxyl is non-essential, with successful 
reactions observed with halogen and methoxy- substitutions at this position.21 
Substitutions on the alkyl region of the phenethylamine are also well tolerated with 
metaraminol and norepinephrine being accepted giving reasonable reaction 
conversions.118,256 The stereochemistry of metaraminol (102) and norepinephrine (101) 
is unchanged during the Pictet-Spengler reaction, so the use of these catecholamines 
as the amine substrate in NCS reactions is an excellent way of gaining multiple chiral 
centres in a molecule in a single reaction step. Example amine substrates tested as 
substrates by TfNCS are given in Figure 6.1.21,31 
 
 
Figure 6.1: The reported phenethylamine substrate scope of TfNCS beyond the natural 
substrate, dopamine.  
 
There have been no previous reports exploring substitution on the nitrogen atom and 
expanding the NCS substrate scope is useful to develop synthetic routes towards single 


















R = H, F or NH2
Accepted as substrates by TfNCS:
Not tolerated as substrates by TfNCS:
126 51 102 101
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 248 
the addition of a single methyl group to a molecule can dramatically increase the binding 
affinity to a target.257 There is therefore interest in trying to find synthetic routes to 
methylated THIQs to increase pharmacological potency. A variety of N-methylated 
isoquinolines have been shown to exhibit anti-malarial (89 and 192) and anti-HIV (193) 
properties in vitro.258 Another N-methylated, C-1 substituted THIQ has been shown to 
have affinity for both D1 and D2 dopamine receptors (194), which are targets in drug 
discovery for the treatment of illnesses such as Parkinson’s disease and 
schizophrenia.259 (S)-Reticuline (9), in the biosynthetic pathway to morphine (1) also 
can act as a central nervous system depressant.260 The structures of various 
medicinally relevant N-methylated isoquinolines and THIQs are given in Figure 6.2.  
 
Figure 6.2: Various biologically active N-methylated isoquinolines and THIQs.  
 
The synthesis of N-methylated THIQs is challenging using traditional organic synthetic 
methods. Chemical alkylating reagents such as methyl iodide tend to over N-methylate, 
resulting in the formation of quaternary nitrogen centres. These reagents also lack 
heteroatom selectivity, so synthetic routes often require a protecting group strategy if 
other heteroatoms are present in the molecule. Alkylating agents are widely known to 
be carcinogenic and cytotoxic, due to the ability to alkylate DNA.261 There are some 
reported biocatalytic routes towards milder and more regioselective O- and N-
methylations. However, the highly selectivity of biocatalysts can also be a hinderance 
with reported methyltransferases often having a narrow substrate scope.262 Performing 
reactions on a larger scale can also be challenging, as the reactions require S-
adenosyl-L-methionine (SAM) as a co-factor, in stoichiometric quantities. SAM is both 




















are promising and may allow methyltransferases to become a more economically-viable 
and benign route to selectively methylated products.203  
 
Attempts to synthesise N-methylated THIQs using a regioselective N-methyltransferase 
proved unsuccessful when CNMT ((S)-coclaurine N-methyltransferase isolated from 
Coptis japonica) was tested in the development of chemoenzymatic cascades towards 
13-Me-THPBs (Chapter 4). Therefore, to develop an alternative route towards N-
methylated THIQs, the aim was to screen a range of N-methyl-phenethylamines as 
substrates for NCS. This would hopefully provide a single-step route to a variety of N-
methylated THIQs without the requirement for a selective methylating reagent after the 
Pictet-Spengler reaction.  
 
6.2 Results and Discussion 
6.2.1 Synthesis of N-methyl dopamine 
N-methyl dopamine (195) was the first selected to screen as it is most structurally 
similar to dopamine (5), the natural phenylethylamine substrate of NCS. Unfortunately, 
N-methyl-dopamine is not commercially available but there are two reported synthetic 
routes (Scheme 6.1). The commercial route to 195 involves the Friedel-Crafts acylation 
of catechol (196) followed by SN2 attack with methylamine to give 197. This was then 
hydrogenated under acidic conditions at 70 oC to give 195. A simpler route was devised 
by Carpenter et al.263 giving 195 in a single step starting from epinephrine (198). Here, 
a novel route using a protecting group strategy was developed to enable potential 




Scheme 6.1: Reported synthetic routes towards N-methyl dopamine.  
 
Novel synthetic routes towards catecholamines are useful as many are known to act on 
dopamine receptors and are of interest as treatments for illnesses such as Parkinson’s 
disease. N-methyl dopamine (195) is also the prodrug of ibopamine, a dopamine 
agonist, which is used for the treatment of glaucoma264 and is also under investigation 
for the treatment of congestive heart failure.265  
 
A synthetic route towards N-methyl dopamine (195) was devised based upon previous 
work in our group to synthesise secondary amine mimics of the NCS reaction iminium 
ion intermediate.30 This involved a protecting group strategy, whereby the catechol 
hydroxyl groups and amine were protected, allowing only a single methylation at the 
nitrogen atom, followed by orthogonal deprotection. Most of the reactions are performed 
at room temperature and literature precedent demonstrated that all reactions are high 
yielding. Purification is often not necessary at each step as many by-products are 
volatile and any remaining protecting group starting materials do not hinder further 

















Commercial route towards N-methyl dopamine (195)















Scheme 6.2: Synthetic route performed to give N-methyl dopamine.  
 
Reactions were all high yielding, and the synthesis of N-methyl dopamine (195) was 
achieved in four-steps in a 42% overall, isolated yield. The initial Boc protection of 
dopamine to give 66 was performed using a biphasic system to remove the 
hydrochloride salt of dopamine and allow for reaction with Boc anhydride. The crude 
product was obtained with unreacted Boc anhydride as a side-product but was carried 
through directly to the next step as the excess Boc anhydride could be removed in the 
final step. Benzyl protection of the catechol was performed using a Williamson ether 
synthesis followed by recrystallisation to give 67. Methylation of 67 was challenging, as 
there were issues with substrate solubility in many organic solvents. Eventually, the 
reaction was performed in DMF in high yield, however removing the solvent after the 
reaction was challenging and purification by silica chromatography was required. In 
order to remove the protecting groups on 199 to give 195, acid hydrolysis was used 
followed by the removal of solvents in vacuo. This however resulted in a product that 
was a viscous brown oil, instead of a yellow crystals as reported in the literature.263 This 
was rationalised to be due to the presence of a small amount of oxidised product. The 
oxidation of dopamine (and therefore likely also N-methyl dopamine) is via a radical 
polymerisation which produces a conjugated aminochrome product.137 To isolate N-
methyl dopamine (195), the brown residue was resuspended in acetone. 195 is known 

































product, would be soluble. This resulted in the desired final product precipitating as a 
white solid which could be isolated by filtration in 70% yield.  
 
6.2.2 Initial screening of N-methyl phenethylamines as TfNCS substrates 
Biocatalytic reactions were performed with 195 and two other N-methyl 
phenethylamines (Figure 6.3), using wild-type D33TfNCS as the reaction catalyst. 
There are two commercially available phenethylamines with an N-methyl group and a 
meta-hydroxyl group, which is essential for a productive NCS-mediated reaction; 
epinephrine (198) (also known as adrenaline) and phenylephrine (200), which is widely 
used as a decongestant.266 Five different aldehydes (76, 62, 78, 201 and 202, Figure 
6.3) were also screened as the corresponding carbonyl substrate. Phenylacetaldehyde 
(76) was used in place of the natural NCS substrate, 4-HPAA (6) as it is commercially 
available and less prone to oxidation. A variety of linear aldehydes (62, 78, 201 and 
202) were also screened as they are normally well-accepted as substrates, with 
conversions comparable to those when using 6.31 The two enantiomers of citronellal 
were also screened, since linear aldehydes were particularly promising as substrates, 
but unfortunately no conversions were observed with any of the amines (196, 198, or 













Figure 6.3: TfNCS reactions with N-methyl dopamine hydrochloride or epinephrine 
bitartrate as the amine substrate. Aldehydes, phenylacetaldehyde, valeraldehyde, hexanal, 
octanal or 4-pentenal were used as the carbonyl substrate. Reaction conditions: amine (10 mM), 
aldehyde (20 mM), sodium ascorbate (10 mM), D33TfNCS (0.2 mg mL-1) in HEPES buffer (100 
mM, pH 7.5) with MeCN (10% v/v) at 37 oC, 250 µL scale reactions for 24 h. Yields were 
determined by a) product formation by analytical HPLC using calibration curves of standards b) 
amine consumption by analytical HPLC based upon calibration curves of the standard. 
 
Reactions were performed with wild-type TfNCS under standard conditions that were 
previously developed.31 For reactions with linear and benzylic aldehydes, and 
dopamine, 0.1 mg mL-1 enzyme has been shown to be sufficient for near complete 
conversions31 but instead here, 0.2 mg mL-1 enzyme was used as it was suspected that 
N-methyl phenethylamines would be particularly challenging substrates. Trace 
conversions were observed with 200 as the amine substrate while reasonable 
conversions were observed using 195 and 198, as shown in Figure 6.3. The poor 
acceptance of 200 suggests that the para-hydroxyl on the phenyl ring is needed, 
perhaps to ‘anchor’ the substrate with the N-methyl group into the active site by a 
catechol hydrogen bonding interaction with K122. Indeed, poorer conversions were also 
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hydroxyl) compared with using dopamine in earlier work148 Perhaps the presence of the 
N-methyl group means that there is a weaker interaction with charged residues in the 
middle of the active site (E110 and D141) to hold the phenethylamine in the enzyme 
active site. Therefore, another hydrogen bonding interaction (such as para-hydroxyl of 
the phenethylamine to the amine of K122) might be required for successful turnover.  It 
was considered that this is likely due to lack of space in the active site or weaker 
interactions with active site residues crucial for turnover, as the amine of the 
phenethylamine is hindered by the methyl group. Interestingly, the best conversions 
were observed with 4-pentenal (202) as the aldehyde substrate. With 195 as the amine, 
around a 50% increase in conversion was observed simply by introducing the alkene 
group. This could be due to favourable 𝜋-stacking interactions with the side chains of 
residues F80 and Y108 in the NCS active site entrance/exit. Regardless, using 202 as 
the aldehyde substrate is useful as the alkene in the THIQ product could be used as a 
metathesis handle to further diversify the products.  
 
Characterisation of the products generated by NMR spectroscopy indicated that two 
conformers were present, probably due to inversion of the nitrogen lone pair leading to 
two different methyl group chemical environments. High temperature (60 oC) 1H-NMR 
analysis of the product of the reaction between N-methyl dopamine (195) and 62 was 
performed to confirm this. In the product, two singlets at around 6.6 ppm are expected, 
corresponding to the two aromatic protons. This is observed at 60 oC but at room 
temperature, two conformers are present, resulting in another pair of two aromatic 




Figure 6.4: Aromatic region of 1H-NMR spectrum of an N-methylated THIQ generated by 
the NCS mediated reaction between 195 and 62 a) Room temperature and b) high 
temperature (60 oC) 1H-NMR spectra (6.7-6.5 ppm).  
 
RP-HPLC and LCMS analysis of the products generated in reactions with epinephrine 
bitartrate suggested that two diastereomers of product were present. From literature 
precedent, the major enantiomer of product formed from an NCS reactions has (S)-
stereochemistry at the C-1 position,267 so it can be assumed that the major 
diastereomer of product formed is (1S,4R). This therefore suggested that a small 
amount of the (1R,4R) product was generated as it was highly unlikely that the mild 
reaction conditions used would racemise the chiral centre at C-4.  
 
 
Figure 6.5 The two isomers of product generated by NCS reactions using epinephrine 
(198) as the phenethylamine substrate.  
 
To probe whether the (1R)-product was formed, chiral HPLC analysis was performed 
with the products of NCS reactions with 195, to give 203-207, as only one chiral centre 













major isomer minor isomer
R = Ph, (CH2)2CH3, (CH2)3CH3,
        (CH2)5CH3, CH2CHCH2
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aldehydes, the THIQ products are usually formed in high e.e. (often >95%),35 Chiral 
HPLC separations were achieved using AD-H columns for all THIQs generated, except 
the THIQ generated from the reaction with hexanal (205) which was surprising 
considering that the THIQs generated from reactions with pentanal and octanal (206 
and 207) were separated.  
 
The chiral HPLC results confirmed that with an N-methyl group on the phenethylamine, 
the high stereoselectivity mediated by the NCS reaction was lost (Table 6.1). From 
mechanistic studies with NCS, it is known that the interaction of the nitrogen on the 
amine substrate with the two charged residues, E110 and D141 is crucial for mediating 
iminium ion formation and may therefore from this work be implicated in determining 
the stereoselectivity of the reaction during cyclisation. Perhaps the introduction of a 
methyl group on nitrogen results in a lack of appropriate interaction with these residues, 
thus leading to a loss of stereoselectivity in the product.28  
 
Table 6.1: Enantiomeric excesses of the products of NCS mediated reactions between N-
methyl dopamine and five different aldehydes. Reactions were performed using 0.2 mg mL-
1 of purified TfNCS under standard conditions. nd = e.e. not determined. The major isomer of 





204 205 206 207 
8% e.e. 29% e.e. nd 20% e.e. 10% e.e. 
 
In an attempt to improve the yields and selectivities, reactions were performed using 
the same conditions, but at increased enzyme concentrations and also when lowering 
the pH of the reaction to 6. Indeed, lower pH had been crucial to gaining high 
enantiomeric excesses in the (1S)-aryl-THIQs generated between dopamine and 


















appeared to minimise the background, racemic Pictet-Spengler reaction and improve 
enzyme activity. Reactions for screening were performed using the same five 
aldehydes (76, 62, 78, 201 and 202, Figure 6.3) and 3-phenylpropanal (203) was also 
utilised as 202 had been particularly promising as a substrate (Figure 6.6).  
 
Figure 6.6: WT-TfNCS catalysed reactions between N-methyl dopamine and a range of 
aldehydes. Reactions were performed with 0.5 mg mL-1 TfNCS at either pH 6 or pH 7.5.  
 
Yields and enantiomeric excesses of products are given in Table 6.2. The product 
generated for reactions with 3-phenylpropanal (203) was not isolated (but instead was 
confirmed by LCMS), so yields and e.e.s are not given. Unfortunately, both yields and 
selectivity were negatively affected by performing reactions at a lower pH. Fairly high 
background reactions were also observed, likely due to the electron donating methyl 
group on the nitrogen increasing nucleophilicity and imine formation, meaning that 
spontaneous, racemic background Pictet-Spengler reactions were more likely. 
However, the background reactions are not significant enough to result in such poor 
reaction selectivities, meaning that the low e.e.s are associated with the NCS sample, 
as may also be the case with the benzaldehydes as discussed in Chapter 5. This could 
be further investigated by using a knockout variant as a negative control, perhaps based 




































Table 6.2: Yields and enantiomeric excesses of products generated by TfNCS reactions 
using 0.5 mg mL-1 enzyme at either pH 6 or pH 7. Yields were determined based upon 
calibration curves of isolated products. Enantiomeric excesses were determined by chiral HPLC 
(method 5).   
THIQ pH 6 pH 7.5 
Yield / %  e.e. / % Yield / %  e.e. / % 
203 19 - 36 - 
204 42 36 >99 55 
205 43 - 77 - 
206 21 32 41 46 
207 24 0 >99 27 
 
 
6.2.3 Screening of NCS variants  
Previous biocatalytic studies have shown that certain active site mutants of 
norcoclaurine synthase can improve conversions with certain substrates. For example, 
the mutant M97V can improve conversions with a-substituted aldehydes as 
substrates,148 while  the mutant A97I can improve yields with ketones.36 With this 
knowledge, a variety of different NCS mutants (L76V, A79I, A79F, F80L, M97V, M97L, 
M97F and Y108F) were screened in the reactions between N-methyl dopamine and 
phenylacetaldehyde (Figure 6.7a) and epinephrine bitartrate and valeraldehyde (Figure 




Figure 6.7: Screening a library of NCS single point variants with N-methyl 
phenethylamines as substrates. Structures of the major isomer of product are given for each. 
a. HPLC conversions by amine consumption to give 203. b. Product peak areas by RP-HPLC 
of the reaction between epinephrine bitartrate (198) and pentanal (62), to give 209. Reaction 
conditions: amine (10 mM), aldehyde (20 mM), sodium ascorbate (10 mM), D33TfNCS (0.2 mg 
mL-1) in HEPES buffer (100 mM, pH 7.5) with MeCN (10% v/v) at 37 oC, 250 mL scale reactions 
for 24 h.  
 
For the formation of 204, improved conversions were observed with the mutant A79I. 
This was also the case with many other NCS substrates such as ketones and aliphatic 
aldehydes31,36 and is rationalised as being due to increased hydrophobicity of the active 
site and so enhanced substrate binding.28 For reactions with epinephrine bitartrate 
(198), a single enantiomer of epinephrine was used and it is unlikely that this chiral 
centre will be racemised during the reaction. Therefore, the presence of two 
diastereomers would be due to altered stereochemistry at the C-1 position. The two 





















































the mutants tested, there was little change in the diastereomeric ratios of the two 
products, however no mutants of the residues at E110 and D141 were tested. From 
mechanistic studies, these two residues are likely to orient the iminium ion during 
cyclisation and thus removing the hydrogen-bonding interaction with these two residues 
may result in a less stereoselective reaction.28 
 
6.2.4 Phosphate reactions to generate racemic products  
To generate racemic standards for chiral HPLC analysis and to provide a comparison 
to the enzymatic reaction, reactions were performed between 195 and aldehydes 76, 
62, 78, 201 and 202, but using inorganic phosphate instead of NCS as the reaction 
catalyst.15 For all substrates tested, complete amine consumption was observed, 
reflecting the high activation of the amine due to electron donation by the N-methyl 
group. Conversions could not be accurately quantified by product formation calibration 
curves as two regioisomers of product were formed. For reactions with N-methyl 
dopamine, the two regioisomers were formed in a 3:1 ratio of para:ortho products by 
NMR spectroscopic analysis. The two regioisomers were separated by preparative-
HPLC (method 9) and the para isomer was used as a racemic standard for chiral HPLC 
analyses.  
 
Figure 6.8: The two regioisomers of product generated by a phosphate-mediated reaction 
between N-methyl dopamine and a variety of aldehydes.  
 
6.2.5 Structural studies to understand the reaction selectivity  
Protein crystallography has been used successfully to rationalise NCS substrate 
acceptance by the co-crystallisation of the enzyme with non-productive reaction 
R = Ph, (CH2)2CH3, (CH2)3CH3,












intermediate mimics.148,149 Therefore, to try to understand the poor conversions and 
stereoselectivities observed in products generated by NCS reactions with N-methyl 
phenethylamines, a reaction intermediate analogue of the reaction between N-methyl 
dopamine (195) and phenylacetaldehyde (76) was synthesised. The rationale behind 
the mimic design (i.e., comparison to the iminium ion intermediate of the reaction) is 
given in Scheme 6.3 Previous attempts to co-crystallise reaction mimics based on 
reactions with linear aldehydes had proved unsuccessful due to a combination of poor 
difference density observed in the active site and multiple ligand conformations. 
Therefore, despite aldehydes 62, 78, 201 and 202 being preferred as the carbonyl 
substrate partner for reactions with 195, 76 was chosen as the aldehyde part of the 
mimic. It was hoped that the phenyl ring would provide additional electron density to aid 
observation in the enzyme active site and that the mimic would be less flexible, to avoid 
previous issues of multiple ligand conformations.  
 
Scheme 6.3: Design of a N-methyl dopamine reaction intermediate analogue, based upon 
the iminium ion intermediate of the NCS reaction.  
 
The mimic, 210 was synthesised in four steps from 68 (Scheme 6.4). Amide coupling 
between 68 and phenylacetyl chloride proceeded to give 211 in 27% isolated yield. The 
N-methyl group was then incorporated by reaction with iodomethane in the presence of 
























isolated by column chromatography in 52% yield. Rotamers were observed by NMR 
spectroscopic analysis of 208 and this was resolved by increasing the temperature at 
which the spectra were collected (60 oC vs. rt).  The amide was reduced to the 
secondary amine (213) using borane and taken through directly to the final reaction 
step, benzyl deprotection by heating at reflux under acidic conditions. The final product, 
210 was isolated as the TFA salt in 6% yield by preparative HPLC. A poor yield was 
obtained due to incomplete benzyl deprotection and would likely be improved by 
increasing the reaction time.  
 
Scheme 6.4 Synthetic route towards an N-methyl dopamine reaction intermediate 
analogue for co-crystallisation experiments with TfNCS.  
 
The mimic (210) was prepared at 200 mM in DMSO and added to D33TfNCS (12.6 mg 
mL-1 in 20 mM TRIS, 50 mM NaCl, pH 7.5) to give 5% v/v mimic in the protein sample. 
Despite extensive screening, crystals were only observed under three conditions which 
is a stark contrast from screening with other mimics where many crystals were gained. 
From crystals sent to the synchrotron, only apo protein structures were observed. The 
lack of co-crystallisation likely reflects the poor acceptance of N-methyl dopamine (195). 
The mimic was also prepared in water or DMSO. and soaking of some apo crystals was 
attempted; however, the crystals were destroyed upon addition of the mimic. Soaking 
with water or DMSO alone did not cause the crystals to dissolve, indicating that this 
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in the crystal lattice29 and TfNCS is known to have a highly dynamic mechanism,26 
crystal destruction was not observed when soaking other reaction mimics which were 
based upon more productive enzymatic reactions.  
 
Alternatively, to gain structural insights into N-methyl phenethylamine acceptance, 
computational docking studies were performed using AutoDock Vina. The iminium ion 
of the reaction between N-methyl dopamine (195) and phenylacetaldehyde (76) was 
used for docking into the active site as this would help gain information on the 
orientation of the substrates before cyclisation. Chain A of 𝛥33TfNCS (PDB: 5NON) 
was used, with the ligand removed. No electrostatic interactions are observed between 
the nitrogen of the iminium ion and any of the heteroatoms of key charged residues in 
the mechanism (E110, D141 and Y108), as shown in Figure 6.9. This is likely to due to 
steric hindrance from the N-methyl group.  
 
Figure 6.9: Placement of iminium ion reaction intermediate of the reaction between N-
methyl dopamine and phenylacetaldehyde in the active site of TfNCS. Residues 65-79 were 
removed to aid visualisation and the figure was made using USCF Chimera.32 Hydrogen bonding 
distances are shown by blue dotted lines.  
 
6.3 Conclusions and future work 
In summary, work described in this chapter demonstrates that TfNCS can accept N-
methylated catecholamines as substrates to give a variety of THIQ products in high 
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regioselectivities, however the stereoselectivity and yields of reactions are poor. 
Conversely, with inorganic phosphate as the reaction catalyst, yields are high but there 
is a lack of stereocontrol. Computational docking studies suggested that this could be 
due to a lack of interaction between the charged residues, E110 and D141, and the 
iminium ion intermediate. A variety of NCS mutants were tested with the aim of 
improving conversions compared with the wild type. Conversions were improved with 
the active site mutant, A97I, likely due to increased hydrophobicity of the active site. 
Although substrates of this type were accepted by TfNCS, a more favourable route to 
single enantiomer N-methylated THIQs would likely be via a biocatalytic cascade 
involving a first step by NCS to generate the THIQ scaffold in a regio- and 
stereoselective manner, followed by selective mono N-methylation using an appropriate 




Chapter 7: Conclusions and Future Work 
7.1 Conclusions 
This work has resulted in the extension of the known substrate scope of TfNCS, 
particularly towards a-methyl-substituted aldehydes and the benzaldehydes. This 
provides novel stereoselective routes towards pharmaceutically relevant THIQs. 
Further functionalisation of the NCS-generated THIQs was performed by regioselective 
methyltransferase enzymes and using chemical Pictet-Spengler reactions. 
Crystallographic investigations of TfNCS by the co-crystallisation of reaction 
intermediate mimics were successfully used to rationalise the acceptance of reactions 
with a-substituted aldehydes.  
 
In Chapter 2, biocatalytic routes towards (R)-THIQs are presented. A range of 
enzymatic variants were explored; TfNCS variants, NCSs from N. nucifera and the 
salsolinol synthase enzyme. Although no changes in stereoselectivity were observed, 
NCS proved to be highly resilient, retaining stereoselectivity despite significant active-
site mutagenesis.  
 
Based upon previous reports of a-substituted aldehydes generally being poorly 
accepted by TfNCS, Chapter 3 describes the use of a-methyl-substituted aldehydes as 
substrates. Indeed, a range of a-methyl-substituted aldehydes were shown to be well-
accepted as substrates. When a racemic aldehyde was used, the (R)-enantiomer was 
preferentially accepted leading to the regio- and stereoselective syntheses of (1S,1’R)-
1’-Me-THIQs. Active site variants improved activities compared to the wild-type enzyme 
and crystallographic studies with a co-crystallised reaction intermediate mimic helped 
to rationalise these improved activities.  
 
Chapter 4 describes the development of chemoenzymatic cascades towards 13-Me-
THPB and 13-Me-PB alkaloids like the biologically active alkaloids isolated in Corydalis 
 266 
plants. The cascades involved regioselective catechol O-methyltransferase and 
chemical Pictet-Spengler reactions.  
 
The improved acceptance of a-methyl-substituted aldehydes, particularly by the TfNCS 
variant, M97V led to the screening of benzaldehydes as substrates, as described in 
chapter 5. After optimisation of the reaction conditions, numerous (1S)-aryl-THIQs were 
generated in high yields and e.e.s. A co-crystallised structure of this M97V variant 
helped rationalise the observed activities. Methylations with catechol O-
methyltransferases were also performed and the selectivities of the enzymes explored.  
 
N-Methyl-phenethylamines were investigated as TfNCS substrates, and the results are 
presented in Chapter 6. Work focused on N-methyl-dopamine which was shown to be 
accepted by the enzyme. The stereoselectivity of the reaction was lost although 
products were still generated in a regioselective manner.  
 
7.2 Future Work 
NCS has proved to be an excellent biocatalyst for generating (S)-THIQs in high yields 
and with high regio- and stereoselective control. Future work could focus on further 
redesign of the enzyme, either by rational design or directed evolution. Particularly, 
these could build on the efforts made in Chapter 2 to develop an NCS that can 
synthesise (R)-THIQs. Changing the positions of the two, charged active site residues, 
E110 and D141 to alter the conformation that the iminium ion reaction intermediate 
adopts may lead to a change in stereoselectivity. Generating new constructs of the 
salsolinol synthase and the sacred lotus NCSs may also result in active enzymes that 
can generate (R)-THIQs. The reticuline epimerase enzyme (Scheme 1.12) converts 
(S)-reticuline to (R)-reticuline. Significant enzyme engineering efforts of this enzyme 
may also provide a route towards (R)-THIQs (as shown in Scheme 7.1a). The variant 
M97V has already proved promising in improving the acceptance of a-substituted 
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aldehydes by TfNCS. Therefore, mutations focusing on decreasing steric bulk and side 
chain flexibility at this position (e.g. M97A and M79G) may allow access to more 
sterically challenging aldehydes such as 2-napthaldehyde and analogues as shown in 
Scheme 7.1b). Deacetylipecoside synthase (DIS) is another known Pictet-Spenglerase 
that has been shown to perform an R-selective reaction (Figure 1.5).92 The sequence 
and substrate scope of the enzyme is unknown, although is hypothesized to have 
similarities with strictosidine synthase. This enzyme may therefore provide a 
stereoselective route to (R)-THIQs.  
 
Scheme 7.1: Ideas for future enzyme engineering efforts to generate novel, enantiopure 
THIQs.  
 
Although crystallographic studies were used successfully in this work to rationalise 
observed NCS activities, gaining high resolution structures with the ligand bound in a 
single conformation with high occupancy was challenging. The highly dynamic nature 
of the NCS mechanism meant that few mechanistic insights could be drawn from NMR 
studies performed in 2008.26 However, based on what is now known about structure 
and mechanistically relevant residues of NCS, further understanding of the dynamics 
of the mechanism by NMR studies may be possible, providing a useful guide for enzyme 
engineering efforts.  
 
Numerous novel alkaloids were also generated in this work, many based upon 
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have been sent to collaborators to assess their activities. Based upon activities with 
similar compounds, malaria, zika virus, anti-bacterial and dopamine receptor inhibitory 
activities are to be explored.   
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Chapter 8: Experimental  
8.1 Enzyme details 
Table 8.1: Plasmids used for this work. All are stored as plasmid DNA and as glycerol stocks 
in E. coli BL21(DE3). SDM = site directed mutagenesis. GS = gene synthesis (purchased from 
aDNA 2.0, bEurofins or Life Technologies with codon optimisation for E. coli expression and 
NdeI/XhoI restriction sites). PCR = gene amplified by colony PCR from NEB 5-alpha E. coli.209 
The sequence and preparation of all D29TfNCSs and wild type D33TfNCS has been previously 
described in the PhD thesis of B. Lichman and published.30,31 The subcloning and sequences of 
two methyltransferases (RnCOMT and MxSafC)209,211 and recycling system enzymes (EcMAT, 
EcMTAN)203 has been reported. Cj6OMT and CjCNMT have also been reported.197 pQR codes 
of these enzymes are not given as they were provided by other groups.  
 
Table 2.1: Plasmids used for this work. All are store  as plasmid NA and as glycerol stocks in 
BL21(DE3). SDM = site directed mutagenesis. GS = gene synthesis (purchased from aDNA 2.0, 
bEurofins or Life Technologies with codon optimisation for E. coli expression and NdeI/XhoI restriction 
sites). PCR = gene amplified by colony PCR from NEB 5-alpha E. coli.1 The sequence and preparation 
of all D29TfNCSs and wild type D33TfNCS has been previously described in the PhD thesis of B. 
Lichman and published.2,3 The subcloning and sequences of two methyltransferases (RnCOMT and 
MxSafC)1,4 and recycling system enzymes (EcMAT, EcMTAN)5 has been reported. 6OMT and CjCNMT 




pQR Plasmid Gene Mutation(s) His-tag 
terminal 
Source Method 
1046 pJ411 D29TfNCS Wild type C B. Lichman GSa 
1045 pJ411 D29TfNCS L76V C B. Lichman GSa 
1047 pJ411 D29TfNCS A79I C B. Lichman GSa 
1833 pJ411 D29TfNCS F80L C B. Lichman GSa 
1841 pJ411 D29TfNCS M97V C B. Lichman SDM 
1840 pJ411 D29TfNCS M97L C B. Lichman SDM 
1839 pJ411 D29TfNCS M97F C B. Lichman SDM 
1834 pJ411 D29TfNCS Y108F C B. Lichman GSa 
1846 pJ411 D29TfNCS K122L A69K C B. Lichman SDM 
1847 pJ411 D29TfNCS K122L L72K C B. Lichman SDM 
1848 pJ411 D29TfNCS K122L I85K C B. Lichman SDM 
1849 pJ411 D29TfNCS K122L F112K C B. Lichman SDM 
1850 pJ411 D29TfNCS K122L L95K C B. Lichman SDM 
1851 pJ411 D29TfNCS K122L M126K C B. Lichman SDM 
1852 pJ411 D29TfNCS K122L M183K C B. Lichman SDM 
1853 pJ411 D29TfNCS K122F F112K C B. Lichman SDM 
1856 pD451-SR D33TfNCS Wild type N-TEV B. Lichman GSa 
1637 pET29a(+) D33TfNCS M97V N-TEV J. Ward GSb 
1648 pET29a(+) D33TfNCS L72A N-TEV Y. Wang GSb 
1649 pET29a(+) D33TfNCS L72V N-TEV Y. Wang GSb 
1650 pET29a(+) D33TfNCS Y108S N-TEV Y. Wang GSb 
1651 pET29a(+) D33TfNCS Y108W N-TEV Y. Wang GSb 
1665 pET29a(+) D33TfNCS P179A N-TEV R. Roddan GSb 
1667 pET29a(+) D33TfNCS P179G N-TEV R. Roddan GSb 
1669 pET29a(+) D33TfNCS P179S N-TEV R. Roddan GSb 
1671 pET29a(+) D33TfNCS F80W N-TEV R. Roddan GSb 
1673 pET29a(+) D33TfNCS F80Y N-TEV R. Roddan GSb 
2339 pET29a(+) NnNCS5 Wild type N-TEV J. Ward GSb 
2340 pET29a(+) NnNCS7 Wild type N-TEV J. Ward GSb 
- pET28a(+) RnCOMT Wild type N J. Andexer GSc 
- pET20b(+) MxSafC Wild type C J. Andexer - 
- pET28a-
SacB-SapI 
Cj6OMT Wild type C F. Subrizi GSb 
- pET28a(+) CjCNMT Wild type C F. Subrizi - 
- pET28a(+) EcMAT Wild type N J. Andexer PCR 
- pET28a(+) EcMTAN Wild type N J. Andexer PCR 
1663 pEX-A128 SS v1 Wild type C J. Ward GSb 
1664 pEX-A128 SS v2 Wild type C J. Ward GSb 
1665 pEX-A128 SS v3 Wild type C J. Ward GSb 
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8.2 Molecular Biology Methods  
8.2.1 Transformations into E. coli 
Transformations were performed with either Stellar™ Competent Cells (Takaka) or 
BL21(DE3) competent cells (NEB). On ice, DNA (2 µL) was added to competent cells 
(50 µL) and incubated for 30 min. Cells were then heat shocked (42 oC, 30 s) and 
incubated on ice (5 min). 500 µL of Super Optimal Broth with Catabolite repression 
(SOC media) was added, and the cells were incubated at 37 oC (250 rpm, 1 h). The 
cells were then plated onto lysogeny broth (LB) agar, containing the appropriate 
antibiotic (kanamycin at 50 µg mL-1) and incubated overnight at 37 oC.  
 
8.2.2 Plasmid isolation 
LB media (10 mL) with appropriate antibiotic (kanamycin at 50 µg mL-1) was inoculated 
with a single colony of E. coli containing the desired plasmid. Cultures were incubated 
overnight at 37 oC, 250 rpm. Cells were isolated by centrifugation (5,000 rcf, 5 min, 4 
oC) and DNA isolated by mini-prep kit (Sigma Aldrich, GenElute™Plasmid Miniprep Kit) 
following the manufacturer’s instructions. DNA was eluted into nuclease free water and 
concentrations were measured using a NanoDrop Spectrophotometer.   
 
8.2.3 Restriction digests  
1-2 µg DNA, 5 µL 10X CutSmart Buffer (NEB), 1 µL NdeI restriction enzyme (NEB) and 
1 µL XhoI restriction enzyme (NEB) were prepared in nuclease free water with a final 
volume of 50 µL. Digests were performed for 1 h at 37 oC then DNA fragments 
separated by agarose gel electrophoresis.  
 
8.2.4 DNA gel electrophoresis  
1% agarose gels in 1 x TBE buffer (0.089 M TRIS HCl, 0.089 M boric acid, 0.002 M 
EDTA) were prepared with SYBR Safe DNA gel stain (0.03% v/v). Purple loading dye 
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(6X, 10 µL) was added to each 50 µL restriction digest reaction. Gels were run at 110 
V, 40 min in 1 x TBE buffer.  
 
8.2.5 Gel extraction 
The desired fragments of DNA were cut from the agarose gels and DNA isolated using 
a Qiagen MinElute® Gel Extraction Kit.  
 
8.2.6 Ligations 
Digested and isolated vector and insert DNA fragments were combined at a molar ratio 
of vector:insert of 1:7 with 20 ng of vector DNA. Reactions were performed using Instant 
Sticky-end Ligase Master Mix (NEB), following the manufacturers instruction then 
placed on ice and transformed into Stellar™ Competent Cells (Takaka).  
 
8.3 Protein preparation 
8.3.1 Protein expression 
Expression of TfNCS (wild-type and variants of both D29 and D33 constructs), NnNCS5 
and salsolinol synthases was performed using the following protocol. All plasmids were 
used to transform E. coli BL21(DE3). 10 mL LB media was inoculated with a single 
colony and grown at 37 oC for 18 h. 500 mL LB media was inoculated with 1% v/v of 
overnight culture and grown at 37 oC for 2 h. IPTG (0.5 mM final concentration) was 
added, and the protein was incubated for 18 h at 25 o C. Cell pellets were isolated by 
centrifugation and stored at -20 oC until further purification or lysis for enzymatic 
reactions.  
 
This expression protocol was adapted for the other enzymes investigated. For the 
expression of RnCOMT, MxSafC, 6OMT, EcMAT and EcMTAN, the same expression 
protocol was used, except for 0.2 mM final concentration of IPTG was used instead. 
For the expression of 6OMT, the protein was instead incubated at 18 oC for 36 h. For 
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the expression of the NnNCS7, induction was performed with 0.5 mM IPTG (final 
concentration) with cultures incubated at 18 oC for 24 h. For the expression of MxSafC, 
where incubation was performed at 16 oC for 36 h. 
 
8.3.2 Lysate preparation 
To prepare lysates for enzymatic reactions, the pellet was resuspended in buffer (4% 
v/v of final culture volume, 50 mM HEPES, pH 7.5) and cells were lysed by sonication 
(10 s ON, 10 s OFF, 10 x). The resulting suspension was centrifuged (10 min, 6000 x 
g, 4 oC) and the supernatant used directly for enzymatic reactions or stored at -20 oC. 
The total protein concentration in the lysate was determined by Bradford assay and 
SDS-PAGE analysis combined with quantification using ImageJ, was used to determine 
the percentage of TfNCS in the lysate.  
 
8.3.3 Protein purification 
For purification of all TfNCSs, NnNCSs, MxSafC and EcMAT, the cell pellet was 
resuspended in lysis buffer (100 mM HEPES, 20 mM imidazole, 100 mM NaCl, pH 7.5, 
15% v/v culture volume) with a small amount of DNAse1. The cells were lysed by 
sonication (3 x [3 min ON, 3 min OFF]) and centrifuged (15,000 x g, 45 min, 4 oC). The 
resulting supernatant was removed and filtered (0.45 µm). A 5 mL His-trap HP column 
was equilibrated with lysis buffer and the lysate loaded onto the column at 1 mL min-1. 
The column was washed with lysis buffer to remove any unbound protein (6 column 
volumes), followed by washings with a stepwise gradient of increasing imidazole 
concentrations by combining lysis buffer and elution buffer (100 mM HEPES, 500 mM 
imidazole, 100 mM NaCl, pH 7.5). The column was washed with 8% elution buffer for 
6 column volumes, 16% elution buffer for 6 column volumes followed by 100% elution 
buffer. All washings were performed at a flow rate of 1 mL min-1. Fractions were 
analysed by SDS-PAGE and fractions containing pure protein were combined and 
dialysed into 20 mM Tris, 50 mM NaCl, pH 7.5 buffer. The protein sample was 
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centrifuged and concentrated to approximately 10 mg mL-1. Aliquots of protein were 
stored at -80 oC until use for enzymatic reactions or in the case of ∆33TfNCS-WT or 
M97V, taken through to the next step of purification for removal of the hexahistidine tag.  
 
For removal of the hexahistidine tag of ∆33TfNCS-WT and M97V, TEV protease was 
added to the pooled fractions and the sample dialysed overnight (20 mM Tris, 50 mM 
NaCl, pH 7.5). The protein sample was then centrifuged (15,000 x g, 20 min, 4 oC) and 
loaded onto a 5 mL His-trap HP column. The supernatant was passed through the 
column. The column was then washed with varying amounts of elution buffer (20 mM 
TRIS, 50 mM NaCl, 500 mM imidazole, pH 7.5) mixed with the dialysis buffer. Fractions 
containing D33TfNCS were pooled and further purified by gel filtration on a Superdex 
S75 column. Fractions within the major UV absorbance peak at 280 nm were pooled, 
concentrated (to approximately 10 mg mL-1) and stored at -80 oC.  
 
For purification of EcMTAN, the pellet was resuspended in buffer (4% v/v final culture 
volume, 50 mM HEPES, pH 7.5) and cells were lysed by sonication (10 s ON, 10 s 
OFF, 10 x). The resulting suspension was centrifuged (10 min, 6000 x g, 4 oC) and 
filtered (0.45 µM). A Ni-NTA gravity column (7 mL volume) was washed with lysis buffer 
(100 mM HEPES, 20 mM imidazole, 100 mM NaCl, pH 7.5) and the lysate supernatant 
loaded onto the column. Any unbound protein was removed by washing with lysate 
buffer (10 column volumes), then 40 mM imidazole buffer (100 mM HEPES, 40 mM 
imidazole, 100 mM NaCl, pH 7.5, 10 column volumes). The pure protein was eluted 
with 500 mM imidazole buffer (100 mM HEPES, 500 mM imidazole, 100 mM NaCl, pH 
7.5). 2 mL fractions were collected and analysed with Bradford reagent to test for 
presence of the protein. Fractions containing high concentrations of protein were pooled 
and buffer exchanged using a PD-10 column, into 50 mM HEPES, 20 mM NaCl, pH 
7.5. The pure protein sample pooled based upon SDS-PAGE analysis of protein 
fractions and stored in aliquots at -80 oC.  
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For the purification of salsolinol synthase, the pellet was resuspended in buffer (5% v/v 
of final culture volume, 50 mM TRIS, pH 7.4) and cells were lysed by sonication (10 s 
ON, 10 s OFF, 10 x). 1 M perchloric acid was added (5 x resuspension volume) and the 
solution centrifuged (5000 x g, 10 min, 4 oC). The supernatant was removed, filtered 
(0.22 µM) and analysed by SDS-PAGE.147 
 
8.3.4 Protein visualisation and concentration determination 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using Bolt™4-12% Bis-Tris Plus gels with 1 x MES running buffer was used 
to run the gels at 200 V for 20 min. Gels were stained using InstantBlue™.    
 
Anti-hexahistidine tag western blot analysis was used to visualise proteins with poor 
expression (NnNCSs and salsolinol synthases). SDS-PAGE was used to separate 
proteins in the sample, which were transferred to a nitrocellulose membrane using iBlot 
PVDF transfer stacks (ThermoFischer). The membrane was incubated for 1 h at rt in 
blocking solution (1 x PBS + 5% non-fat dry milk (Marvel)). The blocking solution was 
removed, and the membrane incubated with 3 x 50 mL washing solution (1 x PBS + 
0.05% TWEEN® 20) every 5 min. 20 mL antibody solution (1 x PBS + 1% non-fat dry 
milk + 0.05% TWEEN + 10 µL anti-polyHistidine Peroxidase conjugate antibody in 0.01 
M Na2PO4, 1% BSA, 0.01% thimasol) was added and the membrane incubated for 2 h 
at rt with rocking. The antibody solution was discarded, and the membrane washed with 
washing solution (3 x 50 mL, replaced every 5 min). The membrane was developed 
using SiGMAFAST 3,3’-diaminobenzidine following the manufacturer’s instructions. 
The reaction was stopped by removal of the development solution and incubation of the 
membrane in dH2O.  
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Purified protein concentrations were determined using a NanoDrop® 
spectrophotometer, measuring the absorbance of light at 280 nm of 2 µL of sample. 
Extinction co-efficients were calculated using ExPASy ProtParam268 and protein 
concentrations estimated using the Beer-Lambert Law (Equation 1). 
 
𝑐 = 	 !!"#
"!"#×	ℓ
×𝑀& Equation 1 
 
Protein percentage in cell lysates was determined using ImageJ (NIH) analysis of SDS-
PAGE. Total protein concentrations in clarified cell lysate were determined using 
Bradford protein assays. Percentage of TfNCS in the lysate was determined by ImageJ 
analysis of the SDS-PAGE gel.  
 
8.4 Biotransformations 
8.4.1 NCS catalysed reactions 
A solution of amine (final reaction concentration of 10 mM) and sodium ascorbate (final 
reaction concentration of 10 mM to prevent catecholamine and aldehyde oxidation) was 
prepared in HEPES buffer (50 mM, pH 7.5). A solution of aldehyde (200 mM in MeCN 
or DMSO) was prepared. The solutions were mixed to give 10 mM amine, 10 mM 
sodium ascorbate, 20 mM aldehyde and TfNCS (at approximately 10 mg mL-1 in 20 mM 
Tris, 50 mM NaCl, pH 7.5) was added (at a final concentration of 0.1, 0.2, 0.5 or 1 mg 
mL-1 as described for each reaction) in HEPES buffer (50 mM pH 7.5) with 10% v/v 
MeCN or DMSO. Reactions were shaken or stirred at 37 oC for 3, 18 or 24 h as 
described. Analytical scale reactions were prepared to give a final reaction volume of 
100 µL or 200 µL. Preparative scale reactions were performed on a 10 mL scale.  
 
For reactions using meta-tyramine as the amine substrate, sodium ascorbate was not 
added as there was no catechol-containing moiety in the reaction mixture. To quench 
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or workup the reactions, different conditions were used depending on the use of the 
sample, as detailed in Section 8.4.3.  
 
8.4.2 Methyltransferase reactions 
The lyophilised NCS reaction (workup method 5) was resuspended in buffer (250 mM 
HEPES, 200 mM MgCl2, 2 M KCl, pH 7.5) and water (1:4 ratio) in an equal volume to 
the NCS reaction sample.  ATP (100 mM in H2O, final concentration 10 mM), L-
methionine (100 mM in H2O, final concentration 10 mM), EcMAT (9 mg mL-1 purified, 
0.4 mg mL-1 final concentration), EcMTAN (2.5 mg mL-1 purified, 0.025 mg mL-1 final 
concentration) and methyltransferase (RnCOMT: 10% v/v lysate, 6OMT: 10% v/v 
lysate, MxSafC: 6 mg mL-1 purified, 0.6 mg mL-1 final concentration) were added. 
Reaction volumes were adjusted by addition of HEPES buffer (50 mM, pH 7.5). 
Reactions were performed at 37 oC, 500 rpm (200 µL scale) or 150 rpm (10-20 mL 
scale).  
 
8.4.3 Workup methods for product isolation or analytical analysis  
Workup method 1 (for RP-HPLC analysis and chiral HPLC analysis with 
methods 3-4): Reactions were quenched by the addition of an equal volume of MeCN. 
Samples were centrifuged (16,000 x g, 10 min, 4 oC), then the supernatant diluted with 
an equal volume of water and analysed immediately by analytical RP-HPLC or stored 
at -20 oC.  
 
Workup method 2 (for chiral HPLC analysis with methods 5-6): The reaction 
was saturated by addition of NaHCO3 and an equal volume of EtOAc to the reaction 
volume was added. The samples were vortexed (30 s) and centrifuged (16,000 x g, 5 
min, 4 oC). The organic layer was removed and left to evaporate until dryness (ca. 48 
h). The sample was resuspended in 80:20:0.1 n-hexane:ethanol:diethylamine(1.5 x 
initial reaction volume) and injected for HPLC analysis.  
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Workup method 3 (to prepare for preparative HPLC purification or crude 
NMR analysis): The reaction was saturated by addition of NaHCO3 and extracted with 
ethyl acetate. The organic phases were dried with Na2SO4 and concentrated under 
reduced pressure.  
 
Workup method 4 (to prepare for preparative HPLC purification or crude 
NMR analysis): The reaction mixture was extracted with ethyl acetate (3 x reaction 
volume). The organic phases were combined, dried with Na2SO4 and concentrated 
under reduced pressure.  
 
Workup method 5 (to prepare for preparative HPLC purification): Reactions 
were quenched by the addition of an equal volume of MeCN. Samples were centrifuged 
(16,000 x g, 10 min, 4 oC) and the supernatant removed and lyophilised.  
 
8.5 Analytical methods 
8.5.1 Achiral analytical HPLC analysis 
Analysis of samples was performed using an Agilent 1260 Infinity liquid 
chromatography system comprising of a G1329B autosampler, G1311C quaternary 
pump, 1260 G1316A column oven and 1260 G1314F variable wavelength detector.  
The system was equipped with a HiChrom ACE C18 column (250 mm x 4.6 mm). 
Acetonitrile (MeCN) in water (0.1% v/v TFA) was used as the mobile phase. 
 
HPLC method 1: The gradient used was: 10% MeCN for 1 min, a linear gradient 
to 70% MeCN over 5 min, 100% MeCN for 30 s, followed by 10% MeCN for 3.5 min. A 
flow rate of 1 mL min-1 was used. 10 𝜇L of sample was injected. UV absorbance was 
measured at 280 nm.  
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HPLC method 2: The gradient used was: 10% MeCN for 1 min, a linear gradient 
to 70% MeCN over 15 min, 100% MeCN for 30 s, followed by 10% MeCN for 3.5 min. 
A flow rate of 1 mL min-1 was used. 10 𝜇L of sample was injected. UV absorbance was 
measured at 280 nm.  
 
8.5.2 Chiral analytical HPLC analysis 
HPLC method 3: A Supelco Astec Chirobiotic™ T2 column (250 mm x 4.6 mm) 
was used with an isocratic MeOH (0.1% AcOH, 0.2% TEA) mobile phase at 1 mL min-
1. UV absorbance at 280 nm was measured. The column temperature used was 30 oC.  
 
HPLC method 4: An Agilent InfinityLab Poroshell 120 Chiral-V column (150 mm 
x 4.6 mm, 2.7 microns) was used with an isocratic MeOH (0.2 wt% ammonium formate) 
mobile phase at 1 mL min-1. UV absorbance at 280 nm was measured. The column 
temperature used was 30 oC.  
 
HPLC method 5: A Diacel Chiralpak® AD-H column (250 mm x 4.6 mm, 5 µM) 
was used with an isocratic n-hexane:ethanol:diethylamine (80:20:0.01) mobile phase 
at 1 mL min-1. UV absorbance at 280 nm was measured. The column temperature used 
was 30 oC.  
 
HPLC method 6: A Diacel Chiralpal® OD column (250 mm x 4.6 mm, 5 µM) 
was used with an isocratic n-hexane:isopropanol:diethylamine (90:10:0.1) mobile 
phase at 1 mL min-1. UV absorbance was measured at 280 nm. The column 
temperature used was 20 oC.250 
 
HPLC method 7: A Diacel Chiralpal® OD column (250 mm x 4.6 mm, 5 µM) 
was used with an isocratic n-hexane:isopropanol:diethylamine (95:5:0.1) mobile phase 
 279 
at 1 mL min-1. UV absorbance was measured at 280 nm. The column temperature used 
was 20 oC.250 
 
8.5.3 Semi-preparative HPLC 
Reversed-phase, semi-preparative HPLC was performed on a Dionex 580 HPLC 
machine with a PDA-100 photodiode array detector, P580 Pump, and a model ASI-100 
automated sample injector. The column used was a Phenomenex Onyx C18 (100 x 10 
mm). Water (0.1% TFA) and acetonitrile (0.1% TFA) were used as the mobile phase 
using a linear gradient of 5-95% acetonitrile over 36 min.  A flow rate of 2 mL min-1 was 
used with detection at 254 nm. 
 
8.5.4 Preparative HPLC 
Purification was performed using Agilent 1200 Infinity series liquid chromatography 
system equipped with G1361A prep pump, G2260A autosampler, G1364A fraction 
collector and G7165 multiple wavelength detector. A Supelco Discovery®BIO Wide 
Pore C18-10 column (25 cm x 21.2 mm, 10 µM) using MeCN and water as the mobile 
phase (both solvents contained 0.1% v/v TFA) as the mobile phase. UV absorbance 
was measured at 280 nm.  
HPLC method 8: 20-minute gradient 5-95% MeCN in water.  
HPLC method 9: 20-minute gradient 25-95% MeCN in water. 
HPLC method 10: 20-minute gradient 35-80% MeCN in water. 
HPLC method 11: 30-minute gradient 5-95% MeCN in water. 
HPLC method 12: 20-minute gradient 25-30% MeCN in water.  
 
8.5.5 GC analysis  
Samples were prepared at 10 mM in ethyl acetate and analysed using an Agilent 7820A 
Gas Chromatograph. 5 𝜇L of sample was injected onto a chiral column (Beta DEX 225, 
fused silica capillary column 30 m x 0.25 mm x 0.25 µm). A step gradient was used: 1, 
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40 oC for 1 min. 2, Ramp to 100 oC at 40 oC min-1. 3, Retained temperature at 100 oC 
for 8 min. 4, Increase temperature to 200 oC at a gradient of 40 oC min-1. 5, 200 oC for 
1 min. This method was devised by Helena Philpott.  
 
8.6 General chemical methods  
Silica column chromatography was performed using Geduran® Si 60 silica (43-60 𝜇M). 
Thin layer chromatography analysis was performed using plates with a silica gel matrix 
on an aluminium support. Ultraviolet light (254 nm) was used to visualise thin layer 
chromatography plates. All reagents were obtained from commercial sources (Sigma 
Aldrich, Fischer, ChemCruz, Alfa Aesar) unless otherwise specified.  
 
1H and 13C NMR spectra were obtained using Bruker Advance III 600 MHz and 700 
MHz spectrometers (as specified in the characterization data). Chemical shifts specified 
are relative to trimethylsilane (set at 0 ppm) and referenced to the residual, protonated 
NMR solvent. Coupling constants in 1H-NMR spectra (J) are given in Hertz (Hz) and 
described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m). Data processing 
was performed using the Bruker Topspin 4.0.8 software package.  
 
Mass spectrometry data was obtained using a Waters Aquity UPLC-MS system (LRMS 
[MS ES+]) or a Waters LCT Premier XE ESI Q-TOF mass spectrometer (HRMS). 
Infrared (IR) data was obtained using a Bruker Alpha Platinum-ATR machine. Optical 









8.7 Characterization of THIQs generated from enzymatic reactions 





An NCS-mediated reaction was performed using wild-type TfNCS (0.1 mg mL-1 final 
concentration) on a 10 mL, 10 mM scale, followed by workup method 5 and purification 
by preparative HPLC (method 8) to give the product as the TFA salt (16 mg, 45%). 1H-
NMR (600 MHz; D2O) 𝛿 7.55 - 7.46 (3H, m, 5’-H and 3’-H), 7.45 – 7.41 (2H, m, 4’-H), 
6.87 (1H, s, 8-H), 6.80 (1H, s, 5-H), 3.64 – 3.58 (2H, m, 3-HH or 1’-HH), 3.41 – 3.36 
(1H, m, 3-HH or 1’-HH), 3.24 – 3.17 (1H, m, 3-HH or 1’-HH), 3.14 - 3.00 (2H, m, 4-H2); 
13C-NMR (176 MHz; D2O) 𝛿	144.8 (C-6 or C-7), 143.5 (C-6 or C-7), 135.7, 130.1, 129.8, 
128.4, 124.4, 123.9, 116.4 (C-5), 114.5 (C-8), 56.7 (C-1), 39.8 (C-3 or C-1’), 39.3 (C-3 
or C-1’), 24.6 (C-4); m/z [ES+] 256 ([M+H]+, 100%); retention time (achiral analytical 




An NCS-mediated reaction was performed using wild-type TfNCS (0.1 mg mL-1 final 
concentration) on a 10 mL, 10 mM scale, followed by workup method 5 and purification 





























NMR (600 MHz; CD3OD) 𝛿 6.65 (1H, s, 8-H), 6.60 (1H, s, 5-H), 4.37 – 4.34 (1H, m, 1-
H), 3.53 – 3.48 (1H, m, 3-HH), 3.35 – 3.27 (1H, m, 3-HH), 3.02 – 2.95 (1H, m, 4-HH), 
2.90 (1H, dt, J = 17.1, 5.9 Hz, 4-HH), 2.08 – 2.00 (1H, m, 1’-H), 1.92 – 1.83 (1H, m, 1’-
H), 1.52 – 1.40 (4H, m, 2’-H and 3’-H), 0.99 (3H, t, J = 7.1 Hz, 4’-H); 13C-NMR (151 
MHz; CD3OD) 𝛿	146.5 (C-6 or C-7), 145.8 (C-6 or C-7), 124.2 (C-8a), 123.4 (C-5a), 
116.2 (C-5), 113.8 (C-8), 61.5 (C-1), 41.0 (C-3), 34.8 (C-1’), 28.6 (C-4), 25.7 (C-2’), 




An NCS-mediated reaction was performed using wild-type TfNCS (0.1 mg mL-1 final 
concentration) on a 10 mL, 10 mM scale, followed by workup method 5 and purification 
by preparative HPLC (method 8) to give the product as the TFA salt (17 mg, 53%). 1H-
NMR (600 MHz; CD3OD) 𝛿 6.64 (1H, s, 8-H), 6.60 (1H, s, 5-H), 4.63 (1H, s, 2-H), 4.34 
– 4.30 (1H, m, 1-H), 3.53 – 3.48 (1H, m, 3-HH), 3.34 – 3.26 (1H, m, 3-HH), 3.02 – 2.94 
(1H, m, 4-HH), 2.90 (1H, dt, J = 17.2, 5.9 Hz, 4-HH), 2.07 – 1.98 (1H, m, 1’-HH), 1.90 
– 1.82 (1H, m, 1’-HH), 1.55 – 1.34 (6H, m, 2’-H, 3’-H and 4’-H), 0.95 (3H, t, J = 6.9 Hz, 
5’-H), 1H-NMR (151 MHz; CD3OD) 𝛿 146.7 (C-6 or C-7), 145.9 (C-6 or C-7), 124.3 (C-
8a), 123.6 (C-5a), 116.2 (C-5), 113.8 (C-8), 56.7 (C-1), 41.0 (C-3), 35.1 (C-1’), 32.7 (C-
3’), 26.1 (C-4 or C-2’), 25.7 (C-4 or C-2’), 23.5 (C-4’), 14.3 (C-5’); m/z [ES+] 236 ([M+H]+, 
























An NCS-mediated reaction was performed using wild-type TfNCS (0.1 mg mL-1 final 
concentration) on a 10 mL, 10 mM scale, followed by workup method 6 and purification 
by preparative HPLC (method 8) to give the product as the TFA salt (3 mg, 10%). 1H-
NMR (600 MHz; CD3OD) 𝛿 6.62 (1H, s, 5-H or 8-H), 6.61 (1H, s, 5-H or 8-H), 4.42 – 
4.37 (1H, m, 1-H), 3.52 – 3.46 (1H, m, 3-HH), 3.35 – 3.29 (1H, m, 3-HH), 3.00 – 2.88 
(2H, m, 4-H2), 1.86 – 1.72 (3H, m, 1’-H and 2’-H), 1.07 (6H, t, J = 6.9 Hz, 3’-H); 13C-
NMR (150 MHz; CD3OD) 𝛿	146.6 (C-6 or C-7), 145.8 (C-6 or C-7), 124.7 (C-8a), 123.7 
(C-5a), 116.2 (C-5), 113.9 (C-8), 54.4 (C-1), 49.9 (C-1’), 40.2 (C-3), 25.7 (C-4), 23.5 (C-
2’), 22.0 (C-3’); m/z [ES+] 222 ([M+H]+, 100%).  
 
8.7.2 Products from NCS reactions with a-methyl and a-ethyl substituted 
aldehydes  
NCS-mediated reactions for product isolation were performed using wild-type TfNCS 
(0.1 mg mL-1 final concentration of purified enzyme) on a 10 mL, 10 mM scale followed 
by workup method 6 and purification by preparative HPLC (method 1). Products were 




The product was isolated as a white solid (11 mg, 34%).  [𝛼]D25 -0.103 (c = 0.69, MeOH); 
























(1H, s, 8-H), 6.80 (1H, s, 5-H), 4.41 (1H, d, J = 5.8 Hz, 1-H), 3.64 – 3.59 (1H, m, 3-HH), 
3.34 – 3.28 (1H, m, 3-HH), 3.07 – 3.00 (1H, m, 4-HH), 2.96 – 2.89 (1H, m, 4-HH), 2.56 
– 2.48 (1H, m, 1’-H), 1.14 (3H, d, J = 8.4 Hz, 2’-H), 0.88 (3H, d, J = 8.5 Hz, 2’-H); 13C-
NMR (176 MHz; D2O) 𝛿 144.4 (C-6 or C-7), 143.7 (C-6 or C-7), 125.4 (C-5a), 123.9 (C-
8a), 116.4 (C-5), 114.5 (C-8), 61.2 (C-1), 41.1 (C-3), 31.0 (C-1’), 24.8 (C-4), 19.0 (C-
2’); m/z [ES+] 208 ([M+H]+, 100%); m/z [HRMS ESI+] found [M+H]+ 208.1336; 
C12H27NO2 requires 208.1338; retention time (achiral analytical HPLC method 1) = 4.4 
min.  
 
 (S)-1-((R)-sec-Butyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (94)148 
 
The product was isolated as a white solid (12 mg, 37%). [𝛼]D25 0.017 (c = 0.32, MeOH); 
umax/ cm-1 (thin film): 3500-2500, 1670, 1615, 1527; 1H-NMR (700 MHz; D2O) 𝛿 6.79 
(1H, s, 8-H), 6.76 (1H, s, 5-H), 4.52 – 4.48 (0.95H, m, 1-H), 4.44 – 4.41 (0.05H, m, 1-
H), 3.61 – 3.55 (1H, m, 3-HH), 3.28 – 3.20 (1H, m, 3-HH), 3.01 (1H, m, 4-HH), 2.88 (1H, 
m, 4-HH), 2.27 (1H, m, 1’-H), 1.53 (1H, m, 2’-H), 1.42 (1H, m, 2’-H), 1.09 (0.18H, d, J = 
7.3 Hz, 1’’-H), 1.02 (2.9H, t, J = 8.6 Hz, 3’-H), 0.89 (0.2H, t, J = 8.4 Hz, 3’-H), 0.80 
(2.87H, d, J = 8.3 Hz, 3’-H); 13C-NMR (176 MHz; D2O) 𝛿 144.3 (C-6 or C-7), 143.8 (C-
6 or C-7), 125.7 (C-5a), 123.9 (C-8a), 116.3 (C-5), 114.1 (C-8), 59.8 (C-1), 41.7 (C-3), 
37.9 (C-1’), 26.4 (C-4), 24.9 (C-2’), 12.6 (C-1’’), 11.8 (C-3’); m/z [ES+] 222 ([M+H]+, 
100%); m/z [HRMS ES+] found [M+H]+ 222.1494; C13H20NO2 requires 222.1494; 
















(S)-1-((R)-Pentan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (95)148  
 
The product was isolated as a white solid (3.0 mg, 9.0%). [𝛼]D25 -0.017 (c = 0.20, 
MeOH); umax/ cm-1 (thin film): 3500-2800, 2965, 2875, 1670, 1613, 1528; 1H-NMR (700 
MHz; D2O) 𝛿 6.79 – 6.75 (1H, m, 8-H), 6.73 (1H, s, 5-H), 4.45 (0.8H, d, J = 4.2 Hz, 1-
H), 4.41 (0.2H, d, J = 3.7 Hz, 1-H), 3.55 - 3.51 (1H, m, 3-HH), 3.24 - 3.18 (1H, m, 3-
HH), 3.00 - 2.93 (1H, m, 4-HH), 2.86 - 2.80 (1H, m, 4-HH), 2.28 – 2.36 (1H, m, 1’-H), 
1.48 - 1.29 (3.6H, m, 2’-H and 3’-H), 1.19 - 1.09 (0.4H, m, 2’-H and 3’-H), 1.06 (0.7H, 
d, J = 6.8 Hz, 4’-H), 0.89 (2.3H, t, J = 7 Hz, 4’-H), 0.77 (3H, d, J = 7.2 Hz, 1’’-H); 13C-
NMR (176 MHz; D2O) 𝛿 144.3 (C-6 or C-7), 143.8 (C-6 or C-7), 125.6 (C-8a), 123.9 (C-
5a), 116.3 (C-5), 114.2 and 114.1 (C-8a), 61.2 and 60.0 (C-1), 41.6 and 41.5 (C-3), 
35.7 and 35.4 (C-1’), 24.9 (C-4), 20.5 and 20.4 (C-3’), 13.8 and 13.7 (C-1’’), 12.9 (C-
4’); m/z [ES+] 236 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 236.1644; 
C14H22NO2 requires 236.1644; retention time (achiral analytical HPLC method 1) = 5.6 
min.148 
 
 (S)-1-((R)-1-Phenylethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (96)148 
 
The product was isolated as a white solid (5.7 mg, 16%). [𝛼]D25 -0.011 (c = 0.12, MeOH); 
umax/ cm-1 (thin film): 3300-2500, 1672, 1610, 1538; 1H-NMR (700 MHz; D2O) 𝛿 7.38 – 
7.31 (2H, m, 4’-H), 7.30 – 7.27 (1H, m, 5’-H), 7.24 – 7.20 (2H, d, J = 7.0 Hz, 3’-H), 6.66 
(1H, s, 8-H), 6.34 (1H, s, 5-H), 4.58 (0.9H, d, J = 6.3 Hz, 1-H), 4.55 (0.1 H, d, J = 9.1 


























HH), 2.95 – 2.85 (1H, m, 4-HH), 2.85 – 2.79 (1H, m, 1’-H), 1.23 (3H, d, J = 7.0 Hz, 1’’-
H); 13C-NMR (176 MHz; D2O) 𝛿 144.6 (C-2’), 143.2 (C-6 or C-7), 141.2 (C-6 or C-7), 
129.6 (C-5a, C-8a or C-4’), 128.7 (C-5a, C-8a or C-4’), 128.3 (C-5a, C-8a or C-4’), 125.0 
(C-3’), 123.0 (C-5’), 116.1 (C-5), 114.9 (C-8), 61.1 (C-1), 41.9 (C-3), 40.1 (C-1’), 24.4 
(C-4), 14.1 (C-1’’); m/z [ES+] 270 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 
270.1488; C17H20NO2 requires 270.1489; retention time (achiral analytical HPLC 




The product was isolated as a white solid (15 mg, 47%). [𝛼]D25 +0.39 (c = 0.35, MeOH); 
umax/ cm-1 (thin film): 3200-2800, 2500-1900, 1714, 1614; 1H-NMR (700 MHz; D2O) 𝛿 
6.74 (1H, s, 8-H), 6.69 (1H, s, 5-H), 4.53 (1H, d, J = 3.4 Hz, 1-H), 3.52 - 3.46 (1H, m, 3-
HH), 3.22 - 3.15 (1H, m, 3-HH), 2.98 - 2.90 (1H, m, 4-HH), 2.84 - 2.77 (1H, m, 4-HH), 
1.95 - 1.88 (1H, m), 1.64 - 1.55 (1H, m), 1.29 - 1.20 (1H, m), 1.20 - 1.13 (1H, m), 1.13 
- 1.06 (1H, m), 0.94 (3H, t, J = 7.2 Hz, 3’-H), 0.77 (3H, t, J = 7.2 Hz, 3’-H); 13C-NMR 
(176 MHz; D2O) 𝛿	144.2 (C-6 or C-7), 143.0 (C-6 or C-7), 125.8 (C-8a), 124.0 (C-5a), 
116.3 (C-5), 114.1 (C-8), 57.8 (C-1), 44.8 (C-1’), 41.8 (C-3), 24.9 (C-4), 23.0 and 21.9 
(C-2’), 12.3 and 11.6 (C-3’); m/z [ES+] 236 ([M+H]+, 100%); m/z [HRMS ES+] found 
[M+H]+ 236.1649; C14H22NO2 requires 236.1651; retention time (achiral analytical 




















A solution of dopamine hydrochloride (18.9 mg, 0.1 mmol) and sodium ascorbate (19.8 
mg, 0.1 mmol) in HEPES buffer (50 mM, pH 7.5) was prepared. A solution of 2-(3,4-
dimethoxyphenyl)propanal (38.8 mg, 0.2 mmol) in acetonitrile (1 mL) was prepared and 
the two solutions mixed. D29TfNCS-M97V (2 mg at 10 mg mL-1 in 20 mM Tris, 50 mM 
NaCl, pH 7.5) was added and the reaction mixture stirred at 37 oC for 18 h. Once the 
reaction was completed (monitored by depletion of dopamine by HPLC method 1), 
workup method 5 was performed and the resulting residue purified by preparative-
HPLC (method 9) to isolate the pure product (as the TFA salt) as white solid (7.8 mg, 
18%) with a diastereomeric ratio of 95:5 (1S,1’R:1S:1’S)-119. [𝛼]D25 +15.2 (c = 0.71, 
MeOH); umax/ cm-1 (thin film): 2971, 2840, 1671, 1609, 1517; 1H-NMR (700 MHz, 
CD3OD) 𝛿 6.94 (1H, d, J = 8.4 Hz, 7’-H), 6.82 (1H, dd, J = 8.4 Hz, 1.9 Hz, 8’-H), 6.78 – 
6.75 (1H, m, 4’-H), 6.60 (1H, s, 5-H), 6.46 (1H, s, 8-H), 4.58 (1H, d, J = 6.1 Hz, 1-H), 
3.82 (3H, s, 9’-OCH3 or 10’-OCH3), 3.77 (3H, s, 9’- OCH3 or 10’- OCH3), 3.53 – 3.48 
(1H, m, 1-H), 3.42 – 3.37 (1H, m, 3-HH), 3.21 – 3.14 (1H, m, 3-HH), 2.92 – 2.82 (2H, 
m, 4-H), 1.31 (3H, d, J = 7.3 Hz, 2’-H);  13C-NMR (176 MHz, CD3OD) 𝛿 150.7 (C-5’), 
150.0 (C-6’), 146.8 (C-6 or C-7), 145.5 (C-6 or C-7), 134.5 (C-3’), 124.2 (C-5a), 122.5 
(C-8a), 121.4 (C-8’), 116.0 (C-5), 114.6 (C-8), 113.1 (C-7’ or C-4’), 113.0 (C-7’ or C-4’), 
61.9 (C-1), 56.3 (C-9’), 56.3 (C-10’), 43.1 (C-1’), 41.0 (C-3), 25.4 (C-4), 15.5 (C-2’), m/z 
[ES+] 330 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 330.1700; C19H24NO4 

























The same method was used as for the synthesis of 119, except 4-methoxytyramine (0.1 
mmol) was used as the phenethylamine substrate, rather than dopamine HCl (5). The 
product (TFA salt) was isolated by preparative HPLC (method 9) as a white solid (35.5 
mg, 81%) with a diastereomeric ratio of 92:8 of (1S,1’R:1S:1’S)-127. [𝛼]D25 +1.5 (c = 
2.2, MeOH); 	𝜈max/ cm-1 (thin film): 2919, 1674, 1608, 1516; 1H-NMR (600 MHz; CD3OD) 
𝛿 6.96 (1H, d, J = 8.3 Hz, 7’-H), 6.82 (1H, dd, J = 8.3, 2.0 Hz, 8’-H), 6.79 (1H, d, J = 2.0 
Hz, 4’-H), 6.63 (1H, s, 5-H), 6.20 (1H, s, 8-H), 4.85 (1H, d, J = 7.7 Hz, 1-H), 3.82 (3H, 
s, 9’- OCH3 or 10’- OCH3), 3.77 (3H, s, 9’- OCH3 or 10’- OCH3), 3.55 (3H, s, 7-OCH3), 
3.54 – 3.42 (2H, m, 1’-H and 3-HH), 3.30 – 3.25 (1H, m, 3-HH), 3.02 – 2.91 (2H, m, 4-
H), 1.38 (3H, d, J = 7.1 Hz, 2’-H); 13C-NMR (151 MHz; CD3OD) 𝛿 150.7 (C-5’ or C-6’), 
150.0 (C-5’ or C-6’), 147.8 (C-6 or C-7),147.7 (C-6 or C-7), 135.1 (C-3’), 125.4 (C-5a), 
122.8 (C-8a), 121.6 (C-8’), 116.0 (C-5), 113.5 (C-4’), 113.2 (C-7’), 111.7 (C-8), 61.9 (C-
1), 56.5 (OCH3), 56.5 (OCH3), 56.2 (OCH3), 43.5 (C-1’), 40.1 (C-3), 25.4 (C-4), 16.3 (C-
2’); m/z [ES+] 344 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 344.1862; 
C20H26NO4 requires 344.1856.  
 
8.7.3 Products from reactions with benzaldehydes 
Preparative scale reactions were performed on a 10 mL scale (10 mM amine, 20 mM 
aldehyde) using wild-type TfNCS (0.2 mg mL-1 final concentration of purified enzyme) 
























Purified by preparative HPLC (method 9) and isolated as a white solid (18 mg, 52%). 
mp > 250 oC (H2O); [a]D25 8.2 (c 0.38, MeOH); 𝜈max/ cm-1 (thin film): 3354, 2933, 2835, 
1622, 1530; 1H-NMR (700 MHz; D2O) 𝛿 6.73 (1H, s, 5-H or 8-H), 6.71 (1H, s, 5-H or 8-
H), 4.26 (1H, d, J = 5.0 Hz, 1-H), 3.54 – 3.48 (1H, dt, J = 12.3, 5.3 Hz, 3-HH), 3.25 – 
3.19 (1H, m, 3-HH), 2.97 – 2.90 (1H, m, 4-HH), 2.84 (1H, dt, J = 16.8, 5.3 Hz, 4-HH), 
2.04 – 1.98 (1H, m, 1’-H), 1.78 – 1.73 (1H, m), 1.71 – 1.66 (2H, m), 1.65 – 1.61 (1H, 
m), 1.48 – 1.43 (1H, m), 1.29 – 1.05 (4H, m), 0.97 (1H, qd, J = 12.6, 3.6 Hz); 13C-NMR 
(176 MHz; CD3OD) 𝛿 147.0 (C-6 or C-7), 145.9 (C-6 or C-7), 138.8 (C-1’ or C-6’), 136.3 
(C-1’ or C-6’), 132.2 (C-4’), 130.7 (C-5’), 130.3 (C-2’), 128.0 (C-3’), 124.2 (C-5a or C-
8a), 123.8 (C-5a or C-8a), 115.9 (C-5), 114.9 (C-8), 57.2 (C-1), 42.0 (C-3), 25.6 (C-4), 
19.3 (C-7’); m/z [ES+] 248 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 248.1645; 





Purified by preparative HPLC (method 9) and isolated as a white solid (17 mg, 51%). 
mp > 250 oC (H2O); [a]D25 6.5 (c 0.37, MeOH); 𝜈max/ cm-1 (thin film): 3033, 2852, 1668, 


























(2H, m, 2’-H), 6.81 (1H, s, 8-H), 6.34 (1H, s, 5-H), 5.63 (1H, s, 1-H), 3.50 – 3.39 (2H, 
m, 3-H), 3.10 – 3.04 (2H, m, 4-H); 13C-NMR (176 MHz, D2O) 𝛿 147.1 (C-6 or C-7), 145.9 
(C-6 or C-7), 138.0 (C-1’), 130.8 (C-2’), 130.8 (C-3’), 130.2 (C-4’), 124.2 (C-5a), 123.1 
(C-8a), 115.8 (C-8), 115.2 (C-5), 60.9 (C-1), 41.4 (C-3), 25.5 (C-4); m/z [ES+] 242 
([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 242.1176; C15H15NO2 requires 




Purified by preparative HPLC (method 9) and isolated as a white solid (8.7 mg, 25%); 
[a]D25 8.8 (c 0.43, MeOH); 𝜈max/ cm-1 (thin film): 3024, 2818, 1663, 1609, 1526; 1H-NMR 
(700 MHz; CD3OD) 𝛿 7.38 – 7.30 (2H, m, 4’-H and 5’-H), 7.29 – 7.24 (1H, m, 3’-H), 7.10 
(1H, d, J = 7.8 Hz, 2’-H), 6.68 (1H, s, 5-H), 6.08 (1H, s, 8-H), 5.80 (1H, s, 1’-H), 3.56 – 
3.47 (2H, m, 3-H), 3.21 – 3.15 (1H, m, 4-HH), 3.04 – 2.97 (1H, dt, J = 17.2, 5.3 Hz, 4-
HH), 2.51 (3H, s, 7’-H);  13C-NMR (176 MHz; CD3OD) 𝛿 147.0 (C-6 or C-7), 145.9 (C-6 
or C-7), 138.8 (C-1’ or C-6’), 136.3 (C-1’ or C-6’), 132.2 (C-4’), 130.7 (C-5’), 130.3 (C-
2’), 128.0 (C-3’), 124.2 (C-5a or C-8a), 123.8 (C-5a or C-8a), 115.9 (C-5), 114.9 (C-8), 
57.2 (C-1), 42.0 (C-3), 25.6 (C-4), 19.3 (C-7’); m/z [ES+] 256 ([M+H]+, 100%); m/z 
[HRMS ES+] found [M+H]+ 256.1331; C16H18NO2 requires 256.1332; retention time 





















(1S)-1-(m-Tolyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (159)149  
 
Purified by preparative HPLC (method 9) and isolated as a white solid (4.3 mg, 12%). 
[a]D25 6.1 (c 0.18, MeOH); 𝜈max/ cm-1 (thin film): 3436, 2977, 2809, 1665, 1607, 1527; 
1H-NMR (700 MHz; CD3OD) 𝛿 7.36 (1H, t, J = 7.7 Hz, 5’-H), 7.29 (1H, d, J = 7.7 Hz, 4’-
H), 7.18 (1H, s, 2’-H), 7.15 (1H, d, J = 7.7 Hz, 6’-H), 6.68 (1H, s, 5-H), 6.19 (1H, s, 8-
H), 5.51 (1H, s, 1-H), 3.50 – 3.45 (1H, m, 3-HH), 3.43 – 3.38 (1H, m, 3-HH), 3.17 – 3.11 
(1H, m, 4-HH), 3.00 (1H, dt, J = 17.2, 5.3 Hz, 4-HH), 2.37 (3H, s, 7’-H); 13C-NMR (176 
MHz; CD3OD) 𝛿 147.1 (C-6 or C-7), 145.8 (C-6 or C-7), 140.3 (C-1’ or C-3’), 138.0 (C-
1’ or C-3’), 131.5 (C-4’), 131.2 (C-2’), 130.1 (C-3’), 127.8 (C-6’), 124.2 (C-5a or C-8a), 
123.2 (C-5a or C-8a), 115.8 (C-5), 115.2 (C-8), 60.9 (C-1), 41.4 (C-3), 25.6 (C-4), 21.2 
(C-7’); m/z [ES+] 256 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 256.1332; 
C16H18NO2 requires 256.1332; retention time (achiral analytical HPLC method 1): 5.3 
min.  
 
(1S)-1-(p-Tolyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (160)149  
 
Purified by preparative HPLC (method 9) and isolated as a white solid (3.8 mg, 11%). 
[a]D25 1.3 (c 0.091, MeOH); 1H-NMR (700 MHz; CD3OD) 𝛿 7.29 (2H, d, J = 8.0 Hz, 3’-
H), 7.23 (2H, d, J = 8.0 Hz, 2’-H), 6.67 (1H, s, 5-H), 6.19 (1H, s, 8-H), 5.51 (1H, s, 1’-





























3.99 (1H, dt, J = 17.2, 5.5 Hz, 4-HH), 2.37 (3H, s, 5’-H); 13C-NMR (176 MHz; CD3OD) 
𝛿 147.0 (C-6 or C-7), 145.8 (C-6 or C-7), 141.1 (C-4’), 135.1 C-1’), 130.8 (C-3’), 130.6 
(C-2’), 124.2 (C-5a), 123.4 (C-8a), 115.8 (C-5), 115.2 (C-8), 60.7 (C-1), 41.3 (C-3), 25.6 
(C-4), 21.1 (C-5’); m/z [ES+] 256 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 
256.1331; C16H18NO2 requires 256.1332; retention time (achiral analytical HPLC 




Purified by preparative HPLC (method 9) and isolated as a white solid (11 mg, 31%). 
[a]D25 -5.2 (c 0.23, MeOH); 𝜈max/ cm-1 (thin film): 3116, 2317, 1670, 1611, 1529; 1H-NMR 
(700 MHz; CD3OD) 𝛿 7.52 (1H, d, J = 5.3 Hz, 3’-H), 7.31 – 7.24 (2H, m, 3’-H and 4’-H), 
7.19 (1H, d, J = 7.3 Hz, 6’-H), 6.70 (1H, s, 5-H), 6.20 (1H, s, 8-H), 5.87 (1H, s, 1-H), 
3.46 (2H, app.t, J = 6.1 Hz, 3-H), 3.16 – 3.09 (1H, m, 4-HH), 3.02 (1H, dt, J = 17.2, 5.5 
Hz, 4-HH); 13C-NMR (176 MHz; CD3OD) 𝛿 162.4 (d, 1JCF = 248 Hz, C-2’), 147.2 (C-6 or 
C-7), 146.0 (C-6 or C-7), 133.2 (d, JCF = 8.4 Hz, C-6’), 132.5 (d, JCF = 2.1 Hz, C-1’), 
126.1 (d, JCF = 3.5 Hz, C-4’), 125.0 (d, 3JCF = 12 Hz, C-5’), 124.4 (C-5a), 121.9 (C-8a), 
117.1 (d, 2JCF = 21 Hz, C-3’), 116.0 (C-5), 114.6 (C-8), 54.0 (C-1), 41.4 (C-3), 25.5 (C-
4); m/z [ES+] 260 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 260.1081; 






















Purified by preparative HPLC (method 9) and isolated as a white solid (11.0 mg, 31%); 
[a]D25 -2.9 (c 0.41, MeOH); 𝜈max/ cm-1 (thin film): 3072, 2558, 2324, 1667, 1612, 1592, 
1519; 1H-NMR (700 MHz; CD3OD) 𝛿 7.51 (1H, dd, J = 5.8 Hz, 5’-H), 7.25 – 7.18 (2H, 
m, 4’-H and 6’-H), 7.13 (1H, d, J = 9.2 Hz, 2’-H), 6.69 (1H, s, 5-H), 6.20 (1H, s, 8-H), 
5.62 (1H, s, 1-H), 3.52 – 3.37 (2H, m, 3-H), 3.18 – 3.09 (1H, m, 4-HH), 3.04 – 2.96 (1H, 
m, 4-HH); 13C-NMR (176 MHz; CD3OD) 𝛿 165.0 (d, 1JCF = 245 Hz, C-3’), 147.3 (C-6 or 
C-7), 145.9 (C-6 or C-7), 140.5 (d,  JCF = 7.0 Hz, C-1’), 132.1 (d, JCF = 8.3 Hz, C-5’), 
126.8 (d, JCF = 2.8 Hz, C-6’), 124.3 (C-5a), 122.6 (C-8a), 117.7 (dd, 2JCF = 21.9, 4.8 Hz, 
C-2’), 115.9 (C-5), 115.1 (C-8), 60.1 (C-1), 41.4 (C-3), 25.5 (C-4); m/z [ES+] 260 
([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 260.1081; C15H15FNO2 requires 
260.1081; retention time (achiral analytical HPLC method 1): 5.0 min.  
 
 (1S)-1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (163)149 
 
Purified by preparative HPLC (method 9) and isolated as a white solid (10 mg, 29%). 
[a]D25 -5.4 (c 0.46, MeOH); 𝜈max/ cm-1 (thin film): 3112, 2819, 1668, 1606, 1560, 1532, 
1508; 1H-NMR (700 MHz; CD3OD) 𝛿 7.43 – 7.37 (2H, m, 2’-H), 7.25 – 7.18 (2H, m, 3’-
H), 6.69 (1H, s, 5-H), 6.19 (1H, s, 8-H), 5.61 (1H, s, 1-H), 3.49 – 3.44 (1H, m, 3-HH), 





























HH); 13C-NMR (176 MHz; CD3OD) 𝛿 164.7 (d, 1JCF = 251 Hz, C-4’), 147.2 (C-6 or C-7), 
145.9 (C-6 or C-7), 134.1 (d, JCF = 3.1 Hz, C-1’), 133.1 (d, JCF = 8.5 Hz, C-2’), 124.3 (C-
5a), 122.9 (C-8a), 117.0 (d, 2JCF = 23 Hz, C-3’), 115.7 (C-5), 115.1 (C-8), 60.0 (C-1), 
41.2 (C-3), 25.5 (C-4); m/z [ES+] 260 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 
260.1081; C15H15FNO2 requires 260.1081; retention time (achiral analytical HPLC 




Purified by preparative HPLC (method 9) and isolated as a white solid (13 mg, 35%). 
[a]D25 2.0 (c 0.12, MeOH); 𝜈max/ cm-1 (thin film): 2995, 2816, 2580, 1663, 1609, 1528; 
1H-NMR (700 MHz; CD3OD) 𝛿 7.61 (1H, dd, J = 8.1, 1.1 Hz, 3’-H), 7.48 (1H, td, J = 7.7, 
1.6 Hz), 7.39 (1H, td, J = 7.7, 1.1 Hz, 5’-H or 4’-H), 7.19 (1H, dd, J = 7.7, 1.6 Hz), 6.70 
(1H, s, 5-H), 6.14 (1H, s, 8-H), 6.04 (1H, s, 1-H), 3.50 – 3.43 (2H, m, 3-H), 3.11 (1H, dt, 
J = 17.3, 6.4 Hz, 4-HH), 3.05 – 3.00 (1H, J = 17.3, 6.2 Hz, 4-HH); 13C-NMR (176 MHz, 
CD3OD) 𝛿 147.3 (C-6 or C-7), 146.2 (C-6 or C-7), 135.8 (C-1’ or C-2’), 135.6 (C-1’ or 
C-2’), 132.6 (C-6’ or C-5’), 132.5 (C-6’ or C-5’), 131.3 (C-3’), 129.0 (C-4’), 124.5 (C-5a), 
122.1 (C-8a), 115.9 (C-5), 114.7 (C-8), 56.9 (C-1), 41.2 (C-3), 25.5 (C-4); m/z [ES+] 
276 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 276.0786; C15H15ClNO2 requires 






















Purified by preparative HPLC (method 9) and isolated as a white solid (5.2 mg, 14%). 
[a]D25 1.5 (c 0.015, MeOH); 𝜈max/ cm-1 (thin film): 3028, 2820, 2343, 2228, 1664, 1604, 
1528; 1H-NMR (700 MHz; CD3OD) 𝛿 7.52 – 7.45 (2H, m, 4’-H and 5’-H), 7.41 (1H, s, 2’-
H), 7.30 (1H, d, J = 7.7 Hz, 6’-H), 6.69 (1H, s, 8-H), 6.19 (1H, s, 5-H), 5.60 (1H, s, 1-H), 
3.51 – 3.38 (2H, m, 3-H), 3.17 – 3.10 (1H, m, 4-HH), 3.01 (1H, dt, J = 17.2, 5.5 Hz, 4-
HH); 13C-NMR (176 MHz; CD3OD) 𝛿 147.3 (C-6 or C-7), 146.0 (C-6 or C-7), 140.2 (C-
1’), 136.1 (C-3’), 131.8 (C-4’), 130.9 (C-2’ or C-5’), 130.8 (C-2’ or C-5’), 129.3 (C-6’), 
124.3 (C-5a), 122.4 (C-8a), 115.9 (C-5), 115.0 (C-8), 60.1 (C-1), 41.4 (C-3), 25.5 (C-4); 
m/z [ES+] 276 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 276.0786; C15H15ClNO2 
requires 276.0786; retention time (achiral analytical HPLC method 1): 5.4 min.  
 
(S)-1-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.TFA (166)149  
 
Purified by preparative HPLC (method 9) and isolated as a white solid (6.9 mg, 19%). 
[a]D25 1.1 (c 0.29, MeOH); 𝜈max/ cm-1 (thin film): 3166, 3102, 2772, 2634, 2556, 1800, 
1670, 1610, 1589, 1535; 1H-NMR (700 MHz; CD3OD) 𝛿 7.49 (2H, d, J = 8.5 Hz, 3’-H), 
7.35 (2H, d, J = 8.5 Hz, 2’-H), 6.68 (1H, s, 5-H), 6.18 (1H, s, 8-H), 5.59 (1H, s, 1-H), 
3.49 – 3.37 (2H, m, 3-H), 2.16 – 3.01 (1H, m, 4-HH), 3.00 (1H, dt, J = 17.2, 5.5 Hz, 4-




























1’), 136.8 (C-4’), 132.5 (C-2’), 130.3 (C-3’), 124.3 (C-5a), 122.7 (C-8a), 115.9 (C-5), 
115.1 (C-8), 60.0 (C-1), 41.2 (C-3), 25.5 (C-4); m/z [ES+] 276 ([M+H]+, 100%); m/z 
[HRMS ES+] found [M+H]+ 276.0786; C15H15ClNO2 requires 276.0786; retention time 




Synthesised from NCS mediated reaction between 4-methoxytyramine hydrochloride 
and cyclohexanecarboxaldehyde. Purified by preparative HPLC (method 9) and 
isolated as a white solid (8.4 mg, 32%). [a]D26 -1.1 (c 0.29, MeOH); 𝜈max/ cm-1 (thin film): 
2971, 2853, 2165, 2033, 1677, 1517; 1H-NMR (700 MHz; CD3OD) 𝛿 6.76 (1H, s, 8-H), 
6.65 (1H, s, 5-H), 4.31 (1H, d, J = 5.6 Hz, C-1), 3.83 (3H, s, OCH3), 3.53 (1H, dt, J = 
12.3, 5.6 Hz, 3-HH), 3.28 – 3.22 (1H, m, 3-HH), 3.01 – 2.95 (1H, m, 4-HH), 2.88 (1H, 
dt, J = 16.9, 5.3 Hz, 4-HH), 2.12 – 2.06 (1H, m, 1’-H), 1.89 – 1.84 (1H, m), 1.83 – 1.71 
(3H, m), 1.59 – 1.54 (1H, m), 1.43 – 1.35 (1H, qt, J = 12.8, 3.6 Hz), 1.35 – 1.26 (1H, 
m), 1.26 – 1.18 (1H, m), 1.10 (1H, qd, J = 12.6, 3.6 Hz); 13C-NMR (176 MHz; CD3OD) 
𝛿 148.3 (C-6 or C-7), 147.7 (C-6 or C-7), 125.9 (C-8a), 122.6 (C-5a), 116.2 (C-5), 111.0 
(C-8), 61.5 (C-1), 56.5 (OCH3), 41.9 (C-1’), 41.2 (C-3), 30.9 (C-2’, C-3’ or C-4’), 27.8 
(C-2’, C-3’ or C-4’), 27.2 (C-2’, C-3’ or C-4’), 27.0 (C-2’, C-3’ or C-4’), 26.9 (C-2’, C-3’ 
or C-4’), 25.5 (C-4); m/z [ES+] 262 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 




















Synthesised from NCS mediated reaction between 4-methoxytyramine hydrochloride 
and benzaldehyde. Purified by preparative HPLC (method 9) and isolated as white solid 
(12 mg, 24%). [a]D26 -2.0 (c 0.35, MeOH); 𝜈max/ cm-1 (thin film): 2925, 2853, 1631, 1515; 
1H-NMR (700 MHz; CD3OD) 𝛿 7.49 – 7.47 (3H, m, 2’-H and 4’-H), 7.38 – 7.35 (2H, m, 
3’-H), 6.73 (1H, s, 5-H), 6.31 (1H, s, 8-H), 5.67 (1H, s, 1-H), 3.61 (3H, s, OCH3), 3.49 – 
3.39 (2H, m, 3-H), 3.17 – 3.12 (1H, m, 4-HH), 3.07 – 3.01 (1H, m, 4-HH); 13C-NMR (176 
MHz; CD3OD) 𝛿 148.5 (C-6 or C-7), 148.2 (C-6 or C-7), 137.9 (C-1’), 130.9 (C-2’ or C-
3’), 130.9 (C-2’ or C-3’), 130.3 (C-4’), 125.8 (C-5a), 122.8 (C-8a), 115.9 (C-5), 111.7 
(C-8), 60.6 (C-1), 56.2 (OCH3), 40.7 (C-3), 25.5 (C-4); m/z [ES+] 256 ([M+H]+, 100%)); 




Purified by preparative HPLC (method 9) and isolated as a white solid (11 mg, 20%). 
[a]D26 +5.5 (c 0.31, MeOH); 𝜈max/ cm-1 (thin film): 3068, 2323, 1666, 1613, 1591, 1529; 
1H-NMR (700 MHz; CD3OD) 𝛿 7.49 – 7.46 (3H, m, 3’-H and 4’-H), 7.37 – 7.33 (2H, m, 
2’-H), 6.72 (1H, s, 5-H), 6.65 – 6.63 (2H, m, 7-H and 8-H), 5.64 (1H, s, 1-H), 3.52 – 3.42 
(2H, m, 3-H), 3.25 – 3.19 (1H, m, 4-HH), 3.10 (1H, dd, J = 17.6, 8.7 Hz, 4-HH); 13C-
NMR (176 MHz; CD3OD) 𝛿 158.7 (C-6), 137.9 (C-8a), 134.5 (C-5a), 130.9, 130.7, 

























3), 26.2 (C-4); m/z [ES+] 226 ([M+H]+, 100%)); m/z [HRMS ES+] found [M+H]+ 
226.1226; C15H16NO requires 226.1226; retention time (achiral analytical HPLC method 
1): 5.8 min.  
 
8.7.4 Products from NCS mediated reactions with N-methyl dopamine 
Preparative scale reactions were performed on a 10 mL scale (10 mM amine, 20 mM 
aldehyde) using wild-type TfNCS (0.2 mg mL-1 final concentration of purified enzyme) 
for 18 h. Workup method 5 was used followed by preparative HPLC purification (method 





The product was isolated as a white solid (4.1 mg, 15%).	𝜈max/ cm-1 (thin film): 3037, 
2756, 1673, 1612, 1530; 1H-NMR (700 MHz; D2O) 𝛿 7.39-7.33 (3H, m, 5’-H and, 3’-H 
or 4’-H), 7.17 (2H, m, 3’-H or 4’-H), 6.76 (1H, s, 8-H), 6.17 (1H, s, 5-H), 4.58 (1H, t, J = 
7.7 Hz, 1-H), 3.70 (1H, m, 1’-H), 3.38 - 3.28 (2H, m, 4-H), 3.20 (1H, m, 1’-H), 3.05 (1H, 
m, 3-HH), 2.97 (1H, m, 3-HH), 2.88 (3H, s, 2-H); 13C-NMR (176 MHz; D2O) 𝛿 145.0 (C-
6 or C-7), 143.2 (C-6 or C-7), 135.3 (C-2’), 130.5, 130.3, 129.6, 129.4, 128.4, 122.5, 
121.5, 116.3, 116.0 (C-8), 115.9 (C-5), 65.3 (C-1), 47.2 (C-3), 45.5 (C-2), 40.4 (C-1’), 
21.0 (C-4); m/z [ES+] 270 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 270.1495, 





















The product was isolated as a white solid (3.3 mg, 14%).	𝜈max/ cm-1 (thin film): 3184, 
2957, 2869, 2724, 1619, 1526; 1H-NMR (700 MHz; D2O) 𝛿 6.62 – 6.52 (2H, m, 5-H and 
8-H), 4.15 – 4.06 (1H, m, 1-H), 3.59 - 3.49 (0.8H, m, 3-HH or 4-HH), 3.37 - 3.33 (0.5H, 
m, 3-HH or 4-HH), 3.19 – 3.13 (0.8H, m, 3-HH or 4-HH), 2.91 – 2.78 (2H, m, 3-HH or 
4-HH), 2.73 (3H, m, 2-H), 1.80 – 1.61 (2H, m, 1’-H), 1.27 – 1.13 (4H, m, 2’-H and 3’-H), 
0.74 – 0.69 (3H, m, 4’-H); 13C-NMR (176 MHz, D2O) 𝛿 144.8 (C-6), 143.7 (C-7), 123.0 
(C-8a), 122.6 (C-5a), 116.3 (C-5), 115.4 (C-8), 64.7 (C-1), 46.4 (C-3), 40.5 (C-2), 34.6 
(C-1’), 27.3 (C-4), 22.4 (C-3), 13.5 (C-4’); m/z [ES+] 236 ([M+H]+, 100%); m/z [HRMS 
ES+] found [M+H]+ 236.1646; C14H22NO2 requires 236.1645; retention time (achiral 




The product was isolated as a white solid (2.1 mg, 8.4%).	𝜈max/ cm-1 (thin film): 3141, 
2954, 2930, 2859, 2726, 1616, 1526; 1H-NMR (700 MHz; D2O) 𝛿 6.71 (1H, s, 8-H), 6.67 
– 6.62 (1H, m, 5-H), 4.25 – 4.16 (1H, m, 1-H), 3.66 – 3.60 (0.8H, m, 3-HH or 4-HH), 
3.48 - 3.43 (0.5H, m, 3-HH or 4-HH), 3.29 – 3.24 (0.8H, m, 3-HH or 4-HH), 3.03 – 2.89 
(2H, m, 3-HH or 4-HH), 2.84 (3H, s, 2-H), 1.91 – 1.68 (2H, m, 1’-H), 1.39 – 1.18 (6H, 
m, 2’-H, 3’-H and 4’-H), 0.82 – 0.76 (3H, m, 5’-H); 13C-NMR (176 MHz; D2O) 𝛿 144.8 
(C-6), 143.6 (C-7), 123.0 (C-8a), 122.6 (C-5a), 116.3 (C-5), 115.4 (C-8), 64.7 (C-1), 































[ES+] 250 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 250.1804; C15H24NO2 




The product was isolated as a white solid (2.8 mg, 10%).	𝜈max/ cm-1 (thin film): 3124, 
2953, 2925, 2854, 2715, 2641, 1619, 1525; 1H-NMR (700 MHz; D2O) 𝛿 6.72 (1H, s, 8-
H), 6.67 – 6.64 (1H, m, 5-H), 4.25 – 4.18 (1H, m, 1-H), 3.67 – 3.61 (0.8H, m, 3-HH or 
4-HH), 3.47 - 3.42 (0.5H, m, 3-HH or 4-HH), 3.28 – 3.23 (0.8H, m, 3-HH or 4-HH), 3.02 
– 2.89 (2H, m, 3-HH or 4-HH), 2.85 – 2.81 (3H, s, 2-H), 1.92 – 1.71 (2H, m, 1’-H), 1.37 
– 1.11 (10H, m, 2’-H, 3’-H, 4’-H, 5’-H and 6’-H), 0.76 (3H, t, J = 7.0 Hz, 7’-H); 13C-NMR 
(176 MHz, D2O) 𝛿 144.8 (C-6), 143.6 (C-7), 123.0 (C-8a), 122.8 (C-5a), 116.3 (C-5), 
115.5 (C-8), 64.8 (C-1), 46.4 (C-3), 40.6 (C-2), 34.7 (C-1’), 31.4 (C-4), 28.8 (C-2’), 28.5 
(C-3’), 24.9 (C-4’), 22.5 (C-5’), 21.8 (C-6’), 13.9 (C-7’); m/z [ES+] 278 ([M+H]+, 100%); 
m/z [HRMS ES+] found [M+H]+ 278.2119; C17H28NO2 requires 278.2115; retention time 




The product was isolated as a white solid (5.3 mg, 23%).	𝜈max/ cm-1 (thin film): 3301, 
3105, 2954, 2693, 2637, 1641, 1610, 1525; 1H-NMR (700 MHz; D2O) 𝛿 6.73 (1H, s, 8-
H), 6.68 – 6.63 (1H, m, 5-H), 5.86 – 5.77 (1H, m, H-3’), 5.12 – 5.03 (2H, m, 5.12 – 5.03), 

































HH or 4-HH), 3.31 – 3.19 (1H, m, 3-HH or 4-HH), 3.04 – 2.87 (2H, m, 3-HH or 4-HH), 
2.14 – 2.09 (2H, m, 2’-H), 2.05 – 1.78 (2H, m, 1’-H); 13C-NMR (176 MHz; D2O) 𝛿 144.9 
(C-6), 143.6 (C-7), 137.4 (C-3’), 122.6 (C-8a), 122.5 (C-5a), 116.6 (C-4’ or C-5), 116.4 
(C-4’ or C-5) 115.5 (C-8), 63.9 (C-1), 46.2 (C-3), 40.4 (C-2), 34.3 (C-1’), 29.4 (C-4), 
21.4 (C-2’); m/z [ES+] 234 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 234.1480; 
C14H20NO2 requires 234.1489; retention time (achiral analytical HPLC method 1) = 4.9 
min. 
 
8.7.5 Products from methyltransferase reactions  
(1S)-1-Cyclohexyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol.TFA (171)149 
 
171 was generated using MxSafC as the methyltransferase on a 10 mL, 5 mM scale. 
Purified by preparative HPLC method 10 and analysed by chiral HPLC method 5. The 
product was isolated as a white solid (4.4 mg, 25%).	[a]D25 1.1 (c 0.022, MeOH); 𝜈max/ 
cm-1 (thin film): 2930, 2855, 1670, 1614, 1516; 1H-NMR (700 MHz; CD3OD) 𝛿 6.77 (1H, 
s, 5-H), 6.68 (1H, s, 8-H), 4.28 (1H, d, J = 5.2 Hz, 1-H), 3.84 (1H, s, OCH3), 3.56 – 3.51 
(1H, m, 3-H), 3.30 – 3.26 (1H, m, 3-H), 3.06 – 2.99 (1H, m, 4-HH), 2.93 (1H, dt, J = 
16.8, 5.3 Hz, 4-HH), 2.08 – 2.02 (1H, m, 1’-H), 1.89 – 1.83 (1H, m), 1.83 – 1.71 (3H, 
m), 1.59 – 1.53 (1H, m), 1.42 – 1.34 (1H, m), 1.34 – 1.26 (1H, m), 1.22 (2H, qd, J = 
12.6, 3.4 Hz); 13C-NMR (176 MHz; CD3OD) 𝛿 149.0 (C-6 or C-7), 146.8 (C-6 or C-7), 
124.3 (C-5a or C-8a), 123.0 (C-5a or C-8a), 114.1 (C-8), 112.6 (C-5), 61.3 (C-1), 56.3 
(OCH3), 41.9 (C-1’), 41.5 (C-3). 30.9 (C-2’, C-3’ or C-4’), 27.6, (C-2’, C-3’ or C-4’) 27.2 
(C-2’, C-3’ or C-4’), 27.0 (C-2’, C-3’ or C-4’), 25.7 (C-4); m/z [ES+] 262 ([M+H]+, 100%); 
m/z [HRMS ES+] found [M+H]+ 262.1802; C16H23NO2 requires 262.1802; retention time 















(1S)-6-Methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-7-ol.TFA (172)149  
 
C6-OMe-172 was generated using RnCOMT as the methyltransferase on a 5 mL, 10 
mM scale. 87:13 ratio of C6-OMe-172:C7-OMe-174 was generated. Purified by 
preparative HPLC method 10 analysed by chiral HPLC method 5. The product was 
isolated as a white solid (3.9 mg, 22%).	 𝜈max/ cm-1 (thin film): 2932, 2855, 2801, 2582, 
1664, 1514; 1H-NMR (700 MHz; CD3OD) 𝛿 7.51 – 7.45 (3H, m, 3’-H and 4’-H), 7.38 – 
7.33 (2H, m, 2’-H), 6.84 (0.9H, s, 5-H), 6.74 (0.1H, s, 5-H), 6.31 (0.1H, s, 8-H), 6.21 
(0.9H, s, 8-H), 5.66 (0.1H, s, 1-H), 5.60 (0.9H, s, 1-H), 3.87 (2.7H, s, OCH3), 3.62 (0.3H, 
s, OCH3), 3.53 – 3.39 (2H, m, 3-H), 3.24 – 3.01 (2H, m, 4-H); 13C-NMR (176 MHz, 
CD3OD) 𝛿 149.5 (C-6 or C-7), 146.9 (C-6 or C-7), 137.8 (C-1’), 130.9 (C-2’ or C-3’), 
130.8 (C-2’ or C-3’), 130.3 (C-4’), 124.4 (C-5a or C-8a), 124.2 (C-5a or C-8a), 115.1 (C-
8), 112.3 (C-5), 60.7 (C-1), 56.3 (OCH3), 41.2 (C-3), 25.7 (C-4); m/z [ES+] 256 ([M+H]+, 
100%); m/z [HRMS ES+] found [M+H]+ 256.1332; C16H18NO2 requires 256.1332; 
retention time (achiral analytical HPLC method 1): 5.7 min.  
 
(1S)-6-Methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-7-ol.TFA (172)149  
 
(157)  was generated using MxSafC as the methyltransferase on a 5 mL, 10 mM scale. 
Purified by preparative HPLC method 10 analysed by chiral HPLC method 5. The 


























cm-1 (thin film): 2932, 2855, 2801, 2582, 1664, 1514; 1H-NMR (700 MHz; CD3OD) 𝛿 
7.50 – 7.45 (3H, m, 3’-H and 4’-H), 7.38 – 7.32 (2H, m, 2’-H), 6.85 (1H, s, 5-H), 6.21 
(1H, s, 8-H), 5.60 (1H, s, 1-H), 3.87 (3H, s, OCH3), 3.52 – 3.47 (1H, m, 3-HH), 3.47 – 
3.41 (1H, m, 3-HH), 3.23 - 3.17 (1H, m, 4-HH), 3.07 (1H, dt, J = 17.2, 5.5 Hz, 4-HH); 
13C-NMR (176 MHz; CD3OD) 𝛿 149.5 (C-6 or C-7), 146.9 (C-6 or C-7), 137.8 (C-1’), 
130.9 (C-2’ or C-3’), 130.8 (C-2’ or C-3’), 130.3 (C-4’), 124.4 (C-5a or C-8a), 124.2 (C-
5a or C-8a), 115.1 (C-8), 112.3 (C-5), 60.7 (C-1), 56.3 (OCH3), 41.2 (C-3), 25.7 (C-4); 
m/z [ES+] 256 ([M+H]+, 100%), 257); m/z [HRMS ES+] found [M+H]+ 256.1332; 






An NCS-mediated reaction between dopamine HCl and 2-(3,4-
dimethoxyphenyl)propanal was performed as detailed in the standard procedure, 
followed by lyophilisation. The residue was resuspended in buffer (4 mL, 250 mM 
HEPES, 200 mM MgCl2, 2 M KCl, pH 7.5). ATP (2 mL, 100 mM in dH2O), L-methionine 
(2 mL, 100 mM in dH2O), EcMAT (888 µL, at 9 mg mL-1 purified in 50 mM HEPES, pH 
7.5, 0.4 mg mL-1 final concentration), EcMTAN (200 µL, 2.5 mg mL-1 purified, 0.025 mg 
mL-1 final concentration) and RnCOMT (10% v/v lysate) were added. The reaction 
volume was adjusted to 20 mL by addition of HEPES buffer (50 mM, pH 7.5). Reactions 
were performed at 37 oC for 24 h. The resulting residue was lyophilised for a further 
reaction step or purified by preparative HPLC (method 9) to give the product as a white 

















2921, 2851, 1710, 1688, 1513; 1H-NMR (700 MHz; CD3OD) 𝛿	6.95 (1H, d, J = 8.3 Hz, 
7’-H), 6.83 (1H, dd, J = 8.1, 2.1 Hz, 8’-H), 6.80 (1H, d, J = 1.8 Hz, 4’-H), 6.76 (1H, s, 5-
H), 6.50 (1H, s, 8-H), 4.62 (1H, d, J = 6.0 Hz, 1-H), 3.84 (3H, s, OCH3), 3.82 (3H, s, 
OCH3), 3.78 (3H, s, OCH3), 3.56 – 3.51 (1H, m, 1’-H), 3.46 – 3.41 (1H, m, 3-HH), 3.23 
– 3.17 (1H, m, 3-HH), 3.01 – 2.90 (2H, m, 4-H). 1.30 (2H, d, J = 7.2 Hz, 2’-H); 13C-NMR 
(176 MHz; CD3OD) 𝛿	150.7 (C-5’ or C-6’), 150.0 (C-5’ or C-6’), 149.1 (C-6), 146.6 (C-
7), 134.4 (C-3’), 124.2 (C-5a or C-8a), 123.9 (C-5a or C-8a), 121.4 (C-8’), 114.5 (C-8), 
113.1 (C-4’ or C-7’), 113.1 (C-4’ or C-7’), 112.4 (C-5), 61.8 (C-1), 56.4 (OCH3), 56.4 
(OCH3), 56.3 (OCH3), 43.0 (C-1’), 41.1 (C-3), 25.6 (C-4), 15.2 (C-2’); m/z [ES+] 344 
([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 344.1853; C20H26NO4 requires 




8.8 Small molecule syntheses  
8.8.1 Aldehyde syntheses 
(R)-4-Benzyl-3-butyryloxazolidin-2-one (105)148,167  
 
Under anhydrous conditions, a solution of (R)-4-benzyloxazolidin-2-one (5.00 g, 28.2 
mmol) in THF (40 mL) was prepared and cooled to -78 oC.  n-Butyllithium (13.5 mL, 
31.0 mmol, 2.3 M in cyclohexanes) was added dropwise over 30 min and the reaction 
mixture stirred for 30 min. Butryl chloride (3.50 mL, 33.8 mmol) was added and the 
reaction mixture stirred for 1 h and then warmed to room temperature and stirred for 1 
h. The reaction was quenched by addition of saturated aqueous NH4Cl (25 mL) and the 
two phases separated. The aqueous phase was extracted with dichloromethane (3 x 
25 mL). The organic layers were combined, washed with 1 M NaOH (20 mL) and brine 
(20 mL), dried (Na2SO4) and concentrated under reduced pressure. The resulting 
residue was purified by column chromatography (2.5% ethyl acetate in petroleum ether 
40-60). This gave the product as a pale-yellow oil (6.73 g, 96.2%). 1H-NMR (700 MHz; 
CDCl3) 𝛿 7.36 – 7.31 (2H, m, 7-H), 7.29 – 7.23 (1H, m, 9-H), 7.22 – 7.18 (2H, m, 8-H), 
4.70 – 4.62 (1H, m, 4-H), 4.20 - 4.13 (2H, m, 5-H), 3.28 (1H, dd, J = 13.5, 2.9 Hz, 1-H), 
2.97 - 2.83 (2H, m, 2’-H), 2.76 (1H, dd, J = 13.5, 3.9 Hz, 1-H), 1.75 – 1.70 (2H, m, 3’-
H), 1.00 (3H, t, J = 7.4 Hz, 4’-H); 13C-NMR (176 MHz, CDCl3) 𝛿 173.3 (C-1’), 153.6 (C-
2), 135.5 (C-6), 129.6, 129.1, 127.4, 66.3 (C-1), 55.2 (C-4), 38.0 (C-5), 37.5 (C-2’), 17.8 

















 (R)-4-Benzyl-3-((R)-2-methylbutanoyl)oxazolidin-2-one (106)148,167  
 
A solution of (R)-4-benzyl-3-butyryloxazolidin-2-one (6.60 g, 26.7 mmol) in THF (40 mL) 
was prepared under anhydrous conditions and cooled to -78 oC. NaHMDS (2 M in THF, 
23.6 mL, 47.3 mmol) was added dropwise over 5 minutes and the reaction mixture was 
stirred (ca. 30 min). Methyl iodide (9.84 mL, 158 mmol) was added, and the reaction 
mixture was stirred until completion (ca. 1 h). The reaction was quenched by addition 
of brine (100 mL) and dichloromethane (150 mL) and warmed to room temperature. 
The phases were separated, and the aqueous phase diluted with water (100 mL) and 
extracted with dichloromethane (3 x 75 mL). The organic phases were combined, dried 
(Na2SO4) and concentrated under reduced pressure. The resulting oil was purified by 
column chromatography (3% ethyl acetate in petroleum ether 40-60) to give the product 
as a pale-yellow oil (5.60 g, 81.0%). 1H-NMR (700 MHz; CDCl3) 𝛿 7.35 – 7.31 (2H, m, 
8-H), 7.26 – 7.24 (1H, m, 9-H), 7.23 – 7.19 (2H, m, 7-H), 4.70 – 4.62 (1H, m, 4-H), 4.22 
- 4.15 (2H, m, 5-H), 3.64 (1H, m, 2’-H), 3.27 (1H, dd, J = 13.3, 3.4 Hz, 1-H), 2.77 (1H, 
dd, J = 13.3, 3.6 Hz, 1-H), 1.74 – 1.68 (1H, m, 4’-H), 1.48 (1H, m, 4’-H), 1.22 (3H, d, J 
= 7.1 Hz, 3’-H), 0.93 (3H, t, J = 7.1 Hz, 5’-H); 13C-NMR (176 MHz; CDCl3) 𝛿 177.3 (C-
1’), 153.2 (C-2), 135.5 (C-6), 129.6, 129.1, 127.5, 66.2 (C-1), 55.5 (C-4), 39.3 (C-5), 
























Under anhydrous conditions, a solution of (R)-4-benzyl-3-((R)-2-
methylbutanoyl)oxazolidin-2-one (5.56 g, 2.13 mmol) in diethyl ether (70 mL) was 
prepared and cooled to 0 oC. Methanol (1.1 mL) and lithium borohydride (43.2 mmol, 
0.94 g) were added. The reaction mixture was stirred for 10 min then quenched by the 
dropwise addition of saturated aqueous NaHCO3 (70 mL) and warmed to room 
temperature. Diethyl ether (70 mL) was added, the phases separated, and the organic 
phases washed with saturated aqueous NaHCO3 (2 x 50 mL). The organic phases were 
combined, dried, and concentrated under reduced pressure. The resulting residue was 
purified by column chromatography (25% ethyl acetate in petroleum ether 40-60) to 
give the product as a colourless oil (0.680 g, 36.0%) 1H-NMR (700 MHz; CDCl3) 𝛿 3.52 
(1H, m, 1-H) 3.43 (1H, m, 1-H), 1.54 (1H, m, 4-H), 1.45 (1H, m, 4-H), 1.15 (1H, m, 2-
H), 0.92 (3H, d, J = 7.1 Hz, 3-H), 0.91 (3H, t, J = 7.1 Hz, 5-H); 13C-NMR (176 MHz; 
CDCl3) 𝛿 68.2 (C-1), 37.5 (C-2), 25.9 (C-4), 16.2 (C-3), 11.5 (C-5); GCMS analysis given 




A solution of oxalyl chloride (2 M in dichloromethane, 1.40 mL, 2.79 mmol) in 
dichloromethane (10 mL) was prepared and cooled to -78 oC. DMSO (295 µL, 5.58 
mmol) was added over 10 min and the reaction mixture stirred for 30 min. 2-
methylbutan-1-ol (200 µL, 1.86 mmol) in dichloromethane (5 mL) was added, and the 
reaction mixture stirred for 30 min. Triethylamine (1.55 mL, 11.2 mmol) was added and 
the reaction mixture stirred for 30 min at -30 oC followed by 30 min at rt. The mixture 
was diluted with pentane (10 mL) and washed with NaHCO3 (2 x 10 mL) and water (2 
x 10 mL). The organic phase was dried and concentrated under reduced pressure to 
give an oil which was partially purified by silica chromatography (100% 




126 mg, 77%, (R)=114 mg, 70%) was used directly for enzymatic reactions without 
further purification. The enantiopurity of the resultant aldehydes was confirmed by GC 
analysis.  
 
Methyl 2-(3,4-dimethoxyphenyl)propanoate (121)199  
 
Under anhydrous conditions, a solution of methyl 2-(3,4-dimethoxyphenyl)acetate (2.00 
g, 9.52 mmol) in THF (10 mL) was prepared and cooled to -78 oC. A solution of LDA 
(7.2 mL, 2.0 M in THF, 14.3 mmol) was added dropwise and the reaction mixture stirred 
(ca. 30 min). Iodomethane (1.2 mL, 19 mmol) was added, and the reaction stirred for 1 
h, then quenched by the addition of 2 M HCl. The resulting solution was extracted with 
ethyl acetate (3 x 20 mL), washed with brine (2 x 20 mL), dried (MgSO4) and 
concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography (10% ethyl acetate in petroleum ether 40-60) to give the product as a 
colourless oil (1.35 g, 63%); 1H-NMR (700 MHz; CDCl3): 𝛿 6.86 - 6.80 (3H, m, 2-H, 5-H 
and 6-H), 3.88 (3H, s, 11-H or 12-H), 3.86 (3H, s, 11-H or 12-H), 3.66 (1H, q, J = 7.3 
Hz, 7-H), 3.66 (3H, s, 10-H), 1.48 (3H, d, J = 7.3 Hz, 8-H); 13C-NMR (176 MHz; CDCl3): 
𝛿 175.3 (C-9), 149.1 (C-3), 148.3 (C-4), 133.2 (C-1), 119.7 (C-6), 111.3 (C-2), 110.8 (C-
5), 56.0 (C-11 or C-12), 56.0 (C-11 or C-12), 52.1 (C-10), 45.1 (C-7), 18.8 (C-8); m/z 































Under anhydrous conditions, a solution of 2-(3,4-dimethoxyphenyl)acetate (858 mg, 
3.83 mmol) in THF (15 mL) was prepared, cooled to -78 oC and DIBAL-H (1.0 M in THF, 
7.65 mmol, 7.65 mL) was added dropwise over 10 min. The reaction mixture was stirred 
for 2 h, then quenched by addition of Rochelle’s solution (10 mL). The reaction was 
warmed to 0 oC and stirred for 1 h and then poured into water (10 mL). The reaction 
mixture was extracted with ethyl acetate (3 x 15 mL), dried with MgSO4 and 
concentrated under reduced pressure to give the product as a yellow oil (710 mg, 95%); 
1H-NMR (600 MHz; CDCl3): 𝛿 6.85 – 6.74 (3H, m, 2-H, 5-H and 6-H), 3.88 (3H, s, 3-
OCH3 or 4-OCH3), 3.86 (3H, s, 3-OCH3 or 4-OCH3), 3.70 - 3.63 (2H, m, 9-H), 2.85 – 
2.92 (1H, m, J = 6.8 Hz, 7-H), 1.25 (3H, d,  J = 6.8 Hz, 8-H); 13C-NMR (151 MHz; CDCl3): 
𝛿 149.2 (C-3 or C-4), 147.9 (C-3 or C-4), 136.3 (C-1), 119.4 (C-6), 111.5 (C-2 or C-5), 
110.9 (C-2 or C-5), 68.9 (C-9), 56.1 (3-OCH3 or 4-OCH3), 56.0 (3-OCH3 or 4-OCH3), 





Under anhydrous conditions, a solution of oxalyl chloride (2 M in CH2Cl2; 1.92 mL, 3.83 
mmol) in dichloromethane (10 mL) was prepared at -78 oC. DMSO (403 µL, 7.64 mmol) 
was added dropwise and the reaction mixture stirred for 30 min. 2-(3,4-
Dimethoxyphenyl)propan-1-ol (500 mg, 2.60 mmol) in dichloromethane (ca. 5 mL) was 
then added and the reaction mixture stirred for 30 min, followed by the addition of 
triethylamine (2.12 mL, 15.3 mmol) and stirring for 30 min at -30 oC, then 30 min at 0 
oC. The mixture was then diluted with pentane (15 mL), washed with sat. aq. NaHCO3 
(2 x 20 mL) and water (2 x 20 mL), dried with Na2SO4 and concentrated under reduced 













CDCl3): 𝛿 9.66 (1H, d, J = 1.5 Hz, 9-H), 6.90 – 6.86 (1H, m, ArH), 6.79 – 6.75 (1H, m, 
ArH), 6.67 – 6.71 (1H, m,  ArH), 3.88 (6H, s, 3-OCH3 and 4-OCH3), 3.88 (1H, m, 7-H), 
1.43 (3H, t, J = 6.9 Hz, 8-H); 13C-NMR (176 MHz; CDCl3): 𝛿 201.2 (C-9), 149.6 (C-3 or 
C-4), 148.7 (C-3 or C-4), 130.1 (C-1), 120.6 (C-6), 111.8 (C-2 or C-5), 111.5 (C-2 or C-
5), 56.1 (3-OCH3 or 4-OCH3), 56.1 (3-OCH3 or 4-OCH3), 52.7 (C-7), 14.7 (C-8); m/z 
[ES+] 195 ([M+H]+, 100%).  
 
8.8.2 Amine syntheses  
tert-Butyl (3,4-bis(benzyloxy)phenethyl)(methyl)carbamate (199)270  
 
A solution of tert-butyl (3,4-bis(benzyloxy)phenethyl)carbamate (3.50 g, 8.07 mmol) in 
DMF (50 mL) was prepared under anhydrous conditions and cooled to 0 oC. The 
reaction mixture was stirred and sodium hydride (60% in mineral oil; 484 mg, 12.1 
mmol) was added, stirred for 1 h, followed by the addition of iodomethane (603 µL, 9.68 
mmol). The solution was allowed to warm to room temperature and stirred for 18 h, then 
diluted with diethyl ether (30 mL) and quenched with H2O (5 mL). The reaction mixture 
was extracted with diethyl ether (3 x 30 mL), the organic layers washed with water (3 x 
50 mL) and brine (3 x 50 mL) then dried (Na2SO4) and concentrated under reduced 
pressure. The resulting residue was purified by column chromatography (5 – 20% ethyl 
acetate in petroleum ether 40-60) to give the product as a colourless oil (3.16 g, 90%). 
Two rotamers of the product were observed by 1H-NMR due to the presence of a tertiary 
amide. 𝜈max/ cm-1 (thin film): 3011, 2929, 1631; 1H-NMR (700 MHz; DMSO-d6) 𝛿 7.47 - 
7.26 (10H, m, ArH), 6.96 – 6.93 (1H, m, ArH), 6.91 – 6.88 (1H, m, ArH), 5.14 – 5.04 
(4H, m, PhCH2O), 2.70 (3H, s, NCH3), 2.68 – 2.60 (2H, m, CH2), 2.51 – 2.46 (2H, m, 























(C-3 or C-4), 147.6 (C-3 or C-4), 137.6 (C-2’), 137.6 (C-2’), 132.9 (C-1), 128.6, 128.6, 
127.9. 127.9, 127.5, 127.5, 121.9 (C-6). 116.0 (C-2), 115.5 (C-5), 79.4 (C-12), 71.6 (C-
1’), 71.6 (C-1’), 51.1 (C-8), 34.6 (C-10), 34.2 (C-7), 28.6 (C-13); m/z [ES+] 448 ([M+H]+, 




A solution of tert-butyl (3,4-bis(benzyloxy)phenethyl)(methyl)carbamate (2.22 g, 4.96 
mmol) in MeOH (25% v/v 37% HCl) was prepared and heated under reflux for 18 h. 
Solvents were removed under reduced pressure. The resulting residue was 
resuspended in acetone and the product was isolated by filtration as a white solid (580 
mg, 70%). 1H-NMR (600 MHz; D2O) 𝛿 6.98 (1H, m, 5-H), 6.92 (1H, m, 2-H), 6.83 (1H, 
m, 6-H), 3.34 (2H, t, J = 7.2 Hz, 8-H), 2.98 (2H, t, J = 7.2 Hz, 7-H), 2.78 (3H, s, 10-H); 
13C-NMR (150 MHz; D2O) 𝛿 144.9 (C-3), 143.7 (C-4), 129.6 (C-1), 121.8 (C-6), 117.2 






A solution of 3-methyoxyphenylacetonitrile (1.00 g, 6.70 mmol) in THF (150 mL) was 
prepared under anhydrous conditions. Boron trifluoride diethyl etherate (1 M in THF, 
495 µL, 4.02 mmol) was added and the solution stirred under reflux for 10 min. Borane 
dimethyl sulfide complex (2 M in THF, 20.1 mL, 20.1 mmol) was added and the reaction 












added and the reaction stirred for 1 h, then warmed to room temperature and stirred for 
18 h. The pH was adjusted to 13 and the product extracted into dichloromethane (3 x 
100 mL). The organic phases were dried with anhydrous NaSO4 and concentrated 
under reduced pressure to give the product as a white solid (0.99 g, 98%). The product 




Under anhydrous conditions, a solution of 2-(3-methoxyphenyl)ethan-1-amine (0.95 g, 
6.3 mmol) in dichloromethane (20 mL) was prepared and cooled to 0 oC. Boron 
tribromide (1 M in dichloromethane, 15.7 mL, 15.7 mmol) was added dropwise and the 
reaction warmed to room temperature. The reaction was then heated under reflux for 
16 h, quenched by the addition of methanol (5 mL) and concentrated under reduced 
pressure. The residue was resuspended in ethyl acetate (80 mL), poured into ice and 
1 M HCl (100 mL) and stirred for 30 min. The two phases were separated, and the 
aqueous layer was concentrated under reduced pressure to give the product as a pale 
brown solid. The product was recrystallised from n-hexane to give a white solid (0.88 
g, 81%). 1H-NMR (700 MHz; CD3OD) 𝛿 7.26 (1H, t, J = 7.9 Hz, 5-H), 6.88 – 6.76 (3H, 
m, 2-H, 4-H, 6-H), 3.23 (2H, t, J = 7.0 Hz, H-8), 2.91 (2H, t, J = 7.0 Hz, H-7); 13C-NMR 
(176 MHz; CD3OD) 𝛿 156.4 (C-1), 139.1 (C-3), 131.0 (C-5), 121.5 (C-2), 116.3 (C-4), 
114.8 (C-6), 41.0 (C-8), 33.2 (C-7); m/z [ES+] 138 ([M+H]+, 100%).  
 
8.8.3 Generation of racemic THIQ using a biomimetic phosphate reaction15 
The phenethylamine (10 mM), sodium ascorbate (10 mM) and aldehyde (20 mM) in KPi 
buffer (300 mM, pH 6) with 50% v/v MeCN was prepared and heated to 60 oC for 18 h. 










scale and products isolated in an identical manner to the corresponding products 
generated by enzyme-catalysed reactions.  
 
8.8.4 Synthesis of reaction mimics for co-crystallisation  
tert-Butyl (3,4-dihydroxyphenethyl)carbamate (66)30   
 
A solution of dopamine hydrochloride (3.00 g, 15.8 mmol) in THF (10 mL) and saturated 
aqueous NaHCO3 (6 mL) was prepared and stirred. Boc anhydride (3.75 g, 17.2 mmol) 
was added and the reaction mixture stirred for 2 h at rt. The aqueous fraction was 
washed with ethyl acetate (3 x 30 mL) and the organic fractions combined and washed 
with brine (3 x 20 mL). The organic phase was dried with MgSO4 and concentrated 
under reduced pressure to give the desired product as a white solid (3.9 g, 89%).251 1H-
NMR (400 MHz; DMSO-d6) 𝛿 8.75 (1H, s, OH), 8.65 (1H, s, OH), 6.85 – 6.81 (1H, m, 
NH), 6.62 – 6.58 (1H, m, 5-H), 6.56 – 6.52 (1H, m, 2-H), 6.42 – 6.39 (1H, m, 6-H), 3.07 
– 3.00 (2H, m, 2’-H), 2.51 – 2.46 (2H, m, 1’-H), 1.37 (9H, s, 6’-H); 13C-NMR (151 MHz; 
DMSO-d6) 𝛿 155.9 (C-4), 144.9 (C-3), 143.4 (C-4), 130.2 (C-1), 119.1 (C-6), 115.8 (C-
2), 115.3 (C-5), 77.4 (C-5’), 42.1 (C-2’), 35.0 (C-1’), 28.2 (C-6’); m/z [ES+] 254 ([M+H]+, 
100%).30 
 
tert-Butyl (3,4-bis(benzyloxy)phenethyl)carbamate (67)30   
 
Under an inert atmosphere, a solution of tert-butyl (3,4-dihydroxyphenethyl)carbamate 








































and stirred at room temperature (ca. 30 min). Benzyl bromide (5.51 mL, 46.4 mmol) 
was added dropwise at 0 oC and the reaction mixture stirred (ca. 16 h). The reaction 
mixture was filtered through Celite and the solid washed with diethyl ether (3 x 40 mL). 
This resulted in the precipitation of the product which was dried under vacuum to give 
a colourless solid (95% crude yield).241 1H-NMR (400 MHz; CDCl3) 𝛿 7.46 - 7.27 (10H, 
m, 3’’-H, 4’’-H and 5’’-H), 6.89 – 6.83 (1H, m, 5-H), 6.74 (1H, s, 2-H), 6.71 – 6.67 (1H, 
m, 6-H), 5.17 – 5.11 (4H, m, 1’’-H), 3.33 – 3.29 (2H, m, 2’-H), 2.70 – 2.66 (2H, m, 1’-H), 
1.45 – 1.40 (9H, s, 6’-H); 13C-NMR (151 MHz; CDCl3) 𝛿 156.0 (C-4’), 149.0 (C-3), 147.7 
(C-4), 137.5 (C-2’’), 137.6 (C-2’’), 132.5 (C-1), 128.6, 127.9, 127.9, 127.5, 127.4, 121.8 
(C-6), 115.9 (C-2), 115.4 (C-5), 79.3 (C-5’), 71.5 (C-1’’), 71.5 (C-1’’), 41.9 (C-2’), 36.6 




A solution of tert-butyl (3,4-bis(benzyloxy)phenethyl)carbamate (0.30 g, 0.70 mmol) in 
dichloromethane (8 mL) and TFA (2 mL) was prepared and stirred at room temperature 
(ca. 30 min). Solvents were removed under reduced pressure to give the product as a 
colourless oil (0.23 g, 100%).241 1H-NMR (400 MHz; CDCl3) 𝛿 7.44-7.27 (10H, m, 2’’-H 
to 5’’-H), 6.92 – 6.89 (1H, m, 5-H), 6.75 – 6.72 (1H, m, 2-H), 6.69 – 6.64 (1H, m, 6-H), 
5.12 – 5.08 (4H, m, 1’’-H), 3.08 – 3.02 (2H, m, 2’-H), 2.75 (2H, t, J = 6.9 Hz, 1’-H); 13C-
NMR (600 MHz; CDCl3) 𝛿 148.8 (C-3), 148.2 (C-4), 129.4 (C-1), 129.1-127.7 (C-3’’ to 
C-5’)’, 122.2 (C-6), 115.8 (C-2), 115.4 (C-5), 71.8 (C-1’)’, 71.5 (C-1’’), 41.6 (C-2), 37.8 
























A solution of 3,4-di(benzyloxy)phenethylamine (230 mg, 0.70 mmol) and triethylamine 
(290 µL, 0.75 mmol) in dichloromethane (8 mL) was prepared under anhydrous 
conditions and stirred. Pentanoic acid (82 µL, 0.75 mmol) and thionyl chloride (54 µL, 
0.75 mmol) were added and the reaction mixture stirred at room temperature for 30 
min. Solvents were removed under reduced pressure and the residue was re-
suspended in dichloromethane (10 mL) washed with 1 M HCl (3 x 10 mL) and 1 M 
NaOH (3 x 10 mL), dried (Na2SO4) and concentrated under reduced pressure. The 
resulting white solid was purified by silica chromatography (15-50% ethyl acetate in 
petroleum ether 40-60) to give the product (95 mg, 38%). 𝜈max/ cm-1 (thin film): 3305, 
2966, 2926, 2869, 1639, 1598, 1545, 1511; 1H-NMR (600 MHz; CDCl3) 𝛿 7.47 – 7.43 
(4H, m, 3’’-H), 7.39 – 7.34 (4H, m, 4’’-H), 7.33 – 7.29 (2H, m, 5’’-H), 6.80 – 6.86 (1H, 
m, 5-H), 6.79 – 6.74 (1H, m, 2-H), 6.72 – 6.69 (1H, m, 6-H), 5.18 – 5.12 (4H, m, 1’’-H), 
3.45 (2H, q, J = 6.6 Hz, 2’-H), 2.70 (2H, t, J = 7.2 Hz, 1’-H), 2.08 (2H, t, J = 7.8 Hz, 5’-
H), 1.56 (2H, m, 6’-H), 1.30 (2H, m, 7’-H), 0.89 (3H, t, J = 7.8 Hz, 8’-H); 13C-NMR (151 
MHz; CDCl3) 𝛿 173.2 (C-4’), 149.0 (C-3), 147.8 (C-4), 137.5 (C-2’’), 137.3 (C-2’’), 132.3 
(C-1), 128.6 (C-4’’), 128.6 (C-4’’), 128.0 (C-5’’), 127.9 (C-5’’), 127.4 (C-3’’), 127.4 (C-
3’’), 121.7 (C-6), 115.7 (C-2), 115.4 (C-5), 40.6 (C-2’), 36.7 (C-1’), 35.3 (C-5’), 27.9 (C-
6’), 22.5 (C-7’), 13.9 (C-8’); m/z [ES+] 418 ([M+H]+, 100%); m/z [HRMS ES+] found 































N-(3,4-Bis(benzyloxy)phenethyl)pentan-1-amine (71)30  
 
Under anhydrous conditions, a solution of N-(3,4-bis(benzyloxy)phenethyl) 
pethanamide (90 mg, 0.21 mmol) in THF (6.5 mL) was prepared. Boron trifluoride 
etherate (14 µL, 0.11 mmol) was added and the reaction mixture heated at reflux for 10 
min. Boron dimethyl sulfide complex (290 µL, 0.64 mmol) was added and the reaction 
mixture stirred under reflux for 3 h. The solution was then cooled to 0 oC and 10 % HCl 
(3.5 mL) was added, and the reaction mixture stirred at 0 oC for 1 h then at rt for 2 h. 
The pH of the solution was adjusted to 13 by addition of 2 M NaOH and the product 
extracted into dichloromethane (3 x 8 mL). The organic phase was dried with Na2SO4 
and concentrated to give the desired product as a colourless oil (73 mg, 86%). 𝜈max/ cm-
1 (thin film): 2920, 2850, 1604, 1586, 1508; 1H-NMR (600 MHz; CDCl3) 𝛿 7.48 – 7.42 
(4H, m, 3’’-H), 7.39 – 7.35 (4H, m, 4’’-H), 7.32 – 7.28 (4H, m, 5’’-H), 6.89 – 6.84 (1H, 
m, 5-H), 6.83 – 6.78 (1H, m, 2-H), 6.74 – 6.70 (1H, m, 6-H), 5.18 – 5.12 (4H, m, 1’’-H), 
2.80 (2H, t, J = 7.1 Hz, 2’-H), 2.71 (2H, t, J = 7.1 Hz, 1’-H), 2.57 (2H, t, J = 7.4 Hz, 4’-
H), 1.47 – 1.42 (2H, m, 5’-H), 1.34 – 1.23 (4H, m, 6’-H and 7’-H), 0.88 (3H, t, J = 6.0 
Hz, 8’-H); 13C-NMR (600 MHz; CDCl3) 𝛿	149.1 (C-3), 147.6 (C-4), 137.6 (C-2’)’, 137.5 
(C-2’’), 129.2 (C-1), 128.6 (C-4’’), 128.3 (C-4’’), 127.9 (C-5’’), 127.9 (C-5’’), 127.5 (C-
3’’), 127.5 (C-3’’), 121.7 (C-6’’), 116.0 (C-2), 115.6 (C-5), 71.7 (C-1’’), 71.5 (C-1’’), 51.3 
(C-4’), 50.0 (C-2’), 35.9 (C-1’), 29.7 (C-5’), 26.6 (C-6’), 22.7 (C-7’), 14.2 (C-8’); m/z 
[ES+] 404 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 404.2579; C27H34NO2 






























A solution of N-(3,4-bis(benzyloxy)phenethyl)pentan-1-amine (55 mg, 0.14 mmol) in 
methanol (6 mL) and 37% HCl (1.2 mL) was prepared and stirred under anhydrous 
conditions for 18 h. Water (5 mL) was added and solvents removed under reduced 
pressure. The resulting residue was purified by preparative-HPLC (method 8) and 
isolated as a white solid (TFA salt, 9.0 mg, 21%). 𝜈max/ cm-1 (thin film): 3038, 2962, 
2862, 1669, 1605, 1529;  1H-NMR (600 MHz; CDCl3) 𝛿 6.75 – 6.72 (1H, m, 5-H), 6.71 
– 6.68 (1H, m, 2-H), 6.60 – 6.56 (1H, m, 6-H), 3.17 (2H, t, J =  7.8 Hz, 2’-H), 2.98 (2H, 
t, J = 7.8 Hz, 1’-H), 2.82 (2H, t, J = 8.0 Hz, 4’-H), 1.69 – 1.65 (2H, m, 5’-H), 1.36 – 1.27 
(4H, m, 6’-H and 7’-H), 0.95 (3H, t, J = 6.9 Hz, 8’-H); 13C-NMR (600 MHz; CDCl3) 𝛿 
146.8 (C-3), 145.7 (C-4), 128.9 (C-1), 120.9 (C-6), 116.7 (C-5), 116.7 (C-20, 50.3 (C-2’ 
or C-4’), 49.6 (C-2’ or C-4’), 32.8 (C-1’), 29.6 (C-5’), 26.9 (C-6’), 23.2 (C-7’), 14.1 (C-8’); 
m/z [ES+] 224 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 224.1651; C13H22NO2 
requires 224.1645.  
 
N-(3,4-Bis(benzyloxy)phenethyl)-3-methylbutanamide (70)30  
 
A solution of 3,4-di(benzyloxy)phenethylamine (280 mg, 0.61 mmol) and triethylamine 
(250 µL, 1.8 mmol) in dichloromethane (8 mL) was prepared under anhydrous 
conditions and stirred. 3-Methylbutanoic acid (82 µL, 0.75 mmol) and thionyl chloride 
(54 µL, 0.75 mmol) were added and the reaction mixture stirred at room temperature 







































suspended in dichloromethane (8 mL) washed with 1 M HCl (3 x 10 mL) followed by 1 
M NaOH (3 x 10 mL), dried with anhydrous Na2SO4 and concentrated under reduced 
pressure. The resulting white solid was purified by silica chromatography (15-50% ethyl 
acetate in petroleum ether 40-60) to yield the product as a white solid (130 mg, 50%). 
𝜈max/ cm-1 (thin film): 3297, 3061, 3030, 2952, 2925, 2865, 1636, 1605, 1586, 1546, 
1514; 1H-NMR (600 MHz; CDCl3) 𝛿 7.48 – 7.42 (4H, m, 3’’-H), 7.39 – 7.35 (4H, m, 4’’-
H), 7.34 – 7.29 (4H, m, 5’’-H), 6.90 – 6.86 (1H, m, 5-H), 6.82 – 6.77 (1H, m, 2-H), 6.73 
– 6.68 (1H, m, 6-H), 5.18 – 5.12 (4H, m, 1’’-H), 3.46 (2H, q, J = 6.5 Hz, 2’-H), 2.71 (2H, 
t, J = 6.5 Hz, 1’-H), 2.09 – 2.03 (1H, m, 6’-H), 1.94 (2H, d, J = 6.5 Hz, 5’-H), 0.91 (6H, 
d, J = 6.5 Hz, 7’-H); 13C NMR (151 MHz; CDCl3) 𝛿 172.5 (C-4’), 149.1 (C-3), 147.8 (C-
4), 137.5 (C-2’’), 137.4 (C-2’’), 132.4 (C-1), 128.6 (C-4’’), 128.6 (C-4’’), 127.9 (C-5’’), 
127.5 (C-3’’), 121.7 (C-6), 115.9 (C-2), 115.6 (C-5), 71.6 (C-1’’), 71.4 (C-1’’), 46.3 (C-
5’), 40.5 (C-2’), 35.4 (C-1’), 26.2 (C-6’), 22.5 (C-7’); m/z [MS ES+] 418 ([M+H]+, 100%); 
m/z [HRMS ES+] found [M+H]+ 418.2407 C27H32NO2 requires 418.2382.  
 
N-(3,4-Bis(benzyloxy)phenethyl)-3-methylbutan-1-amine (72)30   
 
Under anhydrous conditions, a solution of N-(3,4-bis(benzyloxy)phenethyl)-3-
methylbutanamide (120 mg, 0.29 mmol) in THF (8.5 mL) was prepared. Boron trifluoride 
diethyl etherate (19 µL, 0.15 mmol) was added and the reaction heated under reflux for 
10 min. Borane dimethyl sulfide complex (2.0 M in THF, 430 µL, 0.87 mmol) was added 
dropwise and the reaction heated under reflux for a further 3 h. The reaction was cooled 
to 0 oC, 10% HCl was added (4.5 mL) and the reaction stirred for a further 1 h, followed 
by 18 h at rt. The pH of the reaction was adjusted to 13 by addition of 2 M NaOH then 























with Na2SO4 and concentrated under reduced pressure. The resulting residue was 
taken through crude to the next reaction step without further purification. m/z [HRMS 




A solution of N-(3,4-bis(benzyloxy)phenethyl)-3-methylbutan-1-amine (75 mg, 0.19 
mmol) in MeOH (10 mL) and 37% HCl (2 mL) was prepared and heated under reflux 
for 18 h. Solvents were removed under reduced pressure and the resulting residue was 
purified by preparative HPLC (method 8) to give the product as a white solid (TFA salt, 
32 mg, 53%). 𝜈max/ cm-1 (thin film): 2960, 2871, 1667, 1606, 1521;  1H-NMR (600 MHz; 
CDCl3) 𝛿 6.75 – 6.71 (1H, m, 5-H), 6.70 – 6.67 (1H, m, 2-H), 6.60 – 6.55 (1H, m, 6-H), 
3.17 (2H, t, J = 7.6 Hz, 2’-H), 3.04 – 2.97 (2H, m, 1’-H), 2.83 (2H, t, J = 8.2 Hz, 4’-H), 
1.68 – 1.63 (1H, m, 6’-H), 1.57 – 1.52 (2H, m, 5’-H), 0.96 (6H, d, J = 6.4 Hz, 7’-H); 13C-
NMR (151 MHz; CDCl3) 𝛿 146.8 (C-3), 145.7 (C-4), 128.9 (C-1), 120.9 (C-6), 116.7 (C-
5), 116.7 (C-2), 50.3 (C-2’ or C-4’), 47.6 (C-2’ or C-4’), 35.9 (C-5’), 32.9 (C-1’), 27.1 (C-
6’), 22.5 (C-7’); m/z [ES+] 223 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 




Under anhydrous conditions, a solution of 3,4-di(benzyloxy)phenethylamine (300 mg, 







































prepared and stirred. Triethylamine (290 µL, 2.1 mmol) was added followed by thionyl 
chloride (54 µL, 0.75 mmol). The reaction mixture was stirred for 30 min then solvents 
removed under reduced pressure. The residue was resuspended in dichloromethane 
(8 mL) and washed with 1 M HCl (3 x 10 mL) and 1 M NaOH (3 x 10 mL). The organic 
phase was dried with Na2SO4 and concentrated under reduced pressure. The resulting 
residue was purified by column chromatography (20 – 50% ethyl acetate in petroleum 
ether 40-60) and the pure product isolated as a white solid (69 mg, 24%). 𝜈max/ cm-1 
(thin film): 3058, 3028, 2948, 2921, 2861, 1603, 1586, 1508; 1H-NMR (600 MHz; CDCl3) 
𝛿 7.47 – 7.43 (4H, m, 3’’-H), 7.39 – 7.34 (4H, m, 4’’-H), 7.33 – 7.29 (4H, m, 5’’-H), 6.89 
– 6.85 (1H, m, 5-H), 6.83 – 6.79 (1H, m, 2-H), 6.72 – 6.68 (1H, m, 6-H), 5.17 – 5.12 
(4H, m, 1’’-H), 3.49 – 3.44 (2H, m, 2’-H), 2.75 – 2.69 (2H, m, 1’-H), 2.00 – 1.95 (1H, m, 
5’-H), 1.64 – 1.58 (2H, m, 7’-H), 1.08 (3H, d, J = 7.2 Hz, 6’-H), 0.85 (3H, t, J = 7.2 Hz, 
8’-H); 13C NMR (151 MHz; CDCl3) 𝛿 176.4 (C-4’), 149.2 (C-3), 147.8 (C-4), 137.5 (C-
2’’), 137.4 (C-2’’), 132.5 (C-1), 128.6, 128.6, 127.9, 127.9, 127.5, 127.5, 121.8 (C-6), 
115.9 (C-2), 115.6 (C-5), 71.6 (C-1’’), 71.5 (C-1’’), 43.4 (C-5’), 40.5 (C-2’), 35.4 (C-1’), 
27.4 (C-7’), 17.6 (C-6’), 12.0 (C-8’); m/z [ES+] 418 ([M+H]+, 100%); m/z [HRMS ES+] 




Under anhydrous conditions, a solution of N-(3,4-bis(benzyloxy)phenethyl)-2-
methylbutanamide (65 mg, 0.16 mmol) in THF (4.5 mL) was prepared. Boron trifluoride 
diethyl etherate (9.9 µL, 0.080 mmol) was added and the reaction heated under reflux 
for 10 min. Borane dimethyl sulfide complex (2.0 M in THF, 240 µL, 0.48 mmol) was 

























oC, 10% HCl (2.2 mL) was added and the reaction mixture stirred for 1 h. The reaction 
mixture was warmed to room temperature and stirred for a further 18 h. The pH of the 
reaction mixture was adjusted to 13 and the reaction extracted into dichloromethane (3 
x 10 mL). The organic phases were combined, dried with Na2SO4 and concentrated 
under reduced pressure to a purple oil. This crude product was taken through to the 
next reaction step without further purification. m/z [HRMS ES+] found [M+H]+ 404.2586; 




A solution of N-(3,4-bis(benzyloxy)phenethyl)-2-methylbutan-1-amine (40 mg, 0.10 
mmol) in methanol (5 mL) and 37% HCl (1 mL) was prepared and heated under reflux 
for 24 h. Solvents were then removed under reduced pressure and the resulting residue 
purified by preparative HPLC (method 8) to give the desired product as a pale brown 
solid (TFA salt, 26 mg, 81%). 𝜈max/ cm-1 (thin film): 2976, 2860, 1666, 1600, 1521;  1H-
NMR (600 MHz; CDCl3) 𝛿 6.76 – 6.71 (1H, m, 5-H), 6.70 – 6.66 (1H, m, 2-H), 6.62 – 
6.56 (1H, m, 6-H), 3.16 (2H, t, J = 8.2 Hz, 2’-H), 3.02 – 2.93 (1H, m, 4’-H), 2.87-2.78 
(3H, m, 4’-H and 1’-H), 1.79 – 1.74 (1H, m, 5’-H), 1.50 – 1.47 (1H, m, 7’-H), 1.28 – 1.22 
(1H, m, 7’-H), 1.02 (3H, d, J = 6.7 Hz, 6’-H), 0.96 (3H, t, J = 7.5 Hz, 8’-H); 13C-NMR 
(151 MHz, CDCl3) 𝛿 146.8 (C-3), 145.6 (C-4), 129.0 (C-1), 120.9 (C-6), 116.8 (C-5), 
116.7 (C-2), 54.7 (C-4’), 50.9 (C-2’), 33.7 (C-1’), 32.6 (C-5’), 27.9 (C-7’), 17.0 (C-6’), 
11.2 (C-8’); m/z [ES+] 223 ([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 223.1567; 






















A solution of 3,4-di(benzyloxy)phenethylamine (400 mg, 0.92 mmol) and triethylamine 
(416 µL, 3.0 mmol) in dichloromethane (15 mL) was prepared under anhydrous 
conditions and stirred. (R)-2-Phenylpropionic acid (150 mg, 1.0 mmol) and thionyl 
chloride (73 µL, 1.0 mmol) were added and the reaction mixture stirred at room 
temperature for 30 min. Solvents were removed under reduced pressure and the 
resulting residue was re-suspended in dichloromethane (10 mL) and 1 M HCl (10 mL). 
The organic phase was washed with 1 M HCl (2 x 10 mL) and 1 M NaOH (3 x 10 mL), 
dried with Na2SO4 and concentrated under reduced pressure. The resulting residue was 
purified by silica chromatography (20-50% ethyl acetate in petroleum ether 40-60) to 
yield the product (178 mg, 41%) as a colourless oil. [𝛼]D26 0.018 (c = 0.46, CHCl3); 𝜈max/ 
cm-1 (thin film): 2950, 3050, 3000, 2970, 2910, 2845, 1660, 1610, 1550, 1500; 1H-NMR 
(400 MHz; CDCl3) 𝛿 7.47 - 7.16 (15H, m, ArH), 6.78 (1H, d, J = 8.1 Hz, 5-H), 6.70 – 
6.67 (1H, m, 2-H), 6.49 – 6.46 (1H, m, 6-H), 5.13 (2H, s, PhCH2O), 5.08 (2H, s, 
PhCH2O), 3.50 - 3.38 (2H, m, 2’-H), 3.38 - 3.28 (1H, m, 5’-H), 2.63 - 2.56 (2H, m, 1’-H), 
1.48 (3H, d, J = 7.2 Hz, 6’-H); 13C-NMR (176 MHz, CDCl3) 𝛿 174.3 (C-4’), 149.1 (C-3 or 
C-4), 147.7 (C-3 or C-4), 141.3, 137.6, 137.4, 132.3, 129.0, 128.8, 128.6, 128.6, 128.0, 
179.9, 127.8, 127.7, 127.5, 127.4, 71.6 (OCH2Ph), 71.4 (OCH2Ph), 47.2 (C-5’), 40.8 (C-
2’), 35.1 (C-1’), 18.5 (C-6’); m/z [ES+] 467 ([M+H]+, 100%); m/z [HRMS ESI+] found 





















Under anhydrous conditions, a solution of (R)-N-(3,4-bis(benzyloxy)phenethyl)-2-
phenylpropanamide (160 mg, 0.34 mmol) in THF (10 mL) was prepared. Boron 
trifluoride etherate (21 µL, 0.17 mmol) was added and the reaction mixture stirred at 
under reflux for 10 min. Boron dimethyl sulphide complex (2M in THF, 467 µL, 1.2 mmol) 
was added and the reaction mixture stirred under reflux for 3 h. The solution was then 
cooled to 0 oC and 10% HCl (8 mL) was added, and the reaction mixture stirred at 0 oC 
for 1 h then at rt for 2 h. The pH of the solution was adjusted to 13 by addition of 2 M 
NaOH and the product extracted into CH2Cl2 (3 x 10 mL). The organic phase was dried 
(Na2SO4) and concentrated to give a pale-yellow oil (157 mg, 100%). The product was 




A solution of (R)-N-(3,4-bis(benzyloxy)phenethyl)-2-phenylpropan-1-amine (157 mg, 
0.34 mmol) in MeOH (15 mL) and 37% HCl (3 mL) was prepared under anhydrous 
conditions. The reaction mixture was heated under reflux for 18 h then solvents were 
removed under reduced pressure. The resulting residue was purified by preparative, 
HPLC (method 8) to isolate the product as a white solid (TFA salt, 13.6 mg, 15%, >99% 
e.e. as determined by chiral HPLC method 4). [𝛼]D25 0.005 (c = 0.1, MeOH); umax/ cm-1 
(thin film): 3000, 3020, 2860, 1660, 1590, 1500; 1H-NMR (600 MHz; D2O) 𝛿 7.38 – 7.34 




















– 6.77 (1H, m, 5-H), 6.71 – 6.68 (1H, m, 2-H), 6.61 – 6.57 (1H, m, 6-H), 3.27 - 3.19 (3H, 
m, 2’-H and 4’H), 3.17 - 3.06 (2H, m, 1’-H), 2.82 - 2.73 (2H, m, 4’-H and 5’-H), 1.25 (3H, 
d, J = 7.0 Hz, 6’-H); 13C-NMR (151 MHz; D2O) 𝛿 144.8 (C-7’), 143.7 (C-3 or C-4), 141.9 
(C-3 or C-4), 129.9, 129.2, 128.4, 127.8, 121.6 (C-6), 117.1 (C-2 or C-5), 116.9 (C-2 or 
C-5), 53.7 (C-4’), 49.1 (C-2’), 37.4 (C-5’), 31.0 (C-1’), 19.5 (C-6’); m/z [ES+] 273 





A solution of 2-(3,4-bis(benzyloxy)phenyl)ethan-1-amine (317 mg, 0.950 mmol), 
benzoic acid (128 mg, 1.04 mmol) and HATU (362 mg, 0.950 mmol) in DMF (5 mL) was 
prepared in anhydrous conditions and cooled to 0 oC. N,N-Diisopropylethylamine (332 
𝜇L, 1.90 mmol) was added dropwise and the reaction mixture allowed to room 
temperature. The reaction mixture was stirred for 18 h, then solvents removed under 
reduced pressure. The resulting residue was resuspended in ethyl acetate (15 mL), 
washed with 1 M HCl (2 x 15 mL), NaHCO3 (2 x 15 mL) and brine (2 x 15 mL), dried 
and concentrated under reduced pressure. The resulting residue was purified by 
column chromatography (5 – 25% ethyl acetate in petroleum ether 40-60), to give the 
pure product as a white solid (290 mg, 69%). 𝜈max/ cm-1 (thin film): 3309, 3060, 3028, 
2927, 2858, 1637, 1601, 1576.5, 1534, 1510; 1H-NMR (700 MHz; CDCl3) 𝛿 7.68 - 7.64 
(2H, m, COC(CH)2), 7.50 - 7.26 (13H, m, ArH), 6.92 – 6.88 (1H, m, 5-H), 6.84 – 6.81 
(1H, m, 2-H), 6.76 – 6.73 (1H, m, 6-H), 6.10 – 6.05 (1H, m, NH), 5.14 (2H, s, PhCH2O), 
5.11 (2H, s, PhCH2O), 3.65 (2H, q, J = 5.9 Hz, 6.8 Hz, CH2NH), 2.83 (2H, t, J = 6.8 Hz, 
CH2CHNH); 13C-NMR (176 MHz; CDCl3) 𝛿 167.5 (C-10), 149.3 (C-3 or C-4), 147.9 (C-













126.9, 121.8 (C-6), 115.9 (C-2 or C-5), 115.7 (C-2 or C-5), 71.6 (OCH2Ph), 71.5 
(OCH2Ph), 41.2 (C-8), 35.2 (C-7); m/z [ES+] 438 ([M+H]+, 100%); m/z [HRMS ES+] 




A solution of N-(3,4-bis(benzyloxy)phenethyl) benzamide (250 mg, 0.57 mmol) in THF 
(20 mL) was prepared under anhydrous conditions. Boron trifluoride diethyl etherate 
(36 µL, 0.29 mmol) was added and the reaction stirred under reflux for 10 min. Boron 
dimethyl sulfide complex (2M in THF, 860 µL, 1.70 mmol) was added and the reaction 
mixture stirred for a further 3 h. The mixture was then cooled to 0 oC, 1 M HCl (10 mL) 
was added and the reaction stirred for 1 h. The reaction was then warmed to room 
temperature and stirred overnight. The pH was adjusted to 13 by addition of 2 M NaOH, 
the solution extracted with dichloromethane (3 x 20 mL). The organic phase was then 
dried with Na2SO4 and concentrated under reduced pressure to give the crude product 




A solution of N-benzyl-2-(3,4-bis(benzyloxy)phenyl)ethan-1-amine (240 mg, 0.57 
mmol) in MeOH (30 mL) and 37% HCl (6 mL) was heated under reflux for 18 h. Solvents 
were removed under reduced pressure and the resulting residue was purified by 
preparative HPLC (method 9), lyophilised and the pure product isolated as a white solid 
(TFA salt, 57 mg, 29%). 𝜈max/ cm-1 (thin film): 3039, 1661, 1528; 1H-NMR (700 MHz; 





















J = 2.2 Hz, 3-H), 6.68 (1H, dd, J = 8.1, 2.2 Hz, 5-H), 4.19 (2H, s, 10-H), 3.23 (2H, t, J = 
7.6 Hz, 8-H), 2.86 (2H, t, J = 7.6 Hz, 7-H); 13C-NMR (176 MHz; D2O) 𝛿 144.8 (C-1 or C-
2), 143.6 (C-1 or C-2), 131.1 (C-11), 130.3, 130.2, 129.8, 129.6, 121.7, 117.1 (C-3 or 
C-6), 117.0 (C-3 or C-6), 50.8 (C-10), 48.5 (C-8), 31.4 (C-7); m/z [ES+] 244 ([M+H]+, 




A solution of 2-(3,4-bis(benzyloxy)phenyl)ethan-1-amine (200 mg, 0.46 mmol), 4-
bromobenzoic acid (110 mg,  0.55 mmol) and HATU (175 mg, 0.46 mmol) in DMF (5 
mL) was prepared under anhydrous conditions and cooled to 0 oC. N,N-
Diisopropylethylamine (160 𝜇L, 0.92 mmol) was added dropwise and the reaction 
mixture allowed to room temperature. The reaction mixture was stirred for 18 h, then 
solvents removed under reduced pressure. The resulting residue was resuspended in 
ethyl acetate (15 mL), washed with 1 M HCl (2 x 15 mL), NaHCO3 (2 x 15 mL) and brine 
(2 x 15 mL). The organic phases were combined, dried with Na2SO4 and concentrated 
under reduced pressure. The resulting residue was purified by column chromatography 
(5 – 25% ethyl acetate in petroleum ether 40-60) to give the pure product as a white 
solid (120 mg, 61%). 𝜈max/ cm-1 (thin film): 3287, 3061, 3029, 2916, 2848, 1635, 1603, 
1587, 1540, 1513; 1H-NMR (700 MHz; CDCl3) 𝛿 7.55 – 7.27 (14H, m, ArH), 6.93 – 6.90 
(1H, m, 6-H), 6.89 (1H, d, J = 8.5 Hz, 3-H), 6.72 (1H, dd, J = 8.1, 2.0 Hz, 5-H), 5.98 
(0.8H, m, NH), 5.14 (2H, s, 1’-H), 5.11 (2H, s, 1’-H), 3.63 (2H, q, J = 6.4 Hz, 8-H), 2.82 
(2H, t, J = 6.4 Hz, 7-H); 13C-NMR (176 MHz; CDCl3) 𝛿 166.5 (C-10), 149.3 (C-1 or C-
2), 147.9 (C-1 or C-2), 137.4 (C-2’), 137.3 (C-2’), 133.6, 132.2, 131.9, 128.6, 128.6, 




























71.5 (C-1’), 41.2 (C-8), 35.1 (C-7); m/z [ES+] 516 ([M+H]+, 100%); m/z [HRMS ESI+] 




A solution of N-(3,4-bis(benzyloxy)phenethyl)-4-bromobenzamide (120 mg, 0.23 mmol) 
in THF (10 mL) was prepared under anhydrous conditions. Boron trifluoride diethyl 
etherate (16 µL, 0.13 mmol) was added and the reaction stirred under reflux for 10 min. 
Boron dimethyl sulfide complex (2.0 M in THF, 350 µL, 0.69 mmol) was added and the 
reaction mixture stirred for a further 3 h. The mixture was then cooled to 0 oC, 1 M HCl 
(5 mL) was added and the reaction stirred for 1 h. The reaction was then warmed to 
room temperature and stirred overnight. The pH was adjusted to 13 by addition of 2 M 
NaOH, the solution extracted with dichloromethane (3 x 20 mL). The organic phase was 
then dried with Na2SO4 and concentrated under reduced pressure to give the crude 






A solution of 2-(3,4-bis(benzyloxy)phenyl)-N-(4-bromobenzyl)ethan-1-amine (120 mg, 
0.24 mmol) in MeOH (30 mL) and 37% HCl (6 mL) was heated under reflux for 18 h. 
Solvents were removed under reduced pressure and the resulting residue was purified 




















solid as the TFA salt (21 mg, 27%). 𝜈max/ cm-1 (thin film): 3110, 2823, 1664, 1604, 1579, 
1524; 1H-NMR (700 MHz; CDCl3) 𝛿 7.62 - 7.59 (2H, m, 13-H), 7.31 - 7.27 (2H, m, 12-
H), 6.86 – 6.83 (1H, m, 6-H), 6.76 – 6.72 (1H, m, 3-H), 6.71 – 6.66 (1H, m, 5-H), 4.16 
(2H, s, 10-H), 3.23 (2H, t, J  = 7.6 Hz, 8-H), 2.86 (2H, t, J = 7.6 Hz, 7-H); 13C-NMR (176 
MHz; CDCl3) 𝛿 144.8 (C-1 or C-2), 143.6 (C-1 or C-2), 132.8 (ArC), 132.1 (ArC), 130.2 
(ArC), 129.5 (ArC), 123.9 (C-5 or C-14), 121.7 (C-5 or C-14), 117.1 (C-3 or C-6), 117.0 
(C-3 or C-6), 50.8 (C-10), 48.5 (C-8), 31.4 (C-7); m/z [ES+] 322 ([M+H]+, 100%); m/z 




A solution of 3,4-di(benzyloxy)phenethylamine (360 mg, 0.83 mmol) and triethylamine 
(330 µL, 2.4 mmol) in dichloromethane (12 mL) was prepared under anhydrous 
conditions and stirred. Phenylacetic acid (100 µL, 0.80 mmol) was added, then thionyl 
chloride (73 µL, 1.0 mmol) and the reaction mixture stirred for 20 min at rt. Solvents 
were removed under reduced pressure and the resulting residue resuspended in 
dichloromethane (12 mL). The organic phase was washed (3 x 1 M HCl then 3 x 1 M 
NaOH) and then the organic phases dried with Na2SO4 and concentrated under 
reduced pressure. The resulting residue was purified by column chromatography (20 – 
50% ethyl acetate in petroleum ether 40-60) to give the product as a white solid (100 
mg, 27%). 𝜈max/ cm-1 (thin film): 3297, 3062, 3029, 2934, 2869, 1720, 1646, 1603, 1585, 
1511; 1H-NMR (600 MHz; CDCl3) 𝛿 7.47 – 7.42 (4H, m, ArH), 7.40 – 7.22 (9H, m, ArH), 
7.15 – 7.12 (2H, m, ArH), 6.78 (1H, d, J = 8.1 Hz, 6-H), 6.68 (1H, d, J = 2.0 Hz, 3-H), 
6.50 (1H, dd, J = 8.1 Hz, 2.0 Hz), 5.34 – 5.28 (1H, m, 9-H), 5.14 (2H, s, 1’-H), 5.10 (2H, 



























13C-NMR (151 MHz, CDCl3) 𝛿 171.1 (C-10), 149.1 (C-2), 147.7 (C-1), 137.5, 137.3, 
134.8, 133.9, 132.1, 129.6, 129.5, 129.1, 128.7, 128.6, 128.6, 128.0, 127.9, 127.5, 
127.4, 127.4, 127.3, 121.6 (C-5), 115.6 (C-3), 115.4 (C-6), 71.5 (C-1’), 71.3 (C-1’), 43.9 
(C-11), 40.8 (C-7), 35.0 (C-8); m/z [ES+] 452 ([M+H]+, 100%); m/z [HRMS ES+] found 




A solution of N-(3,4-bis(benzyloxy)phenethyl)-2-phenylacetamide (97 mg, 0.21 mmol) 
in DMF (2 mL) was prepared under anhydrous conditions. The solution was cooled to 
0 oC and stirred, then sodium hydride (60% in mineral oil, 13.5 mg, 0.32 mmol) was 
added. Iodomethane (26 µL, 0.42 mmol) was added and the reaction mixture allowed 
to warm to rt and stirred for 18 h. The reaction was quenched by addition of water (500 
µL) and solvents were removed under reduced pressure. The residue was resuspended 
in water (10 mL) and extracted with diethyl ether (3 x 10 mL). The organic phases were 
combined, washed with saturated aqueous NaHCO3 (2 x 10 mL) and brine (2 x 10 mL). 
The organic phase was then dried with Na2SO4 and concentrated under reduced 
pressure. The resulting residue was purified by column chromatography (20% ethyl 
acetate in petroleum ether 40-60) to give the desired product as a white solid (51 mg, 
52%). 𝜈max/ cm-1(thin film):  3062, 3029, 2925, 2856, 1641, 1604, 1512; 1H-NMR (600 
MHz; CDCl3) 𝛿 7.37 – 7.33 (4H, m, ArH), 7.28 – 7.22 (4H, m, ArH), 7.23 – 7.18 (4H, m, 
ArH), 7.15 – 7.11 (2H, m, ArH), 7.08 – 7.04 (1H, m, ArH), 6.80 (1H, d, J = 8.3 Hz, 6-H), 
6.73 (1H, d, J = 1.9 Hz, 3-H), 6.56 (1H, dd, J = 8.3, 1.9 Hz, 5-H), 5.05 (2H, s, 1’-H), 5.03 
(2H, s, 1’-H), 3.56 (2H, s, 11-H), 3.47 (2H, t, J = 7.2 Hz, 8-H), 2.85 (3H, s, 9-H), 2.67 




























Under an inert atmosphere, a solution of N-(3,4-bis(benzyloxy)phenethyl)-N-methyl-2-
phenylacetamide (45 mg, 0.10 mmol) in THF (4 mL) was prepared. Boron trifluoride 
diethyl etherate (7.0 µL, 0.050 mmol) was added, the reaction stirred and heated under 
reflux for 10 min. Borane dimethyl sulfide complex (2.0 M in THF, 160 µL, 0.30 mmol) 
was added dropwise and the reaction heated under reflux for 3 h. The reaction mixture 
was then cooled to 0 oC, quenched by addition of 10% HCl (2.5 mL) then allowed to 
warm to rt and stirred overnight. The pH of the solution was adjusted to 13 by addition 
of 6 M NaOH. This aqueous solution was extracted with dichloromethane (3 x 10 mL), 
then the organic phases combined, dried with Na2SO4 and concentrated under reduced 
pressure. The resulting residue, the crude product, was taken through to the next step 





A solution of N-(3,4-bis(benzyloxy)phenethyl)-N-methyl-2-phenylethan-1-amine (40 
mg, 0.089 mmol) in methanol (8 mL) and 37% HCl (2 mL) was prepared, stirred and 
heated under reflux for 24 h. Solvents were then removed under reduced pressure and 
the residue purified by preparative HPLC (method 11), then prepared by workup 
method 3 to give the pure product as a white solid (2.1 mg, 5.7 µmol, 6.0%). 𝜈max/ cm-1 















or 8’-H), 7.32 - 7.28 (1H, m, 9’-H), 7.26 - 7.22 (2H, m, 7’-H or 8’-H), 6.85 – 6.82 (1H, m, 
5-H), 6.80 – 6.77 (1H, m, 2-H), 6.70 – 6.66 (1H, m, 6-H), 3.49 - 3.42 (2H, m, 2’-H or 4’-
H), 3.37 - 3.28 (2H, m, 2’-H or 4’-H), 3.07 - 2.92 (4H, m, 1’-H and 5’-H), 2.90 (3H, s, 3’-
H); 13C-NMR (176 MHz; D2O) 𝛿 144.9 (C-3), 143.7 (C-4), 136.5 (C-6), 129.7 (C-1), 129.3 
(C-7’ or C-8’), 129.1 (C-7’ or C-8’), 128.0 (C-9’), 121.6 (C-6), 117.2 (C-2 or C-5), 117.0 
(C-2 or C-5), 57.4 (C-2’ or C-4’), 57.3 (C-2’ or C-4’), 40.9 (C-3’), 30.3 (C-1’ or C-5’), 29.7 
(C-1’ or C-5’); m/z [ES+] 272 ([M+H]+, 100%); m/z [HRMS ESI+] found [M+H]+ 272.1641, 
C17H22NO2 requires 272.1645.  
 




isoquinolino[3,2-a]isoquinoline-2,3-diol.TFA (129)198  
 
An NCS-mediated reaction between dopamine HCl and 2-(3,4-
dimethoxyphenyl)propanal was performed on a 5 mL, 10 mM scale, as detailed for the 
synthesis of (S)-1-((R)-1-(3,4-dimethoxyphenyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-
6,7-diol (119) then workup method 5 was performed. The residue was resuspended in 
formic acid (11.6 mL) and formaldehyde (37% in water, 8.4 mL). The reaction mixture 
was stirred at 50 oC for 2 h. Solvents were removed under reduced pressure and the 
residue purified by preparative HPLC (method 11) to give the product (TFA salt) as a 
yellow solid (5.3 mg, 24%). [a]D2 -35.3 (c 0.83, MeOH); 𝜈max/ cm-1 (thin film): 2980, 1672, 






















(1H, s, 1-H), 6.65 (1H, s, 4-H), 4.91 (1H, d, J = 4.0 Hz, 13a-H), 4.54 – 4.51 (2H, m, 8-
H), 3.85 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.79 – 3.74 (2H, m, 13-H and 6-H), 3.51 
(1H, dt, J = 3.8 Hz, 6-H), 3.19 – 3.12 (1H, m, 5-H), 2.90 (1H, dd, J = 17.2 Hz, 2.7 Hz, 
5-H), 1.10 (3H, d, J = 7.3 Hz, 14-H); 13C-NMR (176 MHz, CD3OD) 𝛿 150.9 (C-11), 150.1 
(C-10), 146.7 (C-3), 146.7 (C-2), 131.1 (C-12a), 124.2 (C-4a), 121.7 (C-1a), 119.6 (C-
8a), 115.9 (C-4), 113.0 (C-12), 112.8 (C-1), 109.7 (C-9), 65.6 (C-13a), 57.3 (C-8), 56.4 
(OCH3), 56.4 (OCH3), 52.8 (C-6), 36.7 (C-13), 26.4 (C-5), 17.3 (C-14); m/z [ES+] 342 
([M+H]+, 100%); m/z [HRMS ESI+] found [M+H]+ 342.1701; C20H25NO4 requires 





A crude, lyophilised sample of (S)-1-((R)-1-(3,4-dimethoxyphenyl)ethyl)-6-methoxy-
1,2,3,4-tetrahydroisoquinolin-7-ol was resuspended in formic acid (11.6 mL) and 
formaldehyde (37% in water, 8.4 mL). The reaction mixture was stirred at 50 oC for 2 
h.271 Solvents were removed under reduced pressure and the residue purified by 
preparative HPLC (method 11) to give the product as the TFA salt as a pale yellow solid 
(5.1 mg, 23%). [a]D20 +0.92 (c 0.72, MeOH); 𝜈max/ cm-1 (thin film): 3293, 2967, 2842, 
1757, 1668, 1613; 1H-NMR (700 MHz; CD3OD) 𝛿 6.95 (1H, s, 1-H), 6.83 – 6.81 (2H, m, 
4-H and 12-H), 6.80 (1H, s, 9-H), 4.96 (1H, d, J = 4.1 Hz, 13a-H), 4.54 (2H, s, 8-H), 
3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.82 – 3.77 (2H, m, 6-H 
and 13-H), 3.57 – 3.51 (1H, s, 6-H), 3.25 – 3.17 (1H, m, 5-H), 3.03 – 2.97 (1H, m, 5-H), 
1.09 (3H, d, J = 7.4 Hz, 14-H); 13C-NMR (176 MHz; CD3OD) 𝛿 150.9 (C-10 or C-11), 






















1a), 119.6 (C-12a), 113.0 (C-1), 112.8 (C-12), 112.3 (C-4), 109.7 (C-9), 65.5 (C-13a), 
57.3 (C-8), 56.4 (OCH3), 56.4 (OCH3), 56.3 (OCH3), 52.7 (C-6), 36.5 (C-13), 26.5 (C-
5), 17.2 (C-14); m/z [ES+] 356 ([M+H]+, 100%); m/z [HRMS ESI+] found [M+H]+ 
356.1854, C21H26NO4 requires 352.1856; retention time (achiral analytical HPLC 





Under anhydrous conditions, a crude, lyophilised sample of (S)-1-((R)-1-(3,4-
dimethoxyphenyl)ethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (125) was 
resuspended in DMF (10 mL). Paraformaldehyde (6.0 mg, 0.20 mmol) was added. The 
reaction mixture was stirred at 120 oC for 18 h. Solvents were removed under reduced 
pressure and the resulting residue was purified by preparative HPLC (method 11) to 
give the product as a brown oil (1.7 mg, 4.8%). 𝜈max/ cm-1 (thin film): 3523, 3321, 3012, 
1674, 1605, 1574, 1504; 1H-NMR (700 MHz; CD3OD) 𝛿 9.32 (1H, s, 8-H), 7.62 (1H, s, 
9-H), 7.55 (1H, s, 12-H), 7.33 (1H, s, 1-H), 7.08 (1H, s, 4-H), 4.68 (2H, t, J = 5.9 Hz, 6-
H), 4.16 (3H, s, 11’-H), 4.06 (3H, s, 10’-H), 3.98 (3H, s, 3’-H), 3.14 (2H, t, J = 5.9 Hz, 5-
H), 2.97 (3H, s, 14-H); 13C-NMR (176 MHz; CD3OD) 𝛿 159.6 (C-11), 154.1 (C-10), 151.2 
(C-3), 146.5 (C-2), 144.8 (C-8), 138.9 (C-12a or C-8a), 138.7 (C-12a or C-8a), 131.4 
(C-4a), 129.3 (C-13), 123.1 (C-13a), 121.0 (C-1a), 118.5 (C-1), 111.7 (C-4), 107.9 (C-
9), 104.2 (C-12), 57.9 (C-6), 57.3 (C-11’), 56.9 (C-10’), 56.5 (C-3’), 28.7 (C-5), 18.1 (C-
14); m/z [ES+] 352 ([M]+, 100%); m/z [HRMS ESI+] found [M]+ 352.1543, C21H22NO4 




























A solution of (S)-1-((R)-1-(3,4-dimethoxyphenyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-
6,7-diol (16.5 mg, 0.05 mmol) in formic acid (2.1 mL), water (1.3 mL) and acetaldehyde 
(780 µL, 14.0 mmol) was prepared under anhydrous conditions and stirred at 50 oC for 
24 h. Solvents were removed under reduced pressure and the resulting residue was 
resuspended in a minimum volume of methanol and purified by preparative HPLC 
(method 12) to give the product (TFA salt, not drawn) as brown solid (4.7 mg, 21%) as 
a mixture of two epimers (8S,13R,13aS):(8R,13R,13aS) in a ratio of 3:1. 
Stereochemistry at C-13 and C-13a was assigned based upon precedent of NCS 
reactions involving a-methyl substituted aldehydes and stereochemistry at C-8 was 
assigned based upon the presence or absence of NOE between 8-H and 13a-H. [a]D20 
-24.6 (c 0.45, MeOH); 𝜈max/ cm-1 (thin film): 3449, 3011, 1673, 1650, 1516; 1H-NMR 
(700 MHz; CD3OD) 𝛿 6.92 (0.3H, s, 12-Hmin), 6.88 (1H, s, 12-Hmaj), 6.85 (0.3H, s, 9-
Hmin), 6.82 – 6.79 (1.3H, m, 9-Hmaj and C-1min), 6.77 (1H, s, 1-Hmaj), 6.67 (0.3H, s, 4-
Hmin), 6.65 (1H, s, 4-Hmaj), 5.12 (1H, d, J = 4.1 Hz, 13a-Hmaj), 4.18 (0.3 H, dd, J = 12.1, 
5.0 Hz, 6-HHmin), 3.87 (0.9H, s, 11’-H or 10’-H), 3.86 – 3.83 (7H, m, 11’-H and 10’-H), 
3.79 – 3.77 (0.3H, m, 6-HHmin), 3.75 – 3.71 (0.3 H, m, 13-Hmin), 3.69 – 3.64 (1H, m, 13-
Hmaj), 3.60 – 3.55 (1H, m, 6-HHmaj), 3.52 (1H, td, J = 12.3, 2,8 Hz, 6-HHmaj), 3.44 – 3.37 
(0.3H, m, 5-HHmin), 3.15 – 3.08 (1H, m, 5-HHmaj), 2.94 (0.3H, dd, J = 15.1, 3.3 Hz, 5-
HHmin), 2.90 (1H, d, J = 17.1 Hz, 5-HHmaj), 1.85 (1H, d, J = 6.8 Hz, 8’-Hmin), 1.69 (3H, d, 
J = 6.8 Hz, 8’-Hmaj), 1.17 (1H, d, J = 7.3 Hz, 14-Hmin), 1.04 (3H, d, J = 7.3 Hz, 14-Hmaj). 


























150.1 (C-10min or C-11min), 150.1 (C-10maj or C-11maj), 146.7 (C-2 or C-3), 146.5 (C-2 or 
C-3), 131.2 (C-12amin), 130.1 (C-12amaj), 126.2 (C-8amaj), 124.6 (C-4amaj and C-8amin), 
124.3 (C-1amin or C-4amin), 122.3 (C-1amaj), 122.0 (C-1amin or C-4amin), 115.9 (C-4min), 
115.8 (C-4maj), 113.3 (C-1maj), 113.0 (C-1min), 112.8 (C-12maj), 112.4 (C-12min), 110.3 (C-
9maj), 110.2 (C-9min). 62.0 (C-8), 58.2 (C-13amaj), 56.6 (C-10’ or C-11’), 56.5 (C-10’ or C-
11’), 56.4 (C-10’ or C-11’), 52.0 (C-6min), 50.1 (C-6maj), 49.4 (C-13amin), 26.6 (C-5), 26.6 
(C-5), 19.5 (C-8’min), 17.3 (C-14maj), 17.0 (C-14min), 16.9 (C-8’maj); m/z [ES+] 356 
([M+H]+, 100%); m/z [HRMS ES+] found [M+H]+ 356.1855; C21H26NO4 requires 





An NCS-mediated reaction between dopamine HCl and 2-(3,4-
dimethoxyphenyl)propanal was performed on a 5 mL, 10 mM scale as detailed for the 
synthesis of (S)-1-((R)-1-(3,4-dimethoxyphenyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-
6,7-diol, followed by lyophilisation. Under anhydrous conditions, the resulting residue 
was resuspended in methanol (5 mL) and stirred. Potassium carbonate (13.8 mg, 0.10 
mmol) was added, followed by the dropwise addition of iodomethane (31 µL, 0.5 mmol). 
The reaction mixture was stirred at rt for 18 h. Solvents were removed under reduced 
pressure and the resulting residue purified by preparative HPLC (method 12) to give 
the product as a while solid (2.9 mg, 8.1%). [a]D21 -11.3 (c 0.38, MeOH); 𝜈max/ cm-1 (thin 
film): 3414, 2938, 2839, 1676, 1610, 1517; 1H-NMR (700 MHz; CD3OD) 𝛿	6.94 (1H, s, 
8-H), 6.83 – 6.80 (2H, m, C-5 and C-7’), 6.64 – 6.54 (1H, m, C-8’), 5.86 (1H, s, C-4’), 


















H), 3.76 (3H, s, 5’-OCH3), 3.49 – 3.45 (6H, 2 x s, NCH3 and 6’-OCH3), 3.25 – 3.15 (2H, 
m, 3-H), 3.07 (3H, s, NCH3), 3.01 – 2.93 (1H, m, 4-HH), 2.43 (1H, dd, J = 18.0, 6.5 Hz, 
4-HH), 1.52 (3H, d, J = 7.3 Hz, 2’-H); 13C-NMR (176 MHz; CD3OD) 𝛿	151.7 (C-6), 150.3 
(C-6’), 149.9 (C-5’), 149.2 (C-7), 133.8 (C-8’), 124.3 (C-5a), 122.6 (C-8’), 120.8 (C-8a), 
113.7 (C-8), 112.8 (C-5 or C-7’), 112.7 (C-5 or C-7’), 112.4 (C-4’), 77.1 (C-1), 56.7 (C-
7’), 56.4 (C-6’), 56.2 (5’-OCH3), 55.9 (6’-OCH3 or NCH3), 55.4 (C-3), 53.2 (6’-OCH3 or 
NCH3), 53.0 (NCH3), 40.8 (C-1’), 24.1 (C-4 or C-1), 24.1 (C-4 or C-1); m/z [ES+] 387 
([M]+; m/z [HRMS ESI+] found [M]+ 386.2323, C23H32NO4 requires 386.2323; retention 




A solution of dopamine·HCl (37.9 mg, 0.2 mmol) and sodium ascorbate (39.6 mg, 0.2 
mmol) in HEPES buffer (50 mM, pH 7.5, 18 mL) was prepared. To this, a solution of 
benzaldehyde (0.4 mmol, 40.8 µL) in MeCN (2 mL) was added and 4 mg of TfNCS-
M97V (10 mg mL-1 in 20 mM Tris, 50 mM NaCl, pH 7.5). The reaction mixture was 
stirred for 24 h at 37 oC. The reaction mixture was extracted into ethyl acetate (3 x 20 
mL), dried and concentrated. The residue was resuspended in 1 M HCl (20 mL) and 
washed with dimethyl carbonate (1 x 5 mL). The aqueous layer was dried under 
reduced pressure. The product was resuspended in sat. aq. NaHCO3, extracted into 
EtOAc (3 x 20 mL), dried (Na2SO4) and concentrated under reduced pressure to give 
the crude product as a yellow oil (30.0 mg, 62%) and the identity confirmed by 1H-NMR 










(1S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol (30 mg, 0.12 mmol) was 
resuspended in THF (4 mL) and sat. aq. NaHCO3 (4 mL). Boc anhydride (54 mg, 0.25 
mmol) was added, and the reaction mixture stirred at rt (24 h). The reaction mixture 
was extracted into ethyl acetate (3 x 15 mL), dried (Na2SO4) and concentrated under 






A solution of tert-butyl 6,7-dihydroxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-
carboxylate (28 mg, 0.082 mmol) and base (potassium carbonate or caesium 
carbonate) (0.25 mmol) in methanol (5 mL) was prepared. Iodomethane (100 µL, 1.6 
mmol) was added and the reaction mixture stirred for 24 h at room temperature. 
Solvents were removed under reduced pressure and the resulting residue azeotroped 
with methanol (3 x 10 mL). The product was partially purified by silica chromatography 
(100% dichloromethane) to give the product as a yellow oil (6.5 mg, 21%). The crude 









(S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (143)250  
 
A solution of tert-butyl (S)-6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-
carboxylate (6.5 mg, 0.018 mmol) in dichloromethane (3.2 mL) and trifluoroacetic acid 
(0.8 mL) was prepared and stirred at room temperature for 5 min. Solvents were 
removed under reduced pressure, then resuspended in 50% MeOH in water and 
concentrated. The resulting residue was purified by semi-preparative HPLC or 
preparative HPLC (method 11) to give the desired product in 6% or 20% e.e. as 
determined by chiral HPLC methods 6 and 7, dependent on which base was used for 
the reaction (6% for potassium carbonate and 20% for cesium carbonate). 1H-NMR 
(700 MHz; CD3OD) 𝛿 7.50 – 7.47 (3H, m, ArH), 7.36 – 7.34 (2H, m, ArH), 6.89 (1H, s, 
5-H), 6.34 (1H, s, 8-H), 5.69 (1H, s, 1-H), 3.85 (3H, s, OCH3), 3.59 (3H, s, OCH3), 3.51 
– 3.41 (2H, m, 3-H), 3.25 – 3.18 (1H, m, 4-HH), 3.14 – 3.08 (1H, m, 4-HH); 13C-NMR 
(176 MHz; CD3OD) 𝛿 150.9 (C-6 or C-7), 149.8 (C-6 or C-7), 137.6 (C-1’), 131.0, 130.9, 
130.3, 125.8, 124.0, 112.6 (C-5), 111.9 (C-8), 60.5 (C-1), 56.4 (OCH3), 56.3 (OCH3), 
40.6 (C-3), 25.7 (C-4); m/z [ES+] 271 ([M+H]+, 100%).  
 
8.9 Crystallographic methods 
8.9.1 Crystal preparation 
Purified protein samples were concentrated to around 12 mg mL-1 in buffer (20 mM 
TRIS, 50 mM NaCl, pH 7.5. Initial crystallisation screening was performed using 
commercial 96-well plates (JCSG, PACT, Structure 1 + 2 and Index). For each well, 
two sitting drops were prepared using a Mosquito® robot (TTP Labtech) at 1:1 or 2:1 















Crystal optimisation was performed using either the hanging drop method or by 
preparing four corner screens. For the hanging drop method, two drops were prepared 
per well with 1:1 and 2:1 protein to precipitant, with drop sizes of 2 µL and 3 µL, 
respectively with 500 µL crystallisation solution in the well. Four corner screens involve 
preparing multi-well crystallisation plates, with minor changes in buffer, salt or 
precipitant concentrations around the promising crystallisation condition. Four corner 
screens were prepared as 96 well sitting drop plates or 24 well hanging drop plates.   
 
8.9.2 Data collection and analysis  
Diffraction data was collected from Diamond light source beamlines (i04 and i24). Data 
was analysed using CCP4i2 with the following software packages: XDS Dials172 for 
image processing, Phaser253 for molecular replacement, COOT171 for model building 
and REFMAC5174 for refinement with TLS restraints. Figures were prepared using 
UCSF Chimera32 and CCP4mg.272  
 
8.10 Computational methods 
8.10.1 Data analysis 
For data analysis of conversions of enzymatic assays, the errors given are standard 
deviations. Figures were prepared using Python with the matplotlib software package. 
 
8.10.2 Energy minimization 
Small molecule reaction intermediates, reaction products and substrates for docking 
were energy minimized using the Avogadro273 software package using the universal 
force field (UFF).274  
 
8.10.3 Molecular docking 
AutoDockTools (Scripps) was used to define rotatable bonds in ligands and to prepare 
pdbqt files for docking. Docking was performed using AutoDock Vina (Scripps).255 
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Docking of wild-type TfNCS was performed using PDB: 5NON, subunit A with ligands 
removed with box size (25, 25, 35) and box location (-17.95, -7.43, 16.19). Docking of 
TfNCS-M97F was performed using an energy minimized structure of the variant (using 
the CHARMM GUI) based upon the structure of TfNCS-M97V (PDB: 6Z82). A box size 
of (25, 25, 35) was used with a box centre of (-4, 14.4, 9.6).  
 
8.10.4 Sequence alignment  
Multiple sequence alignment of NCSs and homologs was performed using MAFFT275 
and pairwise sequence alignment was performed using EMBOSS Needle.276 
Alignments were visualised using T-Coffee and BoxShade.277  
 
8.10.5 Structure visualisation 
Protein structures and 3D small molecules were visualised and figures prepared using 
UCSF Chimera.32 Reaction schemes and 2D figures of small molecules were prepared 




Chapter 9: Appendix 
9.1 DNA sequences 
Hexahistidine tags are underlined and TEV cleavage sites given in italics.  
NnNCS5 
CAT ATG CAT CAT CAC CAC CAT CAT TCT AGC GGC GTC GAC TTG GGT ACT GAG AAT 
CTG TAT TTT CAG AGC ATG ATT CAT AGC GTG AGC ACC GAA CTG GAA GTG GAT CTG 
CCG GCG GAT GAT ATT TGG GCG GTG TAT AGC AGC CCG GAA CTG CCG AAA CTG 
GTG GTG AAA CTG ATG CCG CAT GTG TAT GAT AAA ATT GAT ATT GTG GAA GGC GAT 
GGC GGC GTG GGC ACC GTG CTG CAG ATT GTG CTG ACC CCG GAA ATG ATG GAA 
CCG CGC ACC TGG AAA GAA AAA TTT GTG GAA ATT AAC GAT GGC CGC CGC AAA AAA 
GTG GTG CGC CAG ATT GAA GGC GGC TAT CTG GAT ATG GGC TTT CAT TTT TAT GAA 
GAT ATT TTT AAA ATT AAA AAA AAA AGC GAT AGC AGC TGC ATT ATT AAA AGC AAA 
AGC GTG TTT CGC GTG GAT CAT AAA CAT AAA GCG AAC GCG AGC CTG GTG ACC CCG 
GAT GCG AGC GCG GAA ATG GCG AAA GCG GTG GCG GAA TAT GCG AAA CAG AAA 
AAA GCG AAC AGC AGC AGC AGC AGC AAA GAT AAA GCG AAA GCG TGC TAT GAA TAA 




CAT ATG CAT CAT CAC CAC CAT CAT TCT AGC GGC GTC GAC TTG GGT ACT GAG AAT 
CTG TAT TTT CAG AGC ATG ATG ACC GCG CGC GTG ACC AAC GAA ATG GAA GTG GGC 
GTG CCG GCG GAT GAT GTG TGG GCG GTG TAT GGC AGC CCG GAT CTG CCG AAA 
CTG TTT GTG CAG CTG ATG CCG CAG GTG TAT AAA CGC AAC GAT GTG CTG GAA GGC 
GAT GGC ACC GTG GGC ACC GTG ATT CTG ATT GAA CTG GAT GAT GCG CTG CCG 
GAA CCG CGC ATT TGG AAA GAA AAA TTT ATT AAA ATT GAT CAT CAG GAA CGC GAA 
AAA CTG GTG CGC GTG ATT GAA GGC GGC TTT CTG GAT ATT GGC TTT CGC AGC TTT 
GAT ATT ATT TTT AAA GTG ATT GAA AAA GAT GCG AGC AGC TGC ATT ATT CAG AGC 
ACC ACC GCG TTT GAA CTG GAT GAT AAA TTT GAA GAT AAC GCG AAC CGC ATT ACC 
GCG GGC ACC CTG TGG TGG GTG GCG AAA GCG ATT AGC AAC TAT GTG ATT CAG 
AAC AAA AGC AAA AGC AAA AGC GAT AAC AAC TAA TCT CGA G 
 
 
SalSyn v1 (pTac promoter) 
 
GGC AGT GAG CGC AAC GCA ATT AAA AAA GAT CAA AAA ATT TGA CAA TTA ATC ATC 
GGC TCG TAT AAT GTG TGA ATT GTG AGC GGA TAA CAA TTT GAT AAA TTG TTA AAG 
AGC AGT AGG AGA AAC ATA TGC AGA TTT TTG TGA AAA CCC TGA CCG GCA AAA CCA 
TTA CCC TGG AAG TGG AAC CGA GCG ATA CCA TTA AAA ACG TGA AAG CGA AAA TTC 
AGG ATA AAG AAG GCA TTC CGC CGG ATC AGC AGC GCC TGA TTT TTG CGG GCA AAC 
AGC TGG AAG ATG GCC GCA CCC TGA GCG ATT ATA ACA TTC AGA AAA AAA GCA CCC 
TGC ATC TGG TGC TGC GCC TGC GCG TGG ATT ATC ACC ATC ACC ATC ACC ATT AAT 
TGT TCA TTC AGA ACG CTC GGT CTT GCA CAC CGG GCG TTT TTT CTT TGT GAG TCC 
A 
 
SalSyn v2 (pPI promoter) 
 
GGC AGT GAG CGC AAC GCA ATT AAA AAA GAT CAA AAA ATG TTG ACA TAA ATA CCA 
CTG GCG GTT ATA CTG AGG AAT TGT GAG CGG ATA ACA ATT TGA TAA ATT GTT AAA 
GAG CAG TAG GAG AAA CAT ATG CAG ATT TTT GTG AAA ACC CTG ACC GGC AAA ACC 
ATT ACC CTG GAA GTG GAA CCG AGC GAT ACC ATT AAA AAC GTG AAA GCG AAA ATT 
CAG GAT AAA GAA GGC ATT CCG CCG GAT CAG CAG CGC CTG ATT TTT GCG GGC AAA 
CAG CTG GAA GAT GGC CGC ACC CTG AGC GAT TAT AAC ATT CAG AAA AAA AGC ACC 
CTG CAT CTG GTG CTG CGC CTG CGC GTG GAT TAT CAC CAT CAC CAT CAC CAT TAA 






SalSyn v3 (T7 promoter) 
 
GGC AGT GAG CGC AAC GCA ATT AAA AAA GAT CAA AAA ATT TAA TAC GAC TCA CAA 
TCG CGG AGC TGA GGG TGT GAA TTG TGA GCG GAT AAC AAT TTG ATA AAT TGT TAA 
AGA GCA GTA GGA GAA ACA TAT GCA GAT TTT TGT GAA AAC CCT GAC CGG CAA AAC 
CAT TAC CCT GGA AGT GGA ACC GAG CGA TAC CAT TAA AAA CGT GAA AGC GAA AAT 
TCA GGA TAA AGA AGG CAT TCC GCC GGA TCA GCA GCG CCT GAT TTT TGC GGG CAA 
ACA GCT GGA AGA TGG CCG CAC CCT GAG CGA TTA TAA CAT TCA GAA AAA AAG CAC 
CCT GCA TCT GGT GCT GCG CCT GCG CGT GGA TTA TCA CCA TCA CCA TCA CCA TTA 
ATT CTA GCA TAA CCC CTT GGG GCC TCT AAA CGG GTC TTG AGG GGT TTT TTG 
 
9.2 Calibration curves 
Calibration curves were prepared using products purified by preparative HPLC or from 
commercial sources. Samples prepared for standard curves of phenyethylamines were 
prepared with 0.5 molar equivalents of sodium ascorbate (rt = 1.8 min) to minimise 
oxidation of the amine. Absorbance is given in mAU at 280 nm. Representative 
analytical HPLC traces of the isolated products are shown, with analysis performed 
using analytical HPLC method 1.  
 
9.2.1 Chapter 2: Novel Biocatalytic Routes Towards Tetrahydroisoquinoline 
Alkaloids  
 
Figure 9.1: Calibration curve and HPLC spectrum of 79. 
 


































Standard curve of 77
 343 
 
9.2.2 Chapter 3: The Acceptance and Kinetic Resolution of a-Methyl Substituted 
Aldehydes by Norcoclaurine Synthases 
 
Figure 9.3: Calibration curve and HPLC spectrum of 5. 
  
Figure 9.4: Calibration curve and HPLC spectrum of 93. 
 



















Standard curve of 5
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  12
Acq. Instrument : HPLC                            Location :   10
Injection Date  : 23/05/2018 19:05:21                  Inj :   1
                                                Inj Volume : 10.000 µl
Method          : C:\Chem32\1\Data\Rebecca\2RR167 2RR169 NnNCS7 test cal curves 2018-05-23 17
                  -05-51\Benjy_NCS_10muL.M (Sequence Method)
Last changed    : 23/05/2018 17:05:52 by SYSTEM
Additional Info : Peak(s) manually integrated




















                      Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.344 MM    0.1763 3683.56787  348.29312 100.0000
Totals :                  3683.56787  348.29312
=====================================================================
                          *** End of Report ***
Data File C:\Chem32\...7 2RR169 NnNCS7 test cal curves 2018-05-23 17-05-51\010-1101--012.D
Sample Name: DOPAMINE 2.5



















Standard curve for 93
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  67
Acq. Instrument : HPLC                            Location :   66
Injection Date  : 12/05/2018 04:31:13                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method  : C:\Chem32\1\Data\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M
Last changed    : 11/05/2018 16:11:23 by SYSTEM
Analysis Method : C:\Chem32\1\Dat \Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M (Sequence Method)
Last changed    : 14/06/2018 15:44:38 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated













                        Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   4.356 BV R  0.1161 3804.14893  535.59277 100.0000
Totals :                  3804.14893  535.59277
Data File C:\Chem32\...a\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\OnlineEdited--067.D
Sample Name: B 2.5


















Concentration / mM 
Standard curve of 94
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  28
Acq. Instrument : HPLC                            Location :   27
Injection Date  : 09/11/2017 20:15:20                  Inj :   1
                                                Inj Volume : 20.000 µl
Different Inj Volume from Sample Entry!  Actual Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\171109_RR96_alphasubs_calcurves 2017-11-09 15-21-
                  06\Benjy_NCS_10muL.M
Last changed    : 09/11/2017 15:21:06 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\171109_RR96_alphasubs_calcurves 2017-11-09 15-21-
                  06\Benjy_NCS_10muL.M (Sequence Method)
Last changed    : 14/06/2018 15:49:20 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated















                       Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   4.991 VB R  0.0680 3782.45459  680.73041 100.0000
Totals :                  3782.45459  680.73041
Data File C:\Chem32\...ecca\171109_RR96_alphasubs_calcurves 2017-11-09 15-21-06\027-2801.D
Sample Name: 1RR65 15
HPLC 14/06/2018 15:49:54 SYSTEM Page 1 of 2
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Figure 9.6: Calibration curve and HPLC spectrum of 95. 
 
Figure 9.7: Calibration curve and HPLC spectrum of 96. 
 
Figure 9.8: Calibration curve and HPLC spectrum of 98. 
 
 



















Standard curve of 95
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  78
Acq. Instrument : HPLC                            Location :   77
Injection Date  : 12/05/2018 06:30:47                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M
Last changed    : 11/05/2018 16:11:23 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M (Sequence Method)
Last changed    : 14/06/2018 15:46:31 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated














                       Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.610 BV R  0.0673 1501.66956  333.91327 100.0000
Totals :                  1501.66956  333.91327
Data File C:\Chem32\...a\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\OnlineEdited--078.D
Sample Name: D 1.25


















Standard curve of 96
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  73
Acq. Instrument : HPLC                            Location :   72
Injection Date  : 12/05/2018 05:36:28                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M
Last changed  : 11/05/2018 16:11:23 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\Benjy_NCS_
                  10muL.M (Sequence Method)
Las  changed : 14/06/2018 15:45:45 by SYSTEM
          (modified after loading)
Additional Info : Peak(s) manually integrated


















                       Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.767 VV R  0.0580 1464.81567  385.76947  92.2740
   2   5.895 VB E  0.0567  122.64747   33.54919   7.7260
Totals :                  1587.46314  419.31866
Data File C:\Chem32\...a\Rebecca\2RR160 1 3 LL3004 2018-05-11 16-04-44\OnlineEdited--073.D
Sample Name: C 1.25


















Concentration / mM 



















Standard curve of 51
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   7
Acq. Instrument : HPLC                            Location :   31
Injection Date  : 15/06/2018 17:37:06                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M
Last changed    : 15/06/2018 16:31:46 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M (Sequence Method)
Last changed    : 20/06/2018 11:02:45 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated



















                       Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.493 MM    0.1266 2176.57056  286.47101 100.0000
Totals :                  2176.57056  286.47101
Data File C:\Chem32\...615_2RR174 amine cal curves and DANI 2018-06-15 16-31-46\031-0701.D
Sample Name: mTyr 2.5
HPLC 20/06/2018 11:02:53 SYSTEM Page 1 of 2
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Figure 9.11: Calibration curve and HPLC spectrum of 101. 
 
  
Figure 9.12: Calibration curve and HPLC spectrum of 102. 
 
 




















Standard curve of 101
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   2
Acq. Instrument : HPLC                            Location :   26
Injection Date  : 15/06/2018 16:42:49                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M
Last changed    : 15/06/2018 16:31:46 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M (Sequence Method)
Last changed    : 20/06/2018 11:02:45 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated



















                         Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   1.986 MM    0.1251 4210.19141  560.91443 100.0000
Totals :                  4210.19141  560.91443
Data File C:\Chem32\...615_2RR174 amine cal curves and DANI 2018-06-15 16-31-46\026-0201.D
Sample Name: Nor 2.5



















Standard curve of 102
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :  12
Acq. Instrument : HPLC                            Location :   36
Injection Date  : 15/06/2018 18:31:23                  Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M
Last changed    : 15/06/2018 16:31:46 by SYSTEM
Analysis Method : C:\Chem32\1\Data\Rebecca\180615_2RR174 amine cal curves and DANI 2018-06-15
                  16-31-46\Benjy_NCS_10muL.M (Sequence Method)
Last changed    : 20/06/2018 11:02:45 by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated





















                         Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.040 MM    0.1026 2316.61011  376.29041 100.0000
Totals :                  2316.61011  376.29041
Data File C:\Chem32\...615_2RR174 amine cal curves and DANI 2018-06-15 16-31-46\036-1201.D
Sample Name: metaminol 2.5








0 1 2 3
Standard curve of 77
=====================================================================
Acq. Operator   : SYSTEM                         Seq. Line :   8
Acq. Instrument : HPLC                            Location :   30
Injection Date  : 01/08/2018 11:11:53                  Inj :   1
                                                Inj Volume : 10.000 µl
Method          : C:\Chem32\1\Data\Rebecca\3RR183 cal 3RR181 L76V 2018-08-01 09-55-47\Benjy_
                  NCS_10muL.M (Sequence Method)
Last changed    : 01/08/2018 09:55:47 by SYSTEM
Additional Info : Peak(s) manually integrated




















                         Area Percent Report
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=280 nm
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.626 MM    0.0989 3616.83643  609.55786 100.0000
Totals :                  3616.83643  609.55786
=====================================================================
                          *** End of Report ***
Data File C:\Chem32\...ecca\3RR183 cal 3RR181 L76V 2018-08-01 09-55-47\OnlineEdited--008.D
Sample Name: 2.5
HPLC 05/09/2018 17:20:53 SYSTEM Page 1 of 1
 346 
9.2.3 Chapter 4: Chemoenzymatic Cascades Towards Methylated 
Tetrahydroprotoberberine and Protoberberine Alkaloids   
 
Figure 9.14: Calibration curve and HPLC spectrum of 119. 
 
Figure 9.15: Calibration curve and HPLC spectrum of 129. 
 

















































Standard curve of 125
 347 





Figure 9.17: Calibration curve and HPLC spectrum of 156. 
 
Figure 9.18: Calibration curve and HPLC spectrum of 157. 
 
Figure 9.19: Calibration curve and HPLC spectrum of 158. 
 
 
Figure 9.20: Calibration curve and HPLC spectrum of 159. 
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :   7
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-F4
Injec ion Da e  : 3/28/2019 5:37:19 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\3RR236 cal c e  2019-03
                  -28 16-12-05\Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed



















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.415 MM    0.0553 3313.34790  997.73999 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P...ca\3RR236 cal c e  2019-03-28 16-12-05\007-D1F-F4-3RR236C cal 1.D
Sample Name: 3RR236C cal 1
































Standard curve of 158
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :   8
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-B7
Injec ion Da e  : 6/24/2019 1:43:37 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\4RR265 po p ep check
                  2019-06-24 12-25-25\Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed




















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   1.805 BB    0.0910   33.33112    5.18704   5.4944
   2   5.158 VV R  0.0480  573.30634  179.39482  94.5056
 




                          *** End of Repo  ***
Da a File C:\U e \P... a\Rebecca\4RR265 po p ep check 2019-06-24 12-25-25\008-D1F-B7-H.D
Sample Name: H

















Standard curve of 159
=====================================================================
Acq. Ope a o   : SYSTEM                         Seq. Line :  20
Sample Ope a o  : SYSTEM                                                                     
Acq. In n  : Agilen  LC                   Loca ion :   D1F-B7
Injec ion Da e : 8/22/2019 9:05:12 PM         Inj :   1
                                                Inj Vol me : 10.000 l
Me hod        : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25
                  \Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed
















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.295 VB R  0.0655 1594.41028  360.91498 100.0000
 




                          *** End of Repo  ***
Da a F e C:\U e \P... a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25\OnlineEdi ed--020.D
Sample Name: 4RR265B 1


















Standard curve of 156
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Figure 9.21: Calibration curve and HPLC spectrum of 160. 
 
Figure 9.22: Calibration curve and HPLC spectrum of 161. 
 
Figure 9.23: Calibration curve and HPLC spectrum of 162. 
 
 
















Standard curve of 160
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :   2
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-C1
Injec ion Da e  : 9/30/2019 12:20:45 PM                Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\4RR265E and 4RR305 cal
                  c e  2019-09-30 12-08-46\Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed

















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.297 VV R  0.0788 4438.62305  872.58722 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P...5E and 4RR305 cal c e  2019-09-30 12-08-46\002-D1F-C1-4RR265E 1.D
Sample Name: 4RR265E 1

















Standard curve of 161
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :   7
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-C6
Injec ion Da e  : 9/30/2019 1:15:59 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\4RR265E and 4RR305 cal
                  c e  2019-09-30 12-08-46\Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed
















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   4.731 VV R  0.0697 3787.59985  792.18085 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P...65E and 4RR305 cal c e  2019-09-30 12-08-46\007-D1F-C6-2-F BA 1.D
Sample Name: 2-F BA 1

















Standard curve of 162
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :  12
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                     Loca ion :   D1F-D2
Injec ion Da e  : 9/30/2019 2:11:22 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\4RR265E and 4RR305 cal
                c e  2019-09-30 12-08-46\Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed
















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   4.980 VB R  0.0730 3773.67358  798.12543 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P...65E and 4RR305 cal c e  2019-09-30 12-08-46\012-D1F-D2-3-F BA 1.D
Sample Name: 3-F BA 1
















Standard curve of 163
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :  15
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-B2
Injec ion Da e  : 8/22/2019 8:10:02 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25
                  \Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed

















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.052 VV R  0.0779 2286.14038  409.47101 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P... a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25\OnlineEdi ed--015.D
Sample Name: 4RR265A 1
Agilen  LC 1/6/2020 11:13:39 AM SYSTEM Page 1 of 1
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Figure 9.25: Calibration curve and HPLC spectrum of 164. 
 
Figure 9.26: Calibration curve and HPLC spectrum of 165. 
 
Figure 9.27: Calibration curve and HPLC spectrum of 166. 
 
 















Standard curve of 164
=====================================================================
Ac . Ope a o    : SYSTEM                         Se . Line :   7
Sample Ope a o  : SYSTEM                                                                     
Ac . In men  : Agilen  LC                      Loca ion :   D1F-B6
Injec ion Da e  : 6/24/2019 1:32:35 PM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\4RR265 po p ep check
                  2019-06-24 12-25-25\Rebecca_Benji 280 10 MIN.M (Se ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM




















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   1.806 BB    0.0818   26.27298    4.65489   1.9329
   2   5.055 VB    0.0503 1332.98535  405.74420  98.0671
 




                          *** End of Repo  ***
Da a File C:\U e \P... a\Rebecca\4RR265 po p ep check 2019-06-24 12-25-25\007-D1F-B6-G.D
Sample Name: G































Standard curve of 166
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :  25
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                     Loca ion :   D1F-C3
Injec ion Da e  : 8/22/2019 10:00:20 PM                Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25
                  \Rebecca_Benji 280 10 MIN.M (Seq ence Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed

















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.484 BB    0.0712 2057.70361  435.12485 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P... a ion\1\Da a\Fabi\FSM93bi  2019-08-22 15-46-25\OnlineEdi ed--025.D
Sample Name: 4RR265C 1

















Standard curve of 171
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Figure 9.29: Calibration curve and HPLC spectrum of 172. 
 
9.2.4 Chapter 6: N-methyl-phenethylamines as substrates for norcoclaurine 
synthases 
 
Figure 9.30: Calibration curve and HPLC spectrum of 198. 
 
 















Standard curve of 172
=====================================================================
Acq. Ope a o    : SYSTEM                         Seq. Line :   2
Sample Ope a o  : SYSTEM                                                                     
Acq. In men  : Agilen  LC                      Loca ion :   D1F-C1
Injec ion Da e  : 1/9/2020 11:00:07 AM                 Inj :   1
                                                Inj Vol me : 10.000 l
Me hod          : C:\U e \P blic\Doc men \ChemS a ion\1\Da a\Rebecca\5RR351 cal c e  and
                  5RR356 cale p check 2020-01-09 10-48-09\Rebecca_Benji 280 10 MIN.M (Seq ence
                  Me hod)
La  changed    : 1/16/2019 11:16:46 AM b  SYSTEM
Addi ional Info : Peak( ) man all  in eg a ed





















                         A ea Pe cen  Repo                          
=====================================================================
 
So ed B              :      Signal
M l iplie             :      1.0000
Dil ion              :      1.0000
U e M l iplie  & Dil ion Fac o  i h ISTD
 
 
Signal 1: DAD1 B, Sig=280,4 Ref=off
 
Peak Re Time T pe  Wid h     A ea      Heigh      A ea  
  #   [min]        [min]   [mAU* ]     [mAU]        %
---- ------- ---- ------- ---------- ---------- --------
   1   5.720 MM    0.0765 3443.31104  749.75830 100.0000
 




                          *** End of Repo  ***
Da a File C:\U e \P...356 cale p check 2020-01-09 10-48-09\002-D1F-C1-5RR351A_P2 CAL 1.D
Sample Name: 5RR351A_P2 CAL 1


































Standard curve of 203
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Figure 9.32: Calibration curve and HPLC spectrum of 204.  
 
Figure 9.33: Calibration curve and HPLC spectrum of 205.  
 
 
Figure 9.34: Calibration curve and HPLC spectrum of 206. 
  







































































Standard curve of 207
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9.3 Chiral HPLC analyses  
9.3.1 Chapter 2: Novel Biocatalytic Routes Towards Tetrahydroisoquinoline 
Alkaloids 
 
Figure 9.36: Chiral HPLC analysis of THIQ products, 77 and 79, generated by reactions 
with double point variants of D29TfNCS. Reactions were performed in standard conditions 
using 1 mg mL-1 final concentration of enzyme using a. phenylacetaldehyde (76) or b. hexanal 
(78) as the aldehyde substrate. Samples were prepared using workup method 2 and analysis 






Figure 9.37: Chiral HPLC analysis of THIQ products, 77 and 79, generated by reactions 
with L72 and F80 variants of D33TfNCS. Reactions were performed in standard conditions 
using 1 mg mL-1 final concentration of enzyme using a. phenylacetaldehyde (76) or b. hexanal 
(78) as the aldehyde substrate. Samples were prepared using workup method 2 and analysis 








Figure 9.38: Chiral HPLC analysis of THIQ products, 77 and 79, generated by reactions 
with P179 and F80 variants of D33TfNCS. Reactions were performed in standard conditions 
using 0.1 mg mL-1 final concentration of enzyme using a. phenylacetaldehyde (76) or b. hexanal 
(78) as the aldehyde substrate. Samples were prepared using workup method 2 and analysis 
was performed using chiral HPLC method 5.  
 
9.3.2. Chapter 5: Single Step Syntheses of (1S)-Aryl-Tetrahydroisoquinolines by 
Norcoclaurine Synthases 
For the chiral HPLC analyses of products 156-166, traces shown are for reactions 
performed using 0.2 mg mL-1 final concentration of enzyme with a reaction time of 3 h. 
Acetonitrile was used as the reaction co-solvent. Samples were prepared for chiral 
HPLC analysis using workup method 2 and chiral HPLC method 5 was used unless 
otherwise stated. KPi = racemic standard, generated by a phosphate mediated Pictet-
Spengler reaction using conditions described in the methods section and the product 
isolated by the same preparative HPLC method as the NCS-generated products. 
Various NCSs were used as the reaction catalyst: wild-type = WT, D 29TfNCS-M97F = 








Figure 9.39: Chiral HPLC analysis of 156. Retention time (tR) (major, S enantiomer) = 5.1 min, 
tR (minor, R enantiomer) = 5.7 min. Samples were prepared using workup method 1 and analysis 
performed using chiral HPLC method 4.  
 
Figure 9.40: Chiral HPLC analysis of 157. tR (major, S enantiomer) = 4.9 min, tR (minor, R 
enantiomer) = 5.3 min. Samples were prepared using workup method 1 and analysis performed 
using chiral HPLC method 4.  
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Figure 9.41: Chiral HPLC analysis of 158. tR (major, S enantiomer) = 9 min, tR (minor, R 
enantiomer) = 22 min.  
 
Figure 9.42: Chiral HPLC analysis of 159. tR (major, S enantiomer) = 11 min, tR (minor, R 
enantiomer) = 18-19 min. 
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Figure 9.43: Chiral HPLC analysis of 160. tR (major, S enantiomer) = 12-13 min, tR (minor, R 
enantiomer) = 16 – 17 min.  
 
Figure 9.44: Chiral HPLC analysis of 161. tR (major, S enantiomer) = 11 min, tR (minor, R 
enantiomer) = 16-17 min. 
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Figure 9.45: Chiral HPLC analysis of 162. tR (major, S enantiomer) = 11 min, tR (minor, R 
enantiomer) = 17-20 min.  
 
 
Figure 9.46: Chiral HPLC analysis of 163. tR (major, S enantiomer) = 14-15 min, tR (minor, R 
enantiomer) = 21-23 min.  
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Figure 9.47: Chiral HPLC analysis of 164. tR (major, S enantiomer) = 9 min, tR (minor, R 
enantiomer) = 12 min. 
 
Figure 9.48: Chiral HPLC analysis of 165. tR (major, S enantiomer) = 12 min, tR (minor, R 
enantiomer) = 17-18 min. 
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Figure 9.49: Chiral HPLC analysis of 166. tR (major, S enantiomer) = 16 min, tR (minor, R 
enantiomer) = 17 min.  
 
 
Figure 9.50: Chiral HPLC analyses of 173 and 174.   
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9.3.3 Chapter 6: N-methyl-Phenyethylamines as Substrates for Norcoclaurine 
Synthases 
Chiral HPLC analyses shown are for reactions using standard conditions. 0.2 mg mL-1 
final concentration of WT-D29TfNCS was used with a reaction time of 18 h. The THIQ 
products (203, 204, 206 and 207) were isolated by preparative HPLC, any remaining 
TFA salts were removed by workup method 3 and chiral HPLC analysis was performed 
using method 5. Samples were prepared at 2.5 mM in the mobile phase and a 10 µL 
injection volume was used. Racemic standards (denoted racemic standard or KPi) were 
generated using a KPI-mediated reaction. 
 
Figure 9.51: Chiral HPLC analysis of 203.  
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Figure 9.52: Chiral HPLC analysis of 204. 
 
Figure 9.53: Chiral HPLC analysis of 206 THIQ product. 
 
Figure 9.54: Chiral HPLC analysis of 207 THIQ product. 
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9.4 GCMS analysis of (R)-2-methylbutanol 
 
 
Figure 9.55: GCMS analysis of 103. 
 
RT: 0.00 - 24.47


















































2.54 12.640.59 15.515.51 20.6716.45 19.386.37 13.598.29 11.57 21.51 22.5510.93 23.5818.239.74
NL:
1.52E9
Base Peak F: 




2RR132 #947-1407 RT: 3.72-5.28 AV: 461 NL: 5.82E8
F: {0,0}  + c EI Full ms [30.00-400.00]







































72.14 87.12 119.11 147.10 207.06177.25 221.08 255.01 280.91 305.37 380.06321.27 362.05339.31 395.69
 364 




























































































































9.6 Multiple sequence alignment of NCSs 
TfNCS     1 MMKMEV-VFVFLMLLGTINCQKLILTGRPFLHHQGIINQVST-VTKVIHHELEVAASADD 
CjNCS2    1 MRM-EVVLVVFLMFIGTINCERLIFNGRPLLHR------VTKEETVMLYHELEVAASADE 
NnNCS1    1 MM----------------------------IGR--------------VVNEMEVGVPADD 
NnNCS3    1 M-----------------------------RGQ--------------VTNELDVDVPVDD 
NnNCS5    1 M-----------------------------IHS--------------VSTELEVDLPADD 
NnNCS7    1 MM----------------------------TAR--------------VTNEMEVGVPADD 
 
 
TfNCS    59 IWTVYSWPGLAKHLPDLLPG-AFEKLEI-IGDGGVGTILDMTFVPGE-FPHEYKEKFILV 
CjNCS2   54 VWSVEGSPELGLHLPDLLPAGIFAKFEI-TGDGGEGSILDMTFPPGQ-FPHHYREKFVFF 
NnNCS1   19 IWAVYSSPELPRLFVQLMPN-VYKKIDILQGDGTVGTVLHIELADGIPEPRTWKEKFIKI 
NnNCS3   18 IWAVYGTPVLPTHIVQLQPD-VFQKVDFIHGNGGVGTILYVQLVPGAPEPRTWKEKFIKI 
NnNCS5   18 IWAVYSSPELPKLVVKLMPH-VYDKIDIVEGDGGVGTVLQIVLTPEMMEPRTWKEKFVEI 
NnNCS7   19 VWAVYGSPDLPKLFVQLMPQ-VYKRNDVLEGDGTVGTVILIELDDALPEPRIWKEKFIKI 
 
 
TfNCS   116 DNEHRLKKVQMIEGGYLDLGVTYYMDTIHVVPTGKDSCVIKSSTEYHVKPEFVKIVEPLI 
CjNCS2  112 DHKNRYKLVEQIDGDFFDLGVTYYMDTIRVVATGPDSCVIKSTTEYHVKPEFAKIVKPLI 
NnNCS1   78 DHQHREKVVRQIEGGFLDMGFRVFDVIFKIIEKDACSCIIRSTTAFELDEKFENN-ANLI 
NnNCS3   77 DDEERLKVIRMIEGGYLDLGFTLFEYNTQIIEKDAESCTIRSTTVFEVDEKFEAN-AALI 
NnNCS5   77 NDGRRKKVVRQIEGGYLDMGFHFYEDIFKIKKKSDSSCIIKSKSVFRVDHKHKAN-ASLV 
NnNCS7   78 DHQEREKLVRVIEGGFLDIGFRSFDIIFKVIEKDASSCIIQSTTAFELDDKFEDN-ANRI 
 
 
TfNCS   176 TTGPLAAMADAISKLVLEHKSKSNSDEIEAAIIT-V 
CjNCS2  172 DTVPLAIMSEAIAKVVLENKHKSSE----------- 
NnNCS1  137 TAGNLWGAAKAISNYVIQNKSKRRN----------H 
NnNCS3  136 NATSAYGLAKAVANYVIQKKAKACD----------V 
NnNCS5  136 TPDASAEMAKAVAEYAKQKKANSSSSSKDKAKACYE 





Figure 9.56:  Multiple sequence alignment of NCSs. Protein sequences were compared with 
TfNCS. Black indicates conserved residues and grey indicates residue similarity.
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